{"docstore/data": {"89e91609-8300-403c-8a16-5c909af0a20f": {"__data__": {"id_": "89e91609-8300-403c-8a16-5c909af0a20f", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n05-May -2022  \nMcKesson Corp.   (MCK ) \nQ4 2022 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n05-May -2022  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "baae0df7-953e-4720-95bd-38a16e5bf756", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1894790c921e53a6fa7d2a901101cca30244cf6702e53ae3ff5656aba01d653d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d778772-5bfa-4e89-bf36-0bb7977b33ee", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n05-May -2022  \nMcKesson Corp.   (MCK ) \nQ4 2022 Earnings Call    ", "original_text": "(MCK ) \nQ4 2022 Earnings Call    "}, "hash": "420078c27e4c52e1dbb666facbe5818a8160b5227d2c21315550d9a1f65c2250", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n05-May -2022  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d778772-5bfa-4e89-bf36-0bb7977b33ee": {"__data__": {"id_": "8d778772-5bfa-4e89-bf36-0bb7977b33ee", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n05-May -2022  \nMcKesson Corp.   (MCK ) \nQ4 2022 Earnings Call    ", "original_text": "(MCK ) \nQ4 2022 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "baae0df7-953e-4720-95bd-38a16e5bf756", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1894790c921e53a6fa7d2a901101cca30244cf6702e53ae3ff5656aba01d653d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89e91609-8300-403c-8a16-5c909af0a20f", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n05-May -2022  \nMcKesson Corp.   (MCK ) \nQ4 2022 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n05-May -2022  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5cfc1ab61a9ff19e7528682a9c20764f6d16c7b98c4502cf93b611f785231f28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2feead10-4c59-4c4f-8b15-8c432c0f088b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "McKesson Corp.  "}, "hash": "413faeb8cfaa5a3ac818ca1e8ff77f5480ebf3bd142a7d113af464a847b200f5", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call    ", "start_char_idx": 166, "end_char_idx": 199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2feead10-4c59-4c4f-8b15-8c432c0f088b": {"__data__": {"id_": "2feead10-4c59-4c4f-8b15-8c432c0f088b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d778772-5bfa-4e89-bf36-0bb7977b33ee", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n05-May -2022  \nMcKesson Corp.   (MCK ) \nQ4 2022 Earnings Call    ", "original_text": "(MCK ) \nQ4 2022 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fe7ba83ab58a087a8284a17f6cba418ddda333b0e1a1e2870801dd29984f67b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64ac9878-9309-4ecc-a1ea-b90553d9ad49", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "069eea0da755792bc1f89e3643678e373ece78eae82e78923d853521e9f4255b", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64ac9878-9309-4ecc-a1ea-b90553d9ad49": {"__data__": {"id_": "64ac9878-9309-4ecc-a1ea-b90553d9ad49", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2feead10-4c59-4c4f-8b15-8c432c0f088b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94f595c07abdcce751113c0ca81fca5ed059795aca4fa8d1b29a006992caa29c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43a439df-074a-4278-8358-8582e42fe32f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n "}, "hash": "035625dc9c0561864bc280c98f3d713a47eca26690cae7bea78749f536852c61", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43a439df-074a-4278-8358-8582e42fe32f": {"__data__": {"id_": "43a439df-074a-4278-8358-8582e42fe32f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64ac9878-9309-4ecc-a1ea-b90553d9ad49", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "460079a58a01bb9e4f44e8268e478510a4eeb449ccd0fa7139008a6d4e6cb59b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fc16a0b-0bbd-4830-a3ac-d81781261c50", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n"}, "hash": "72aac062613e9a6dbf4f6fdc29cd1915f48d986d0e549119cd16f8e92647564f", "class_name": "RelatedNodeInfo"}}, "text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "start_char_idx": 341, "end_char_idx": 428, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fc16a0b-0bbd-4830-a3ac-d81781261c50": {"__data__": {"id_": "8fc16a0b-0bbd-4830-a3ac-d81781261c50", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43a439df-074a-4278-8358-8582e42fe32f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca92ee3e5ab9b8f26ca55065714582a5bb03a6b5118480fec40be09a5df9ffd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4786bc9c-763a-413a-91f9-b4a3ba612cd8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "d29620bb6fcac4de746dbd11b518a2bc8992e90620f89d9f7feba8bcf4ddf151", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "start_char_idx": 428, "end_char_idx": 775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4786bc9c-763a-413a-91f9-b4a3ba612cd8": {"__data__": {"id_": "4786bc9c-763a-413a-91f9-b4a3ba612cd8", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fc16a0b-0bbd-4830-a3ac-d81781261c50", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2612c097dde70757b1cc3b194aeeb4aab891c9e458c8645b696fcb940ecb41f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d198de46-9ea7-4082-88f7-96f23f538a18", "node_type": "1", "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n ", "original_text": "LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  "}, "hash": "9320a0cdd7b44b41cb93ef0e3628d6ea4c0da2acb0ba9a61108588ca3108252c", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 775, "end_char_idx": 859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d198de46-9ea7-4082-88f7-96f23f538a18": {"__data__": {"id_": "d198de46-9ea7-4082-88f7-96f23f538a18", "embedding": null, "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n ", "original_text": "LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4786bc9c-763a-413a-91f9-b4a3ba612cd8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f17b44b6fea187fd38588ab214918886ec44ee0d43c2f228b12a7fe206cc8f64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94174878-5cdb-4c24-bd5e-a24217bfd767", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call. ", "original_text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "75fd3b430df3950b73b648f78f27cfac0226f5428b9df69dea37c60a2764e45d", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "start_char_idx": 859, "end_char_idx": 970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94174878-5cdb-4c24-bd5e-a24217bfd767": {"__data__": {"id_": "94174878-5cdb-4c24-bd5e-a24217bfd767", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call. ", "original_text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d198de46-9ea7-4082-88f7-96f23f538a18", "node_type": "1", "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n ", "original_text": "LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1af5b54f2d6e9b9bc75c1db2f0fa79734fcf33fc6d3956eb3be6ccc76398e25b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e278bfba-e323-46a8-98f3-fef431761110", "node_type": "1", "metadata": {"window": "Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded. ", "original_text": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n"}, "hash": "1714880d4e36126655a17fb77b2beabadebcac3fe0c3ddf546ba683f2847f9f6", "class_name": "RelatedNodeInfo"}}, "text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 970, "end_char_idx": 1022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e278bfba-e323-46a8-98f3-fef431761110": {"__data__": {"id_": "e278bfba-e323-46a8-98f3-fef431761110", "embedding": null, "metadata": {"window": "Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded. ", "original_text": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94174878-5cdb-4c24-bd5e-a24217bfd767", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call. ", "original_text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ed269342d1bbde82be2849a1fd024abaed2d7ae4e3a9b6aeced3903d2243ae4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "656c1288-957d-48a4-833d-f690b311deb7", "node_type": "1", "metadata": {"window": "LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations. ", "original_text": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n "}, "hash": "afe1ef55a18541bcaaefc8c13dd52f7fb40fb11b6ddba29f30dd95b67a79ea15", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "start_char_idx": 1022, "end_char_idx": 1136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "656c1288-957d-48a4-833d-f690b311deb7": {"__data__": {"id_": "656c1288-957d-48a4-833d-f690b311deb7", "embedding": null, "metadata": {"window": "LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations. ", "original_text": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e278bfba-e323-46a8-98f3-fef431761110", "node_type": "1", "metadata": {"window": "Eric Percher  \nAnalyst, Nephron Research LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded. ", "original_text": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "769ca083a793a3c616efdd0db29e13bdb991d121ddff1d3e4b3a547d45703a46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a50431fa-7351-4370-8ef3-270d6fc1e202", "node_type": "1", "metadata": {"window": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call. "}, "hash": "76cd8357901987febbc2f68ee21875200e8e91ba16448bcad751a2317513d0cb", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n ", "start_char_idx": 1136, "end_char_idx": 1238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a50431fa-7351-4370-8ef3-270d6fc1e202": {"__data__": {"id_": "a50431fa-7351-4370-8ef3-270d6fc1e202", "embedding": null, "metadata": {"window": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "656c1288-957d-48a4-833d-f690b311deb7", "node_type": "1", "metadata": {"window": "LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations. ", "original_text": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b609cc4f503472bcaeeb043f5c528106259f402d9f7c87e7e2fee965504dfaa9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cf794a0-ef8e-4575-a584-800b2d1c92b6", "node_type": "1", "metadata": {"window": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator. ", "original_text": "Please be advised \nthat today's conference is being recorded. "}, "hash": "96325d2113732d8313d0b85ec2cd6b0b85a78ccdb17c8e0989278b4a7c6aa71b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call. ", "start_char_idx": 1238, "end_char_idx": 1633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cf794a0-ef8e-4575-a584-800b2d1c92b6": {"__data__": {"id_": "1cf794a0-ef8e-4575-a584-800b2d1c92b6", "embedding": null, "metadata": {"window": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator. ", "original_text": "Please be advised \nthat today's conference is being recorded. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a50431fa-7351-4370-8ef3-270d6fc1e202", "node_type": "1", "metadata": {"window": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc2753730ae90a7f461bcae2c90de61289b97446eaf54b1c6d5d52782455dd23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc3c2b17-5152-46b9-8c01-77696e6e7010", "node_type": "1", "metadata": {"window": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall. ", "original_text": "At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations. "}, "hash": "d84ab459240bb7cc1c246a9a175fe755a97f6e0af1894813f5c987d2af23979f", "class_name": "RelatedNodeInfo"}}, "text": "Please be advised \nthat today's conference is being recorded. ", "start_char_idx": 1633, "end_char_idx": 1695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc3c2b17-5152-46b9-8c01-77696e6e7010": {"__data__": {"id_": "dc3c2b17-5152-46b9-8c01-77696e6e7010", "embedding": null, "metadata": {"window": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall. ", "original_text": "At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cf794a0-ef8e-4575-a584-800b2d1c92b6", "node_type": "1", "metadata": {"window": "LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator. ", "original_text": "Please be advised \nthat today's conference is being recorded. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92b19c5a7ba0a8f9c8271a7ffa39b4f73e003a257781938d2f0bbd8c299da302", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a0492f6-9225-468a-b2ab-ea3c69e118d8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "Please go ahead.  \n "}, "hash": "78c86084ddef4b5369d1038416f9dd320f68bae0e2fc3ae9c40e3e27077dc79d", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations. ", "start_char_idx": 1695, "end_char_idx": 1793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a0492f6-9225-468a-b2ab-ea3c69e118d8": {"__data__": {"id_": "2a0492f6-9225-468a-b2ab-ea3c69e118d8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "Please go ahead.  \n ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc3c2b17-5152-46b9-8c01-77696e6e7010", "node_type": "1", "metadata": {"window": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall. ", "original_text": "At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17fb1fd929859232845c6027177956aaf676b19a4d022a5f99b6ccff24311588", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "096abc7d-af08-40d6-bb8d-6b32101a1e4c", "node_type": "1", "metadata": {"window": "Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator. "}, "hash": "61db2687a410869bed81b3ca272898799e3ea8305959eec117711678123d6ae3", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1793, "end_char_idx": 1813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "096abc7d-af08-40d6-bb8d-6b32101a1e4c": {"__data__": {"id_": "096abc7d-af08-40d6-bb8d-6b32101a1e4c", "embedding": null, "metadata": {"window": "Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a0492f6-9225-468a-b2ab-ea3c69e118d8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Fourth Quarter Fiscal 2022 Earnings Conference Call.  Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "Please go ahead.  \n ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7971cb55e2c706c6633c21810b1e705649945978808bf2cfe6b20e6c9f77dfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25951412-b0b7-4c07-b807-8178d738dfad", "node_type": "1", "metadata": {"window": "At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall. "}, "hash": "82548bd05211f8cf21d8c783acb271ab013dae6ba13871db820089559c793b61", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator. ", "start_char_idx": 1813, "end_char_idx": 2169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25951412-b0b7-4c07-b807-8178d738dfad": {"__data__": {"id_": "25951412-b0b7-4c07-b807-8178d738dfad", "embedding": null, "metadata": {"window": "At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "096abc7d-af08-40d6-bb8d-6b32101a1e4c", "node_type": "1", "metadata": {"window": "Please be advised \nthat today's conference is being recorded.  At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ade4122428280e448ee40ce46843c9563ab0a7cfbd294215336a6cdca6bc8cd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52002498-2c4c-4a52-a673-bce6487dec92", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n"}, "hash": "f1251b5741a9d10397c234f95495423ad8cd3f01d46bb2c948dbb60d416063d1", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall. ", "start_char_idx": 2169, "end_char_idx": 2265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52002498-2c4c-4a52-a673-bce6487dec92": {"__data__": {"id_": "52002498-2c4c-4a52-a673-bce6487dec92", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25951412-b0b7-4c07-b807-8178d738dfad", "node_type": "1", "metadata": {"window": "At this time, I would li ke to turn the call over to Rachel Rodriguez, VP of \nInvestor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a36fc16830ec8795499d45cbf74884341193e2ff88bd674fcd98c55f1d32da7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7d1b1a6-4dce-48ac-9654-cc5f40c9970c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n"}, "hash": "fbc897203299fb1472f2c39e7500a18c9fd21776eafff3ad4ca802b265693d73", "class_name": "RelatedNodeInfo"}}, "text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "start_char_idx": 2265, "end_char_idx": 2377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7d1b1a6-4dce-48ac-9654-cc5f40c9970c": {"__data__": {"id_": "f7d1b1a6-4dce-48ac-9654-cc5f40c9970c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52002498-2c4c-4a52-a673-bce6487dec92", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b30506f57fb4366b0d41aafd999ab6388ddce4fe77f2e590fa6821d64540975e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2717e0fc-cd94-44a0-ad67-b17d46547955", "node_type": "1", "metadata": {"window": "Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptio ns. ", "original_text": "Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results. "}, "hash": "b331dfed5cb878e501b89d07a2e95a9a71b0dda511b1fbc144becaaa34721948", "class_name": "RelatedNodeInfo"}}, "text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "start_char_idx": 2377, "end_char_idx": 2478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2717e0fc-cd94-44a0-ad67-b17d46547955": {"__data__": {"id_": "2717e0fc-cd94-44a0-ad67-b17d46547955", "embedding": null, "metadata": {"window": "Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptio ns. ", "original_text": "Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7d1b1a6-4dce-48ac-9654-cc5f40c9970c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, operator.  Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "357ac8dcc59391ffa700368d935a40d911a5ba6e7e895de9f57e7c8b9a1dc5c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07533d6d-b587-4c20-8789-b9defb73b1ab", "node_type": "1", "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptio ns. ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n"}, "hash": "2c56522ffd65c3a03c94f321a850a7aa219fbbd4c57b6cdb1ad517b86a8f2a71", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "start_char_idx": 2478, "end_char_idx": 2606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07533d6d-b587-4c20-8789-b9defb73b1ab": {"__data__": {"id_": "07533d6d-b587-4c20-8789-b9defb73b1ab", "embedding": null, "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptio ns. ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2717e0fc-cd94-44a0-ad67-b17d46547955", "node_type": "1", "metadata": {"window": "Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2022 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptio ns. ", "original_text": "Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "265d01dd38c40f103f9e5e8132d97fb00646a43a6fba1cd9a556c316ede41964", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b8e8fd6-d29a-4d4d-8f57-f95654ef8cdc", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptio ns. ", "original_text": "Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides. "}, "hash": "ffe229b3d1e18c597bf70afd8696a8d24b0fa2ea14a5af38992b19c5e8ab762e", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "start_char_idx": 2606, "end_char_idx": 2974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b8e8fd6-d29a-4d4d-8f57-f95654ef8cdc": {"__data__": {"id_": "3b8e8fd6-d29a-4d4d-8f57-f95654ef8cdc", "embedding": null, "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptio ns. ", "original_text": "Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07533d6d-b587-4c20-8789-b9defb73b1ab", "node_type": "1", "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptio ns. ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4185a6fbd7b3c6cadd595510d3f92b0e264406efbcc0151288285011a178163", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d888966-792e-440d-ba47-ec3143ae25fc", "node_type": "1", "metadata": {"window": "Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptio ns. ", "original_text": "The presentation slides also include a summary of our results for the quarter and guidance assumptio ns. "}, "hash": "b69e2ccfcf7d831c8cbdc47a05db1ef191240a3957611c7080cb38db516646b7", "class_name": "RelatedNodeInfo"}}, "text": "Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides. ", "start_char_idx": 2974, "end_char_idx": 3194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d888966-792e-440d-ba47-ec3143ae25fc": {"__data__": {"id_": "8d888966-792e-440d-ba47-ec3143ae25fc", "embedding": null, "metadata": {"window": "Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptio ns. ", "original_text": "The presentation slides also include a summary of our results for the quarter and guidance assumptio ns. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a08a76fc1e860e5b8bb0703cfb67e5a1a1e0721dade60cf9e5b70cb560c8eea2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b8e8fd6-d29a-4d4d-8f57-f95654ef8cdc", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptio ns. ", "original_text": "Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf608322bf7266f8621c4622cf7c1389b6d06512699597158c9a362e2e942682", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c1db801-9393-456f-8b74-c581df4d1279", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody. ", "original_text": "McKesson Corp.  "}, "hash": "90f36ea2f4e4d770f3f6096227378ea1de6f184f6b42bb34b2e02869793e726d", "class_name": "RelatedNodeInfo"}}, "text": "The presentation slides also include a summary of our results for the quarter and guidance assumptio ns. ", "start_char_idx": 3194, "end_char_idx": 3299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c1db801-9393-456f-8b74-c581df4d1279": {"__data__": {"id_": "4c1db801-9393-456f-8b74-c581df4d1279", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d888966-792e-440d-ba47-ec3143ae25fc", "node_type": "1", "metadata": {"window": "Today's discussion will include f orward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com, and to the Risk Fac tors section of our periodic SEC filings for \nadditional information concerning risk factors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will d iscuss during this webcast, including a \nreconciliation of those measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and guidance assumptio ns. ", "original_text": "The presentation slides also include a summary of our results for the quarter and guidance assumptio ns. ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ce805ed0c4ad7a8931d0ab1bb5c0299feb4e04b8bb4792db1948be7481b3813", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5fac8b6-b329-4b53-b0b4-4257bdb18c9c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n "}, "hash": "7d7e598966017807d6d0b0dc61716a022a3462a3e323063eea2cefceb59f8f65", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5fac8b6-b329-4b53-b0b4-4257bdb18c9c": {"__data__": {"id_": "e5fac8b6-b329-4b53-b0b4-4257bdb18c9c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c1db801-9393-456f-8b74-c581df4d1279", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e75f5a0037a68cbfc261a30fc3fe050e7b14ecc9ed140a485a20dd9fe329c97e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5e885aa-2a4d-48fe-8134-047337be6f73", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "f648310cfeb294b2882f65ef6bfffc35a8d61e9a54ccf9299582525c6b2b97cf", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n ", "start_char_idx": 16, "end_char_idx": 226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5e885aa-2a4d-48fe-8134-047337be6f73": {"__data__": {"id_": "e5e885aa-2a4d-48fe-8134-047337be6f73", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5fac8b6-b329-4b53-b0b4-4257bdb18c9c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af1a8db74b8babcd7d6a11310619259bdf4700858a3ffeded8bbb637a785374c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "082d9b25-2b05-42e4-abf9-58d197abf50a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments. ", "original_text": "Thank you, Rachel, and good afternoon, everybody. "}, "hash": "8a082e500a54ec23d3ded3570c287001cc13ca6f6dab501a181cb63d5b473d5f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 226, "end_char_idx": 568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "082d9b25-2b05-42e4-abf9-58d197abf50a": {"__data__": {"id_": "082d9b25-2b05-42e4-abf9-58d197abf50a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments. ", "original_text": "Thank you, Rachel, and good afternoon, everybody. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5e885aa-2a4d-48fe-8134-047337be6f73", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "071fff5bf2e796a3cd3f2ae2436713410293de6d00ce3906951fd5afbc6fc816", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5614a1b-4f45-4307-bec8-bce3d7e827a0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise. ", "original_text": "Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022. "}, "hash": "3025f7adee4740637528bdce30cdfd832f320df7905ea22beee8c674a3322530", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Rachel, and good afternoon, everybody. ", "start_char_idx": 568, "end_char_idx": 618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5614a1b-4f45-4307-bec8-bce3d7e827a0": {"__data__": {"id_": "e5614a1b-4f45-4307-bec8-bce3d7e827a0", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise. ", "original_text": "Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "082d9b25-2b05-42e4-abf9-58d197abf50a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments. ", "original_text": "Thank you, Rachel, and good afternoon, everybody. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "abae596015cc0d878e9219ce31414abd3c927c422005af87da51308555f1e2bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d0caadb-bdd7-4177-9d6c-51715ebc48f5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services. ", "original_text": "Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n"}, "hash": "3a4c1bc1725bce574a8889f42f1f986e6c40b71db5f04108c2cecf2abfd0a5da", "class_name": "RelatedNodeInfo"}}, "text": "Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022. ", "start_char_idx": 618, "end_char_idx": 718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d0caadb-bdd7-4177-9d6c-51715ebc48f5": {"__data__": {"id_": "2d0caadb-bdd7-4177-9d6c-51715ebc48f5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services. ", "original_text": "Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5614a1b-4f45-4307-bec8-bce3d7e827a0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise. ", "original_text": "Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "178eb8f8bce2094d2a306d7985d578c391d03327fb9114af5fc84547be4e4a3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7bd429c-c3cf-4e77-9900-2dffff7e5653", "node_type": "1", "metadata": {"window": "Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation. ", "original_text": "We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments. "}, "hash": "dfcdc53352aad7a0768d1ef1efcbfd01f1f751e449afa06869eda33180bad645", "class_name": "RelatedNodeInfo"}}, "text": "Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n", "start_char_idx": 718, "end_char_idx": 925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7bd429c-c3cf-4e77-9900-2dffff7e5653": {"__data__": {"id_": "b7bd429c-c3cf-4e77-9900-2dffff7e5653", "embedding": null, "metadata": {"window": "Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation. ", "original_text": "We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d0caadb-bdd7-4177-9d6c-51715ebc48f5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services. ", "original_text": "Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa38c4c72027f49919d1e66bfeab4200c341a1bf62c2f0ecf8e9aa4135da5e5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4047de3-01ca-422d-801f-1b29462e3660", "node_type": "1", "metadata": {"window": "Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n", "original_text": "We have good \nmomentum across the enterprise. "}, "hash": "ee865dafff039f71326a5a29c6983c4ac6ffdc5739358031e5549a40ab34df08", "class_name": "RelatedNodeInfo"}}, "text": "We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments. ", "start_char_idx": 925, "end_char_idx": 1126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4047de3-01ca-422d-801f-1b29462e3660": {"__data__": {"id_": "c4047de3-01ca-422d-801f-1b29462e3660", "embedding": null, "metadata": {"window": "Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n", "original_text": "We have good \nmomentum across the enterprise. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7bd429c-c3cf-4e77-9900-2dffff7e5653", "node_type": "1", "metadata": {"window": "Thank you, Rachel, and good afternoon, everybody.  Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation. ", "original_text": "We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf2d9cb6744a7e5af659c20b9e45396253777774d9e135e72080631785d29836", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "357fa8f7-5cc4-425d-ab54-0fe77a68c821", "node_type": "1", "metadata": {"window": "Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation. ", "original_text": "We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services. "}, "hash": "a6c9b869bf7bff43622d6e3cb5fbed6443a7f5a37156f0bddbc0871e677065eb", "class_name": "RelatedNodeInfo"}}, "text": "We have good \nmomentum across the enterprise. ", "start_char_idx": 1126, "end_char_idx": 1172, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "357fa8f7-5cc4-425d-ab54-0fe77a68c821": {"__data__": {"id_": "357fa8f7-5cc4-425d-ab54-0fe77a68c821", "embedding": null, "metadata": {"window": "Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation. ", "original_text": "We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4047de3-01ca-422d-801f-1b29462e3660", "node_type": "1", "metadata": {"window": "Today, we announced our fourth quarter results, marking a \nsolid finish to our strong fiscal  2022.  Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n", "original_text": "We have good \nmomentum across the enterprise. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01be8a711cd1fed81aaecea5944aa191076aa3340889cac3e586061c07ad3629", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97818f61-bd83-451a-b046-2ef5f2071b0b", "node_type": "1", "metadata": {"window": "We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement. ", "original_text": "We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation. "}, "hash": "755d63c7c203bfa4754e77ec4e63e6985c0204e2588e6cb6df741e599ad67104", "class_name": "RelatedNodeInfo"}}, "text": "We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services. ", "start_char_idx": 1172, "end_char_idx": 1293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97818f61-bd83-451a-b046-2ef5f2071b0b": {"__data__": {"id_": "97818f61-bd83-451a-b046-2ef5f2071b0b", "embedding": null, "metadata": {"window": "We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement. ", "original_text": "We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "357fa8f7-5cc4-425d-ab54-0fe77a68c821", "node_type": "1", "metadata": {"window": "Thanks to the dedication and excellent execution from Team McKesson, we \nmade outstanding progress against our company priorities and in our transformation to a diversified healthcare \nservices company.  \n \n We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation. ", "original_text": "We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06f36e90ec7f9aa078d2e7ee96beffa073506e353c9e1f08744e5aa773c46c40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f8e2e4f-d023-4cd7-bb2a-04fcba40deab", "node_type": "1", "metadata": {"window": "We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n", "original_text": "My remarks today will be centered around \nthese themes.  \n \n"}, "hash": "39e5a1a637e2646e533f1e7cfca082ca134c623c590f5fd13128d7ec05df297b", "class_name": "RelatedNodeInfo"}}, "text": "We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation. ", "start_char_idx": 1293, "end_char_idx": 1431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f8e2e4f-d023-4cd7-bb2a-04fcba40deab": {"__data__": {"id_": "4f8e2e4f-d023-4cd7-bb2a-04fcba40deab", "embedding": null, "metadata": {"window": "We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n", "original_text": "My remarks today will be centered around \nthese themes.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97818f61-bd83-451a-b046-2ef5f2071b0b", "node_type": "1", "metadata": {"window": "We achieved 31% growth in adjusted earnings per  diluted share when excluding the impacts attributable to \nCOVID -19 related items, and net gains associated with McKesson Ventures' equity investments.  We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement. ", "original_text": "We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8fe1cd479a958f16922ceda7398f36784122d6c34ae585345b723018521f77f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ef94ccf-d797-4fc9-9eea-c3cced54c926", "node_type": "1", "metadata": {"window": "We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities. ", "original_text": "Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation. "}, "hash": "ab900e35c284c1660e80d47497b62040a37dcfb64a9165de3effe2f3cca5cf1c", "class_name": "RelatedNodeInfo"}}, "text": "My remarks today will be centered around \nthese themes.  \n \n", "start_char_idx": 1431, "end_char_idx": 1491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ef94ccf-d797-4fc9-9eea-c3cced54c926": {"__data__": {"id_": "3ef94ccf-d797-4fc9-9eea-c3cced54c926", "embedding": null, "metadata": {"window": "We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities. ", "original_text": "Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f8e2e4f-d023-4cd7-bb2a-04fcba40deab", "node_type": "1", "metadata": {"window": "We have good \nmomentum across the enterprise.  We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n", "original_text": "My remarks today will be centered around \nthese themes.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "437793672c6b6ee005549ece5802d94a479de5b928e04a592ae4d62cadf2b312", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ecd5abe-c37a-44d8-a668-4caf27f7664d", "node_type": "1", "metadata": {"window": "We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years. ", "original_text": "In \nFebruary, we announced the approval of the proposed opioid settlement agreement. "}, "hash": "5c7d24d6e6e7f697a5ebe69dbc1db5f7a1eb06732e60c796af8295f9078a4e3d", "class_name": "RelatedNodeInfo"}}, "text": "Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation. ", "start_char_idx": 1491, "end_char_idx": 1609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ecd5abe-c37a-44d8-a668-4caf27f7664d": {"__data__": {"id_": "8ecd5abe-c37a-44d8-a668-4caf27f7664d", "embedding": null, "metadata": {"window": "We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years. ", "original_text": "In \nFebruary, we announced the approval of the proposed opioid settlement agreement. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ef94ccf-d797-4fc9-9eea-c3cced54c926", "node_type": "1", "metadata": {"window": "We saw strength in our core distribution business and our st rategic growth \npillars of oncology and biopharma services.  We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities. ", "original_text": "Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b456e762d3af3596597813880a7be903ef6ada49c731195c1b4fff03b4ee854", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5753debf-d048-4bec-939a-a3953bbd8cd6", "node_type": "1", "metadata": {"window": "My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2. ", "original_text": "46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n"}, "hash": "14f21ff2f43247a9d5b8b6a2ccc68596b3bcaa681924e52566eee8e059f79339", "class_name": "RelatedNodeInfo"}}, "text": "In \nFebruary, we announced the approval of the proposed opioid settlement agreement. ", "start_char_idx": 1609, "end_char_idx": 1694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5753debf-d048-4bec-939a-a3953bbd8cd6": {"__data__": {"id_": "5753debf-d048-4bec-939a-a3953bbd8cd6", "embedding": null, "metadata": {"window": "My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2. ", "original_text": "46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ecd5abe-c37a-44d8-a668-4caf27f7664d", "node_type": "1", "metadata": {"window": "We remain focused on the company priorities, which are foundational \nto our sustainable long -term growth and shareholder value creation.  My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years. ", "original_text": "In \nFebruary, we announced the approval of the proposed opioid settlement agreement. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7c2f779d153504f182fdf89649d8943213836819248a043d6d6d3254ac18126", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae74e046-4632-4aff-a06a-af08e6f0cc8e", "node_type": "1", "metadata": {"window": "Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n", "original_text": "The resolution delivers much needed relief for the impacted communities. "}, "hash": "8ef85e2356f36c43c43c93b414da74205217c0f390beec3019d74e3085a5ac26", "class_name": "RelatedNodeInfo"}}, "text": "46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n", "start_char_idx": 1694, "end_char_idx": 1977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae74e046-4632-4aff-a06a-af08e6f0cc8e": {"__data__": {"id_": "ae74e046-4632-4aff-a06a-af08e6f0cc8e", "embedding": null, "metadata": {"window": "Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n", "original_text": "The resolution delivers much needed relief for the impacted communities. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5753debf-d048-4bec-939a-a3953bbd8cd6", "node_type": "1", "metadata": {"window": "My remarks today will be centered around \nthese themes.  \n \n Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2. ", "original_text": "46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72602b82327b6a206f820a4b125edef4a07a5cfdb3dc897a3f5e9371b5ea1d57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2502a652-a707-4995-9e43-aa0474e3b394", "node_type": "1", "metadata": {"window": "In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions. ", "original_text": "It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years. "}, "hash": "7a89055a2bb3fa13f06919b450030244ebab4b0e9d7c391dbf85208db6159579", "class_name": "RelatedNodeInfo"}}, "text": "The resolution delivers much needed relief for the impacted communities. ", "start_char_idx": 1977, "end_char_idx": 2050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2502a652-a707-4995-9e43-aa0474e3b394": {"__data__": {"id_": "2502a652-a707-4995-9e43-aa0474e3b394", "embedding": null, "metadata": {"window": "In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions. ", "original_text": "It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae74e046-4632-4aff-a06a-af08e6f0cc8e", "node_type": "1", "metadata": {"window": "Befor e I jump into company priorities, I do want to talk briefly about the recent developments in opioid litigation.  In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n", "original_text": "The resolution delivers much needed relief for the impacted communities. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "033e91b0d038a1ff4c3b4294a016c7dcc69cfb3d3ddddf6b458ace15f7b52d01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d06dfa6-7550-48b8-b0f9-7fe2f378e08d", "node_type": "1", "metadata": {"window": "46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs. ", "original_text": "The agreement became \neffective on April 2. "}, "hash": "ef39f9aa96d6531188a0b71401cd86523eb624be974af980baf54692afc4dde1", "class_name": "RelatedNodeInfo"}}, "text": "It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years. ", "start_char_idx": 2050, "end_char_idx": 2173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d06dfa6-7550-48b8-b0f9-7fe2f378e08d": {"__data__": {"id_": "6d06dfa6-7550-48b8-b0f9-7fe2f378e08d", "embedding": null, "metadata": {"window": "46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs. ", "original_text": "The agreement became \neffective on April 2. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2502a652-a707-4995-9e43-aa0474e3b394", "node_type": "1", "metadata": {"window": "In \nFebruary, we announced the approval of the proposed opioid settlement agreement.  46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions. ", "original_text": "It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6dfbc2ba036ff08566397f060c07d95a2dd0547911cdd3ea90b6c6f7184aed21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40525deb-909c-401b-a150-e56826d05f62", "node_type": "1", "metadata": {"window": "The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions. ", "original_text": "The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n"}, "hash": "c364c2ef88d07abd0c67c686732fc81717c063ce997a3adc19b68bf225a82917", "class_name": "RelatedNodeInfo"}}, "text": "The agreement became \neffective on April 2. ", "start_char_idx": 2173, "end_char_idx": 2217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40525deb-909c-401b-a150-e56826d05f62": {"__data__": {"id_": "40525deb-909c-401b-a150-e56826d05f62", "embedding": null, "metadata": {"window": "The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions. ", "original_text": "The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d06dfa6-7550-48b8-b0f9-7fe2f378e08d", "node_type": "1", "metadata": {"window": "46 of the 49 eligible states \nand the District of Columbia an d all eligible territories joined the settlement, representing more than 98% of the \neligible political subdivisions that have brought opioid related suits against us as calculated by population under \nthe agreement.  \n \n The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs. ", "original_text": "The agreement became \neffective on April 2. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f017176988339692e19d03da65a2ea7ee868d17d16d0b1f41b1ffdf974dc3d38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "193f0654-cc72-437a-81b6-2511473c7985", "node_type": "1", "metadata": {"window": "It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution. ", "original_text": "In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions. "}, "hash": "55e8fbf5d4c2b7ba5021fd98c18913c638568c7aa1e66dc6e441c485c66b185e", "class_name": "RelatedNodeInfo"}}, "text": "The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n", "start_char_idx": 2217, "end_char_idx": 2445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "193f0654-cc72-437a-81b6-2511473c7985": {"__data__": {"id_": "193f0654-cc72-437a-81b6-2511473c7985", "embedding": null, "metadata": {"window": "It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution. ", "original_text": "In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40525deb-909c-401b-a150-e56826d05f62", "node_type": "1", "metadata": {"window": "The resolution delivers much needed relief for the impacted communities.  It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions. ", "original_text": "The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d729d9ae9e3eb515c19f319af61056b9e199145929c7c961d152d12b6dc34c18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb66e65c-9049-414f-b0ad-858d12bf857f", "node_type": "1", "metadata": {"window": "The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n", "original_text": "On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs. "}, "hash": "aad8eddeafc1f6700dd48199f8910342c2d39b0bea749f92c5af04ce0bc1a475", "class_name": "RelatedNodeInfo"}}, "text": "In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions. ", "start_char_idx": 2445, "end_char_idx": 2772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb66e65c-9049-414f-b0ad-858d12bf857f": {"__data__": {"id_": "fb66e65c-9049-414f-b0ad-858d12bf857f", "embedding": null, "metadata": {"window": "The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n", "original_text": "On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "193f0654-cc72-437a-81b6-2511473c7985", "node_type": "1", "metadata": {"window": "It will collectively provide thousands of \ncommunities across the United States approximately $19.5 billion over 18 years.  The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution. ", "original_text": "In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ac98dfc2950beec75255761ea59c3cd456b93f93a76e3c6336618704ee3065d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d95f2a1a-0ad7-4719-a24b-138c11bf1f8d", "node_type": "1", "metadata": {"window": "The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022. ", "original_text": "This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions. "}, "hash": "6f6444ce467dfd2a6112378479749050acb25fcff1608f17c514aecfd2c5296a", "class_name": "RelatedNodeInfo"}}, "text": "On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs. ", "start_char_idx": 2772, "end_char_idx": 3058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d95f2a1a-0ad7-4719-a24b-138c11bf1f8d": {"__data__": {"id_": "d95f2a1a-0ad7-4719-a24b-138c11bf1f8d", "embedding": null, "metadata": {"window": "The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022. ", "original_text": "This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb66e65c-9049-414f-b0ad-858d12bf857f", "node_type": "1", "metadata": {"window": "The agreement became \neffective on April 2.  The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n", "original_text": "On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05b4937703849d952df3a2549b5e5779503191e30518de93481d8727de748c14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afec1a3b-f4ed-4e6d-a800-d2fd0b919a12", "node_type": "1", "metadata": {"window": "In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022.  We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization. ", "original_text": "That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution. "}, "hash": "294a8dffe9f2474d43ae2d637e7a4984c2e3608e6f3dd341aee6c6a8ff0c6670", "class_name": "RelatedNodeInfo"}}, "text": "This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions. ", "start_char_idx": 3058, "end_char_idx": 3165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afec1a3b-f4ed-4e6d-a800-d2fd0b919a12": {"__data__": {"id_": "afec1a3b-f4ed-4e6d-a800-d2fd0b919a12", "embedding": null, "metadata": {"window": "In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022.  We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization. ", "original_text": "That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d95f2a1a-0ad7-4719-a24b-138c11bf1f8d", "node_type": "1", "metadata": {"window": "The approval of the settlement agreement also removed a significant portion of operational \nand financial uncertainty in the business, allowing us to redirect resources for more focused execution on our \ncompany strategies.  \n \n In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022. ", "original_text": "This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e55669c4dfeaaa3e18354c1a3dc2bb4314acabad6eb3634e7b1c4d73fcd8a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40f643db-d67a-4ff0-b2cc-0f79f73306db", "node_type": "1", "metadata": {"window": "On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022.  We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization.  After \nour fiscal 2022 discussion, I'll walk you through each of the operating segments and lay out how they are \npositioned for growth, as we head into fiscal 2023.  \n ", "original_text": "This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n"}, "hash": "61ef19bc5f262381eb958fb4e764e2b89cf3a10163b91819d510d89ab472b65a", "class_name": "RelatedNodeInfo"}}, "text": "That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution. ", "start_char_idx": 3165, "end_char_idx": 3529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40f643db-d67a-4ff0-b2cc-0f79f73306db": {"__data__": {"id_": "40f643db-d67a-4ff0-b2cc-0f79f73306db", "embedding": null, "metadata": {"window": "On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022.  We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization.  After \nour fiscal 2022 discussion, I'll walk you through each of the operating segments and lay out how they are \npositioned for growth, as we head into fiscal 2023.  \n ", "original_text": "This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afec1a3b-f4ed-4e6d-a800-d2fd0b919a12", "node_type": "1", "metadata": {"window": "In addition to the 46 states participating in the previously announced agreement, on Ap ril 4, an agreement was \nreached in the Alabama matter, in which McKesson will pay $141 million and an additional $33 million in \nattorneys' fees and costs to resolve the opioid related claims of the State of Alabama and its subdivisions.  On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022.  We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization. ", "original_text": "That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b60d60a8d5c46199da3808d75d22523ec484ed4e19ed8268baa0c5d2654689e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b336b42-e38f-48c5-8185-617cd53850c1", "node_type": "1", "metadata": {"window": "This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022.  We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization.  After \nour fiscal 2022 discussion, I'll walk you through each of the operating segments and lay out how they are \npositioned for growth, as we head into fiscal 2023.  \n ", "original_text": "Let me now take you through our company priorities and the progress we made in fiscal 2022. "}, "hash": "4d2ff6e75214ff942f04658132a38cbac23c3506cb8a2fb9038b6a3ec1171de9", "class_name": "RelatedNodeInfo"}}, "text": "This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n", "start_char_idx": 3529, "end_char_idx": 3668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b336b42-e38f-48c5-8185-617cd53850c1": {"__data__": {"id_": "0b336b42-e38f-48c5-8185-617cd53850c1", "embedding": null, "metadata": {"window": "This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022.  We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization.  After \nour fiscal 2022 discussion, I'll walk you through each of the operating segments and lay out how they are \npositioned for growth, as we head into fiscal 2023.  \n ", "original_text": "Let me now take you through our company priorities and the progress we made in fiscal 2022. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40f643db-d67a-4ff0-b2cc-0f79f73306db", "node_type": "1", "metadata": {"window": "On \nMay 3, an agreem ent was also reached in the Washington matter, in which McKesson will pay $197 million, \nconsistent with the State of Washington's allocation under the previously announced comprehensive settlement \nframework, as well as certain additional attorney fees and costs.  This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022.  We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization.  After \nour fiscal 2022 discussion, I'll walk you through each of the operating segments and lay out how they are \npositioned for growth, as we head into fiscal 2023.  \n ", "original_text": "This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7f65fe6ae002f5cf4180a6e7dba7a5fdec94f89b79d371b344d922a4acf71e6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b9a6dd2-b1f8-4463-8c32-c7e06eb62816", "node_type": "1", "metadata": {"window": "That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022.  We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization.  After \nour fiscal 2022 discussion, I'll walk you through each of the operating segments and lay out how they are \npositioned for growth, as we head into fiscal 2023.  \n ", "original_text": "We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization. "}, "hash": "80d101efaff9fdd66112e8bdd04fcedaf51a741d7b9863036613631969e0cf57", "class_name": "RelatedNodeInfo"}}, "text": "Let me now take you through our company priorities and the progress we made in fiscal 2022. ", "start_char_idx": 3668, "end_char_idx": 3760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b9a6dd2-b1f8-4463-8c32-c7e06eb62816": {"__data__": {"id_": "6b9a6dd2-b1f8-4463-8c32-c7e06eb62816", "embedding": null, "metadata": {"window": "That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022.  We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization.  After \nour fiscal 2022 discussion, I'll walk you through each of the operating segments and lay out how they are \npositioned for growth, as we head into fiscal 2023.  \n ", "original_text": "We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b336b42-e38f-48c5-8185-617cd53850c1", "node_type": "1", "metadata": {"window": "This resolution will result in the settlement of the \nState of Washington and its litigating subdivisions.  That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022.  We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization.  After \nour fiscal 2022 discussion, I'll walk you through each of the operating segments and lay out how they are \npositioned for growth, as we head into fiscal 2023.  \n ", "original_text": "Let me now take you through our company priorities and the progress we made in fiscal 2022. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d70c96c548803e00fd5f5e7fd249c230031f0756fd7443594705ec1bf5199f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "174c494e-f0b3-4bbb-93ee-6597f3b31dc9", "node_type": "1", "metadata": {"window": "This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022.  We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization.  After \nour fiscal 2022 discussion, I'll walk you through each of the operating segments and lay out how they are \npositioned for growth, as we head into fiscal 2023.  \n ", "original_text": "After \nour fiscal 2022 discussion, I'll walk you through each of the operating segments and lay out how they are \npositioned for growth, as we head into fiscal 2023.  \n "}, "hash": "acdeb19ad684e2c5fabce01254914abe73a8a678e2f95c0e4a4fe4cb935f1dea", "class_name": "RelatedNodeInfo"}}, "text": "We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization. ", "start_char_idx": 3760, "end_char_idx": 3888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "174c494e-f0b3-4bbb-93ee-6597f3b31dc9": {"__data__": {"id_": "174c494e-f0b3-4bbb-93ee-6597f3b31dc9", "embedding": null, "metadata": {"window": "This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022.  We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization.  After \nour fiscal 2022 discussion, I'll walk you through each of the operating segments and lay out how they are \npositioned for growth, as we head into fiscal 2023.  \n ", "original_text": "After \nour fiscal 2022 discussion, I'll walk you through each of the operating segments and lay out how they are \npositioned for growth, as we head into fiscal 2023.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8d074d81-1bd7-425e-811e-44bde442548f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd7e5c09e2c8e54be5f0f348f7abca3ca4759dbb3495537e3d253237d5e8549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b9a6dd2-b1f8-4463-8c32-c7e06eb62816", "node_type": "1", "metadata": {"window": "That will bring the total number of states settling opioid -related \nclaims with McKesson to 48 of 49 eligible states and the District of Columbi a. \n \nAs a company, we remain deeply concerned about the impact the opioid epidemic is having on individuals, on \nfamilies and communities across the nation, and we continue to be committed to be part of the solution.  This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022.  We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization.  After \nour fiscal 2022 discussion, I'll walk you through each of the operating segments and lay out how they are \npositioned for growth, as we head into fiscal 2023.  \n ", "original_text": "We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization. ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62d1f1ef54948059b53fded8bd5f28afa4ae6efb2c82d560f5309fea05ab21bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58fda9e2-dc1a-4e28-a0c6-e8fd841ab362", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding.  We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "cc7821b4b751d568f0f44d2aa04f34e7750d3a32695bf4da770d64a704d93d32", "class_name": "RelatedNodeInfo"}}, "text": "After \nour fiscal 2022 discussion, I'll walk you through each of the operating segments and lay out how they are \npositioned for growth, as we head into fiscal 2023.  \n ", "start_char_idx": 3888, "end_char_idx": 4057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58fda9e2-dc1a-4e28-a0c6-e8fd841ab362": {"__data__": {"id_": "58fda9e2-dc1a-4e28-a0c6-e8fd841ab362", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding.  We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "174c494e-f0b3-4bbb-93ee-6597f3b31dc9", "node_type": "1", "metadata": {"window": "This \nincludes our controlled substance mo nitoring program, advanced customer purchasing analytics and many, many \nother initiatives.  \n \n Let me now take you through our company priorities and the progress we made in fiscal 2022.  We are excited \nabout these initiatives, as we continue to deliver strong  results and improve our strength as an organization.  After \nour fiscal 2022 discussion, I'll walk you through each of the operating segments and lay out how they are \npositioned for growth, as we head into fiscal 2023.  \n ", "original_text": "After \nour fiscal 2022 discussion, I'll walk you through each of the operating segments and lay out how they are \npositioned for growth, as we head into fiscal 2023.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f9adabbeb7de0078ab8f4f445353d5ae0fde22fbd3cff525998ef0e312a5127", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6dd38de-ac47-48d7-b352-e66a29fd0be1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding.  We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding. "}, "hash": "8137964e6d98d9b47886ec2b253cc02a9e682ce32860cc0dbd01874eabc8fa25", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6dd38de-ac47-48d7-b352-e66a29fd0be1": {"__data__": {"id_": "a6dd38de-ac47-48d7-b352-e66a29fd0be1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding.  We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58fda9e2-dc1a-4e28-a0c6-e8fd841ab362", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding.  We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9367fc8a45d62756444e483a554a3b7278b0b5f401972d84491f5b9f349884cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17d08110-8fa2-4256-8eb3-f84090361c53", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding.  We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years. ", "original_text": "We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business. "}, "hash": "8fb2bcfb44d9d36f069ed8996b98054d1f50f41fe1251bfcf1c7d056a10a67b6", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding. ", "start_char_idx": 16, "end_char_idx": 369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17d08110-8fa2-4256-8eb3-f84090361c53": {"__data__": {"id_": "17d08110-8fa2-4256-8eb3-f84090361c53", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding.  We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years. ", "original_text": "We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6dd38de-ac47-48d7-b352-e66a29fd0be1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding.  We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3fa1cce2710347b8039dcb2fc4fd2ca888c07b748852c19a69e66fc93ae24b42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72d8f633-051b-4ea5-bc44-ee32e466aa25", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding.  We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n", "original_text": "Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n"}, "hash": "8dcd6cda056085fe132045e99504e82d13ea1e40e823daf5c5629416a0902349", "class_name": "RelatedNodeInfo"}}, "text": "We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business. ", "start_char_idx": 369, "end_char_idx": 506, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72d8f633-051b-4ea5-bc44-ee32e466aa25": {"__data__": {"id_": "72d8f633-051b-4ea5-bc44-ee32e466aa25", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding.  We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n", "original_text": "Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17d08110-8fa2-4256-8eb3-f84090361c53", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding.  We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years. ", "original_text": "We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07fb89b23c6afdb17a165f036c5456d843fa0e1fee65c4aa55698aed25359afc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46d06cdb-d344-403a-ae6f-2e8065d5ed94", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding.  We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year. ", "original_text": "Now, let me briefly walk you through the progress on each of them. "}, "hash": "e6e2999c91d3079f5d40d8bc8eeae1c8fee99bf426c2941d25a70e814e3631d6", "class_name": "RelatedNodeInfo"}}, "text": "Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n", "start_char_idx": 506, "end_char_idx": 736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46d06cdb-d344-403a-ae6f-2e8065d5ed94": {"__data__": {"id_": "46d06cdb-d344-403a-ae6f-2e8065d5ed94", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding.  We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year. ", "original_text": "Now, let me briefly walk you through the progress on each of them. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72d8f633-051b-4ea5-bc44-ee32e466aa25", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding.  We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n", "original_text": "Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e2dfe6dbb2d15c59cecf4fdddbead90ac02ffc9857b7c42c6704ddf18daec85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b44256d8-13ca-4538-abbb-e09cd993944f", "node_type": "1", "metadata": {"window": "We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n", "original_text": "I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years. "}, "hash": "b7e3194d1c619b3a882ae521b5c2df75cb16c37bf09c9d014b4d3817ca03e3a2", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me briefly walk you through the progress on each of them. ", "start_char_idx": 736, "end_char_idx": 803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b44256d8-13ca-4538-abbb-e09cd993944f": {"__data__": {"id_": "b44256d8-13ca-4538-abbb-e09cd993944f", "embedding": null, "metadata": {"window": "We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n", "original_text": "I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46d06cdb-d344-403a-ae6f-2e8065d5ed94", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding.  We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year. ", "original_text": "Now, let me briefly walk you through the progress on each of them. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7774481e478d39ce8befbaa93828801e9bbeb8acc2a42c745ee3788da484fc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07c48158-25ac-4f58-91af-560e0fb63e7b", "node_type": "1", "metadata": {"window": "Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way. ", "original_text": "We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n"}, "hash": "5f776ef768b57931e053a798fb1bede81236f5a581488d35151b8e6b192557ca", "class_name": "RelatedNodeInfo"}}, "text": "I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years. ", "start_char_idx": 803, "end_char_idx": 1060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07c48158-25ac-4f58-91af-560e0fb63e7b": {"__data__": {"id_": "07c48158-25ac-4f58-91af-560e0fb63e7b", "embedding": null, "metadata": {"window": "Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way. ", "original_text": "We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b44256d8-13ca-4538-abbb-e09cd993944f", "node_type": "1", "metadata": {"window": "We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n", "original_text": "I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e4339ac5ca5099071dfb233acd489dfbabbf3d618cadc48f63c6fc2e8b91e91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a84597eb-df79-431a-b8db-0546684b499a", "node_type": "1", "metadata": {"window": "Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve. ", "original_text": "In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year. "}, "hash": "4b29dfa88fe432b54a4b93430ff9938b4783997cc8db42fbeb59cc30742fadf5", "class_name": "RelatedNodeInfo"}}, "text": "We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n", "start_char_idx": 1060, "end_char_idx": 1198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a84597eb-df79-431a-b8db-0546684b499a": {"__data__": {"id_": "a84597eb-df79-431a-b8db-0546684b499a", "embedding": null, "metadata": {"window": "Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve. ", "original_text": "In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07c48158-25ac-4f58-91af-560e0fb63e7b", "node_type": "1", "metadata": {"window": "Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way. ", "original_text": "We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bd05f2f527a6b80c6bd085f38ccdf94174c7f09ae9ade1b192a7a1827ef1415", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91a3cca3-8889-4e7c-954b-e29be15699f8", "node_type": "1", "metadata": {"window": "I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n", "original_text": "Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n"}, "hash": "56d2245b0409207f69ba5879763138a5ca206316175da0f083e64acb6b1c7bfe", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year. ", "start_char_idx": 1198, "end_char_idx": 1415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91a3cca3-8889-4e7c-954b-e29be15699f8": {"__data__": {"id_": "91a3cca3-8889-4e7c-954b-e29be15699f8", "embedding": null, "metadata": {"window": "I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n", "original_text": "Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a84597eb-df79-431a-b8db-0546684b499a", "node_type": "1", "metadata": {"window": "Now, let me briefly walk you through the progress on each of them.  I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve. ", "original_text": "In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca4ad2d79316ce8475c0c7d4d0b977578355dcf91e43f1e2241e091d43087b6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68973b4c-b39d-4e9e-a4f3-71a4a6eb17c0", "node_type": "1", "metadata": {"window": "We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks. ", "original_text": "Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way. "}, "hash": "e79e3e73a451205e5374b6b78c6f4f6f9819a674657f526c152c6b02c38fd1f7", "class_name": "RelatedNodeInfo"}}, "text": "Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n", "start_char_idx": 1415, "end_char_idx": 1551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68973b4c-b39d-4e9e-a4f3-71a4a6eb17c0": {"__data__": {"id_": "68973b4c-b39d-4e9e-a4f3-71a4a6eb17c0", "embedding": null, "metadata": {"window": "We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks. ", "original_text": "Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91a3cca3-8889-4e7c-954b-e29be15699f8", "node_type": "1", "metadata": {"window": "I'll start with our first priority, which is our \nfocus on people and culture, our ICARE values, our enterprise -first mindset and our commitment to Team \nMcKesson, our commitment to each other,  were critical to successfully navigating the last few years.  We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n", "original_text": "Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8f764552ce67f4dc85491890bf28d4017138c2cac5ec941ae1fdb4f72a84464", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c485067f-8878-4e7c-a878-deadce5cffa1", "node_type": "1", "metadata": {"window": "In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities. ", "original_text": "As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve. "}, "hash": "54a8a1e3997e9c21df5e8672353e13b98ab29d6af9bd43de2293a644ed0f0191", "class_name": "RelatedNodeInfo"}}, "text": "Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way. ", "start_char_idx": 1551, "end_char_idx": 1716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c485067f-8878-4e7c-a878-deadce5cffa1": {"__data__": {"id_": "c485067f-8878-4e7c-a878-deadce5cffa1", "embedding": null, "metadata": {"window": "In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities. ", "original_text": "As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68973b4c-b39d-4e9e-a4f3-71a4a6eb17c0", "node_type": "1", "metadata": {"window": "We are \ncommitted to being the best place to work in healthcare, and our best talent strategy is accelerating our business \nmomentum.  \n \n In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks. ", "original_text": "Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d151c41cdc17cae079712e0f77e81eb02d6f72131f42856e2b8addaf47c0c921", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "638ab611-bcb1-4007-a4fd-06d337f0be6a", "node_type": "1", "metadata": {"window": "Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n", "original_text": "Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n"}, "hash": "c64b0da14cce971036a03685450a5ad589c1d908ad571d821efebbf90325e18a", "class_name": "RelatedNodeInfo"}}, "text": "As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve. ", "start_char_idx": 1716, "end_char_idx": 1837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "638ab611-bcb1-4007-a4fd-06d337f0be6a": {"__data__": {"id_": "638ab611-bcb1-4007-a4fd-06d337f0be6a", "embedding": null, "metadata": {"window": "Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n", "original_text": "Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c485067f-8878-4e7c-a878-deadce5cffa1", "node_type": "1", "metadata": {"window": "In fiscal 2022, we made investments in our workforce includin g the frontline workers through additional labor \ninvestments in the US Pharmaceutical and Medical -Surgical segments in the back half of our fiscal year.  Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities. ", "original_text": "As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7290b065c1699e5b1418cd403a7a97b52ca2f5cb86dca6913d9fce2bc9e00d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fabb066-fe80-45a0-86b3-7c25f5d00c47", "node_type": "1", "metadata": {"window": "Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment. ", "original_text": "To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks. "}, "hash": "ce746c0387bde30d174e1c16d1cc671266473d882fe84de17e90bfcdfb5a629d", "class_name": "RelatedNodeInfo"}}, "text": "Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n", "start_char_idx": 1837, "end_char_idx": 1991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fabb066-fe80-45a0-86b3-7c25f5d00c47": {"__data__": {"id_": "1fabb066-fe80-45a0-86b3-7c25f5d00c47", "embedding": null, "metadata": {"window": "Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment. ", "original_text": "To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "638ab611-bcb1-4007-a4fd-06d337f0be6a", "node_type": "1", "metadata": {"window": "Our \ncompany culture, our purpose, our mission and the investments we've made in our teams underpin our \nperformance as a business.  \n \n Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n", "original_text": "Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5fa0c0c08a6167f4d78b937697d4dcc23d49a28094dbd7d50987e8c0cf22b61a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4caa1008-b2cb-45fc-9645-d40f0bec8220", "node_type": "1", "metadata": {"window": "As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board. ", "original_text": "We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities. "}, "hash": "708731bf08d9ccdf0d34cb2872ae29bfb136186ed6821d45ffe522fa9823a84c", "class_name": "RelatedNodeInfo"}}, "text": "To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks. ", "start_char_idx": 1991, "end_char_idx": 2170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4caa1008-b2cb-45fc-9645-d40f0bec8220": {"__data__": {"id_": "4caa1008-b2cb-45fc-9645-d40f0bec8220", "embedding": null, "metadata": {"window": "As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board. ", "original_text": "We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fabb066-fe80-45a0-86b3-7c25f5d00c47", "node_type": "1", "metadata": {"window": "Our people and culture strategy is integrated with our continued focus on ESG initiatives, ensuring we not only do \ngood business, but we do business the right way.  As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment. ", "original_text": "To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5d7fc0924aed1c12f2a674f913dbd74957482cef8b172ce36e36202531d79eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec591f95-4724-409d-9507-01914ef461bf", "node_type": "1", "metadata": {"window": "Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr. ", "original_text": "We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n"}, "hash": "ae3ef817bc9039ce9dbe54080de121cd8dce80849b103074802ef4e2b77ae224", "class_name": "RelatedNodeInfo"}}, "text": "We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities. ", "start_char_idx": 2170, "end_char_idx": 2326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec591f95-4724-409d-9507-01914ef461bf": {"__data__": {"id_": "ec591f95-4724-409d-9507-01914ef461bf", "embedding": null, "metadata": {"window": "Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr. ", "original_text": "We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4caa1008-b2cb-45fc-9645-d40f0bec8220", "node_type": "1", "metadata": {"window": "As an impact -driven organization, we embrace our \nresponsibility to enable lasting changes in the communities we serve.  Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board. ", "original_text": "We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a63e11e72c1af8eb126e72514e25e8b0a302ab071d8b0ab012bff034cc357f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54ea9f1f-591c-42ff-9dba-1ca8554a39a4", "node_type": "1", "metadata": {"window": "To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n", "original_text": "Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment. "}, "hash": "3c4e20fd9c065a99f11112a8cb9a92a3a260ea6c42491c9124e20581e3da68c3", "class_name": "RelatedNodeInfo"}}, "text": "We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n", "start_char_idx": 2326, "end_char_idx": 2463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54ea9f1f-591c-42ff-9dba-1ca8554a39a4": {"__data__": {"id_": "54ea9f1f-591c-42ff-9dba-1ca8554a39a4", "embedding": null, "metadata": {"window": "To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n", "original_text": "Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec591f95-4724-409d-9507-01914ef461bf", "node_type": "1", "metadata": {"window": "Over the past year, we made great \nprogress in many areas, particularly around advancing access to care, health equity and climate action for health.  \n \n To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr. ", "original_text": "We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c258a9a5c7ef98aa00e1617f2a6dfd5719660cedf4257ad08c2c945a987ddad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5c8bac8-65bb-4cf9-8b59-c0463a0559e9", "node_type": "1", "metadata": {"window": "We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr. ", "original_text": "In April, we announced the election of Roy Dunbar as the new Director of the Board. "}, "hash": "c94729fd7f046e905545a62e7310cb66245b6fcb27110109f795a5a64c3c0e64", "class_name": "RelatedNodeInfo"}}, "text": "Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment. ", "start_char_idx": 2463, "end_char_idx": 2589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5c8bac8-65bb-4cf9-8b59-c0463a0559e9": {"__data__": {"id_": "f5c8bac8-65bb-4cf9-8b59-c0463a0559e9", "embedding": null, "metadata": {"window": "We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr. ", "original_text": "In April, we announced the election of Roy Dunbar as the new Director of the Board. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54ea9f1f-591c-42ff-9dba-1ca8554a39a4", "node_type": "1", "metadata": {"window": "To promote diversity, equity and inclusion, we have  set specific and measurable goals to increase representation \nof both women and people of color amongst our leadership ranks.  We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n", "original_text": "Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af6e3c85126f81833214da010fedfa184a782d6ea7594e0aee1338fd8d8db672", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce1362f8-468d-4071-a0dd-e2710ac25a1a", "node_type": "1", "metadata": {"window": "We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience. ", "original_text": "Mr. "}, "hash": "f6b9480d2e246a376b9e50b280e8bc89c94b8951be89c6116bc43fb0020d9c24", "class_name": "RelatedNodeInfo"}}, "text": "In April, we announced the election of Roy Dunbar as the new Director of the Board. ", "start_char_idx": 2589, "end_char_idx": 2673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce1362f8-468d-4071-a0dd-e2710ac25a1a": {"__data__": {"id_": "ce1362f8-468d-4071-a0dd-e2710ac25a1a", "embedding": null, "metadata": {"window": "We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience. ", "original_text": "Mr. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5c8bac8-65bb-4cf9-8b59-c0463a0559e9", "node_type": "1", "metadata": {"window": "We released our employment information \nreport, including our EEO -1 data, to improve transparency and accountability and equal empl oyment \nopportunities.  We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr. ", "original_text": "In April, we announced the election of Roy Dunbar as the new Director of the Board. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db2515d28dce99758d74a0c8f5b69d9c562df3fea765f5ffb99c24ec9efb0e7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19396ee7-cfa1-40b7-ad62-a6db98a9f1fb", "node_type": "1", "metadata": {"window": "Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n", "original_text": "Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n"}, "hash": "dad4dcdc4949abcef479f42dea420f048ffb198b613eb5c4ba8a4af837444c25", "class_name": "RelatedNodeInfo"}}, "text": "Mr. ", "start_char_idx": 2673, "end_char_idx": 2677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19396ee7-cfa1-40b7-ad62-a6db98a9f1fb": {"__data__": {"id_": "19396ee7-cfa1-40b7-ad62-a6db98a9f1fb", "embedding": null, "metadata": {"window": "Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n", "original_text": "Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce1362f8-468d-4071-a0dd-e2710ac25a1a", "node_type": "1", "metadata": {"window": "We also launched company -wide inclusion training, fostering positive behaviors and teaching ways \nto address bias in the workplace.  \n \n Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience. ", "original_text": "Mr. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d89f014a81048a42b62ac4ddee1b1299d477a6261792dbc7149eee26a1c2dc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a821f068-f1ca-4ab0-a9de-b57047866b02", "node_type": "1", "metadata": {"window": "In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth. ", "original_text": "In addition to the appointment of Mr. "}, "hash": "597d5a7e9691c59a2ca70c3d21afd8d9b5db93e5ae2e2c24a0e9c754f233497f", "class_name": "RelatedNodeInfo"}}, "text": "Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n", "start_char_idx": 2677, "end_char_idx": 2832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a821f068-f1ca-4ab0-a9de-b57047866b02": {"__data__": {"id_": "a821f068-f1ca-4ab0-a9de-b57047866b02", "embedding": null, "metadata": {"window": "In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth. ", "original_text": "In addition to the appointment of Mr. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19396ee7-cfa1-40b7-ad62-a6db98a9f1fb", "node_type": "1", "metadata": {"window": "Our commitment to diversity starts with our board as evidenced by the recent successful completion of our board \nrefreshment.  In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n", "original_text": "Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a65263f1235fcdd87ed1e09a2a9f79fa661d6bf701193ac023bd0a82c16d9e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbe10637-90b5-4e04-9b6b-9b8b1de4b1f4", "node_type": "1", "metadata": {"window": "Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions. ", "original_text": "Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience. "}, "hash": "f2e23b5efd508833af47f5b8d2d9898904b77b9192bcd6fa30c52bf5ee2d2275", "class_name": "RelatedNodeInfo"}}, "text": "In addition to the appointment of Mr. ", "start_char_idx": 2832, "end_char_idx": 2870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbe10637-90b5-4e04-9b6b-9b8b1de4b1f4": {"__data__": {"id_": "bbe10637-90b5-4e04-9b6b-9b8b1de4b1f4", "embedding": null, "metadata": {"window": "Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions. ", "original_text": "Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a821f068-f1ca-4ab0-a9de-b57047866b02", "node_type": "1", "metadata": {"window": "In April, we announced the election of Roy Dunbar as the new Director of the Board.  Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth. ", "original_text": "In addition to the appointment of Mr. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e34880444f9d66de5e5d1fe06f724e5803091f38adc01e5b2e79aafc03f7e65e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2455a41-0131-4b46-929c-60855624774c", "node_type": "1", "metadata": {"window": "Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities. ", "original_text": "Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n"}, "hash": "a288f281c949e9b2559885576ad3dd1bc309228ccbdf59705143075034b3b253", "class_name": "RelatedNodeInfo"}}, "text": "Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience. ", "start_char_idx": 2870, "end_char_idx": 3029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2455a41-0131-4b46-929c-60855624774c": {"__data__": {"id_": "b2455a41-0131-4b46-929c-60855624774c", "embedding": null, "metadata": {"window": "Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities. ", "original_text": "Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbe10637-90b5-4e04-9b6b-9b8b1de4b1f4", "node_type": "1", "metadata": {"window": "Mr.  Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions. ", "original_text": "Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0669f12f3bc26f7d2a09cbbd69842e2f6148e94e3fdcf033c68ec79f9d79bb94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f535ce6f-06ab-4e50-9fa2-78a4f3a9db31", "node_type": "1", "metadata": {"window": "In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n", "original_text": "Moving to our second priority, which is driving sustainable core growth. "}, "hash": "3c563bddc1962f649bbcca0e84b63461d028e49484f7c04c8256f5cc14a9d83c", "class_name": "RelatedNodeInfo"}}, "text": "Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n", "start_char_idx": 3029, "end_char_idx": 3186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f535ce6f-06ab-4e50-9fa2-78a4f3a9db31": {"__data__": {"id_": "f535ce6f-06ab-4e50-9fa2-78a4f3a9db31", "embedding": null, "metadata": {"window": "In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n", "original_text": "Moving to our second priority, which is driving sustainable core growth. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2455a41-0131-4b46-929c-60855624774c", "node_type": "1", "metadata": {"window": "Dunbar \nbrings decades of experience in technology, operations and healthcare and will be instrumental in guiding the \ncompany's strategic prioriti es. \n \n In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities. ", "original_text": "Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e7fe2dc7eb28b64a5f86e55502f238f5402e3e1afdfdde6f6fc11baaa5c07b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "489e7690-4ee3-4293-b4c2-99cf6d9c7f0d", "node_type": "1", "metadata": {"window": "Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence. ", "original_text": "At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions. "}, "hash": "1cb4142819c3961d16903c139b4b10a5acbb037f8def3e5cca23fd63549fe12a", "class_name": "RelatedNodeInfo"}}, "text": "Moving to our second priority, which is driving sustainable core growth. ", "start_char_idx": 3186, "end_char_idx": 3259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "489e7690-4ee3-4293-b4c2-99cf6d9c7f0d": {"__data__": {"id_": "489e7690-4ee3-4293-b4c2-99cf6d9c7f0d", "embedding": null, "metadata": {"window": "Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence. ", "original_text": "At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f535ce6f-06ab-4e50-9fa2-78a4f3a9db31", "node_type": "1", "metadata": {"window": "In addition to the appointment of Mr.  Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n", "original_text": "Moving to our second priority, which is driving sustainable core growth. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df3d7b70e7ac6d57e3f3dc7237d746e928c3fea565731d5a5be0be8000923103", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0567a2c-924b-4c3c-b551-e2c79adbf1cf", "node_type": "1", "metadata": {"window": "Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service. ", "original_text": "Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities. "}, "hash": "f1a4a8b3c488b3d4c0e3a5b559835184072ef7a30618f7359525b819d1b6cd07", "class_name": "RelatedNodeInfo"}}, "text": "At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions. ", "start_char_idx": 3259, "end_char_idx": 3357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0567a2c-924b-4c3c-b551-e2c79adbf1cf": {"__data__": {"id_": "c0567a2c-924b-4c3c-b551-e2c79adbf1cf", "embedding": null, "metadata": {"window": "Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service. ", "original_text": "Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "489e7690-4ee3-4293-b4c2-99cf6d9c7f0d", "node_type": "1", "metadata": {"window": "Dunbar, in fiscal 2022, we elected a new independent Chair of the Board and \nintroduced three other new board members with diverse backgrounds and experience.  Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence. ", "original_text": "At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f37209a858a24e70b27964596d53536ad9ced4f3b757f097072c7a90d229f040", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ee3416f-f4c9-4f7c-8a1c-fad340f80653", "node_type": "1", "metadata": {"window": "Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service.  Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide. ", "original_text": "Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n"}, "hash": "575dc543892eae61dea48c47031103aec867023b5f2ba16b5140e51be03c5993", "class_name": "RelatedNodeInfo"}}, "text": "Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities. ", "start_char_idx": 3357, "end_char_idx": 3481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ee3416f-f4c9-4f7c-8a1c-fad340f80653": {"__data__": {"id_": "8ee3416f-f4c9-4f7c-8a1c-fad340f80653", "embedding": null, "metadata": {"window": "Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service.  Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide. ", "original_text": "Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0567a2c-924b-4c3c-b551-e2c79adbf1cf", "node_type": "1", "metadata": {"window": "Women and people of \ncolor now represent 50% of our Boar d of Directors, and we look forward to benefiting from their leadership and \ntheir stewardship.  \n \n Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service. ", "original_text": "Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a1c5d6b5d1d112feb2877e0570336fd6b650d4bab3b658e151f073658a07e25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21922e87-afe8-4f74-9d0d-644e96c8598d", "node_type": "1", "metadata": {"window": "At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service.  Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide.  With an \nincreasing demand in virtual and home care, we've seen si gnificant growth in this channel in the past few years. ", "original_text": "We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence. "}, "hash": "1b0eab10816a4b3d2cb6b70ce1143b49ce462434d5b95bf90e952783bda234b6", "class_name": "RelatedNodeInfo"}}, "text": "Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n", "start_char_idx": 3481, "end_char_idx": 3736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21922e87-afe8-4f74-9d0d-644e96c8598d": {"__data__": {"id_": "21922e87-afe8-4f74-9d0d-644e96c8598d", "embedding": null, "metadata": {"window": "At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service.  Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide.  With an \nincreasing demand in virtual and home care, we've seen si gnificant growth in this channel in the past few years. ", "original_text": "We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ee3416f-f4c9-4f7c-8a1c-fad340f80653", "node_type": "1", "metadata": {"window": "Moving to our second priority, which is driving sustainable core growth.  At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service.  Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide. ", "original_text": "Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ee2c100d6e41e8e5ee1aca43ea7af20661179612d5bd144604e4ebdd931f343", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d132fe53-de53-420c-824e-d86c09017b6c", "node_type": "1", "metadata": {"window": "Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service.  Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide.  With an \nincreasing demand in virtual and home care, we've seen si gnificant growth in this channel in the past few years. ", "original_text": "A great e xample of this is our patient home delivery service. "}, "hash": "702d2b71740d0142338684cf3d680d8db043728465a37b10cf41af2795a79113", "class_name": "RelatedNodeInfo"}}, "text": "We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence. ", "start_char_idx": 3736, "end_char_idx": 3860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d132fe53-de53-420c-824e-d86c09017b6c": {"__data__": {"id_": "d132fe53-de53-420c-824e-d86c09017b6c", "embedding": null, "metadata": {"window": "Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service.  Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide.  With an \nincreasing demand in virtual and home care, we've seen si gnificant growth in this channel in the past few years. ", "original_text": "A great e xample of this is our patient home delivery service. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21922e87-afe8-4f74-9d0d-644e96c8598d", "node_type": "1", "metadata": {"window": "At the core of our offering is the \nPharmaceutical and Medical -Surgical distribution sol utions.  Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service.  Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide.  With an \nincreasing demand in virtual and home care, we've seen si gnificant growth in this channel in the past few years. ", "original_text": "We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31633e4a5acd349eee72bb5915a0d5e8cfa48d265f61b6ee5cb90029585512e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e52ff292-435f-4172-bb77-4b025e7b239b", "node_type": "1", "metadata": {"window": "Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service.  Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide.  With an \nincreasing demand in virtual and home care, we've seen si gnificant growth in this channel in the past few years. ", "original_text": "Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide. "}, "hash": "b81d5a209b25a27df522de189ca711554f6f841dcfb0d2903c0fd350153150a5", "class_name": "RelatedNodeInfo"}}, "text": "A great e xample of this is our patient home delivery service. ", "start_char_idx": 3860, "end_char_idx": 3923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e52ff292-435f-4172-bb77-4b025e7b239b": {"__data__": {"id_": "e52ff292-435f-4172-bb77-4b025e7b239b", "embedding": null, "metadata": {"window": "Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service.  Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide.  With an \nincreasing demand in virtual and home care, we've seen si gnificant growth in this channel in the past few years. ", "original_text": "Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d132fe53-de53-420c-824e-d86c09017b6c", "node_type": "1", "metadata": {"window": "Building upon the momentum in fiscal 2022, we \ncontinue to innovate and invest in our distribution assets and capabilities.  Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service.  Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide.  With an \nincreasing demand in virtual and home care, we've seen si gnificant growth in this channel in the past few years. ", "original_text": "A great e xample of this is our patient home delivery service. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ec8032feef3c36ce09b5153122d7ca7bc1bf99e956f764da342ed50ea5a54f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fc5da29-b25c-4fa8-a5fb-0da8022a5b67", "node_type": "1", "metadata": {"window": "We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service.  Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide.  With an \nincreasing demand in virtual and home care, we've seen si gnificant growth in this channel in the past few years. ", "original_text": "With an \nincreasing demand in virtual and home care, we've seen si gnificant growth in this channel in the past few years. "}, "hash": "7f35fc290153ae5e390a5473f4e88131f6301a9dfcb645aab39dc70f07bef55c", "class_name": "RelatedNodeInfo"}}, "text": "Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide. ", "start_char_idx": 3923, "end_char_idx": 4063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fc5da29-b25c-4fa8-a5fb-0da8022a5b67": {"__data__": {"id_": "4fc5da29-b25c-4fa8-a5fb-0da8022a5b67", "embedding": null, "metadata": {"window": "We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service.  Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide.  With an \nincreasing demand in virtual and home care, we've seen si gnificant growth in this channel in the past few years. ", "original_text": "With an \nincreasing demand in virtual and home care, we've seen si gnificant growth in this channel in the past few years. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a53b4cd4-682b-463e-878b-a2b9249c415b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f71be3ffe4b04b6a0c73d2a3fce8122f8948b7fd9d0b178b744664dfe04d9fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e52ff292-435f-4172-bb77-4b025e7b239b", "node_type": "1", "metadata": {"window": "Some of the latest advancements over \nthe past year include automated picking and packing solutions and robotics, which help u s improve productivity, \nso we can pick more accurately, pack medications faster and ultimately serve our customers better.  \n \n We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service.  Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide.  With an \nincreasing demand in virtual and home care, we've seen si gnificant growth in this channel in the past few years. ", "original_text": "Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5107cf9e7ef14faf4fafc2df1f2309b29f5862736b9e483d11b135c7f5dc2c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ab5be79-b572-4bcd-ab10-cc5ad47cd760", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies. ", "original_text": "McKesson Corp.  "}, "hash": "d45cce928b74fa9914ce9be3270a2c3259cd8c50102457ac93baaf6897216c1c", "class_name": "RelatedNodeInfo"}}, "text": "With an \nincreasing demand in virtual and home care, we've seen si gnificant growth in this channel in the past few years. ", "start_char_idx": 4063, "end_char_idx": 4186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ab5be79-b572-4bcd-ab10-cc5ad47cd760": {"__data__": {"id_": "5ab5be79-b572-4bcd-ab10-cc5ad47cd760", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fc5da29-b25c-4fa8-a5fb-0da8022a5b67", "node_type": "1", "metadata": {"window": "We're also expanding the reach of our core business by entering adjacent markets while maintaining operational \nexcellence.  A great e xample of this is our patient home delivery service.  Leveraging our scale distribution \nnetwork, we help our partners deliver medical -surgical products directly to patients' homes nationwide.  With an \nincreasing demand in virtual and home care, we've seen si gnificant growth in this channel in the past few years. ", "original_text": "With an \nincreasing demand in virtual and home care, we've seen si gnificant growth in this channel in the past few years. ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64510abb7ae57f3d4bdfc82923486070b721c064d16f2d58ef534e951eb15065", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ac388f5-6b06-4d74-9354-f8ce7ffee17e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n"}, "hash": "041351b67fc37c8e5d4b72d580cbd092863684c917e025b6d1e928116a8c1f23", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ac388f5-6b06-4d74-9354-f8ce7ffee17e": {"__data__": {"id_": "9ac388f5-6b06-4d74-9354-f8ce7ffee17e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ab5be79-b572-4bcd-ab10-cc5ad47cd760", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f3adbf1f3aa58577faed507f9983479b52f4e2a5e0fde5657a80d8d534e88dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "945b463b-c738-4652-b48a-2ac15c8be6e3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities. ", "original_text": "We also continued to partner closely with the US government in its COVID -19 response effort. "}, "hash": "2fcab05efcbe16be4fdf0e09a3f34831dfe7e3e8ec81a4a4013fbb6e0ac8e777", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n", "start_char_idx": 16, "end_char_idx": 397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "945b463b-c738-4652-b48a-2ac15c8be6e3": {"__data__": {"id_": "945b463b-c738-4652-b48a-2ac15c8be6e3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities. ", "original_text": "We also continued to partner closely with the US government in its COVID -19 response effort. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ac388f5-6b06-4d74-9354-f8ce7ffee17e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd46ad335ae390809e35625effe58155e2e3d079774495ec2902aaecab68bc18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01c2a223-cf44-44e6-bf5c-528d66536c90", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n", "original_text": "It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies. "}, "hash": "2816a170e212e9d4cf5c22cb0a8d89966979c3749568a5c5b3ce487e4c856ec2", "class_name": "RelatedNodeInfo"}}, "text": "We also continued to partner closely with the US government in its COVID -19 response effort. ", "start_char_idx": 397, "end_char_idx": 491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01c2a223-cf44-44e6-bf5c-528d66536c90": {"__data__": {"id_": "01c2a223-cf44-44e6-bf5c-528d66536c90", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n", "original_text": "It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "945b463b-c738-4652-b48a-2ac15c8be6e3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities. ", "original_text": "We also continued to partner closely with the US government in its COVID -19 response effort. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea1223cedcae533ff2c2e4d1f2120fdd2ca6dad9d0efb59cae64a49aa6c8806", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bff08f0f-f372-49eb-bc86-0cb170baebb4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business. ", "original_text": "Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n"}, "hash": "b6a8f50ead7566bf5140b09970474dedd502555d98acf75f55e3182d1b987b5d", "class_name": "RelatedNodeInfo"}}, "text": "It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies. ", "start_char_idx": 491, "end_char_idx": 595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bff08f0f-f372-49eb-bc86-0cb170baebb4": {"__data__": {"id_": "bff08f0f-f372-49eb-bc86-0cb170baebb4", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business. ", "original_text": "Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01c2a223-cf44-44e6-bf5c-528d66536c90", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n", "original_text": "It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ec0b16da3053d707925a19431f511077da5b1cc2cc010a931da8f3716bf034a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d1e896c-1256-42fb-90d5-619f9ab57f61", "node_type": "1", "metadata": {"window": "We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries. ", "original_text": "Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities. "}, "hash": "b4b8acbd5b417f09d562116527547027c79ab62d2692d543949f5ffc7bd29298", "class_name": "RelatedNodeInfo"}}, "text": "Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n", "start_char_idx": 595, "end_char_idx": 837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d1e896c-1256-42fb-90d5-619f9ab57f61": {"__data__": {"id_": "4d1e896c-1256-42fb-90d5-619f9ab57f61", "embedding": null, "metadata": {"window": "We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries. ", "original_text": "Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bff08f0f-f372-49eb-bc86-0cb170baebb4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business. ", "original_text": "Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf69fda33bfc0d14f115ca72bbc76655c7b33410e48512e760d8c8d939953a59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2a16816-adda-4586-94bf-099105089531", "node_type": "1", "metadata": {"window": "It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023. ", "original_text": "And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n"}, "hash": "ebbfb8d29a485b580c0073f4b6568aed0e03b59efae85b15b7c5f164c28a3917", "class_name": "RelatedNodeInfo"}}, "text": "Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities. ", "start_char_idx": 837, "end_char_idx": 1043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2a16816-adda-4586-94bf-099105089531": {"__data__": {"id_": "c2a16816-adda-4586-94bf-099105089531", "embedding": null, "metadata": {"window": "It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023. ", "original_text": "And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d1e896c-1256-42fb-90d5-619f9ab57f61", "node_type": "1", "metadata": {"window": "We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries. ", "original_text": "Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d86638081f15618c7bf332a29920f1fa78508605647b2a11024ea26833d5275c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ff855f2-4404-4b3b-86b5-4e39a8219c68", "node_type": "1", "metadata": {"window": "Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n", "original_text": "In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business. "}, "hash": "918a333ff25c61b74aedd9bffb4c1ed8854978a9692791a0bc4272e220709900", "class_name": "RelatedNodeInfo"}}, "text": "And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n", "start_char_idx": 1043, "end_char_idx": 1218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ff855f2-4404-4b3b-86b5-4e39a8219c68": {"__data__": {"id_": "8ff855f2-4404-4b3b-86b5-4e39a8219c68", "embedding": null, "metadata": {"window": "Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n", "original_text": "In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2a16816-adda-4586-94bf-099105089531", "node_type": "1", "metadata": {"window": "It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies.  Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023. ", "original_text": "And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3a656d8f9bbef419ad205fa825fae312bc11243146ea440848e8083842ea4a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea4142de-0b4f-4733-8ffd-de467d47073c", "node_type": "1", "metadata": {"window": "Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems. ", "original_text": "Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries. "}, "hash": "00706ccfbe260da55a671a620308654ecef71568be4a79955030c8a23a5eb3e3", "class_name": "RelatedNodeInfo"}}, "text": "In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business. ", "start_char_idx": 1218, "end_char_idx": 1374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea4142de-0b4f-4733-8ffd-de467d47073c": {"__data__": {"id_": "ea4142de-0b4f-4733-8ffd-de467d47073c", "embedding": null, "metadata": {"window": "Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems. ", "original_text": "Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ff855f2-4404-4b3b-86b5-4e39a8219c68", "node_type": "1", "metadata": {"window": "Through March 31, we have \nsuccessfully distributed over 380 million Moderna and Johnson & Johnson COVID -19 vaccines to administration \nsites across the United States and in support of the US government's international donation mission.  \n \n Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n", "original_text": "In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97886e7498ab2ffa733257a4f699d12f7861c845d9d8ee6c15da6eceb70e65bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34dbb818-1c77-4821-97f8-a6248313213e", "node_type": "1", "metadata": {"window": "And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas. ", "original_text": "We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023. "}, "hash": "1934b7120f05dbadb46648a2b2402664647aa3ddda45ce323abc6a7bfe19b545", "class_name": "RelatedNodeInfo"}}, "text": "Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries. ", "start_char_idx": 1374, "end_char_idx": 1530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34dbb818-1c77-4821-97f8-a6248313213e": {"__data__": {"id_": "34dbb818-1c77-4821-97f8-a6248313213e", "embedding": null, "metadata": {"window": "And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas. ", "original_text": "We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea4142de-0b4f-4733-8ffd-de467d47073c", "node_type": "1", "metadata": {"window": "Although the contract with the US government to serve as a centralized distributor is expected to end in July, this \nexperience has been a strong testimony to our vast and scaled supply chain capabilities.  And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems. ", "original_text": "Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ee03606796e6ad68cc20f9cbfb7bb405093000b6821b2cf1ad0b7bb3e54f43b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b09e1998-e572-4043-a356-bb50a043edbc", "node_type": "1", "metadata": {"window": "In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives. ", "original_text": "The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n"}, "hash": "3305da31a350bda2f2e94ffed0cc57fc69b15e2624ce9728841a9908c4f3f896", "class_name": "RelatedNodeInfo"}}, "text": "We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023. ", "start_char_idx": 1530, "end_char_idx": 1811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b09e1998-e572-4043-a356-bb50a043edbc": {"__data__": {"id_": "b09e1998-e572-4043-a356-bb50a043edbc", "embedding": null, "metadata": {"window": "In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives. ", "original_text": "The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34dbb818-1c77-4821-97f8-a6248313213e", "node_type": "1", "metadata": {"window": "And I am incredibly \nproud of the way our employees rose to the challenges brought on by the pandemic through our focus on meeting \nthe needs of the healthcare community.  \n \n In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas. ", "original_text": "We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30eb766f47da81413d2b4841999d2204002120c057a83e29530befd27cf1a047", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15d60f01-c451-415c-b01a-012e01a5921f", "node_type": "1", "metadata": {"window": "Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n", "original_text": "The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems. "}, "hash": "ba9f343c83c81a41c6a93420165f8cc0d85a4710ee8b722535d8637b2c7b949a", "class_name": "RelatedNodeInfo"}}, "text": "The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n", "start_char_idx": 1811, "end_char_idx": 2022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15d60f01-c451-415c-b01a-012e01a5921f": {"__data__": {"id_": "15d60f01-c451-415c-b01a-012e01a5921f", "embedding": null, "metadata": {"window": "Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n", "original_text": "The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b09e1998-e572-4043-a356-bb50a043edbc", "node_type": "1", "metadata": {"window": "In early fiscal 2022, we announced our intent to exit the European market, which aligns with our company priority \nto streamline and simplify the business.  Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives. ", "original_text": "The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e9504851d0f51f86941c5a5903255c946ad7fb31a034db2290aa7378ecc33f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edcaa561-82d5-4d08-91a7-d492fe98f770", "node_type": "1", "metadata": {"window": "We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n", "original_text": "At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas. "}, "hash": "7a044ce53e1add02a44f7f9d3a0012ee173194c30ad77ede2ff16ee7842a2246", "class_name": "RelatedNodeInfo"}}, "text": "The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems. ", "start_char_idx": 2022, "end_char_idx": 2142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edcaa561-82d5-4d08-91a7-d492fe98f770": {"__data__": {"id_": "edcaa561-82d5-4d08-91a7-d492fe98f770", "embedding": null, "metadata": {"window": "We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n", "original_text": "At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15d60f01-c451-415c-b01a-012e01a5921f", "node_type": "1", "metadata": {"window": "Over the past 12 months, we've made significant progress as we have \nsuccessfully entered into agreements to sell the operations in 10 of the 12 countries.  We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n", "original_text": "The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2631f12b012040b965c6d7b602281d731e43ef6f2eaaa569ca2e7af2bd409f81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85e6f891-4c75-4612-b641-1aeaaa48e6c6", "node_type": "1", "metadata": {"window": "The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence. ", "original_text": "We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives. "}, "hash": "30c47bd6858902b639517466d7577967662dd2b8c6f36b3d8f5a8efdcd1f81b1", "class_name": "RelatedNodeInfo"}}, "text": "At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas. ", "start_char_idx": 2142, "end_char_idx": 2269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85e6f891-4c75-4612-b641-1aeaaa48e6c6": {"__data__": {"id_": "85e6f891-4c75-4612-b641-1aeaaa48e6c6", "embedding": null, "metadata": {"window": "The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence. ", "original_text": "We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edcaa561-82d5-4d08-91a7-d492fe98f770", "node_type": "1", "metadata": {"window": "We've completed the \ndivestiture of the Austria and UK businesses, and our German joint venture with Walgreens Boots Alliance, \nbringing all the in -process transactions to closure and exploring strategic alternatives for the remaining countries \nis a top priority in fiscal 2023.  The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n", "original_text": "At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fda412b61f81a9572f81de532cb0e3cd60efbd9679dd947b09e9ab95b47344a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6668e86e-0a9a-4818-a7c1-00d0ee72ecb3", "node_type": "1", "metadata": {"window": "The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications. ", "original_text": "The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n"}, "hash": "fcf6d9bb5c80368904b114b67e3f5f9f801c8804a01e7adf6c851d2e911931c8", "class_name": "RelatedNodeInfo"}}, "text": "We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives. ", "start_char_idx": 2269, "end_char_idx": 2382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6668e86e-0a9a-4818-a7c1-00d0ee72ecb3": {"__data__": {"id_": "6668e86e-0a9a-4818-a7c1-00d0ee72ecb3", "embedding": null, "metadata": {"window": "The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications. ", "original_text": "The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85e6f891-4c75-4612-b641-1aeaaa48e6c6", "node_type": "1", "metadata": {"window": "The actions we're taking in Europe build upon our deliberate efforts over the past \nyears to maximize the organization's operatio nal efficiency and focus our resources on the highest growth \nopportunities.  \n \n The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence. ", "original_text": "We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae295dd5eefd4f1aa348bcd2f19aba3d0f8304d1f7d4b98f3bc8ed2e7f0172c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9ca4c93-bf85-4fe4-80e4-d22061b7aae6", "node_type": "1", "metadata": {"window": "At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times. ", "original_text": "Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n"}, "hash": "2d69e6a31e871f3ffeb165be9307761fae427fc1fa0604198aca28327833f177", "class_name": "RelatedNodeInfo"}}, "text": "The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n", "start_char_idx": 2382, "end_char_idx": 2571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9ca4c93-bf85-4fe4-80e4-d22061b7aae6": {"__data__": {"id_": "f9ca4c93-bf85-4fe4-80e4-d22061b7aae6", "embedding": null, "metadata": {"window": "At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times. ", "original_text": "Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6668e86e-0a9a-4818-a7c1-00d0ee72ecb3", "node_type": "1", "metadata": {"window": "The last company priority that we're excited about is the expansion of our oncology and biopharma services \necosystems.  At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications. ", "original_text": "The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6c7fd9a7fe2cd77cec39e76f4cdc2375b7fe785d03a2fd7858fdbab06a2dc3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03543b73-9e11-436c-b5d1-d2e1a59183d0", "node_type": "1", "metadata": {"window": "We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one. ", "original_text": "Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence. "}, "hash": "25598a6de34a7e05501d64a993f816b52956a4a86979e02b005e6cb592045b66", "class_name": "RelatedNodeInfo"}}, "text": "Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n", "start_char_idx": 2571, "end_char_idx": 2683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03543b73-9e11-436c-b5d1-d2e1a59183d0": {"__data__": {"id_": "03543b73-9e11-436c-b5d1-d2e1a59183d0", "embedding": null, "metadata": {"window": "We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one. ", "original_text": "Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9ca4c93-bf85-4fe4-80e4-d22061b7aae6", "node_type": "1", "metadata": {"window": "At our Investor Day in December 2021, we shared details abou t our differentiated assets and \ncapabilities in these two areas.  We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times. ", "original_text": "Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51e00eb15c7d31ea5088c6d8eddcb72db658ef50fdf85c641b40c7011543aee8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6925a4d9-e3bb-4e35-80f0-e05a7de8ed29", "node_type": "1", "metadata": {"window": "The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n", "original_text": "In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications. "}, "hash": "42b236f1518c05663d3538c6c1669993ecf90ffb214e64d24104ea623733356a", "class_name": "RelatedNodeInfo"}}, "text": "Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence. ", "start_char_idx": 2683, "end_char_idx": 2819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6925a4d9-e3bb-4e35-80f0-e05a7de8ed29": {"__data__": {"id_": "6925a4d9-e3bb-4e35-80f0-e05a7de8ed29", "embedding": null, "metadata": {"window": "The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n", "original_text": "In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03543b73-9e11-436c-b5d1-d2e1a59183d0", "node_type": "1", "metadata": {"window": "We believe that these ecosystems can help solve complicated problems, and \nimportantly, improve patients' lives.  The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one. ", "original_text": "Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d1de5448e72c30596f5390466ba9926470d9f9202d80568c4a1b40ac1a54088", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2144bd6-1fd6-4d3e-9566-3b934ca24256", "node_type": "1", "metadata": {"window": "Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions . ", "original_text": "We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times. "}, "hash": "8f3f2bca3e1e2121d7c03d194f4aaf0b40efbb46e3bc6534cb49aa61428b55c7", "class_name": "RelatedNodeInfo"}}, "text": "In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications. ", "start_char_idx": 2819, "end_char_idx": 2921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2144bd6-1fd6-4d3e-9566-3b934ca24256": {"__data__": {"id_": "e2144bd6-1fd6-4d3e-9566-3b934ca24256", "embedding": null, "metadata": {"window": "Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions . ", "original_text": "We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6925a4d9-e3bb-4e35-80f0-e05a7de8ed29", "node_type": "1", "metadata": {"window": "The goal to help ease the frictions and eliminate inefficiencies in the \nhealthc are system and to improve patients' lives is what motivates us continuously to innovate and to execute.  \n \n Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n", "original_text": "In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2a274edfc07a0136d99a46168a209e0c0dcc730c5fe958872d99aacaee23747", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "835df4e2-9a47-4124-8ad2-f9f69517a392", "node_type": "1", "metadata": {"window": "Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars. ", "original_text": "We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one. "}, "hash": "099dc66d7ef72800c2be4a61976d6ac827d4f655a79265e65b629b99e0cef946", "class_name": "RelatedNodeInfo"}}, "text": "We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times. ", "start_char_idx": 2921, "end_char_idx": 3102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "835df4e2-9a47-4124-8ad2-f9f69517a392": {"__data__": {"id_": "835df4e2-9a47-4124-8ad2-f9f69517a392", "embedding": null, "metadata": {"window": "Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars. ", "original_text": "We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2144bd6-1fd6-4d3e-9566-3b934ca24256", "node_type": "1", "metadata": {"window": "Our biopharma ecosystem represents a scaled network of assets and capabilities that are highly differentiated. \n Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions . ", "original_text": "We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd386e7881ebbecc885848fffaeb77c23ca84c9df400cd5cf0e439f69fe413aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91b74c32-3ba3-4c8c-864f-8f8c13caebca", "node_type": "1", "metadata": {"window": "In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n", "original_text": "The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n"}, "hash": "cb2d92c80d6b59a40ffb2a5c4263e6df4f1573a56d4455370f9a4516bdba2682", "class_name": "RelatedNodeInfo"}}, "text": "We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one. ", "start_char_idx": 3102, "end_char_idx": 3248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91b74c32-3ba3-4c8c-864f-8f8c13caebca": {"__data__": {"id_": "91b74c32-3ba3-4c8c-864f-8f8c13caebca", "embedding": null, "metadata": {"window": "In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n", "original_text": "The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "835df4e2-9a47-4124-8ad2-f9f69517a392", "node_type": "1", "metadata": {"window": "Within the ecosystem, we're expanding th e reach of our products and services that aim to improve access, \naffordability and adherence.  In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars. ", "original_text": "We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0348307eb6557c0908c60d9e50de4ca12a46f9adecd0a13702bb473d71a8af0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59fc82d6-2de2-4483-9a25-afb9c223c377", "node_type": "1", "metadata": {"window": "We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience. ", "original_text": "In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions . "}, "hash": "384134c3261d2296e47bf258165aa95ffc4f4f4b331f3b5f816f1d8c8dc3b6d1", "class_name": "RelatedNodeInfo"}}, "text": "The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n", "start_char_idx": 3248, "end_char_idx": 3385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59fc82d6-2de2-4483-9a25-afb9c223c377": {"__data__": {"id_": "59fc82d6-2de2-4483-9a25-afb9c223c377", "embedding": null, "metadata": {"window": "We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience. ", "original_text": "In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions . ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91b74c32-3ba3-4c8c-864f-8f8c13caebca", "node_type": "1", "metadata": {"window": "In the past year, we helped patients save more than $6 billion on branded and \nspecialty medications.  We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n", "original_text": "The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bda2f770d790869f139bc3b88df439b651b76d3ebb65111168e246d5c6eb8ae8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9320ba0d-23a8-4b84-8afb-190a946c05a1", "node_type": "1", "metadata": {"window": "We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies. ", "original_text": "Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars. "}, "hash": "9b9cbed4086e1c0f7b85d643862a14b3f2c7a0b57e9fa9594953a294e97dcfc8", "class_name": "RelatedNodeInfo"}}, "text": "In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions . ", "start_char_idx": 3385, "end_char_idx": 3508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9320ba0d-23a8-4b84-8afb-190a946c05a1": {"__data__": {"id_": "9320ba0d-23a8-4b84-8afb-190a946c05a1", "embedding": null, "metadata": {"window": "We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies. ", "original_text": "Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59fc82d6-2de2-4483-9a25-afb9c223c377", "node_type": "1", "metadata": {"window": "We helped prevent more than 9 million prescriptions from bein g abandoned due to \naffordability challenges, and we helped patients access their medicine more than 67 million times.  We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience. ", "original_text": "In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions . ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7348ce42999732dcc169b3e081521d2681b9a6cb71a1c49ca083e8ec5d6f6f60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fa60293-f663-40ce-bae3-77b164862455", "node_type": "1", "metadata": {"window": "The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial. ", "original_text": "Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n"}, "hash": "a64c9e173708fd57079d74da2fc987216f510160c69c4b65a5357cb73fb39324", "class_name": "RelatedNodeInfo"}}, "text": "Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars. ", "start_char_idx": 3508, "end_char_idx": 3629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fa60293-f663-40ce-bae3-77b164862455": {"__data__": {"id_": "6fa60293-f663-40ce-bae3-77b164862455", "embedding": null, "metadata": {"window": "The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial. ", "original_text": "Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9320ba0d-23a8-4b84-8afb-190a946c05a1", "node_type": "1", "metadata": {"window": "We created an \necosystem that's more efficient and more valuable to the customers and patients than each of the pieces would \nbe standing al one.  The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies. ", "original_text": "Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afe62c4f466ded613531762a3d056c5f967c25bdc4c2fcbf48ac0500dea60f6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68477a31-b874-419a-98de-2dfe1987eb59", "node_type": "1", "metadata": {"window": "In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial.  And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence. ", "original_text": "A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience. "}, "hash": "7a3a8031a1dcdc67e8b8145d6771affb300bc4c58f81cc584cd5017cd0f511d3", "class_name": "RelatedNodeInfo"}}, "text": "Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n", "start_char_idx": 3629, "end_char_idx": 3793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68477a31-b874-419a-98de-2dfe1987eb59": {"__data__": {"id_": "68477a31-b874-419a-98de-2dfe1987eb59", "embedding": null, "metadata": {"window": "In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial.  And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence. ", "original_text": "A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fa60293-f663-40ce-bae3-77b164862455", "node_type": "1", "metadata": {"window": "The cohesive business strategy and coordinated go -to-market solutions are both critical \nenabling continued growth in this segment.  \n \n In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial. ", "original_text": "Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e18e4ab1e4cff5292ec25859d1c32abc58ee9dd36e0ab3b9c276157c570bd9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc73872b-aeeb-4ebd-89b9-c87e2d399f49", "node_type": "1", "metadata": {"window": "Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial.  And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence.  We've published more than 200 real-world studies in leading industry publications for over 70 oncology ", "original_text": "As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies. "}, "hash": "cad061d7abfbc1595f61185fa8cfea664657df665590c4eb51f516f126f29e8f", "class_name": "RelatedNodeInfo"}}, "text": "A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience. ", "start_char_idx": 3793, "end_char_idx": 3916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc73872b-aeeb-4ebd-89b9-c87e2d399f49": {"__data__": {"id_": "dc73872b-aeeb-4ebd-89b9-c87e2d399f49", "embedding": null, "metadata": {"window": "Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial.  And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence.  We've published more than 200 real-world studies in leading industry publications for over 70 oncology ", "original_text": "As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68477a31-b874-419a-98de-2dfe1987eb59", "node_type": "1", "metadata": {"window": "In our oncology ecosystem, we're strategically positioned to improve cancer care with a range of services and \nsolutions .  Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial.  And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence. ", "original_text": "A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf4b5c9ed57013c658577aaddc2202b9213ff5071f7a0cd236e7f558e7331a8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "336e013f-1b92-4803-a9a3-76e54d8b0e9d", "node_type": "1", "metadata": {"window": "Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial.  And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence.  We've published more than 200 real-world studies in leading industry publications for over 70 oncology ", "original_text": "Last year, nearly 900 physicians actively accrued patients to clinical trial. "}, "hash": "25ededdda2871f3cc0e4487cdac92ef4d0f6b391f92cfc8a14927f1d5b36b12d", "class_name": "RelatedNodeInfo"}}, "text": "As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies. ", "start_char_idx": 3916, "end_char_idx": 4051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "336e013f-1b92-4803-a9a3-76e54d8b0e9d": {"__data__": {"id_": "336e013f-1b92-4803-a9a3-76e54d8b0e9d", "embedding": null, "metadata": {"window": "Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial.  And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence.  We've published more than 200 real-world studies in leading industry publications for over 70 oncology ", "original_text": "Last year, nearly 900 physicians actively accrued patients to clinical trial. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc73872b-aeeb-4ebd-89b9-c87e2d399f49", "node_type": "1", "metadata": {"window": "Our distribution and GPO capabilities continue to provide patients access to life -saving drugs, including \nbiosimilars.  Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial.  And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence.  We've published more than 200 real-world studies in leading industry publications for over 70 oncology ", "original_text": "As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3cdce3b0e9aa9c9616c813a3b7c31f65ec4bb840b8749b625dd3f6b636ee67e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69cf131d-5e5a-4f44-8755-8c0ae5bd214b", "node_type": "1", "metadata": {"window": "A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial.  And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence.  We've published more than 200 real-world studies in leading industry publications for over 70 oncology ", "original_text": "And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence. "}, "hash": "5c3ab9e19a04f81589af4604fa5b47b15a121dba963af54c11526954e8f745ed", "class_name": "RelatedNodeInfo"}}, "text": "Last year, nearly 900 physicians actively accrued patients to clinical trial. ", "start_char_idx": 4051, "end_char_idx": 4129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69cf131d-5e5a-4f44-8755-8c0ae5bd214b": {"__data__": {"id_": "69cf131d-5e5a-4f44-8755-8c0ae5bd214b", "embedding": null, "metadata": {"window": "A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial.  And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence.  We've published more than 200 real-world studies in leading industry publications for over 70 oncology ", "original_text": "And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "336e013f-1b92-4803-a9a3-76e54d8b0e9d", "node_type": "1", "metadata": {"window": "Combined with our reach through the US oncology network, we help promote awareness and bring \nmore affordable treatment options to both providers and patients.  \n \n A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial.  And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence.  We've published more than 200 real-world studies in leading industry publications for over 70 oncology ", "original_text": "Last year, nearly 900 physicians actively accrued patients to clinical trial. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c72a3cdd6727bac3df49d065474dec9013c2af0a8d79a49a72a2fe6b73f44c39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8256e61f-f149-4b59-867f-a9dce617a158", "node_type": "1", "metadata": {"window": "As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial.  And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence.  We've published more than 200 real-world studies in leading industry publications for over 70 oncology ", "original_text": "We've published more than 200 real-world studies in leading industry publications for over 70 oncology "}, "hash": "aa449112b71fe80d0b470ddb3016c58b467a56858e95d223a8d8bfaf8083f5a7", "class_name": "RelatedNodeInfo"}}, "text": "And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence. ", "start_char_idx": 4129, "end_char_idx": 4256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8256e61f-f149-4b59-867f-a9dce617a158": {"__data__": {"id_": "8256e61f-f149-4b59-867f-a9dce617a158", "embedding": null, "metadata": {"window": "As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial.  And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence.  We've published more than 200 real-world studies in leading industry publications for over 70 oncology ", "original_text": "We've published more than 200 real-world studies in leading industry publications for over 70 oncology ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59636fb-a268-4883-88cc-1c218d89aa46", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ab01deafd1202c2f48c5813aec59d7be0d5e478e50290f753a9da4a237ae216", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69cf131d-5e5a-4f44-8755-8c0ae5bd214b", "node_type": "1", "metadata": {"window": "A great example is our US oncology research, which continues to play a central role in accelerating research and \nscience.  As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial.  And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence.  We've published more than 200 real-world studies in leading industry publications for over 70 oncology ", "original_text": "And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence. ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a761268d5ffd9f2409161ac9244f3194326acaf4d3b5e43a8f5164f24af9746", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98451494-4b63-4cd0-8f87-c676e55694fa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications.  We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients. ", "original_text": "McKesson Corp.  "}, "hash": "68469419d1b2c94e6f332b0fce4c27cdc44aa0f1ed78d2cb0e2ecd7d4ec6c3e2", "class_name": "RelatedNodeInfo"}}, "text": "We've published more than 200 real-world studies in leading industry publications for over 70 oncology ", "start_char_idx": 4256, "end_char_idx": 4359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98451494-4b63-4cd0-8f87-c676e55694fa": {"__data__": {"id_": "98451494-4b63-4cd0-8f87-c676e55694fa", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications.  We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8256e61f-f149-4b59-867f-a9dce617a158", "node_type": "1", "metadata": {"window": "As one of the largest community based oncology research programs, it has contributed to more than 100 \nFDA app roved cancer therapies.  Last year, nearly 900 physicians actively accrued patients to clinical trial.  And \nthrough Ontada, we're leveraging the reach and resources across the ecosystem to generate real -world data and \nevidence.  We've published more than 200 real-world studies in leading industry publications for over 70 oncology ", "original_text": "We've published more than 200 real-world studies in leading industry publications for over 70 oncology ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8559d3606cd548e3d3dfa623c3a674c46d5a28be12c6afa806407c44796d6378", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48c7fbf9-0805-41af-994d-26905b185118", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications.  We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications. "}, "hash": "5c364e4684fea793779b7a1d2423f2f0005dd6c4bec8f290e19eee98a31471fb", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48c7fbf9-0805-41af-994d-26905b185118": {"__data__": {"id_": "48c7fbf9-0805-41af-994d-26905b185118", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications.  We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98451494-4b63-4cd0-8f87-c676e55694fa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications.  We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ba0228420c55695cbdafd788da1eaca140ccb49d0529fb26b16f05ad92710f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a2d3023-7b0a-4b3a-a160-c91704ee2781", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications.  We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n", "original_text": "We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n"}, "hash": "8472bf2bd4debb6fa832513179a744038abc13e4c60c81a661effec656362930", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications. ", "start_char_idx": 16, "end_char_idx": 193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a2d3023-7b0a-4b3a-a160-c91704ee2781": {"__data__": {"id_": "9a2d3023-7b0a-4b3a-a160-c91704ee2781", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications.  We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n", "original_text": "We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48c7fbf9-0805-41af-994d-26905b185118", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications.  We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0726945ca19050b9a518ddcd66599a39d203f196c4f15031c5c1b0c15ecbf235", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e18f049-b282-46a9-974f-02a2ebabaf51", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications.  We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023. ", "original_text": "As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients. "}, "hash": "afce655c4c7ef7bcaaa53658e9d72c7221ddc126e2e46b1d28e3a6169aa7d0d5", "class_name": "RelatedNodeInfo"}}, "text": "We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n", "start_char_idx": 193, "end_char_idx": 339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e18f049-b282-46a9-974f-02a2ebabaf51": {"__data__": {"id_": "7e18f049-b282-46a9-974f-02a2ebabaf51", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications.  We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023. ", "original_text": "As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a2d3023-7b0a-4b3a-a160-c91704ee2781", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications.  We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n", "original_text": "We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33dd947f1c82a3be4225284855f134036e67c3ac8fb77f9eb0ab34ad66fca83e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e675f606-3713-4992-baeb-7727df3c6746", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications.  We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives. ", "original_text": "The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023. "}, "hash": "10213ca874c4a918afb3da0f9fa35445b24cf570110b12400f935924bf2ad226", "class_name": "RelatedNodeInfo"}}, "text": "As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients. ", "start_char_idx": 339, "end_char_idx": 510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e675f606-3713-4992-baeb-7727df3c6746": {"__data__": {"id_": "e675f606-3713-4992-baeb-7727df3c6746", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications.  We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives. ", "original_text": "The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e18f049-b282-46a9-974f-02a2ebabaf51", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications.  We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023. ", "original_text": "As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed1e0f7bd65efaba94a24c117baa28e345f3cf1f2f715c5f6ae6aa5c2f90eb24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b0de301-8d82-4046-a86d-a37a1459a604", "node_type": "1", "metadata": {"window": "We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets. ", "original_text": "I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n"}, "hash": "68e3c7b64cf37fe76bc046b6de449cd6c693ee791f96b90977b18fd8381b626e", "class_name": "RelatedNodeInfo"}}, "text": "The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023. ", "start_char_idx": 510, "end_char_idx": 597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b0de301-8d82-4046-a86d-a37a1459a604": {"__data__": {"id_": "3b0de301-8d82-4046-a86d-a37a1459a604", "embedding": null, "metadata": {"window": "We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets. ", "original_text": "I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e675f606-3713-4992-baeb-7727df3c6746", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications.  We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives. ", "original_text": "The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03715b464ef81627b40e380f313e90a858f2fc3d865aa1929e663a8e866470f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f82d514b-77ad-4154-9614-7930af66e07c", "node_type": "1", "metadata": {"window": "As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation. ", "original_text": "Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023. "}, "hash": "7f6e2860977d7b3c39f40127c138eb391450c9c5d1bdc568fe17a360c3b6445c", "class_name": "RelatedNodeInfo"}}, "text": "I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n", "start_char_idx": 597, "end_char_idx": 723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f82d514b-77ad-4154-9614-7930af66e07c": {"__data__": {"id_": "f82d514b-77ad-4154-9614-7930af66e07c", "embedding": null, "metadata": {"window": "As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation. ", "original_text": "Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b0de301-8d82-4046-a86d-a37a1459a604", "node_type": "1", "metadata": {"window": "We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets. ", "original_text": "I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6e31496ad768dc933427a8aa36d955dbe0ce9e5e0e2ba23f899eb35aac093ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "781f2940-427b-4605-adc5-5c9771c20be7", "node_type": "1", "metadata": {"window": "The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n", "original_text": "First, I want to share an exciting update  on our ESG initiatives. "}, "hash": "07260f22d1175b60f991f99ebd6f49c6e3f305292971f80fe31334cb99d5a46f", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023. ", "start_char_idx": 723, "end_char_idx": 847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "781f2940-427b-4605-adc5-5c9771c20be7": {"__data__": {"id_": "781f2940-427b-4605-adc5-5c9771c20be7", "embedding": null, "metadata": {"window": "The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n", "original_text": "First, I want to share an exciting update  on our ESG initiatives. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f82d514b-77ad-4154-9614-7930af66e07c", "node_type": "1", "metadata": {"window": "As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients.  The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation. ", "original_text": "Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e83d12cdcac6cb90297e4676ff22f61034714cc3a09b03474ea9dee22c53393e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd4cc339-ec70-432f-b791-371b14549512", "node_type": "1", "metadata": {"window": "I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends. ", "original_text": "At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets. "}, "hash": "bb46c9028c308abe1cd100f258b7802273616aed37e07e8c31db754a18b7861c", "class_name": "RelatedNodeInfo"}}, "text": "First, I want to share an exciting update  on our ESG initiatives. ", "start_char_idx": 847, "end_char_idx": 914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd4cc339-ec70-432f-b791-371b14549512": {"__data__": {"id_": "dd4cc339-ec70-432f-b791-371b14549512", "embedding": null, "metadata": {"window": "I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends. ", "original_text": "At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "781f2940-427b-4605-adc5-5c9771c20be7", "node_type": "1", "metadata": {"window": "The strategy is working and will continue McKesson's \ngrowth journey into fiscal 2023.  I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n", "original_text": "First, I want to share an exciting update  on our ESG initiatives. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "847cb99eaf024f7355bb09bee1562e7106f8a17886e383cf37be8fdc894c210b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85910fe1-e6d5-4de2-9927-a908820dd349", "node_type": "1", "metadata": {"window": "Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business. ", "original_text": "We have already submitted our targets to the \nScience Based Targets initiative for official validation. "}, "hash": "516b4a820436d177d37bcb3d9aa9463bac094ffe14767ffc4d9ad74fd38cefd7", "class_name": "RelatedNodeInfo"}}, "text": "At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets. ", "start_char_idx": 914, "end_char_idx": 1017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85910fe1-e6d5-4de2-9927-a908820dd349": {"__data__": {"id_": "85910fe1-e6d5-4de2-9927-a908820dd349", "embedding": null, "metadata": {"window": "Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business. ", "original_text": "We have already submitted our targets to the \nScience Based Targets initiative for official validation. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd4cc339-ec70-432f-b791-371b14549512", "node_type": "1", "metadata": {"window": "I'm confident in our ability to continuously execute, innovate and deliver \nsustainable profit growth for the long -term.  \n \n Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends. ", "original_text": "At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b01e9e47b0b1ae6485e6482a215a07f14d8a6be6886f4da2a2e4d5b084c9b3ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4a5446e-45e2-4f28-83fd-86f67b6ab95b", "node_type": "1", "metadata": {"window": "First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its. ", "original_text": "Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n"}, "hash": "004ab66effe5dfe2a0680f75b3fc65f5cdc9bc3ccc9c263ced57f2e0d67934bf", "class_name": "RelatedNodeInfo"}}, "text": "We have already submitted our targets to the \nScience Based Targets initiative for official validation. ", "start_char_idx": 1017, "end_char_idx": 1121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4a5446e-45e2-4f28-83fd-86f67b6ab95b": {"__data__": {"id_": "b4a5446e-45e2-4f28-83fd-86f67b6ab95b", "embedding": null, "metadata": {"window": "First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its. ", "original_text": "Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85910fe1-e6d5-4de2-9927-a908820dd349", "node_type": "1", "metadata": {"window": "Now, let me turn to the performance over the past 12 months and how we're positioned for success heading into \nfiscal 2023.  First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business. ", "original_text": "We have already submitted our targets to the \nScience Based Targets initiative for official validation. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80f733ae73a5a006128ce242008b3c6aef38cefdd7ecb599a358a876a70052bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "123a6163-eebd-4916-9d1d-432858c146b9", "node_type": "1", "metadata": {"window": "At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels. ", "original_text": "Next, let me provide so me observations on volume and utilization trends. "}, "hash": "322f2fcbe617aea7374cdf4d746019e9617625528376fecb197c31cd67bd9a9a", "class_name": "RelatedNodeInfo"}}, "text": "Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n", "start_char_idx": 1121, "end_char_idx": 1386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "123a6163-eebd-4916-9d1d-432858c146b9": {"__data__": {"id_": "123a6163-eebd-4916-9d1d-432858c146b9", "embedding": null, "metadata": {"window": "At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels. ", "original_text": "Next, let me provide so me observations on volume and utilization trends. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4a5446e-45e2-4f28-83fd-86f67b6ab95b", "node_type": "1", "metadata": {"window": "First, I want to share an exciting update  on our ESG initiatives.  At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its. ", "original_text": "Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c87c26d7c1b47d5261b50ce592c31546a10e6653391c3dc8127cd702f5ff63b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd66ed84-b850-42f9-9233-62d8bdf2bf38", "node_type": "1", "metadata": {"window": "We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n", "original_text": "We're encouraged by the prescription \nvolume and medical visit levels across the business. "}, "hash": "ad4257d806ad3a0bdf7dc87be08b7df853d1d8f9f07fb1a7ae705957f246aeeb", "class_name": "RelatedNodeInfo"}}, "text": "Next, let me provide so me observations on volume and utilization trends. ", "start_char_idx": 1386, "end_char_idx": 1460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd66ed84-b850-42f9-9233-62d8bdf2bf38": {"__data__": {"id_": "dd66ed84-b850-42f9-9233-62d8bdf2bf38", "embedding": null, "metadata": {"window": "We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n", "original_text": "We're encouraged by the prescription \nvolume and medical visit levels across the business. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "123a6163-eebd-4916-9d1d-432858c146b9", "node_type": "1", "metadata": {"window": "At the beginning of fiscal 2022, we \ncommitted to set science -based greenhouse gas reduction targets.  We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels. ", "original_text": "Next, let me provide so me observations on volume and utilization trends. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "434c823bf461bfefa5cfd45713030fddfaa2e04a96aae3631642814340d79e23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2816ba57-cbdb-4cdf-b04c-e0cfb87bec59", "node_type": "1", "metadata": {"window": "Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022. ", "original_text": "We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its. "}, "hash": "26ed4e610090e41203c6bb7a492bd2dc7a570ec0aeefc2b79f1451d690c482b0", "class_name": "RelatedNodeInfo"}}, "text": "We're encouraged by the prescription \nvolume and medical visit levels across the business. ", "start_char_idx": 1460, "end_char_idx": 1551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2816ba57-cbdb-4cdf-b04c-e0cfb87bec59": {"__data__": {"id_": "2816ba57-cbdb-4cdf-b04c-e0cfb87bec59", "embedding": null, "metadata": {"window": "Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022. ", "original_text": "We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd66ed84-b850-42f9-9233-62d8bdf2bf38", "node_type": "1", "metadata": {"window": "We have already submitted our targets to the \nScience Based Targets initiative for official validation.  Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n", "original_text": "We're encouraged by the prescription \nvolume and medical visit levels across the business. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2bb1c5407d05c7ad7c70d317889a3b42a288a9819af30bbd29e2d91bd0fb93e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ca47f81-6757-486b-a689-d53717395cc6", "node_type": "1", "metadata": {"window": "Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n", "original_text": "While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels. "}, "hash": "f655d125c37a307f74ac2f465a2745955f0c6869169c2a72c539aa47dabcdd58", "class_name": "RelatedNodeInfo"}}, "text": "We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its. ", "start_char_idx": 1551, "end_char_idx": 1674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ca47f81-6757-486b-a689-d53717395cc6": {"__data__": {"id_": "5ca47f81-6757-486b-a689-d53717395cc6", "embedding": null, "metadata": {"window": "Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n", "original_text": "While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2816ba57-cbdb-4cdf-b04c-e0cfb87bec59", "node_type": "1", "metadata": {"window": "Through initiatives across operations and supply chain \nmanagement, we're setting measurable and specific goals to reduce both Scope 1 and Scope 2 emissions, \nbuilding a more sustainable business, and ultimately, serving the health of patients and communities.  \n \n Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022. ", "original_text": "We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4273bc1c4f9b70375bdb7645c1477f1f610e4df3f0f4dc87b8b61569b6cd11a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86367960-0e92-431c-a6ee-940ef861a68a", "node_type": "1", "metadata": {"window": "We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n", "original_text": "We anticipate the \npositive trends to continue in fiscal 2023.  \n \n"}, "hash": "5a8f886ad12434c441601e4e0b5a5a08c377c4b175075568eafc83afff7fb601", "class_name": "RelatedNodeInfo"}}, "text": "While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels. ", "start_char_idx": 1674, "end_char_idx": 1808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86367960-0e92-431c-a6ee-940ef861a68a": {"__data__": {"id_": "86367960-0e92-431c-a6ee-940ef861a68a", "embedding": null, "metadata": {"window": "We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n", "original_text": "We anticipate the \npositive trends to continue in fiscal 2023.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ca47f81-6757-486b-a689-d53717395cc6", "node_type": "1", "metadata": {"window": "Next, let me provide so me observations on volume and utilization trends.  We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n", "original_text": "While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84a232c56d0b7aff1bf8a0b3eaec6e6f2d7fa44a6d17a57faf1d4fecd1048df3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08b1d8af-df10-46d3-bc31-6dabbe0e14b6", "node_type": "1", "metadata": {"window": "We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations. ", "original_text": "In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022. "}, "hash": "4bcba154c2e3f3b0ce1ca05962c986f2404aab694d9789e1977bb1b9c4548d30", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate the \npositive trends to continue in fiscal 2023.  \n \n", "start_char_idx": 1808, "end_char_idx": 1875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08b1d8af-df10-46d3-bc31-6dabbe0e14b6": {"__data__": {"id_": "08b1d8af-df10-46d3-bc31-6dabbe0e14b6", "embedding": null, "metadata": {"window": "We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations. ", "original_text": "In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86367960-0e92-431c-a6ee-940ef861a68a", "node_type": "1", "metadata": {"window": "We're encouraged by the prescription \nvolume and medical visit levels across the business.  We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n", "original_text": "We anticipate the \npositive trends to continue in fiscal 2023.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9160850c73708663b620c9a3cdc8299d9290b56c0b6126192148410281b1d18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5615432-a377-4d22-9309-b043a3ea4e07", "node_type": "1", "metadata": {"window": "While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n", "original_text": "Our ability to drive sustainable growth in this business derives from a few factors. \n"}, "hash": "7c6e4d76c305114fe6ca16aca0085797088e50b41643dfb0b3c239b17a5ef542", "class_name": "RelatedNodeInfo"}}, "text": "In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022. ", "start_char_idx": 1875, "end_char_idx": 2020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5615432-a377-4d22-9309-b043a3ea4e07": {"__data__": {"id_": "a5615432-a377-4d22-9309-b043a3ea4e07", "embedding": null, "metadata": {"window": "While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n", "original_text": "Our ability to drive sustainable growth in this business derives from a few factors. \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08b1d8af-df10-46d3-bc31-6dabbe0e14b6", "node_type": "1", "metadata": {"window": "We've seen continued improvement in pharmaceutical \nprescription volume, oncology visits and primary care patient vis its.  While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations. ", "original_text": "In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6aefb16b20c4cd67f4347d4a9c07876ec818102c450461ae28a884d686c5ce01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "288c46e9-fe5b-4bbe-a627-3078e37bab4a", "node_type": "1", "metadata": {"window": "We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem. ", "original_text": "As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n"}, "hash": "7061581dc55de40f70eb13fb9512e03d1d8a5822850047113207782d0d896c82", "class_name": "RelatedNodeInfo"}}, "text": "Our ability to drive sustainable growth in this business derives from a few factors. \n", "start_char_idx": 2020, "end_char_idx": 2106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "288c46e9-fe5b-4bbe-a627-3078e37bab4a": {"__data__": {"id_": "288c46e9-fe5b-4bbe-a627-3078e37bab4a", "embedding": null, "metadata": {"window": "We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem. ", "original_text": "As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5615432-a377-4d22-9309-b043a3ea4e07", "node_type": "1", "metadata": {"window": "While recovery in certain markets like \nextended care may be lagging, we are seeing other markets recover close to pre -COVID levels.  We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n", "original_text": "Our ability to drive sustainable growth in this business derives from a few factors. \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "620b5ff01572558e043e885874c411bd2341fd52a414e5695efa956e72a5439e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4723a1f4-6ea3-4c66-9d75-1a5680542769", "node_type": "1", "metadata": {"window": "In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada. ", "original_text": "On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations. "}, "hash": "85f5133fb083dee772d39c2f688cb0cb0ba728766dc22cc76841f80b187cdd7a", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n", "start_char_idx": 2106, "end_char_idx": 2283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4723a1f4-6ea3-4c66-9d75-1a5680542769": {"__data__": {"id_": "4723a1f4-6ea3-4c66-9d75-1a5680542769", "embedding": null, "metadata": {"window": "In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada. ", "original_text": "On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "288c46e9-fe5b-4bbe-a627-3078e37bab4a", "node_type": "1", "metadata": {"window": "We anticipate the \npositive trends to continue in fiscal 2023.  \n \n In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem. ", "original_text": "As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c0f8cb3e51e5ea815d771e6d9740aa89fe66f681ff4679ab81595537c38b3c6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2a25d0c-5efb-4fa4-b1e4-db7d5a4f2b2f", "node_type": "1", "metadata": {"window": "Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n", "original_text": "Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n"}, "hash": "de50bb69527a2710f5a6f0cb680aa6ccc50b67a452203327fa7d6b8e8f53d43b", "class_name": "RelatedNodeInfo"}}, "text": "On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations. ", "start_char_idx": 2283, "end_char_idx": 2429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2a25d0c-5efb-4fa4-b1e4-db7d5a4f2b2f": {"__data__": {"id_": "c2a25d0c-5efb-4fa4-b1e4-db7d5a4f2b2f", "embedding": null, "metadata": {"window": "Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n", "original_text": "Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4723a1f4-6ea3-4c66-9d75-1a5680542769", "node_type": "1", "metadata": {"window": "In US Pharmaceutical, we saw stability in the distributi on fundamentals reflected in solid growth in adjusted \noperating profit in fiscal 2022.  Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada. ", "original_text": "On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01e33501f6c87e34580aebe8403122d09a02557fbc8e4a3452841808670ed287", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2f548b0-abec-4ad3-92b9-9156acfb766f", "node_type": "1", "metadata": {"window": "As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered. ", "original_text": "We remain focused on the investment and expansion of our oncology ecosystem. "}, "hash": "13140edaa44ff96ea0253f7a74a0b47d374273e3aba056d4f4537e24df122ee6", "class_name": "RelatedNodeInfo"}}, "text": "Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n", "start_char_idx": 2429, "end_char_idx": 2629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2f548b0-abec-4ad3-92b9-9156acfb766f": {"__data__": {"id_": "b2f548b0-abec-4ad3-92b9-9156acfb766f", "embedding": null, "metadata": {"window": "As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered. ", "original_text": "We remain focused on the investment and expansion of our oncology ecosystem. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2a25d0c-5efb-4fa4-b1e4-db7d5a4f2b2f", "node_type": "1", "metadata": {"window": "Our ability to drive sustainable growth in this business derives from a few factors. \n As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n", "original_text": "Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd06ab973c2745d1d5fffc1d7d99c6e0b7de5b918c95bf66a1196a3302cfd0f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cfe7d68-aa5f-4d31-a15f-032105460c55", "node_type": "1", "metadata": {"window": "On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago. ", "original_text": "We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada. "}, "hash": "9c9e3cc094fff0a93792b75fc5b1a0e5d348f0737efac625419fb190fe70030c", "class_name": "RelatedNodeInfo"}}, "text": "We remain focused on the investment and expansion of our oncology ecosystem. ", "start_char_idx": 2629, "end_char_idx": 2706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cfe7d68-aa5f-4d31-a15f-032105460c55": {"__data__": {"id_": "1cfe7d68-aa5f-4d31-a15f-032105460c55", "embedding": null, "metadata": {"window": "On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago. ", "original_text": "We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2f548b0-abec-4ad3-92b9-9156acfb766f", "node_type": "1", "metadata": {"window": "As I mentioned earlier, we continue to invest in the core distribution assets expand ing and strengthening our \ncapabilities and unlocking new efficiencies in the business.  \n \n On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered. ", "original_text": "We remain focused on the investment and expansion of our oncology ecosystem. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3fd94097e3c8e868277a4db2d8ca11510658b02e1ef731038b4dc0870874955f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e9dc1e5-f147-4a67-b6ba-e93d9f1353fd", "node_type": "1", "metadata": {"window": "Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients. ", "original_text": "They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n"}, "hash": "875eab08499308f986b1dc57e1d5f0996a9c9adb7246f069a138f9ea13bd237e", "class_name": "RelatedNodeInfo"}}, "text": "We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada. ", "start_char_idx": 2706, "end_char_idx": 2873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e9dc1e5-f147-4a67-b6ba-e93d9f1353fd": {"__data__": {"id_": "7e9dc1e5-f147-4a67-b6ba-e93d9f1353fd", "embedding": null, "metadata": {"window": "Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients. ", "original_text": "They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cfe7d68-aa5f-4d31-a15f-032105460c55", "node_type": "1", "metadata": {"window": "On the generics and branded front, the fundamentals of the pricing environment remains stable and generally \ntrack in line with our expectations.  Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago. ", "original_text": "We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b0ba6fb0725e9148e21a44ef7fd78ceb7b8d71c82bfb8d438dc8c2ba26fa7ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3821714c-cc1d-4e76-a207-480259b7a4b4", "node_type": "1", "metadata": {"window": "We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program. ", "original_text": "In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered. "}, "hash": "e18c32b9cc7c2861d426e2ea0e66f6bd8a6c6b292a36632b65140301078cc76f", "class_name": "RelatedNodeInfo"}}, "text": "They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n", "start_char_idx": 2873, "end_char_idx": 3039, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3821714c-cc1d-4e76-a207-480259b7a4b4": {"__data__": {"id_": "3821714c-cc1d-4e76-a207-480259b7a4b4", "embedding": null, "metadata": {"window": "We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program. ", "original_text": "In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e9dc1e5-f147-4a67-b6ba-e93d9f1353fd", "node_type": "1", "metadata": {"window": "Our balanced approach o f managing a broad portfolio of pharmaceutical \nproducts allows us to strengthen our competitive position and enables us to be resilient and flexible to market \nmovements.  \n \n We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients. ", "original_text": "They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "002ff23226e5510aed97ad90792cbb4080a103f58bbd1bfbc38ff851868b0eff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eef3ae1e-65e8-43d3-ae66-fe9f83b6ac62", "node_type": "1", "metadata": {"window": "We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n", "original_text": "A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago. "}, "hash": "df6f834c902a4cef9aa46b9dd915facd058cd2e5997a8c6eeffcf7e758daf59f", "class_name": "RelatedNodeInfo"}}, "text": "In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered. ", "start_char_idx": 3039, "end_char_idx": 3281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eef3ae1e-65e8-43d3-ae66-fe9f83b6ac62": {"__data__": {"id_": "eef3ae1e-65e8-43d3-ae66-fe9f83b6ac62", "embedding": null, "metadata": {"window": "We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n", "original_text": "A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3821714c-cc1d-4e76-a207-480259b7a4b4", "node_type": "1", "metadata": {"window": "We remain focused on the investment and expansion of our oncology ecosystem.  We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program. ", "original_text": "In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d997d40b55c51622dd1b40fdaf621f35793ab1ff093c22ade29dc0a1aa4b5a00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b22915bf-2b18-4cec-a473-1c7e2457be7f", "node_type": "1", "metadata": {"window": "They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n", "original_text": "The solution is focused on automating \nbenefit verification and hu b enrollments for patients. "}, "hash": "64e2fdbe1087646adbd09ec9f764eed44d7f6fd8d76c4d5031bbd5c6ffa5882a", "class_name": "RelatedNodeInfo"}}, "text": "A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago. ", "start_char_idx": 3281, "end_char_idx": 3429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b22915bf-2b18-4cec-a473-1c7e2457be7f": {"__data__": {"id_": "b22915bf-2b18-4cec-a473-1c7e2457be7f", "embedding": null, "metadata": {"window": "They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n", "original_text": "The solution is focused on automating \nbenefit verification and hu b enrollments for patients. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eef3ae1e-65e8-43d3-ae66-fe9f83b6ac62", "node_type": "1", "metadata": {"window": "We're pl eased with the growth \nmomentum across our oncology assets from provider solutions in the US oncology network to our data and our \ninsights business, Ontada.  They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n", "original_text": "A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d18ccd6b5ccf6d3ae7e781545ad12d92e7933eaeb88296551b5e2ea7b40c0a01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afc2d9bc-fe55-4d99-85c4-c626e82b43e4", "node_type": "1", "metadata": {"window": "In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n Our future innovations and investments will be centered aro und expanding the reach of our current products into ", "original_text": "And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program. "}, "hash": "c35b4ab7725970fa0e01767ad31a6412115da8d958e1299d61fb86b68220034b", "class_name": "RelatedNodeInfo"}}, "text": "The solution is focused on automating \nbenefit verification and hu b enrollments for patients. ", "start_char_idx": 3429, "end_char_idx": 3524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afc2d9bc-fe55-4d99-85c4-c626e82b43e4": {"__data__": {"id_": "afc2d9bc-fe55-4d99-85c4-c626e82b43e4", "embedding": null, "metadata": {"window": "In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n Our future innovations and investments will be centered aro und expanding the reach of our current products into ", "original_text": "And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b22915bf-2b18-4cec-a473-1c7e2457be7f", "node_type": "1", "metadata": {"window": "They are critical pieces to the long -term growth of this segment, and we're excited to \ncapture the m arket opportunity and further our progress in fiscal 2023.  \n \n In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n", "original_text": "The solution is focused on automating \nbenefit verification and hu b enrollments for patients. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "699a662a52790168a9c10d3c175338172901032fdd2087433e5b3d61129f1b26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4cfbd8b-14b8-4047-b91e-f72123eb3c27", "node_type": "1", "metadata": {"window": "A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n Our future innovations and investments will be centered aro und expanding the reach of our current products into ", "original_text": "It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n"}, "hash": "f7da3e889a534248f49e971467f7bf193dd6757a85b80bcb880308675d0ed91d", "class_name": "RelatedNodeInfo"}}, "text": "And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program. ", "start_char_idx": 3524, "end_char_idx": 3629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4cfbd8b-14b8-4047-b91e-f72123eb3c27": {"__data__": {"id_": "a4cfbd8b-14b8-4047-b91e-f72123eb3c27", "embedding": null, "metadata": {"window": "A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n Our future innovations and investments will be centered aro und expanding the reach of our current products into ", "original_text": "It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afc2d9bc-fe55-4d99-85c4-c626e82b43e4", "node_type": "1", "metadata": {"window": "In Prescription Technology Solutions, we saw another year of adjusted operating profit growth, driven by \nexpansion of our product offerings, as we bring more brands onto the platform and increase transaction volume \nas the market recovered.  A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n Our future innovations and investments will be centered aro und expanding the reach of our current products into ", "original_text": "And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program. ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b1318f2fd0165e767209aed91c99422fbf28a175565c726ca8599c13ca5cf90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "972e6428-79f6-4c33-b812-6ec6a28e7c03", "node_type": "1", "metadata": {"window": "The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n Our future innovations and investments will be centered aro und expanding the reach of our current products into ", "original_text": "We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n"}, "hash": "ce68e8c261897c84e43a9913de252d2545cb55750e38606617b04b401eb3e877", "class_name": "RelatedNodeInfo"}}, "text": "It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n", "start_char_idx": 3629, "end_char_idx": 3838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "972e6428-79f6-4c33-b812-6ec6a28e7c03": {"__data__": {"id_": "972e6428-79f6-4c33-b812-6ec6a28e7c03", "embedding": null, "metadata": {"window": "The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n Our future innovations and investments will be centered aro und expanding the reach of our current products into ", "original_text": "We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4cfbd8b-14b8-4047-b91e-f72123eb3c27", "node_type": "1", "metadata": {"window": "A good example of growth in this segment is our Access for More Patients, or AMP \nsolution, which was developed and launched about three years ago.  The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n Our future innovations and investments will be centered aro und expanding the reach of our current products into ", "original_text": "It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53da391fff613981700fa7fbbf20cdb08e52c6379390ed9e91194ca707dec339", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c61139b9-ce3a-4e9a-9f17-57446da1a7b4", "node_type": "1", "metadata": {"window": "And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n Our future innovations and investments will be centered aro und expanding the reach of our current products into ", "original_text": "Our future innovations and investments will be centered aro und expanding the reach of our current products into "}, "hash": "c00525d0fbb6eb60de68b913f406f5bae8f125015f8e5fa94ea17c39a2b8948b", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n", "start_char_idx": 3838, "end_char_idx": 3957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c61139b9-ce3a-4e9a-9f17-57446da1a7b4": {"__data__": {"id_": "c61139b9-ce3a-4e9a-9f17-57446da1a7b4", "embedding": null, "metadata": {"window": "And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n Our future innovations and investments will be centered aro und expanding the reach of our current products into ", "original_text": "Our future innovations and investments will be centered aro und expanding the reach of our current products into ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "efcdcca8-a1b8-4097-ad70-f9603582a650", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5a60dc6260d077caad19faf50830904b3356740362a7c53d030ea3dc4b1ca28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "972e6428-79f6-4c33-b812-6ec6a28e7c03", "node_type": "1", "metadata": {"window": "The solution is focused on automating \nbenefit verification and hu b enrollments for patients.  And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n Our future innovations and investments will be centered aro und expanding the reach of our current products into ", "original_text": "We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "350ce4d64eca77bcfa814692036002d041c08dd8008ec3fd2fea99a68268ea49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bf18227-d224-42b0-bf69-378bc64c813e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits.  We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year. ", "original_text": "McKesson Corp.  "}, "hash": "d856ab35c0444109dc0748e5a0c7dbdf8ef214494ed15b03d04805b2b9c2e87c", "class_name": "RelatedNodeInfo"}}, "text": "Our future innovations and investments will be centered aro und expanding the reach of our current products into ", "start_char_idx": 3957, "end_char_idx": 4070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bf18227-d224-42b0-bf69-378bc64c813e": {"__data__": {"id_": "6bf18227-d224-42b0-bf69-378bc64c813e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits.  We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c61139b9-ce3a-4e9a-9f17-57446da1a7b4", "node_type": "1", "metadata": {"window": "And in fiscal 2022, we saw accelerated growth with 25% \nincrease in the number of brands on the program.  It has contributed to the overall growth across the enterprise \nand more importantly, help patients get on therapies up to ei ght days faster and stay on therapies longer, driving \nbetter health outcomes.  \n \n We anticipate innovations like this will continue to fuel growth and strengthen our differentiated product offerings. \n Our future innovations and investments will be centered aro und expanding the reach of our current products into ", "original_text": "Our future innovations and investments will be centered aro und expanding the reach of our current products into ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d0e0f75343621db9b7f94c24c2811aa2ac759711feb3bebbe679c3bc4f21bf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1246137c-41ec-45c1-aa05-0d16c44f06b1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits.  We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits. "}, "hash": "2996a1ac5ec28f8989ecddc1647d7e69f4d3389cf15951a9b159b9a15bf6ac9c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1246137c-41ec-45c1-aa05-0d16c44f06b1": {"__data__": {"id_": "1246137c-41ec-45c1-aa05-0d16c44f06b1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits.  We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bf18227-d224-42b0-bf69-378bc64c813e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits.  We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ac0da37e1ad52db5a64fab94ab853a32adcbf19a8979135a1ede5ffd34373d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac8bbf51-4da6-467d-9163-9c313da7136a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits.  We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory. ", "original_text": "We continue to invest into the future growth of \nthis segment.  \n \n"}, "hash": "13291e005bb2cc0e16c203a1a5d1d6f36c1d14718e23353443332b502f7aaabe", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits. ", "start_char_idx": 16, "end_char_idx": 245, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac8bbf51-4da6-467d-9163-9c313da7136a": {"__data__": {"id_": "ac8bbf51-4da6-467d-9163-9c313da7136a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits.  We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory. ", "original_text": "We continue to invest into the future growth of \nthis segment.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1246137c-41ec-45c1-aa05-0d16c44f06b1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits.  We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9596dbac8942c61338bb0c4e9485740c75793a1bcecfabc869510e5f78ddbc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe72e066-2e1e-49a4-aef7-32bf38f8ddf8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits.  We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment. ", "original_text": "Moving on to Medical -Surgical, which has performed exceedingly well this pa st year. "}, "hash": "3f1f71a6ec8a2c2b583a0e1978ffbe61b355c6053cf28d795852d9790200557b", "class_name": "RelatedNodeInfo"}}, "text": "We continue to invest into the future growth of \nthis segment.  \n \n", "start_char_idx": 245, "end_char_idx": 312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe72e066-2e1e-49a4-aef7-32bf38f8ddf8": {"__data__": {"id_": "fe72e066-2e1e-49a4-aef7-32bf38f8ddf8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits.  We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment. ", "original_text": "Moving on to Medical -Surgical, which has performed exceedingly well this pa st year. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac8bbf51-4da6-467d-9163-9c313da7136a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits.  We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory. ", "original_text": "We continue to invest into the future growth of \nthis segment.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4c0492dae4c31c88fecb6758f91813edd76f7f913313ac865f9baaf15a82ccb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9ee8681-b886-4edb-b2b4-e9572984e55a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits.  We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities. ", "original_text": "Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit. "}, "hash": "2a41d1140d0ad392cb46d9cbe53f0fbb9532d9047473d179c7f7e44dac563488", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to Medical -Surgical, which has performed exceedingly well this pa st year. ", "start_char_idx": 312, "end_char_idx": 398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9ee8681-b886-4edb-b2b4-e9572984e55a": {"__data__": {"id_": "f9ee8681-b886-4edb-b2b4-e9572984e55a", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits.  We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities. ", "original_text": "Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe72e066-2e1e-49a4-aef7-32bf38f8ddf8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits.  We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment. ", "original_text": "Moving on to Medical -Surgical, which has performed exceedingly well this pa st year. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a7aa55f1cf44b24dd6af97e9a50b82c4aab551c1264eee069bdbd8305480037", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87a43fee-fb98-4c40-87c2-0fbaef3f86d0", "node_type": "1", "metadata": {"window": "We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n", "original_text": "The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory. "}, "hash": "3e0d022f9d58fff00e1b1978f0896d0d8036d28ee6293df139fdb12ef03864bf", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit. ", "start_char_idx": 398, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87a43fee-fb98-4c40-87c2-0fbaef3f86d0": {"__data__": {"id_": "87a43fee-fb98-4c40-87c2-0fbaef3f86d0", "embedding": null, "metadata": {"window": "We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n", "original_text": "The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9ee8681-b886-4edb-b2b4-e9572984e55a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits.  We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities. ", "original_text": "Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6009cf41d9c7c0ecf4379fa79164ab0f37ee3e447f1eaf0971e764e501e3345f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb1d3003-07a8-48ff-950c-173e49a0bbcd", "node_type": "1", "metadata": {"window": "Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n", "original_text": "Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment. "}, "hash": "21eb2fcc59089981bde82e4240d9f4495afb6dd81590b873816e0fdaff2d00de", "class_name": "RelatedNodeInfo"}}, "text": "The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory. ", "start_char_idx": 559, "end_char_idx": 672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb1d3003-07a8-48ff-950c-173e49a0bbcd": {"__data__": {"id_": "bb1d3003-07a8-48ff-950c-173e49a0bbcd", "embedding": null, "metadata": {"window": "Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n", "original_text": "Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87a43fee-fb98-4c40-87c2-0fbaef3f86d0", "node_type": "1", "metadata": {"window": "We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n", "original_text": "The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1255b3657f72ae831a5962071855f45acf417898f243a6f05e55c758d5ff036", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e841066-3a0b-42d6-b724-d865871f7861", "node_type": "1", "metadata": {"window": "Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca. ", "original_text": "Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities. "}, "hash": "26dce61365253cfd2b01ebd7e9ffed62810607fe07559292d748eceb5bc29abd", "class_name": "RelatedNodeInfo"}}, "text": "Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment. ", "start_char_idx": 672, "end_char_idx": 818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e841066-3a0b-42d6-b724-d865871f7861": {"__data__": {"id_": "6e841066-3a0b-42d6-b724-d865871f7861", "embedding": null, "metadata": {"window": "Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca. ", "original_text": "Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb1d3003-07a8-48ff-950c-173e49a0bbcd", "node_type": "1", "metadata": {"window": "Moving on to Medical -Surgical, which has performed exceedingly well this pa st year.  Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n", "original_text": "Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6aee82ba40d8f78196f50c821c0fc6d87cb6b7eec237707df2015d9525037dfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "299c3038-c5cf-4261-b678-7585f1145bf1", "node_type": "1", "metadata": {"window": "The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n", "original_text": "Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n"}, "hash": "f1082b36028e5a316368ebdeb5fe76e362a74f899d69e9e5621dadfb23a08264", "class_name": "RelatedNodeInfo"}}, "text": "Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities. ", "start_char_idx": 818, "end_char_idx": 975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "299c3038-c5cf-4261-b678-7585f1145bf1": {"__data__": {"id_": "299c3038-c5cf-4261-b678-7585f1145bf1", "embedding": null, "metadata": {"window": "The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n", "original_text": "Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e841066-3a0b-42d6-b724-d865871f7861", "node_type": "1", "metadata": {"window": "Excluding the benefit from \nCOVID -19 items, the underlying Medical -Surgical Distribution business grew at a double -digit rate for adjusted \noperating profit.  The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca. ", "original_text": "Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ddbaa4061eb6ced9a43cc734dddac81eabd7d379bd2c28a0826e048010afa24d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d5ee86d-fe89-4a36-89d3-4105bef4aad7", "node_type": "1", "metadata": {"window": "Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company. ", "original_text": "In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n"}, "hash": "0c0412d55da72717e3e5990e23817dd28ebf042ad20347dcd7b2aec622ca1ee7", "class_name": "RelatedNodeInfo"}}, "text": "Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n", "start_char_idx": 975, "end_char_idx": 1142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d5ee86d-fe89-4a36-89d3-4105bef4aad7": {"__data__": {"id_": "3d5ee86d-fe89-4a36-89d3-4105bef4aad7", "embedding": null, "metadata": {"window": "Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company. ", "original_text": "In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "299c3038-c5cf-4261-b678-7585f1145bf1", "node_type": "1", "metadata": {"window": "The lab business that we highlighted before is just one of the drivers for this outstanding  growth \ntrajectory.  Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n", "original_text": "Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "699d2bd1b47bf73e0d81fba855bf22c2ae4fc57160569929d0918643262c4cee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37b07e55-1f54-4e2e-98e3-1eefd2e69fbf", "node_type": "1", "metadata": {"window": "Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment. ", "original_text": "McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca. "}, "hash": "9c1e7c1a29be8556b8312980b028a429aeec2c82ec1adb5538a3092554dcdd66", "class_name": "RelatedNodeInfo"}}, "text": "In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n", "start_char_idx": 1142, "end_char_idx": 1247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37b07e55-1f54-4e2e-98e3-1eefd2e69fbf": {"__data__": {"id_": "37b07e55-1f54-4e2e-98e3-1eefd2e69fbf", "embedding": null, "metadata": {"window": "Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment. ", "original_text": "McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d5ee86d-fe89-4a36-89d3-4105bef4aad7", "node_type": "1", "metadata": {"window": "Recovery in the primary care market and our expansion of selling prescription drugs into the non -acute \nchannel also contributed to the segment.  Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company. ", "original_text": "In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54dc43a7413a0c18e30e1a9cf087efbdde8b85c718b1135f3a14bd24234266af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ab69789-a2d1-4568-a0d6-6996870ac038", "node_type": "1", "metadata": {"window": "Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n", "original_text": "We will \ncontinue to build and grow this business.  \n \n"}, "hash": "b6f2bd0cd8f9b82e75d6933abf7ad085811aa35c569c93d7957e336aa7e2a3cb", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca. ", "start_char_idx": 1247, "end_char_idx": 1467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ab69789-a2d1-4568-a0d6-6996870ac038": {"__data__": {"id_": "4ab69789-a2d1-4568-a0d6-6996870ac038", "embedding": null, "metadata": {"window": "Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n", "original_text": "We will \ncontinue to build and grow this business.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37b07e55-1f54-4e2e-98e3-1eefd2e69fbf", "node_type": "1", "metadata": {"window": "Looking ahead, as a leader in the alternate site market, we believe that \nthis segment is wel l positioned, as more site of care moves into the communities.  Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment. ", "original_text": "McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56bf5f038eb8197cab9d31161f22b30c5c456c04ac3db7c6a7e344dea5061614", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57182291-3090-40d3-ad02-24fd0efc644b", "node_type": "1", "metadata": {"window": "In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember. ", "original_text": "In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company. "}, "hash": "dc61e9ed71e2acea0ed21c8cbc337916a06203f02c6b9ef499f403685a043222", "class_name": "RelatedNodeInfo"}}, "text": "We will \ncontinue to build and grow this business.  \n \n", "start_char_idx": 1467, "end_char_idx": 1522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57182291-3090-40d3-ad02-24fd0efc644b": {"__data__": {"id_": "57182291-3090-40d3-ad02-24fd0efc644b", "embedding": null, "metadata": {"window": "In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember. ", "original_text": "In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ab69789-a2d1-4568-a0d6-6996870ac038", "node_type": "1", "metadata": {"window": "Our experience and our \nrelationships in every channel and setting of the alternate site markets enable us to capture this growth \nopportunity in the years ahead.  \n \n In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n", "original_text": "We will \ncontinue to build and grow this business.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ba16c55133ad6ab90dff78ee189ac487193568238c25159ecd1161d9b48ff8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6490911-41d9-4cd6-b743-f952f888da13", "node_type": "1", "metadata": {"window": "McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n", "original_text": "Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment. "}, "hash": "2da249eeb72120f3a62e8d869dcfb073ebda7e2b5b5bdb0a638ea2bb6ab1ffbf", "class_name": "RelatedNodeInfo"}}, "text": "In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company. ", "start_char_idx": 1522, "end_char_idx": 1681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6490911-41d9-4cd6-b743-f952f888da13": {"__data__": {"id_": "a6490911-41d9-4cd6-b743-f952f888da13", "embedding": null, "metadata": {"window": "McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n", "original_text": "Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57182291-3090-40d3-ad02-24fd0efc644b", "node_type": "1", "metadata": {"window": "In the International segment, our strategy and commitment to the Canadian operations remains unchanged. \n McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember. ", "original_text": "In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0659663189ceacdeb65389b20e113ca16e5d2dad7aa253aeb8f090771291e26f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f79cf1e5-4f33-4b28-8d1e-d156f1bee76f", "node_type": "1", "metadata": {"window": "We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n", "original_text": "Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n"}, "hash": "996d6cd20c1da66f8f8a282063a4ce1e8f41eba6757a688a924abd943573a188", "class_name": "RelatedNodeInfo"}}, "text": "Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment. ", "start_char_idx": 1681, "end_char_idx": 1920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f79cf1e5-4f33-4b28-8d1e-d156f1bee76f": {"__data__": {"id_": "f79cf1e5-4f33-4b28-8d1e-d156f1bee76f", "embedding": null, "metadata": {"window": "We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n", "original_text": "Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6490911-41d9-4cd6-b743-f952f888da13", "node_type": "1", "metadata": {"window": "McKesson Canada is a leader in pharmaceutical distribution in the country and has a portfolio of valuable assets, \nincluding the retail banner groups, Rexall, specialty pharmacies and  digital offerings such as Well.ca.  We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n", "original_text": "Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "480c3e720bb06c6dbc233c985d3abd1093ed23bde319489e067dac99c0b4b9d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1d715ee-20dd-42cf-9fd3-aacd07c3c0fc", "node_type": "1", "metadata": {"window": "In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation. ", "original_text": "We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember. "}, "hash": "a281788e67a5721948d5a4f2c6a5c5abe3c01f425ddf919cdac2b7e930461a50", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n", "start_char_idx": 1920, "end_char_idx": 2154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1d715ee-20dd-42cf-9fd3-aacd07c3c0fc": {"__data__": {"id_": "e1d715ee-20dd-42cf-9fd3-aacd07c3c0fc", "embedding": null, "metadata": {"window": "In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation. ", "original_text": "We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f79cf1e5-4f33-4b28-8d1e-d156f1bee76f", "node_type": "1", "metadata": {"window": "We will \ncontinue to build and grow this business.  \n \n In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n", "original_text": "Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5db09a89d297fc0c4ef6889f03b7c540aede63527e3ce0074ff4542c08547f3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76784bda-8c8b-4382-8747-3adf92373023", "node_type": "1", "metadata": {"window": "Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n", "original_text": "We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n"}, "hash": "573a5713d3f23abe65adaf3822b33ed37050d855cc7c656e3bfc1208ec6f3a76", "class_name": "RelatedNodeInfo"}}, "text": "We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember. ", "start_char_idx": 2154, "end_char_idx": 2390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76784bda-8c8b-4382-8747-3adf92373023": {"__data__": {"id_": "76784bda-8c8b-4382-8747-3adf92373023", "embedding": null, "metadata": {"window": "Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n", "original_text": "We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1d715ee-20dd-42cf-9fd3-aacd07c3c0fc", "node_type": "1", "metadata": {"window": "In summary, we're extremely pleased with the progress we've made in fiscal 2022 to further our transformation \ninto a diversified healthcare services company.  Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation. ", "original_text": "We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42e4151fe59f4842a8876fb7dfce96845d5765c72e285c0a972123a7be5027db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c15bdcc-b26c-45db-a69e-88d5765a8bb8", "node_type": "1", "metadata": {"window": "Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position. ", "original_text": "We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n"}, "hash": "4870ba37da278f7e7d7bd40061107ecc5636765b81b65bd906672aa57efe501b", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n", "start_char_idx": 2390, "end_char_idx": 2494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c15bdcc-b26c-45db-a69e-88d5765a8bb8": {"__data__": {"id_": "0c15bdcc-b26c-45db-a69e-88d5765a8bb8", "embedding": null, "metadata": {"window": "Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position. ", "original_text": "We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76784bda-8c8b-4382-8747-3adf92373023", "node_type": "1", "metadata": {"window": "Looking ahe ad, to our fiscal 2023, our guidance of $22.90 to \n$23.60 of adjusted earnings per diluted share includes organic growth of the underlying businesses, improved \noperating leverage and a balanced approach to capital deployment.  Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n", "original_text": "We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46258b12eb4a6d2174583aae5a391321556ef986cd440c93a662fe5117842dfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8089abb8-6866-4686-a736-3af4a14037dd", "node_type": "1", "metadata": {"window": "We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry. ", "original_text": "Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation. "}, "hash": "be22d6f3e72eab9b89438a19f5c8474f98dcdf217ef892ed626d05a7c7be90fd", "class_name": "RelatedNodeInfo"}}, "text": "We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n", "start_char_idx": 2494, "end_char_idx": 2605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8089abb8-6866-4686-a736-3af4a14037dd": {"__data__": {"id_": "8089abb8-6866-4686-a736-3af4a14037dd", "embedding": null, "metadata": {"window": "We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry. ", "original_text": "Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c15bdcc-b26c-45db-a69e-88d5765a8bb8", "node_type": "1", "metadata": {"window": "Excluding the contribution from  COVID -19-\nrelated items in both fiscal 2023 and fiscal 2022, and net gains from McKesson Ventures in fiscal 2022, we expect \nadjusted earnings per diluted share to grow 9% to 14% year -over-year.  \n \n We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position. ", "original_text": "We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cca4278b17bb313765d2ca9235c0f4a144cb8948104ef0f7d1440398f904584f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0a8ff78-3829-42ae-baf0-6c4fcbbec85c", "node_type": "1", "metadata": {"window": "We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n", "original_text": "Britt will w alk you through the additional details that we've included in the outlook.  \n \n"}, "hash": "522a34a5239bd3a185f2817c3868b442383fac70a7a079a4d7b10c61b1c85df1", "class_name": "RelatedNodeInfo"}}, "text": "Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation. ", "start_char_idx": 2605, "end_char_idx": 2726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0a8ff78-3829-42ae-baf0-6c4fcbbec85c": {"__data__": {"id_": "c0a8ff78-3829-42ae-baf0-6c4fcbbec85c", "embedding": null, "metadata": {"window": "We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n", "original_text": "Britt will w alk you through the additional details that we've included in the outlook.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8089abb8-6866-4686-a736-3af4a14037dd", "node_type": "1", "metadata": {"window": "We expect the adjusted operating profit growth in our US Phar maceutical, Prescription Technology and Medical -\nSurgical segments to be in line or above the long -term financial framework we laid out at our Investor Day last \nDecember.  We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry. ", "original_text": "Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1939e32e65a83f9c6e21dcb4964d77c7edfe5c4df360bf562cc623d547f3482", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce44142d-4a41-4700-88e9-2192a8b73c2f", "node_type": "1", "metadata": {"window": "We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners. ", "original_text": "As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position. "}, "hash": "1735ab602e0adaa8cb5851a62a95a2ad7b13092c1787e8d53ce0facd171b80ba", "class_name": "RelatedNodeInfo"}}, "text": "Britt will w alk you through the additional details that we've included in the outlook.  \n \n", "start_char_idx": 2726, "end_char_idx": 2818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce44142d-4a41-4700-88e9-2192a8b73c2f": {"__data__": {"id_": "ce44142d-4a41-4700-88e9-2192a8b73c2f", "embedding": null, "metadata": {"window": "We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners. ", "original_text": "As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0a8ff78-3829-42ae-baf0-6c4fcbbec85c", "node_type": "1", "metadata": {"window": "We anticipate the market to remain dynamic, particularly as it relates to supply chain  and inflation. \n We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n", "original_text": "Britt will w alk you through the additional details that we've included in the outlook.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92ef5b34c9ff3c1f82a1978aeaeab6cd4279e515500b41bb4fbe487f6d2977ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5055356-aeac-48de-a002-2e3f14105c56", "node_type": "1", "metadata": {"window": "Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time. ", "original_text": "We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry. "}, "hash": "41569441a2e6a9f9dcb14a8e317ff07a727880b9a3d18d955ec51ce2f83625b9", "class_name": "RelatedNodeInfo"}}, "text": "As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position. ", "start_char_idx": 2818, "end_char_idx": 2954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5055356-aeac-48de-a002-2e3f14105c56": {"__data__": {"id_": "b5055356-aeac-48de-a002-2e3f14105c56", "embedding": null, "metadata": {"window": "Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time. ", "original_text": "We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce44142d-4a41-4700-88e9-2192a8b73c2f", "node_type": "1", "metadata": {"window": "We're confident in the resiliency of our business model and our ability to minimize any potential impacts.  \n \n Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners. ", "original_text": "As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47c1f69564b0042d54514bc72ce0678f08a8dd8e07fcd3b38cc7d13ea879c511", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e288efb5-0178-4b17-9333-8a492e1f1f4c", "node_type": "1", "metadata": {"window": "Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n", "original_text": "Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n"}, "hash": "744ad817d3ad3e8dc714cdb4f5eeaadcd08dd3bd17f7acaad75d15e80c04e452", "class_name": "RelatedNodeInfo"}}, "text": "We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry. ", "start_char_idx": 2954, "end_char_idx": 3250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e288efb5-0178-4b17-9333-8a492e1f1f4c": {"__data__": {"id_": "e288efb5-0178-4b17-9333-8a492e1f1f4c", "embedding": null, "metadata": {"window": "Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n", "original_text": "Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5055356-aeac-48de-a002-2e3f14105c56", "node_type": "1", "metadata": {"window": "Our fiscal 2023 guidance does not assume a material headwind from supply chain disruption or sustained price \ninflation.  Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time. ", "original_text": "We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6cab8b313b544c7c1232480a83d3b2ade9300d6887dc7eaad24cca7825f7379", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6877b028-1d28-40e8-91eb-6c48635d90ae", "node_type": "1", "metadata": {"window": "As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon. ", "original_text": "I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners. "}, "hash": "c121a22c3ba9a43cc281ee63f1f09c774350d7b36ddd571354dbf4aa5e036ed2", "class_name": "RelatedNodeInfo"}}, "text": "Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n", "start_char_idx": 3250, "end_char_idx": 3440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6877b028-1d28-40e8-91eb-6c48635d90ae": {"__data__": {"id_": "6877b028-1d28-40e8-91eb-6c48635d90ae", "embedding": null, "metadata": {"window": "As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon. ", "original_text": "I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e288efb5-0178-4b17-9333-8a492e1f1f4c", "node_type": "1", "metadata": {"window": "Britt will w alk you through the additional details that we've included in the outlook.  \n \n As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n", "original_text": "Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8e5ff55da4055a034c7a6a79bd0346d22cddb56ad27de1632a9d0b352103dcc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1ca2b38-7781-423a-8c5d-a1568bca4ceb", "node_type": "1", "metadata": {"window": "We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon.  And now I'm going to hand it over to Britt.  \n ", "original_text": "Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time. "}, "hash": "6d090378c7377bceef155ea5f0fdbc6c0c1fa16b2d2818620f1840f4dc477d50", "class_name": "RelatedNodeInfo"}}, "text": "I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners. ", "start_char_idx": 3440, "end_char_idx": 3594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1ca2b38-7781-423a-8c5d-a1568bca4ceb": {"__data__": {"id_": "e1ca2b38-7781-423a-8c5d-a1568bca4ceb", "embedding": null, "metadata": {"window": "We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon.  And now I'm going to hand it over to Britt.  \n ", "original_text": "Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6877b028-1d28-40e8-91eb-6c48635d90ae", "node_type": "1", "metadata": {"window": "As we look ahead to fiscal 2023, we're excited and energized to build on the momentum and to capitalize on our \nstrong market position.  We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon. ", "original_text": "I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8483b600c873e863dc958ab53be424cbcfe5ae7d59dc7b6831d7cdac7449342b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd0e40ab-d27e-4a82-b510-ef92e0866ef0", "node_type": "1", "metadata": {"window": "Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon.  And now I'm going to hand it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We are truly \nenabling better health for all.  \n \n"}, "hash": "456121f3753ed3743578b0c6837247800fe1c4e7b3dc6caa3ae3be9e521afb56", "class_name": "RelatedNodeInfo"}}, "text": "Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time. ", "start_char_idx": 3594, "end_char_idx": 3764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd0e40ab-d27e-4a82-b510-ef92e0866ef0": {"__data__": {"id_": "cd0e40ab-d27e-4a82-b510-ef92e0866ef0", "embedding": null, "metadata": {"window": "Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon.  And now I'm going to hand it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We are truly \nenabling better health for all.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1ca2b38-7781-423a-8c5d-a1568bca4ceb", "node_type": "1", "metadata": {"window": "We're advancing our transformation to a diver sified healthcare services company, \nextending our long tradition of innovation and evolving our business while reaffirming our strong commitment to \naddressing the changing needs of our customers, their patients and the broader healthcare industry.  Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon.  And now I'm going to hand it over to Britt.  \n ", "original_text": "Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ce6da82cd18cf3af666eb2c1ee7a492654d84cfd855702e02604c4dbcf0ea02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7e2d9d6-0ba8-4158-a80c-dcd43c338344", "node_type": "1", "metadata": {"window": "I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon.  And now I'm going to hand it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Thank you for your time this afternoon. "}, "hash": "28b3efd775f9393e5ebbe457b36c98d747c8d9733901284e8f5b21fbca85ed30", "class_name": "RelatedNodeInfo"}}, "text": "We are truly \nenabling better health for all.  \n \n", "start_char_idx": 3764, "end_char_idx": 3814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7e2d9d6-0ba8-4158-a80c-dcd43c338344": {"__data__": {"id_": "e7e2d9d6-0ba8-4158-a80c-dcd43c338344", "embedding": null, "metadata": {"window": "I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon.  And now I'm going to hand it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Thank you for your time this afternoon. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd0e40ab-d27e-4a82-b510-ef92e0866ef0", "node_type": "1", "metadata": {"window": "Our succ ess \nin building differentiated assets and capabilities positions us well to support better health outcomes and to \naccelerate profitability and healthy growth for the company.  \n \n I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon.  And now I'm going to hand it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We are truly \nenabling better health for all.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e465b2e9c1a02bff8ff6a8ccb17daac720783459444469ec9a5a3181a90bb30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f9bb349-2a96-47a9-96f6-4bd42cac966a", "node_type": "1", "metadata": {"window": "Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon.  And now I'm going to hand it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And now I'm going to hand it over to Britt.  \n "}, "hash": "0eed8fa1ba094e04c2097b972aeec4b270b7af5e60bd19bc5c9c18e6ff144b49", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for your time this afternoon. ", "start_char_idx": 3814, "end_char_idx": 3854, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f9bb349-2a96-47a9-96f6-4bd42cac966a": {"__data__": {"id_": "5f9bb349-2a96-47a9-96f6-4bd42cac966a", "embedding": null, "metadata": {"window": "Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon.  And now I'm going to hand it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And now I'm going to hand it over to Britt.  \n ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7e2d9d6-0ba8-4158-a80c-dcd43c338344", "node_type": "1", "metadata": {"window": "I want to conclude my remarks by acknowledging our employees, who are dedicated to bringing insight products \nand services to our customers and partners.  Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon.  And now I'm going to hand it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Thank you for your time this afternoon. ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f0dcc47ff7f6f3e8ca6fccf657fa2306af5dbb4ceec675719405b4899b09147", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcc2e226-2c68-41d3-9a37-5eb8f6af3012", "node_type": "1", "metadata": {"window": "We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon.  And now I'm going to hand it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "705bf3196d791903b8ed8df7e15e61d4a0d68c158f5e376ef7e39d35e6c9f95c", "class_name": "RelatedNodeInfo"}}, "text": "And now I'm going to hand it over to Britt.  \n ", "start_char_idx": 3854, "end_char_idx": 3901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcc2e226-2c68-41d3-9a37-5eb8f6af3012": {"__data__": {"id_": "dcc2e226-2c68-41d3-9a37-5eb8f6af3012", "embedding": null, "metadata": {"window": "We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon.  And now I'm going to hand it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5a5d9a2c81021102b64bff62766152684d66ae9d167856cb4534aa91861d11", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f9bb349-2a96-47a9-96f6-4bd42cac966a", "node_type": "1", "metadata": {"window": "Thanks to their execution and their commitment to McKesson and to \neach other, we're improving care in every setting, one product, one partner and one patient at a time.  We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon.  And now I'm going to hand it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And now I'm going to hand it over to Britt.  \n ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3781d51f2676ca0439cec1ceb552c0b2dae6f747bb25671bb0034b1a5317651d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44bde4bf-342a-4588-a87e-92b8a2805fb2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian.  Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance. ", "original_text": "McKesson Corp.  "}, "hash": "b27a1ab8a037fb9dc89e85b6d8b6440786f9177334e7a6e58440d62e5fcbaeb6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 3901, "end_char_idx": 4258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44bde4bf-342a-4588-a87e-92b8a2805fb2": {"__data__": {"id_": "44bde4bf-342a-4588-a87e-92b8a2805fb2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian.  Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcc2e226-2c68-41d3-9a37-5eb8f6af3012", "node_type": "1", "metadata": {"window": "We are truly \nenabling better health for all.  \n \n Thank you for your time this afternoon.  And now I'm going to hand it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3bd940f76744170aab0d441cc27d78859fc4479f226bb673a9600e4641cab42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72ec6a54-4e0f-404e-8cde-9ddcf21b6551", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian.  Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian. "}, "hash": "320be464c7c6bd90102d16e2fefb7a3fd81cc58dbe6f93e770a5facf1ed1fb66", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72ec6a54-4e0f-404e-8cde-9ddcf21b6551": {"__data__": {"id_": "72ec6a54-4e0f-404e-8cde-9ddcf21b6551", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian.  Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44bde4bf-342a-4588-a87e-92b8a2805fb2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian.  Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e35a9aa5477acf59bdd715a8051c21b9f2cabd40682eb3a2322463eeedb92f1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21d062a3-7281-4cf1-a8b9-2b300aff087b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian.  Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company. ", "original_text": "Good afternoon. "}, "hash": "bcdff29e6eafeabc303643378909d325dc5682ead98cd91009d71c64161ffb90", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian. ", "start_char_idx": 16, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21d062a3-7281-4cf1-a8b9-2b300aff087b": {"__data__": {"id_": "21d062a3-7281-4cf1-a8b9-2b300aff087b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian.  Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company. ", "original_text": "Good afternoon. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72ec6a54-4e0f-404e-8cde-9ddcf21b6551", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian.  Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf3526eaf2432370145ba5c151188eef17fb36e70ee016878f75dadcd67bb495", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e16355f8-be5d-4c83-8e99-c89cddfb2e3f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian.  Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n", "original_text": "Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance. "}, "hash": "e49da2849010e65e0aac27ea1e7e14e164aa1cfd321fe6479289819dc77312fd", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon. ", "start_char_idx": 198, "end_char_idx": 214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e16355f8-be5d-4c83-8e99-c89cddfb2e3f": {"__data__": {"id_": "e16355f8-be5d-4c83-8e99-c89cddfb2e3f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian.  Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n", "original_text": "Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21d062a3-7281-4cf1-a8b9-2b300aff087b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian.  Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company. ", "original_text": "Good afternoon. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f914be146621ce7b7f03b5105a4d76b071240de50022feaf9de149e4e9b57b0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e58c2849-e4d3-40bb-933e-92d112dc1d54", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian.  Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution. ", "original_text": "At our Investor Day in December, we discussed the transformation underway at \nMcKesson. "}, "hash": "3c050dc5a417bf04d8a6d6f7d12fe4be961e3cd78c2d1ff5a351b54bb4cb2017", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance. ", "start_char_idx": 214, "end_char_idx": 333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e58c2849-e4d3-40bb-933e-92d112dc1d54": {"__data__": {"id_": "e58c2849-e4d3-40bb-933e-92d112dc1d54", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian.  Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution. ", "original_text": "At our Investor Day in December, we discussed the transformation underway at \nMcKesson. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e16355f8-be5d-4c83-8e99-c89cddfb2e3f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian.  Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n", "original_text": "Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "446ff5d1968bfa50e39eaff66b0d4c362cbe721b5d4e47f75c3c288a04445e0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d6dc1e9-de0d-4b87-ad8d-fee5ac76d19a", "node_type": "1", "metadata": {"window": "Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n", "original_text": "Distribution remains a core part of our company. "}, "hash": "e01116dc487ef5d6d329c03442eb23ecaf251b0594cde3bcc35a9c0942e1551a", "class_name": "RelatedNodeInfo"}}, "text": "At our Investor Day in December, we discussed the transformation underway at \nMcKesson. ", "start_char_idx": 333, "end_char_idx": 421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d6dc1e9-de0d-4b87-ad8d-fee5ac76d19a": {"__data__": {"id_": "8d6dc1e9-de0d-4b87-ad8d-fee5ac76d19a", "embedding": null, "metadata": {"window": "Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n", "original_text": "Distribution remains a core part of our company. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e58c2849-e4d3-40bb-933e-92d112dc1d54", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian.  Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution. ", "original_text": "At our Investor Day in December, we discussed the transformation underway at \nMcKesson. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd3535557554050a89d9ace3a34285f2e6ce57593fbe156b290e29a6e227f454", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19e1a2c6-16f2-4684-9ce4-ced99fb747d8", "node_type": "1", "metadata": {"window": "Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope. ", "original_text": "However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n"}, "hash": "a3821648ec82fb60c1418cda3ab66d37f7ebd9244158b1f0047d0123c38b34b0", "class_name": "RelatedNodeInfo"}}, "text": "Distribution remains a core part of our company. ", "start_char_idx": 421, "end_char_idx": 470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19e1a2c6-16f2-4684-9ce4-ced99fb747d8": {"__data__": {"id_": "19e1a2c6-16f2-4684-9ce4-ced99fb747d8", "embedding": null, "metadata": {"window": "Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope. ", "original_text": "However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d6dc1e9-de0d-4b87-ad8d-fee5ac76d19a", "node_type": "1", "metadata": {"window": "Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n", "original_text": "Distribution remains a core part of our company. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "035a1d8224002e19161869ae856c11764bbed21987c3ee5cf674f8ca25748aa6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92808fee-f86d-4be1-a71b-73ad0caeaad2", "node_type": "1", "metadata": {"window": "At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region. ", "original_text": "As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution. "}, "hash": "a9937c7f3c312f3c19686e92639c86be2f166770f64676b1bc65fa15498f51bb", "class_name": "RelatedNodeInfo"}}, "text": "However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n", "start_char_idx": 470, "end_char_idx": 689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92808fee-f86d-4be1-a71b-73ad0caeaad2": {"__data__": {"id_": "92808fee-f86d-4be1-a71b-73ad0caeaad2", "embedding": null, "metadata": {"window": "At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region. ", "original_text": "As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19e1a2c6-16f2-4684-9ce4-ced99fb747d8", "node_type": "1", "metadata": {"window": "Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance.  At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope. ", "original_text": "However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f889db876fa0a4190fbb7aeeee44db2359196001d8c3bd61306f821fc9bd5ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0490f44e-7c9b-41f8-a360-6d3b77fd20f3", "node_type": "1", "metadata": {"window": "Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n", "original_text": "We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n"}, "hash": "b68951f3453ca6328f1169fb1de27c8d245a89391ded00573231656441a8a7c6", "class_name": "RelatedNodeInfo"}}, "text": "As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution. ", "start_char_idx": 689, "end_char_idx": 1075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0490f44e-7c9b-41f8-a360-6d3b77fd20f3": {"__data__": {"id_": "0490f44e-7c9b-41f8-a360-6d3b77fd20f3", "embedding": null, "metadata": {"window": "Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n", "original_text": "We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92808fee-f86d-4be1-a71b-73ad0caeaad2", "node_type": "1", "metadata": {"window": "At our Investor Day in December, we discussed the transformation underway at \nMcKesson.  Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region. ", "original_text": "As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3a9d9c0bac4f07c2db7aba32718e6f14ce729728665548cf3556771da1495f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de02070c-bbca-46c0-98c3-758b247725a3", "node_type": "1", "metadata": {"window": "However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress. ", "original_text": "Let me start by discussing our focus to streamline the portfolio with an update on Eur ope. "}, "hash": "e96bfe55f3adb704fc79ea960410e9aaac865e0840671647513b2f90e4027a93", "class_name": "RelatedNodeInfo"}}, "text": "We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n", "start_char_idx": 1075, "end_char_idx": 1190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de02070c-bbca-46c0-98c3-758b247725a3": {"__data__": {"id_": "de02070c-bbca-46c0-98c3-758b247725a3", "embedding": null, "metadata": {"window": "However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress. ", "original_text": "Let me start by discussing our focus to streamline the portfolio with an update on Eur ope. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0490f44e-7c9b-41f8-a360-6d3b77fd20f3", "node_type": "1", "metadata": {"window": "Distribution remains a core part of our company.  However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n", "original_text": "We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac6ecd1c83d916a25d007140db2b701fb0f55aff0be8182e4db3ba014c29fb47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c66ee338-994d-446c-87ec-782f7b556ca6", "node_type": "1", "metadata": {"window": "As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress.  We remain committed to this set of actions. ", "original_text": "In early fiscal 2022, we \nannounced our strategic intent to exit the European region. "}, "hash": "214546715e21a7fc6f02bf3d508a2957fa9b9dc22534c7ec14b79626bcccd89f", "class_name": "RelatedNodeInfo"}}, "text": "Let me start by discussing our focus to streamline the portfolio with an update on Eur ope. ", "start_char_idx": 1190, "end_char_idx": 1282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c66ee338-994d-446c-87ec-782f7b556ca6": {"__data__": {"id_": "c66ee338-994d-446c-87ec-782f7b556ca6", "embedding": null, "metadata": {"window": "As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress.  We remain committed to this set of actions. ", "original_text": "In early fiscal 2022, we \nannounced our strategic intent to exit the European region. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de02070c-bbca-46c0-98c3-758b247725a3", "node_type": "1", "metadata": {"window": "However, we continue t o advance and grow as a \ndiversified healthcare services company, built on differentiated assets and strategies we're executing, delivering \nsustainable earnings growth across our businesses.  \n \n As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress. ", "original_text": "Let me start by discussing our focus to streamline the portfolio with an update on Eur ope. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4fa1a18c151b83737625cdc836a0debefa4f47c241c5d418f0439ddd2269635d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccb7ebdd-76e9-4497-b6a4-6982e52caf67", "node_type": "1", "metadata": {"window": "We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress.  We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets. ", "original_text": "The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n"}, "hash": "f49f818322991adc7caeb05462bb37616f2a6321606359874b52270543a33981", "class_name": "RelatedNodeInfo"}}, "text": "In early fiscal 2022, we \nannounced our strategic intent to exit the European region. ", "start_char_idx": 1282, "end_char_idx": 1368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccb7ebdd-76e9-4497-b6a4-6982e52caf67": {"__data__": {"id_": "ccb7ebdd-76e9-4497-b6a4-6982e52caf67", "embedding": null, "metadata": {"window": "We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress.  We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets. ", "original_text": "The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c66ee338-994d-446c-87ec-782f7b556ca6", "node_type": "1", "metadata": {"window": "As we articulated then, our confidence is based on three intercon nected factors: the successful focus to advance \nMcKesson's oncology and biopharma services ecosystems; leveraging our best -in-class assets and capabilities; \neffective allocation of capital, including streamlining our portfolio; and the momentum we've been generating \nthrough operating and working capital execution.  We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress.  We remain committed to this set of actions. ", "original_text": "In early fiscal 2022, we \nannounced our strategic intent to exit the European region. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23b04b0b7b1e24a116e7a8e150711ba1e4bd3eb095358c2abb84f76fa9d89895", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd3c9335-8347-468f-8dcf-d4697c1c62c1", "node_type": "1", "metadata": {"window": "Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress.  We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n", "original_text": "We've made good progress. "}, "hash": "9efac59a02b2d4d5f64bb04ae1fb9d3ff2254ced2dc8451c9a339d3dafe3d9ad", "class_name": "RelatedNodeInfo"}}, "text": "The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n", "start_char_idx": 1368, "end_char_idx": 1562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd3c9335-8347-468f-8dcf-d4697c1c62c1": {"__data__": {"id_": "bd3c9335-8347-468f-8dcf-d4697c1c62c1", "embedding": null, "metadata": {"window": "Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress.  We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n", "original_text": "We've made good progress. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccb7ebdd-76e9-4497-b6a4-6982e52caf67", "node_type": "1", "metadata": {"window": "We remain confident that we'll achieve the long -term targets that \nwe've provided for fiscal 2023 and beyond.  \n \n Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress.  We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets. ", "original_text": "The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3cb3340b792eefbfeaacb24afe88ae3447b1a047592d204e9d320db56b315349", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bc01857-8d11-40e6-b3a5-5d0bdf663596", "node_type": "1", "metadata": {"window": "In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress.  We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions. ", "original_text": "We remain committed to this set of actions. "}, "hash": "f42de362ee343192228b8b4aa1ed888f900e5a0f3d2c412852afe012ecba3f96", "class_name": "RelatedNodeInfo"}}, "text": "We've made good progress. ", "start_char_idx": 1562, "end_char_idx": 1588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bc01857-8d11-40e6-b3a5-5d0bdf663596": {"__data__": {"id_": "6bc01857-8d11-40e6-b3a5-5d0bdf663596", "embedding": null, "metadata": {"window": "In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress.  We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions. ", "original_text": "We remain committed to this set of actions. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd3c9335-8347-468f-8dcf-d4697c1c62c1", "node_type": "1", "metadata": {"window": "Let me start by discussing our focus to streamline the portfolio with an update on Eur ope.  In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress.  We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n", "original_text": "We've made good progress. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b8244fcb9e38df4f60a00db60e0df8a73ba78bb623ba7369768d6eec2ad58d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aedd1890-6915-4b91-a83c-384640e01b6d", "node_type": "1", "metadata": {"window": "The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress.  We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance. ", "original_text": "In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets. "}, "hash": "f90306f29211e9383299b0bda369d2ee0c02a9adc28571727823df627572144f", "class_name": "RelatedNodeInfo"}}, "text": "We remain committed to this set of actions. ", "start_char_idx": 1588, "end_char_idx": 1632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aedd1890-6915-4b91-a83c-384640e01b6d": {"__data__": {"id_": "aedd1890-6915-4b91-a83c-384640e01b6d", "embedding": null, "metadata": {"window": "The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress.  We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance. ", "original_text": "In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bc01857-8d11-40e6-b3a5-5d0bdf663596", "node_type": "1", "metadata": {"window": "In early fiscal 2022, we \nannounced our strategic intent to exit the European region.  The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress.  We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions. ", "original_text": "We remain committed to this set of actions. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "964a62398ffe56737de8d1894a11f929e747b129324855cfe5b5226affc6d2cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64217049-961d-440d-beb1-558a25ca4b0f", "node_type": "1", "metadata": {"window": "We've made good progress.  We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6. ", "original_text": "The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n"}, "hash": "9aadb2a02018ae62fec8726135994aaedf0c1dec78a1261865901ee41dad6acb", "class_name": "RelatedNodeInfo"}}, "text": "In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets. ", "start_char_idx": 1632, "end_char_idx": 1764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64217049-961d-440d-beb1-558a25ca4b0f": {"__data__": {"id_": "64217049-961d-440d-beb1-558a25ca4b0f", "embedding": null, "metadata": {"window": "We've made good progress.  We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6. ", "original_text": "The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aedd1890-6915-4b91-a83c-384640e01b6d", "node_type": "1", "metadata": {"window": "The transaction to complete a full exit of our European \noperations allow McKesson to streamline the portfolio, aligning future investments through our growth strategi es \nin North America.  \n \n We've made good progress.  We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance. ", "original_text": "In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7facf9eb5b1bab187409a61029f556b5ae2c727dacb1433b584ffb84f22ad21d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "913596ed-20b0-480e-82db-fa35541f40f5", "node_type": "1", "metadata": {"window": "We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n", "original_text": "We have successfully closed the following transactions. "}, "hash": "436f823430316f64168f742480131a3bf16e39c06491e0da9ec17cd4ffd7a0e6", "class_name": "RelatedNodeInfo"}}, "text": "The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n", "start_char_idx": 1764, "end_char_idx": 1869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "913596ed-20b0-480e-82db-fa35541f40f5": {"__data__": {"id_": "913596ed-20b0-480e-82db-fa35541f40f5", "embedding": null, "metadata": {"window": "We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n", "original_text": "We have successfully closed the following transactions. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64217049-961d-440d-beb1-558a25ca4b0f", "node_type": "1", "metadata": {"window": "We've made good progress.  We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6. ", "original_text": "The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59034704771c7c96c61d0f2df78dec0315ffc0277e4849e5b23a0af494139566", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "690bcf89-6ea6-4344-b070-0bb25bb860c0", "node_type": "1", "metadata": {"window": "In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark. ", "original_text": "In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance. "}, "hash": "0c2506b67e421dd727b9123b2a1ee333cfe3bcb49ecc85f5373e5d2d81809607", "class_name": "RelatedNodeInfo"}}, "text": "We have successfully closed the following transactions. ", "start_char_idx": 1869, "end_char_idx": 1925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "690bcf89-6ea6-4344-b070-0bb25bb860c0": {"__data__": {"id_": "690bcf89-6ea6-4344-b070-0bb25bb860c0", "embedding": null, "metadata": {"window": "In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark. ", "original_text": "In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "913596ed-20b0-480e-82db-fa35541f40f5", "node_type": "1", "metadata": {"window": "We remain committed to this set of actions.  In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n", "original_text": "We have successfully closed the following transactions. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc3629b15c9f60e1bc911b4d8b674c80422a530fd42d82cfdb46a0049664c2b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c75ba3e8-4611-4d0c-9532-4cac7df35e47", "node_type": "1", "metadata": {"window": "The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share. ", "original_text": "Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6. "}, "hash": "8890ce74aea1fe7c22ffcb493fc80568dbcf32365f6c5978c94309f226a2dc5f", "class_name": "RelatedNodeInfo"}}, "text": "In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance. ", "start_char_idx": 1925, "end_char_idx": 2140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c75ba3e8-4611-4d0c-9532-4cac7df35e47": {"__data__": {"id_": "c75ba3e8-4611-4d0c-9532-4cac7df35e47", "embedding": null, "metadata": {"window": "The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share. ", "original_text": "Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "690bcf89-6ea6-4344-b070-0bb25bb860c0", "node_type": "1", "metadata": {"window": "In July of 2021, we announced the \ntransaction with the PHOENIX Group to sell operations in six countries and other certain assets.  The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark. ", "original_text": "In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "041655904fb4be4718ff45f94548deff7849595d8f766a4e02feb59b09059c34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf4f6b40-360f-42f5-8c8c-c2aeee783f6d", "node_type": "1", "metadata": {"window": "We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group. ", "original_text": "During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n"}, "hash": "ee44b9505539a7c252b22fe652abeabb70f5cca0f1c9a39805286e3bfb8e3bfb", "class_name": "RelatedNodeInfo"}}, "text": "Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6. ", "start_char_idx": 2140, "end_char_idx": 2263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf4f6b40-360f-42f5-8c8c-c2aeee783f6d": {"__data__": {"id_": "cf4f6b40-360f-42f5-8c8c-c2aeee783f6d", "embedding": null, "metadata": {"window": "We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group. ", "original_text": "During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c75ba3e8-4611-4d0c-9532-4cac7df35e47", "node_type": "1", "metadata": {"window": "The transaction \nis proceeding wel l. We anticipate it will close in the second half of fiscal 2023.  \n \n We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share. ", "original_text": "Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62f5b99790a641fc77416785d3b01c74e86bc44fc8150a96424cf2da4c7b01ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c36818ee-1044-423f-bfeb-337bab6ffce4", "node_type": "1", "metadata": {"window": "In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n", "original_text": "Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark. "}, "hash": "3eeae066564c6cfce927695911a8b10e4bba03b9c5c9a2d9d26941184daf09dc", "class_name": "RelatedNodeInfo"}}, "text": "During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n", "start_char_idx": 2263, "end_char_idx": 2434, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c36818ee-1044-423f-bfeb-337bab6ffce4": {"__data__": {"id_": "c36818ee-1044-423f-bfeb-337bab6ffce4", "embedding": null, "metadata": {"window": "In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n", "original_text": "Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf4f6b40-360f-42f5-8c8c-c2aeee783f6d", "node_type": "1", "metadata": {"window": "We have successfully closed the following transactions.  In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group. ", "original_text": "During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0da75b92cad54ff40c64cc687e130f0f4259537f211dd6f902f5ba7fa0d2e0df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d21cd9b8-de22-415b-b8a5-8555d1799ff4", "node_type": "1", "metadata": {"window": "Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results. ", "original_text": "In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share. "}, "hash": "f99d6e7ca09d28b189b5fd8a2c03f763b013f8267338b357e8213cbc2494e4e7", "class_name": "RelatedNodeInfo"}}, "text": "Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark. ", "start_char_idx": 2434, "end_char_idx": 2545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d21cd9b8-de22-415b-b8a5-8555d1799ff4": {"__data__": {"id_": "d21cd9b8-de22-415b-b8a5-8555d1799ff4", "embedding": null, "metadata": {"window": "Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results. ", "original_text": "In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c36818ee-1044-423f-bfeb-337bab6ffce4", "node_type": "1", "metadata": {"window": "In the fourth quarter of fiscal 2022, we completed the sale \nof our Austrian business to Quadrifolia Management, and the sale of McKes son's remaining share of our German \njoint venture to Walgreens Boots Alliance.  Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n", "original_text": "Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2942a5dc2554c64b4af4ffe88838bb166522f5409798547af1783109064ae27e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e070d70-1f37-405b-8821-bfd51171919b", "node_type": "1", "metadata": {"window": "During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise. ", "original_text": "For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group. "}, "hash": "a53474664a2197d5f99201896560c19f202627e6682b3c425bf3a8d1abb2b34e", "class_name": "RelatedNodeInfo"}}, "text": "In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share. ", "start_char_idx": 2545, "end_char_idx": 2726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e070d70-1f37-405b-8821-bfd51171919b": {"__data__": {"id_": "9e070d70-1f37-405b-8821-bfd51171919b", "embedding": null, "metadata": {"window": "During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise. ", "original_text": "For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d21cd9b8-de22-415b-b8a5-8555d1799ff4", "node_type": "1", "metadata": {"window": "Recently, we completed the sale of McKesson's UK retail and \ndistribution businesses to AURELIUS, which closed on April 6.  During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results. ", "original_text": "In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c795e5ee062dc28a673dc5f1fe8b8264882c709a6d40c3af7870c18afc2a414", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4344dc0-e97e-4444-bfae-9bc6b6a24ecb", "node_type": "1", "metadata": {"window": "Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n", "original_text": "As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n"}, "hash": "9fd57945e64af2ee87764df9dd1960287626337aaf3f1187f7b0b7c5600be4e2", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group. ", "start_char_idx": 2726, "end_char_idx": 2952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4344dc0-e97e-4444-bfae-9bc6b6a24ecb": {"__data__": {"id_": "c4344dc0-e97e-4444-bfae-9bc6b6a24ecb", "embedding": null, "metadata": {"window": "Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n", "original_text": "As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e070d70-1f37-405b-8821-bfd51171919b", "node_type": "1", "metadata": {"window": "During the fourth quarter of fiscal 2022, we \nrecorded a  GAAP -only charge of $343 million related to our agreement to sell the UK retail and distribution \nbusiness.  \n \n Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise. ", "original_text": "For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34e7a2df838b20da9cf52a912bbe16b3f3cf39520ed5c0568b6361b03ddfe227", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f28bb7ea-75b3-402f-a95f-fcc81d749292", "node_type": "1", "metadata": {"window": "In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69. ", "original_text": "Let me now move to a review of our fiscal 2022 results. "}, "hash": "c2f363fb1300ea66df55a90008302be21c6180f46124428b6a53cbdf2af0c82b", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n", "start_char_idx": 2952, "end_char_idx": 3129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f28bb7ea-75b3-402f-a95f-fcc81d749292": {"__data__": {"id_": "f28bb7ea-75b3-402f-a95f-fcc81d749292", "embedding": null, "metadata": {"window": "In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69. ", "original_text": "Let me now move to a review of our fiscal 2022 results. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4344dc0-e97e-4444-bfae-9bc6b6a24ecb", "node_type": "1", "metadata": {"window": "Finally, we continue to explore strategic alternatives to exit our remaining operations in Norway and Denmark.  In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n", "original_text": "As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90d97eac0d0865d8ef125f4252b73af8921be347340805290b9e05874886f6a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cb1b2c8-546e-4148-849f-64a070332db0", "node_type": "1", "metadata": {"window": "For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n", "original_text": "My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise. "}, "hash": "a78ce58fdc3cd1132636b24ea97043c51de8159f14a64af4caba18934f77d951", "class_name": "RelatedNodeInfo"}}, "text": "Let me now move to a review of our fiscal 2022 results. ", "start_char_idx": 3129, "end_char_idx": 3185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cb1b2c8-546e-4148-849f-64a070332db0": {"__data__": {"id_": "1cb1b2c8-546e-4148-849f-64a070332db0", "embedding": null, "metadata": {"window": "For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n", "original_text": "My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f28bb7ea-75b3-402f-a95f-fcc81d749292", "node_type": "1", "metadata": {"window": "In \nfiscal 2022, our European operati ons, including held -for-sale accounting treatment impacts, contributed $409 \nmillion of adjusted operating profit or $1.97 per diluted share.  For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69. ", "original_text": "Let me now move to a review of our fiscal 2022 results. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1d444bdc9044d2d84206ab008c49d9f6846db6525acf5ad0e21ac72f7fa922a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bde514c-461b-4369-a413-2ccaa1958449", "node_type": "1", "metadata": {"window": "As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items. ", "original_text": "Fiscal 2022 was another year of strong execution for McKesson. \n"}, "hash": "160204398718387289352b354f50c63c9ea3f55f8aee6f43f8464a44378b9344", "class_name": "RelatedNodeInfo"}}, "text": "My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise. ", "start_char_idx": 3185, "end_char_idx": 3292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bde514c-461b-4369-a413-2ccaa1958449": {"__data__": {"id_": "9bde514c-461b-4369-a413-2ccaa1958449", "embedding": null, "metadata": {"window": "As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items. ", "original_text": "Fiscal 2022 was another year of strong execution for McKesson. \n", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cb1b2c8-546e-4148-849f-64a070332db0", "node_type": "1", "metadata": {"window": "For fiscal 2023, we anticipate our remaining \nEuropean operations will contribute approximately $0.85 to $1.15, whic h includes accretion resulting from the \nheld-for-sale accounting for the transaction for the PHOENIX Group.  As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n", "original_text": "My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3f180b1d8a942c49d82947082a7df23f3821ba5108f0fdc9a8848ea7ef21530", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c0a0d13-7165-4596-8afc-c62b605b613d", "node_type": "1", "metadata": {"window": "Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items.  The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts. ", "original_text": "We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69. "}, "hash": "aa8a9e3cff22ce0105e9de81be0a68cdfe32185ee95cbb4084a6e09ea9232f09", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal 2022 was another year of strong execution for McKesson. \n", "start_char_idx": 3292, "end_char_idx": 3356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c0a0d13-7165-4596-8afc-c62b605b613d": {"__data__": {"id_": "8c0a0d13-7165-4596-8afc-c62b605b613d", "embedding": null, "metadata": {"window": "Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items.  The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts. ", "original_text": "We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bde514c-461b-4369-a413-2ccaa1958449", "node_type": "1", "metadata": {"window": "As I mentioned on our third quarter earnings \ncall, we intend to deploy capital through share repurchases to offset the dilution resulting from the E uropean \ndivestitures.  \n \n Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items. ", "original_text": "Fiscal 2022 was another year of strong execution for McKesson. \n", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1c3e8afbd117fc0a238bc66aaada7b55439cb13aae0fed73121b54e6823d527", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cff709f-49c0-4d32-ae0b-a56a1d6acfe1", "node_type": "1", "metadata": {"window": "My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items.  The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts.  Excluding these items and the ", "original_text": "Our full year results included revenue and profit growth \nacross every business segment.  \n \n"}, "hash": "abdd3755cd5bcccee9e0d4d9c0f8907d8dc0f07a54430c4c8258d700c8e0c38d", "class_name": "RelatedNodeInfo"}}, "text": "We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69. ", "start_char_idx": 3356, "end_char_idx": 3535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cff709f-49c0-4d32-ae0b-a56a1d6acfe1": {"__data__": {"id_": "3cff709f-49c0-4d32-ae0b-a56a1d6acfe1", "embedding": null, "metadata": {"window": "My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items.  The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts.  Excluding these items and the ", "original_text": "Our full year results included revenue and profit growth \nacross every business segment.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c0a0d13-7165-4596-8afc-c62b605b613d", "node_type": "1", "metadata": {"window": "Let me now move to a review of our fiscal 2022 results.  My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items.  The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts. ", "original_text": "We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b14010fa14454fa1318713c690ff22c70f0347a39387720cd283ab6634a0dc1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "203dcdb7-3cd1-4c2f-a2c3-e514b5eac310", "node_type": "1", "metadata": {"window": "Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items.  The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts.  Excluding these items and the ", "original_text": "In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items. "}, "hash": "a82b944e0c3a93d7ede66381564ee2ba974a119f321ab37ed53885ee44e5a80b", "class_name": "RelatedNodeInfo"}}, "text": "Our full year results included revenue and profit growth \nacross every business segment.  \n \n", "start_char_idx": 3535, "end_char_idx": 3628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "203dcdb7-3cd1-4c2f-a2c3-e514b5eac310": {"__data__": {"id_": "203dcdb7-3cd1-4c2f-a2c3-e514b5eac310", "embedding": null, "metadata": {"window": "Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items.  The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts.  Excluding these items and the ", "original_text": "In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cff709f-49c0-4d32-ae0b-a56a1d6acfe1", "node_type": "1", "metadata": {"window": "My comments today will refer to our adjusted results on a \nyear-over-year basis, unless I state otherwise.  Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items.  The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts.  Excluding these items and the ", "original_text": "Our full year results included revenue and profit growth \nacross every business segment.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc8be76be680b9c7ebe4a49b26021661a6bd603be15da67a76f68b54207092fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ab86fff-da33-469f-b00b-31aee2e29dcc", "node_type": "1", "metadata": {"window": "We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items.  The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts.  Excluding these items and the ", "original_text": "The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts. "}, "hash": "a64d32cb2f275484b15e2f36f1f0e001408912d948dcea6c0b7e1416d18f7383", "class_name": "RelatedNodeInfo"}}, "text": "In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items. ", "start_char_idx": 3628, "end_char_idx": 3755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ab86fff-da33-469f-b00b-31aee2e29dcc": {"__data__": {"id_": "2ab86fff-da33-469f-b00b-31aee2e29dcc", "embedding": null, "metadata": {"window": "We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items.  The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts.  Excluding these items and the ", "original_text": "The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "203dcdb7-3cd1-4c2f-a2c3-e514b5eac310", "node_type": "1", "metadata": {"window": "Fiscal 2022 was another year of strong execution for McKesson. \n We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items.  The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts.  Excluding these items and the ", "original_text": "In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68143c0b3e0d7ee4d2fda25a4dfa3cfa7f5925f04fffa54b580e7579e7651b1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4fd860e-e1d6-4caa-9a71-2a6f5ae2e22a", "node_type": "1", "metadata": {"window": "Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items.  The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts.  Excluding these items and the ", "original_text": "Excluding these items and the "}, "hash": "2ddaf4136c82b9ebc1239536cb351e7f5d49439345749ce46abdf1dd2362b5d8", "class_name": "RelatedNodeInfo"}}, "text": "The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts. ", "start_char_idx": 3755, "end_char_idx": 4150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4fd860e-e1d6-4caa-9a71-2a6f5ae2e22a": {"__data__": {"id_": "e4fd860e-e1d6-4caa-9a71-2a6f5ae2e22a", "embedding": null, "metadata": {"window": "Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items.  The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts.  Excluding these items and the ", "original_text": "Excluding these items and the ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8a429be820f13c465e338bb3f97ba2268164d27fe8d3332c4ab9b76a9273848", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ab86fff-da33-469f-b00b-31aee2e29dcc", "node_type": "1", "metadata": {"window": "We're ex iting the year with solid operating performance, delivering fiscal 2022 fourth quarter earnings per share of \n$5.83, and for the full year, earnings per share of $23.69.  Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items.  The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts.  Excluding these items and the ", "original_text": "The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts. ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba748f4419d393253615022677f5fb7f5de6562fde4e5a8a8f9afb5067a69188", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "373b48b0-6822-45c1-affd-35f1e1da06f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "4ce624a02c6fae30fedb64b22de048a1db4dd97e7db146d26f947a02b34fb74b", "class_name": "RelatedNodeInfo"}}, "text": "Excluding these items and the ", "start_char_idx": 4150, "end_char_idx": 4180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "373b48b0-6822-45c1-affd-35f1e1da06f1": {"__data__": {"id_": "373b48b0-6822-45c1-affd-35f1e1da06f1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4fd860e-e1d6-4caa-9a71-2a6f5ae2e22a", "node_type": "1", "metadata": {"window": "Our full year results included revenue and profit growth \nacross every business segment.  \n \n In addition to growth in our core businesses, fiscal 2022 earnings per diluted share also included the following \nthree items.  The first is $1.79 related to the US government's centralized COVID -19 vaccine and kitting \ndistribution program, which included $0.89 related to COVID -19 vaccine distribution and $0.90 related to the \nkitting, distribution and storage of ancillary supplies; $0.88 was related to COVID -19 tests; and finally, $0.47 \nrelated to net gains associated with McKesson Ventures equity investmen ts.  Excluding these items and the ", "original_text": "Excluding these items and the ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f592ddca6a984cdc34997e938a7a02c95e4603ab1e92b2e28c1b3bbaa86e10b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36759b1b-bd98-4a3c-b1ec-f00151f111bb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n"}, "hash": "8d7c2a282a7b81907cfb8b5b8997e2f0eafacf9eb9796c288e461f3f48d01038", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36759b1b-bd98-4a3c-b1ec-f00151f111bb": {"__data__": {"id_": "36759b1b-bd98-4a3c-b1ec-f00151f111bb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "373b48b0-6822-45c1-affd-35f1e1da06f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49a8cc17712f421f68c949f3de695e650affd1b96b0f529ff5f5cac6f164c463", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2933499a-944f-4e2b-b0bb-dea584594463", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n", "original_text": "For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions. "}, "hash": "9d61361d8070ce763a9163b787683148bd2a457e36c2d4fbdced600456f07314", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n", "start_char_idx": 16, "end_char_idx": 375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2933499a-944f-4e2b-b0bb-dea584594463": {"__data__": {"id_": "2933499a-944f-4e2b-b0bb-dea584594463", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n", "original_text": "For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36759b1b-bd98-4a3c-b1ec-f00151f111bb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b17decb186833221d92bd6b8d6b12a5acee298809f0b0b85d3325c0a97d43fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3c0f5bf-8a22-42c7-8898-958b661413f9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests. ", "original_text": "Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n"}, "hash": "e5cddebe1e164092c80d3bb7cb1c5b75e4f58a261b6dc05639ce414fb19ad279", "class_name": "RelatedNodeInfo"}}, "text": "For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions. ", "start_char_idx": 375, "end_char_idx": 690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3c0f5bf-8a22-42c7-8898-958b661413f9": {"__data__": {"id_": "f3c0f5bf-8a22-42c7-8898-958b661413f9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests. ", "original_text": "Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2933499a-944f-4e2b-b0bb-dea584594463", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n", "original_text": "For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a508fe96d64b64e856ed423e68a2403c17b6533cffdbf775704964c87ea0b5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c08c001-f687-4ac2-be7e-d3927641889f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n", "original_text": "Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment. "}, "hash": "cce9d8725b8933793653612f7a1dfb7a796b12f1fb3f6d2302b7430860aa6f6e", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n", "start_char_idx": 690, "end_char_idx": 965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c08c001-f687-4ac2-be7e-d3927641889f": {"__data__": {"id_": "8c08c001-f687-4ac2-be7e-d3927641889f", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n", "original_text": "Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3c0f5bf-8a22-42c7-8898-958b661413f9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests. ", "original_text": "Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "447de49295131d3002fddc0a4ce2851b298115ec0e850b77611b2f8171212f9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04cb480e-3b88-45c6-96a8-b11b77e18d5c", "node_type": "1", "metadata": {"window": "For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022. ", "original_text": "Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n"}, "hash": "2530faf7c7e900c7ad35f4caa42041b1faee9e90db126bbc154463debbb1acc5", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment. ", "start_char_idx": 965, "end_char_idx": 1110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04cb480e-3b88-45c6-96a8-b11b77e18d5c": {"__data__": {"id_": "04cb480e-3b88-45c6-96a8-b11b77e18d5c", "embedding": null, "metadata": {"window": "For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022. ", "original_text": "Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c08c001-f687-4ac2-be7e-d3927641889f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n", "original_text": "Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7cc59cafde26b2703ffb0b8daf02a806ddce7a99aea85480b8967e7fbfe2330", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8438f943-4596-4b5c-8a09-f4e32fd4a413", "node_type": "1", "metadata": {"window": "Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter. ", "original_text": "Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests. "}, "hash": "8dee8bbf2467c2d97e0fbb5ce13c3e5d223280cd34ed2c4d49e62df371902d3d", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n", "start_char_idx": 1110, "end_char_idx": 1360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8438f943-4596-4b5c-8a09-f4e32fd4a413": {"__data__": {"id_": "8438f943-4596-4b5c-8a09-f4e32fd4a413", "embedding": null, "metadata": {"window": "Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter. ", "original_text": "Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04cb480e-3b88-45c6-96a8-b11b77e18d5c", "node_type": "1", "metadata": {"window": "For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022. ", "original_text": "Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7951e9d854a37dc147548c748db671759e01d0354298a28b790455e830b2d85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b274f89-fc4e-409d-ac15-9e47749947a2", "node_type": "1", "metadata": {"window": "Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n", "original_text": "When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n"}, "hash": "1a8df296c7da0c0039214ef5467bcb719997fa17b6d6c120194386e7080dc021", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests. ", "start_char_idx": 1360, "end_char_idx": 1646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b274f89-fc4e-409d-ac15-9e47749947a2": {"__data__": {"id_": "9b274f89-fc4e-409d-ac15-9e47749947a2", "embedding": null, "metadata": {"window": "Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n", "original_text": "When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8438f943-4596-4b5c-8a09-f4e32fd4a413", "node_type": "1", "metadata": {"window": "Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter. ", "original_text": "Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45af692554276dfc547f3782440992b09d3cc221034484dfa2593bd5d23bf80a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1de86ad0-a55e-4127-a76f-e02b86c3bc90", "node_type": "1", "metadata": {"window": "Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12. ", "original_text": "Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022. "}, "hash": "a8cdcc6aef052cebdd5de4a29612b8aa94a671cda5512d8dfa031afdbae1c314", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n", "start_char_idx": 1646, "end_char_idx": 1901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1de86ad0-a55e-4127-a76f-e02b86c3bc90": {"__data__": {"id_": "1de86ad0-a55e-4127-a76f-e02b86c3bc90", "embedding": null, "metadata": {"window": "Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12. ", "original_text": "Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b274f89-fc4e-409d-ac15-9e47749947a2", "node_type": "1", "metadata": {"window": "Gross profit was also positively impacted by increased volume with new and existing customers in our \nPrescription Technology Solutions segment.  Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n", "original_text": "When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "789201a02efa783a7db029302f603d856010f130e7999cde267dc5349a992c3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd277f21-520a-4766-9def-f2ccd8e4d5fe", "node_type": "1", "metadata": {"window": "Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical. ", "original_text": "Our tax rate was 21.9% for the quarter. "}, "hash": "b13d04eac97bd2297ea1df67be80df6a40c9eb8089712fd5f102abd0348c1bde", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022. ", "start_char_idx": 1901, "end_char_idx": 2169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd277f21-520a-4766-9def-f2ccd8e4d5fe": {"__data__": {"id_": "cd277f21-520a-4766-9def-f2ccd8e4d5fe", "embedding": null, "metadata": {"window": "Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical. ", "original_text": "Our tax rate was 21.9% for the quarter. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1de86ad0-a55e-4127-a76f-e02b86c3bc90", "node_type": "1", "metadata": {"window": "Operating expenses in the quarter increased 4% due to increased \nvolumes in our  Medical -Surgical Solutions segment, which were partially offset by the impact of held -for-sale \naccounting on announced divestitures in the International segment.  \n \n Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12. ", "original_text": "Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9153a234d3eed953ad581a4600dd7e2c2bfecc494e4e88ae2a5d8675efcf91f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33899571-221f-48de-94ef-ffad9473c5de", "node_type": "1", "metadata": {"window": "When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions. ", "original_text": "And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n"}, "hash": "6aa97cf07438bb4319224abadbd7f16100a11a831fb58ac0be41a4bea3f44638", "class_name": "RelatedNodeInfo"}}, "text": "Our tax rate was 21.9% for the quarter. ", "start_char_idx": 2169, "end_char_idx": 2209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33899571-221f-48de-94ef-ffad9473c5de": {"__data__": {"id_": "33899571-221f-48de-94ef-ffad9473c5de", "embedding": null, "metadata": {"window": "When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions. ", "original_text": "And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd277f21-520a-4766-9def-f2ccd8e4d5fe", "node_type": "1", "metadata": {"window": "Operating profit of $1.2 billion for the quarter was an increase of 3%, led by solid operati ng performance across \nthe segments, partially offset by the distribution of COVID -19 vaccines and ancillary supplies for the US \ngovernment and lower contribution related to COVID -19 tests.  When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical. ", "original_text": "Our tax rate was 21.9% for the quarter. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8708c6de4def091bc25738b8b5c2b1a537c599c23824f4921d3e37f5e715c21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e9d9d30-99c4-4e34-beac-04717da66eb2", "node_type": "1", "metadata": {"window": "Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n", "original_text": "Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12. "}, "hash": "5af2833ac7db8914d0167e26eafe7c54dc8ee772b67e73a694f3da8b55b0534e", "class_name": "RelatedNodeInfo"}}, "text": "And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n", "start_char_idx": 2209, "end_char_idx": 2426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e9d9d30-99c4-4e34-beac-04717da66eb2": {"__data__": {"id_": "4e9d9d30-99c4-4e34-beac-04717da66eb2", "embedding": null, "metadata": {"window": "Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n", "original_text": "Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33899571-221f-48de-94ef-ffad9473c5de", "node_type": "1", "metadata": {"window": "When excluding the impact related to the \ndistribution of COVID -19 related products, net gains associated with McKesson Ventures' equity investments and \nthe prior year PPE impairments in the Medical -Surgical segment, operating profit increased 8%.  \n \n Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions. ", "original_text": "And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04fd3f68c3f76b417d57d8ca82da21c950ddc9e3e00e33b8c4b7acea69e5288f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "385549a4-e0be-4c16-ba88-a07b991911bc", "node_type": "1", "metadata": {"window": "Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions. ", "original_text": "And \nstarting with US Pharmaceutical. "}, "hash": "9ab37ed0dd17dfe73e47c0e0be61b2a7cc88485f259f866597e74c19c6107b6f", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12. ", "start_char_idx": 2426, "end_char_idx": 2536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "385549a4-e0be-4c16-ba88-a07b991911bc": {"__data__": {"id_": "385549a4-e0be-4c16-ba88-a07b991911bc", "embedding": null, "metadata": {"window": "Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions. ", "original_text": "And \nstarting with US Pharmaceutical. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e9d9d30-99c4-4e34-beac-04717da66eb2", "node_type": "1", "metadata": {"window": "Moving below the line, interest expense was $43 million in the quarter, a d ecrease of 17% due to the net \nretirement of approximately $1.1 billion of long -term debt in fiscal 2022, including a previously announced tender \noffer in the second quarter of fiscal 2022.  Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n", "original_text": "Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf8ad5e4cb68e5abcd6c24fa450864050c0c77c543ca9e4d4b65cb6376c51ab0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e5cccc7-a0e2-4bf0-85b2-e544a703a5c4", "node_type": "1", "metadata": {"window": "And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n", "original_text": "Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions. "}, "hash": "cea58e4a432cb371889c0326bd0ca03bd0e3c9ade42d609e98090297dd6ea886", "class_name": "RelatedNodeInfo"}}, "text": "And \nstarting with US Pharmaceutical. ", "start_char_idx": 2536, "end_char_idx": 2574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e5cccc7-a0e2-4bf0-85b2-e544a703a5c4": {"__data__": {"id_": "9e5cccc7-a0e2-4bf0-85b2-e544a703a5c4", "embedding": null, "metadata": {"window": "And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n", "original_text": "Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "385549a4-e0be-4c16-ba88-a07b991911bc", "node_type": "1", "metadata": {"window": "Our tax rate was 21.9% for the quarter.  And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions. ", "original_text": "And \nstarting with US Pharmaceutical. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8f8d423ca1f91663eeecdcb95d7b63f1ca09abac7953d90e33cfbf804a7ff74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "581798f0-677e-4d6e-8ff7-485945ef2d08", "node_type": "1", "metadata": {"window": "Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket. ", "original_text": "Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n"}, "hash": "496bbeeee607d5098f71438a89dfceb661ba8ce829c6ee7d210dbf2496a52a8a", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions. ", "start_char_idx": 2574, "end_char_idx": 2810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "581798f0-677e-4d6e-8ff7-485945ef2d08": {"__data__": {"id_": "581798f0-677e-4d6e-8ff7-485945ef2d08", "embedding": null, "metadata": {"window": "Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket. ", "original_text": "Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e5cccc7-a0e2-4bf0-85b2-e544a703a5c4", "node_type": "1", "metadata": {"window": "And ramping up our \nconsolid ated results, fourth quarter diluted weighted average shares outstanding were 149.2 million, a decrease \nof 7% year -over-year resulting from share repurchases throughout fiscal 2022.  \n \n Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n", "original_text": "Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5bc8279a30a758e9f169c5df816ef529abd27a99789e1410774d146b5f7c30cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "454c8d1b-569c-40d1-b1ad-d6468ab386cb", "node_type": "1", "metadata": {"window": "And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n", "original_text": "The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions. "}, "hash": "c0ebea5155b474791d17d7896fd5af8697e0020e7f313c297763fcd9e345df6b", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n", "start_char_idx": 2810, "end_char_idx": 3016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "454c8d1b-569c-40d1-b1ad-d6468ab386cb": {"__data__": {"id_": "454c8d1b-569c-40d1-b1ad-d6468ab386cb", "embedding": null, "metadata": {"window": "And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n", "original_text": "The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "581798f0-677e-4d6e-8ff7-485945ef2d08", "node_type": "1", "metadata": {"window": "Moving now to fiscal fourth quarter and full year segment results, which can be found on slides 7 through 12.  And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket. ", "original_text": "Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6d82355f8b7dbb9064e158eb8169b61dcb82f1db8768a825a08cec109b7300b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b477abee-75fc-4134-8ff8-f8952a93393e", "node_type": "1", "metadata": {"window": "Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%. ", "original_text": "COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n"}, "hash": "4db9dc54964eb6e23bdbd99e1c2722e827c3f8db462def2189561d1236b89828", "class_name": "RelatedNodeInfo"}}, "text": "The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions. ", "start_char_idx": 3016, "end_char_idx": 3226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b477abee-75fc-4134-8ff8-f8952a93393e": {"__data__": {"id_": "b477abee-75fc-4134-8ff8-f8952a93393e", "embedding": null, "metadata": {"window": "Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%. ", "original_text": "COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "454c8d1b-569c-40d1-b1ad-d6468ab386cb", "node_type": "1", "metadata": {"window": "And \nstarting with US Pharmaceutical.  Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n", "original_text": "The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9fa1a5cac48a216af5903959090e10fa66c21e4e87008d6d5aa54759dff55a94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8261fff9-f121-4f26-bd77-2e29f4d2bb42", "node_type": "1", "metadata": {"window": "Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%.  For the full year, operating profit increased \n8% to $2.9 billion, driven by growth in distribution of specialty products to providers and health systems and the \ncontribution from COVID -19 vaccine distribution.  \n ", "original_text": "As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket. "}, "hash": "ba8451fb3066cb9212b30cc01954ca95b844ecf06690a46903ef9a65c5a697ed", "class_name": "RelatedNodeInfo"}}, "text": "COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n", "start_char_idx": 3226, "end_char_idx": 3394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8261fff9-f121-4f26-bd77-2e29f4d2bb42": {"__data__": {"id_": "8261fff9-f121-4f26-bd77-2e29f4d2bb42", "embedding": null, "metadata": {"window": "Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%.  For the full year, operating profit increased \n8% to $2.9 billion, driven by growth in distribution of specialty products to providers and health systems and the \ncontribution from COVID -19 vaccine distribution.  \n ", "original_text": "As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b477abee-75fc-4134-8ff8-f8952a93393e", "node_type": "1", "metadata": {"window": "Revenues were $53.7 billion, an increase of 14%, driven by increased volume of \nspecialty products, including higher volumes from retail national account customers and market growth, partially \noffset by branded to generic conversions.  Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%. ", "original_text": "COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72b30af1e252cf9c50497d787346079b04ab8ff8a914c9d1fd0a5ec891d2b980", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57c3ff36-1420-4a19-b901-d47113db1208", "node_type": "1", "metadata": {"window": "The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%.  For the full year, operating profit increased \n8% to $2.9 billion, driven by growth in distribution of specialty products to providers and health systems and the \ncontribution from COVID -19 vaccine distribution.  \n ", "original_text": "On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n"}, "hash": "d6471a82387f85b04ec72a9e8389605385aad9268191f434f5c424e261c8945b", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket. ", "start_char_idx": 3394, "end_char_idx": 3549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57c3ff36-1420-4a19-b901-d47113db1208": {"__data__": {"id_": "57c3ff36-1420-4a19-b901-d47113db1208", "embedding": null, "metadata": {"window": "The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%.  For the full year, operating profit increased \n8% to $2.9 billion, driven by growth in distribution of specialty products to providers and health systems and the \ncontribution from COVID -19 vaccine distribution.  \n ", "original_text": "On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8261fff9-f121-4f26-bd77-2e29f4d2bb42", "node_type": "1", "metadata": {"window": "Operating profit decreased 4% to $780 million, due to lower demand of \nCOVID -19 vaccine distribution, partially offset by growth in distribution of specialty products to providers and \nhealth systems.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%.  For the full year, operating profit increased \n8% to $2.9 billion, driven by growth in distribution of specialty products to providers and health systems and the \ncontribution from COVID -19 vaccine distribution.  \n ", "original_text": "As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd0fe8a2df0e136a26b7e61ffab8bca560be1563b98fd01c43ae44c375d57a73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6d02924-a9a9-4b20-89c7-7b116112f604", "node_type": "1", "metadata": {"window": "COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%.  For the full year, operating profit increased \n8% to $2.9 billion, driven by growth in distribution of specialty products to providers and health systems and the \ncontribution from COVID -19 vaccine distribution.  \n ", "original_text": "When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%. "}, "hash": "2f3525c4450ca16b777d7eb4e836744223f20b181d4027f4d7cec7435abe016c", "class_name": "RelatedNodeInfo"}}, "text": "On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n", "start_char_idx": 3549, "end_char_idx": 3737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6d02924-a9a9-4b20-89c7-7b116112f604": {"__data__": {"id_": "e6d02924-a9a9-4b20-89c7-7b116112f604", "embedding": null, "metadata": {"window": "COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%.  For the full year, operating profit increased \n8% to $2.9 billion, driven by growth in distribution of specialty products to providers and health systems and the \ncontribution from COVID -19 vaccine distribution.  \n ", "original_text": "When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57c3ff36-1420-4a19-b901-d47113db1208", "node_type": "1", "metadata": {"window": "The contribution from our contract with the US government for the distribution of COVID -19 vaccines declined \nsequentially, as demand continued to lessen along with continued easing of COVID -19 restrictions.  COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%.  For the full year, operating profit increased \n8% to $2.9 billion, driven by growth in distribution of specialty products to providers and health systems and the \ncontribution from COVID -19 vaccine distribution.  \n ", "original_text": "On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6805b38b18a5b8d02f6fbe07f5802f7b1564918d846405b2de1e7d66c66ef5fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3198925-3788-4679-947d-4f6651eb97fe", "node_type": "1", "metadata": {"window": "As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%.  For the full year, operating profit increased \n8% to $2.9 billion, driven by growth in distribution of specialty products to providers and health systems and the \ncontribution from COVID -19 vaccine distribution.  \n ", "original_text": "For the full year, operating profit increased \n8% to $2.9 billion, driven by growth in distribution of specialty products to providers and health systems and the \ncontribution from COVID -19 vaccine distribution.  \n "}, "hash": "f9103d527ebe372b5e2e518ae161c428fef7e87aa7104deb7d225be50e8d6032", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%. ", "start_char_idx": 3737, "end_char_idx": 3917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3198925-3788-4679-947d-4f6651eb97fe": {"__data__": {"id_": "c3198925-3788-4679-947d-4f6651eb97fe", "embedding": null, "metadata": {"window": "As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%.  For the full year, operating profit increased \n8% to $2.9 billion, driven by growth in distribution of specialty products to providers and health systems and the \ncontribution from COVID -19 vaccine distribution.  \n ", "original_text": "For the full year, operating profit increased \n8% to $2.9 billion, driven by growth in distribution of specialty products to providers and health systems and the \ncontribution from COVID -19 vaccine distribution.  \n ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1e991624-f5f5-427d-b6b2-05772e7eff65", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901cfcbd74a8cb59178b9750eb6d0b3325190b4be73a339c20c6dded2b27f981", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6d02924-a9a9-4b20-89c7-7b116112f604", "node_type": "1", "metadata": {"window": "COVID -19 \nvaccine distribution provided a benefit of a pproximately $0.06 per share in the fourth quarter, compared to $0.26 \nin the third quarter of fiscal 2022.  \n \n As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%.  For the full year, operating profit increased \n8% to $2.9 billion, driven by growth in distribution of specialty products to providers and health systems and the \ncontribution from COVID -19 vaccine distribution.  \n ", "original_text": "When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%. ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0642e63ca34935672b49452f42729f02081f8bde72a593c62b4c96088a75b1dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a705803-ad45-4b78-a17b-808f3af55086", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes.  Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "089377aef72e919dbeef5729b2a08b64d86b82628ddd06f328e00779fa3c5fec", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, operating profit increased \n8% to $2.9 billion, driven by growth in distribution of specialty products to providers and health systems and the \ncontribution from COVID -19 vaccine distribution.  \n ", "start_char_idx": 3917, "end_char_idx": 4133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a705803-ad45-4b78-a17b-808f3af55086": {"__data__": {"id_": "6a705803-ad45-4b78-a17b-808f3af55086", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes.  Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3198925-3788-4679-947d-4f6651eb97fe", "node_type": "1", "metadata": {"window": "As a reminder, fiscal fourth quarter operating profit growth included previously announced investments made in \nresponse to the competitive labor mar ket.  On our earnings call in February, we reiterated our expectation for \nadditional labor -related expenses to ensure continued service continuity through the second half of our fiscal year. \n When excluding the impact of COVID -19 vaccine distribution and the  previously outlined labor investments, the \nUS Pharmaceutical segment delivered operating profit growth of 4%.  For the full year, operating profit increased \n8% to $2.9 billion, driven by growth in distribution of specialty products to providers and health systems and the \ncontribution from COVID -19 vaccine distribution.  \n ", "original_text": "For the full year, operating profit increased \n8% to $2.9 billion, driven by growth in distribution of specialty products to providers and health systems and the \ncontribution from COVID -19 vaccine distribution.  \n ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52937342ccccf0e2ecc60f2c7e381c9408f055d34826c6c2e51e21681de59117", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "385c028f-c654-4d1c-86fa-305c8841e92a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes.  Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes. "}, "hash": "d4447295d00b3b640befff28a22f3ce3e5b53bf09730aa235089c210a2c04300", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "385c028f-c654-4d1c-86fa-305c8841e92a": {"__data__": {"id_": "385c028f-c654-4d1c-86fa-305c8841e92a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes.  Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a705803-ad45-4b78-a17b-808f3af55086", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes.  Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3499c5ed275911213788b54938ba18a8cd6f79e468cbf6f71b381c80fbf14ca9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acb32a72-88a4-465e-b0b9-26b02953fe65", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes.  Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business. ", "original_text": "Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions. "}, "hash": "d11719eae68c8e8d50ff02aaf8218641d523c258b7425e10fe1e09ec32a079fc", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes. ", "start_char_idx": 16, "end_char_idx": 484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acb32a72-88a4-465e-b0b9-26b02953fe65": {"__data__": {"id_": "acb32a72-88a4-465e-b0b9-26b02953fe65", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes.  Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business. ", "original_text": "Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "385c028f-c654-4d1c-86fa-305c8841e92a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes.  Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5f5f3f91b49b745d4a84fa7d004cb549c7722b3ff541406a8bd3ba99ba0d7cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de29fbf8-ec2f-4976-8286-4b75f9f57be2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes.  Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million. ", "original_text": "For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n"}, "hash": "1a9327e2bad3b352f85cc3ec44b756fa91095a15d2c6036e5bba7f6fff0a46a6", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions. ", "start_char_idx": 484, "end_char_idx": 587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de29fbf8-ec2f-4976-8286-4b75f9f57be2": {"__data__": {"id_": "de29fbf8-ec2f-4976-8286-4b75f9f57be2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes.  Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million. ", "original_text": "For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acb32a72-88a4-465e-b0b9-26b02953fe65", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes.  Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business. ", "original_text": "Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2498e9b3ccf6e6d19e15d817a9291a666d05c5ba5a1d8d1466409e90cdd2a6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fe7e4cd-c4c6-46db-a0f5-7c59023f9c53", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes.  Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n", "original_text": "Next, Medical -Surgical Solutions. "}, "hash": "1e4f2a0f269c4ddddbd4fc07154559f026d4e4ecd2a29996490414fb136ec613", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n", "start_char_idx": 587, "end_char_idx": 667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fe7e4cd-c4c6-46db-a0f5-7c59023f9c53": {"__data__": {"id_": "6fe7e4cd-c4c6-46db-a0f5-7c59023f9c53", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes.  Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n", "original_text": "Next, Medical -Surgical Solutions. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de29fbf8-ec2f-4976-8286-4b75f9f57be2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes.  Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million. ", "original_text": "For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c778cb680b19f6084216ca178fcfe7c3d6c455cc0e7596b661d5ad92e031c65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e257afae-8dda-446e-bee7-6314f68de5e1", "node_type": "1", "metadata": {"window": "Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business. ", "original_text": "Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business. "}, "hash": "8c6c478676d3fab57e88e3be0b029f52f3d1b79704cdaaadf33c94bd7824b188", "class_name": "RelatedNodeInfo"}}, "text": "Next, Medical -Surgical Solutions. ", "start_char_idx": 667, "end_char_idx": 702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e257afae-8dda-446e-bee7-6314f68de5e1": {"__data__": {"id_": "e257afae-8dda-446e-bee7-6314f68de5e1", "embedding": null, "metadata": {"window": "Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business. ", "original_text": "Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fe7e4cd-c4c6-46db-a0f5-7c59023f9c53", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes.  Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n", "original_text": "Next, Medical -Surgical Solutions. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4070b4e3a75f2349ce046733d82369750b69848b223055ee6c3e52e61692a09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f79d9e8b-5196-4473-86a2-2a878b586ece", "node_type": "1", "metadata": {"window": "For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion. ", "original_text": "Operating profit increased 55% to $298 million. "}, "hash": "3576ee0381573937471fa06969bbf1c7a4c8b3fdac99806af6ef210dbba8e067", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business. ", "start_char_idx": 702, "end_char_idx": 793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f79d9e8b-5196-4473-86a2-2a878b586ece": {"__data__": {"id_": "f79d9e8b-5196-4473-86a2-2a878b586ece", "embedding": null, "metadata": {"window": "For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion. ", "original_text": "Operating profit increased 55% to $298 million. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e257afae-8dda-446e-bee7-6314f68de5e1", "node_type": "1", "metadata": {"window": "Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business. ", "original_text": "Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f874536db148b5af60caed39c4d5ddad9bde2598f5aeaeae16817602bf657b54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b72e8c7d-c0a8-4b58-95e5-2be009bb409f", "node_type": "1", "metadata": {"window": "Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n", "original_text": "In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n"}, "hash": "04fadd55ae97d558f9f0c6e7d4dc6be12cad710760c4fd431eae64c31c78b835", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit increased 55% to $298 million. ", "start_char_idx": 793, "end_char_idx": 841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b72e8c7d-c0a8-4b58-95e5-2be009bb409f": {"__data__": {"id_": "b72e8c7d-c0a8-4b58-95e5-2be009bb409f", "embedding": null, "metadata": {"window": "Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n", "original_text": "In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f79d9e8b-5196-4473-86a2-2a878b586ece", "node_type": "1", "metadata": {"window": "For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion. ", "original_text": "Operating profit increased 55% to $298 million. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3225ab181ffce281384fb57b1498a74fcf9c276b9f346cbcb4abdf959fd3b81d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db7f4066-6772-4991-87d6-db6cf04abbab", "node_type": "1", "metadata": {"window": "Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability. ", "original_text": "Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business. "}, "hash": "0a3e96cc7ffb7145610f0f7a0c30b5693cee19163b9142eb9d70ebc2f9651790", "class_name": "RelatedNodeInfo"}}, "text": "In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n", "start_char_idx": 841, "end_char_idx": 1187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db7f4066-6772-4991-87d6-db6cf04abbab": {"__data__": {"id_": "db7f4066-6772-4991-87d6-db6cf04abbab", "embedding": null, "metadata": {"window": "Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability. ", "original_text": "Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b72e8c7d-c0a8-4b58-95e5-2be009bb409f", "node_type": "1", "metadata": {"window": "Next, Medical -Surgical Solutions.  Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n", "original_text": "In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7a75efc7eec8bc4ff9736914d59f2bf9945c880133c9b10331f0afe34db9ce6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b95cac1-3b64-4ffd-a244-90fffb52d9c6", "node_type": "1", "metadata": {"window": "Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic. ", "original_text": "For the full year, operating \nprofit  increased 50% to $1.2 billion. "}, "hash": "723a2cafdf49087d635996696210ccf66f3040aa7457fbb2266971355faa8fea", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business. ", "start_char_idx": 1187, "end_char_idx": 1382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b95cac1-3b64-4ffd-a244-90fffb52d9c6": {"__data__": {"id_": "5b95cac1-3b64-4ffd-a244-90fffb52d9c6", "embedding": null, "metadata": {"window": "Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic. ", "original_text": "For the full year, operating \nprofit  increased 50% to $1.2 billion. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db7f4066-6772-4991-87d6-db6cf04abbab", "node_type": "1", "metadata": {"window": "Revenues were $2.9 billion, an increase of 6% due to growth in the primary \ncare business.  Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability. ", "original_text": "Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "70093946f7957643d4463a9488b454377f1fcd2b6aaeeba40f360c1d270059a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a668adef-fbb9-4b8f-99b0-88742941e0a2", "node_type": "1", "metadata": {"window": "In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels. ", "original_text": "When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n"}, "hash": "1642a5df72410236234d6f47d5ae5775cd43b176db7b83881d7a8300c325c7a7", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, operating \nprofit  increased 50% to $1.2 billion. ", "start_char_idx": 1382, "end_char_idx": 1451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a668adef-fbb9-4b8f-99b0-88742941e0a2": {"__data__": {"id_": "a668adef-fbb9-4b8f-99b0-88742941e0a2", "embedding": null, "metadata": {"window": "In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels. ", "original_text": "When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b95cac1-3b64-4ffd-a244-90fffb52d9c6", "node_type": "1", "metadata": {"window": "Operating profit increased 55% to $298 million.  In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic. ", "original_text": "For the full year, operating \nprofit  increased 50% to $1.2 billion. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1601e8e2c1c9ccce0e16c4bf23f7c97408a65f6d0dee5507c8e3771cb6f975d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "beedcc14-36dc-4a19-ac6e-860b42219152", "node_type": "1", "metadata": {"window": "Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult. ", "original_text": "During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability. "}, "hash": "174c86a64b9cda02b6f1dd52bd7f4c3fde1c4f3ff8b99fd4b35b02d754a36c1c", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n", "start_char_idx": 1451, "end_char_idx": 1604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "beedcc14-36dc-4a19-ac6e-860b42219152": {"__data__": {"id_": "beedcc14-36dc-4a19-ac6e-860b42219152", "embedding": null, "metadata": {"window": "Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult. ", "original_text": "During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a668adef-fbb9-4b8f-99b0-88742941e0a2", "node_type": "1", "metadata": {"window": "In the fourth quarter, operating profit in the \nMedi cal-Surgical Solutions segment included $0.22 of earnings per diluted share contribution related to COVID -\n19 tests and $0.20 of earnings per diluted share contribution related to the kitting, distribution and storage of \nancillary supplies for COVID -19 vacc ines for the US government.  \n \n Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels. ", "original_text": "When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb5aad3a5423c0930d93d206ddfc2e1c93dd752ff3b1eef4d8da873591a611cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c372ded-94f5-4c68-ab21-7be039c548b4", "node_type": "1", "metadata": {"window": "For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n", "original_text": "The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic. "}, "hash": "628aa51d2e6aa185b3da955fe7e788ccfb9b5dee9d54c6f12855637d00b0b330", "class_name": "RelatedNodeInfo"}}, "text": "During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability. ", "start_char_idx": 1604, "end_char_idx": 1713, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c372ded-94f5-4c68-ab21-7be039c548b4": {"__data__": {"id_": "8c372ded-94f5-4c68-ab21-7be039c548b4", "embedding": null, "metadata": {"window": "For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n", "original_text": "The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "beedcc14-36dc-4a19-ac6e-860b42219152", "node_type": "1", "metadata": {"window": "Excluding the impacts of these COVID -19 related items, and the prior year inventory charges on PPE -related \nproducts, operating profit increased 26% due to growth in the primary care business.  For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult. ", "original_text": "During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91303b0c7919abad56ed72324ceab97d97729c9b1b127b3268680cd796bff55e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d16cf4a8-d3ae-4a1a-9bd2-c8defb66e57b", "node_type": "1", "metadata": {"window": "When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant. ", "original_text": "However, \nthe direction generally followed the volume of COVID -19 case levels. "}, "hash": "a06faa4ac34f03898e09a9001ef8096a20a8488c48daaaa02e3ccdadabc39ef5", "class_name": "RelatedNodeInfo"}}, "text": "The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic. ", "start_char_idx": 1713, "end_char_idx": 1817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d16cf4a8-d3ae-4a1a-9bd2-c8defb66e57b": {"__data__": {"id_": "d16cf4a8-d3ae-4a1a-9bd2-c8defb66e57b", "embedding": null, "metadata": {"window": "When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant. ", "original_text": "However, \nthe direction generally followed the volume of COVID -19 case levels. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c372ded-94f5-4c68-ab21-7be039c548b4", "node_type": "1", "metadata": {"window": "For the full year, operating \nprofit  increased 50% to $1.2 billion.  When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n", "original_text": "The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16cc5a000b927b5551ae50279774787fdb3c1319a0abd7bccc4d55a27f18fa52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7364491f-78ed-4024-8fb2-bf057f42b3ee", "node_type": "1", "metadata": {"window": "During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter. ", "original_text": "Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult. "}, "hash": "d5d02190ec075d3990bdaf4c757cb8341365677e2eb6ab56205e0191ba8b925d", "class_name": "RelatedNodeInfo"}}, "text": "However, \nthe direction generally followed the volume of COVID -19 case levels. ", "start_char_idx": 1817, "end_char_idx": 1897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7364491f-78ed-4024-8fb2-bf057f42b3ee": {"__data__": {"id_": "7364491f-78ed-4024-8fb2-bf057f42b3ee", "embedding": null, "metadata": {"window": "During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter. ", "original_text": "Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d16cf4a8-d3ae-4a1a-9bd2-c8defb66e57b", "node_type": "1", "metadata": {"window": "When excluding the impacts of COVID -19-related items and prior year \ninventory charges on PPE and related products, operating profit increased 22%.  \n \n During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant. ", "original_text": "However, \nthe direction generally followed the volume of COVID -19 case levels. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb22d0ae14fe4ec38da52e784b2a2cd4b4ed511618c18a120b3060cf336f91f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c5e2992-ee2a-494d-bfa1-0dd66bbb3ef8", "node_type": "1", "metadata": {"window": "The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n", "original_text": "We continue to track new guidance and \nvariants.  \n \n"}, "hash": "34d77868d0ebc5cc0cf6486909f24e5b6592f631322ecbec9916d2d753be1f65", "class_name": "RelatedNodeInfo"}}, "text": "Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult. ", "start_char_idx": 1897, "end_char_idx": 2012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c5e2992-ee2a-494d-bfa1-0dd66bbb3ef8": {"__data__": {"id_": "7c5e2992-ee2a-494d-bfa1-0dd66bbb3ef8", "embedding": null, "metadata": {"window": "The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n", "original_text": "We continue to track new guidance and \nvariants.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7364491f-78ed-4024-8fb2-bf057f42b3ee", "node_type": "1", "metadata": {"window": "During the fourth quarter, COVID -19 and the direction of the disease continu ed to demonstrate variability.  The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter. ", "original_text": "Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0fb1abf8542f71848fdbdd13f01fcfae2c6d81cd31aeefc007951fb1dfa5515", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "372f4ab3-9b86-44d0-bc3c-d971b3b3d607", "node_type": "1", "metadata": {"window": "However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average. ", "original_text": "In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant. "}, "hash": "2c32052e7938994e62c307c69fe1871d676b7c6bed2c1ff085ee6d3638ecbeac", "class_name": "RelatedNodeInfo"}}, "text": "We continue to track new guidance and \nvariants.  \n \n", "start_char_idx": 2012, "end_char_idx": 2065, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "372f4ab3-9b86-44d0-bc3c-d971b3b3d607": {"__data__": {"id_": "372f4ab3-9b86-44d0-bc3c-d971b3b3d607", "embedding": null, "metadata": {"window": "However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average. ", "original_text": "In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c5e2992-ee2a-494d-bfa1-0dd66bbb3ef8", "node_type": "1", "metadata": {"window": "The \ndemand for COVID -19-related products and services has fluctuated over the course of the pandemic.  However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n", "original_text": "We continue to track new guidance and \nvariants.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4173c9df0a42016379c61640dce8f766c07f6a806e36ac29ce26157c2e63a267", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a8d944e-2f28-41ec-8f87-a975fa0cac3e", "node_type": "1", "metadata": {"window": "Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter. ", "original_text": "We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter. "}, "hash": "ae7f023d17638eab833307724e12748183cea264b1ae51d9ac3208489bd902f2", "class_name": "RelatedNodeInfo"}}, "text": "In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant. ", "start_char_idx": 2065, "end_char_idx": 2203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a8d944e-2f28-41ec-8f87-a975fa0cac3e": {"__data__": {"id_": "0a8d944e-2f28-41ec-8f87-a975fa0cac3e", "embedding": null, "metadata": {"window": "Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter. ", "original_text": "We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "372f4ab3-9b86-44d0-bc3c-d971b3b3d607", "node_type": "1", "metadata": {"window": "However, \nthe direction generally followed the volume of COVID -19 case levels.  Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average. ", "original_text": "In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "980307db2b6f649653e854ce0928e440cc81ced7cb7c68d285b98c3608bfd525", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba024599-da96-4f8f-82e6-70958cf4375e", "node_type": "1", "metadata": {"window": "We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n", "original_text": "In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n"}, "hash": "e5bd225fccbceb96501066cf46442f31997f31f6366d7b397ffd772fdb192df1", "class_name": "RelatedNodeInfo"}}, "text": "We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter. ", "start_char_idx": 2203, "end_char_idx": 2327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba024599-da96-4f8f-82e6-70958cf4375e": {"__data__": {"id_": "ba024599-da96-4f8f-82e6-70958cf4375e", "embedding": null, "metadata": {"window": "We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n", "original_text": "In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a8d944e-2f28-41ec-8f87-a975fa0cac3e", "node_type": "1", "metadata": {"window": "Forecasting COVID -19 vaccine distribution \nand testing demand more than a few months at a time remains difficult.  We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter. ", "original_text": "We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4542c1a7fb8ac7d43a5f33af593105d5d28aecc84beafd920348a94a836ba46c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df9d9f0b-4900-485e-9cdd-b5acf67efd73", "node_type": "1", "metadata": {"window": "In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults. ", "original_text": "In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average. "}, "hash": "1a3f249394b8198ccb3c31178adf2a30f28d6d371c245567eca1df70af8115ef", "class_name": "RelatedNodeInfo"}}, "text": "In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n", "start_char_idx": 2327, "end_char_idx": 2446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df9d9f0b-4900-485e-9cdd-b5acf67efd73": {"__data__": {"id_": "df9d9f0b-4900-485e-9cdd-b5acf67efd73", "embedding": null, "metadata": {"window": "In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults. ", "original_text": "In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba024599-da96-4f8f-82e6-70958cf4375e", "node_type": "1", "metadata": {"window": "We continue to track new guidance and \nvariants.  \n \n In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n", "original_text": "In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b26e1560d03894ed9e508766c13a2f900fb70cc3a315c6d2b8de8a15b89be94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2879bc6-a4fb-46c3-8255-15ac3cfbc2b5", "node_type": "1", "metadata": {"window": "We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults.  Revenues were $8.5 billion on a reported basis. ", "original_text": "The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter. "}, "hash": "1b436ab164e465166d06eaefdd32f5cca3e6da8177de4b0f479f9bb487ad5c48", "class_name": "RelatedNodeInfo"}}, "text": "In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average. ", "start_char_idx": 2446, "end_char_idx": 2576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2879bc6-a4fb-46c3-8255-15ac3cfbc2b5": {"__data__": {"id_": "a2879bc6-a4fb-46c3-8255-15ac3cfbc2b5", "embedding": null, "metadata": {"window": "We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults.  Revenues were $8.5 billion on a reported basis. ", "original_text": "The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df9d9f0b-4900-485e-9cdd-b5acf67efd73", "node_type": "1", "metadata": {"window": "In the fourth quarter of fiscal 2022, we experienced increased demand in January related to a spike in cases due \nto the Omicron variant.  We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults. ", "original_text": "In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8fc9c078d97bc0df059c0cf51980de4395042e04fbdf57ec0ab661b951e6bb37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5e05e7c-5d55-4c60-bbf7-44643cb6dec6", "node_type": "1", "metadata": {"window": "In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults.  Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n", "original_text": "We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n"}, "hash": "1949317f44d771f17c2487d5532641228d92448dfd308d6bcf681c6efb3a8d03", "class_name": "RelatedNodeInfo"}}, "text": "The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter. ", "start_char_idx": 2576, "end_char_idx": 2698, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5e05e7c-5d55-4c60-bbf7-44643cb6dec6": {"__data__": {"id_": "e5e05e7c-5d55-4c60-bbf7-44643cb6dec6", "embedding": null, "metadata": {"window": "In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults.  Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n", "original_text": "We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2879bc6-a4fb-46c3-8255-15ac3cfbc2b5", "node_type": "1", "metadata": {"window": "We  experienced a 60% volume increase related to COVID -19 tests in January, compared \nto the average in the third quarter.  In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults.  Revenues were $8.5 billion on a reported basis. ", "original_text": "The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e12e452668b6e5a733cf24745dd8eadc61083bcb48ecedf8d336de2985122518", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18610205-32a7-4d9a-9a76-6ad7686b625e", "node_type": "1", "metadata": {"window": "In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults.  Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million. ", "original_text": "Let me address our international r esults. "}, "hash": "de39a263f8a7f142b119afea020121f3634f421adfd00e1e2cea3efa519879dd", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n", "start_char_idx": 2698, "end_char_idx": 2958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18610205-32a7-4d9a-9a76-6ad7686b625e": {"__data__": {"id_": "18610205-32a7-4d9a-9a76-6ad7686b625e", "embedding": null, "metadata": {"window": "In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults.  Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million. ", "original_text": "Let me address our international r esults. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5e05e7c-5d55-4c60-bbf7-44643cb6dec6", "node_type": "1", "metadata": {"window": "In February and March, COVID cases declined month -over-month with a \ncorresponding decline in COVID test volumes.  \n \n In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults.  Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n", "original_text": "We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66e56ffe65e5b00ee6093223be3b519eff79b167bea580e124edcf6103faf2bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00d1c903-fe15-42a3-b67b-2abc4616edb3", "node_type": "1", "metadata": {"window": "The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults.  Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business. ", "original_text": "Revenues were $8.5 billion on a reported basis. "}, "hash": "a579c14e0cc44e5cfce102f76f394257a1e62b67b290c2587732cc1c9945db9c", "class_name": "RelatedNodeInfo"}}, "text": "Let me address our international r esults. ", "start_char_idx": 2958, "end_char_idx": 3001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00d1c903-fe15-42a3-b67b-2abc4616edb3": {"__data__": {"id_": "00d1c903-fe15-42a3-b67b-2abc4616edb3", "embedding": null, "metadata": {"window": "The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults.  Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business. ", "original_text": "Revenues were $8.5 billion on a reported basis. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18610205-32a7-4d9a-9a76-6ad7686b625e", "node_type": "1", "metadata": {"window": "In March, we experience d approximately a 90% decrease related to COVID -19 test volumes, compared to the \nthird quarter average.  The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults.  Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million. ", "original_text": "Let me address our international r esults. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df9ee50a711f2f0a35b37044be0b954cbb1dd5322993734ae3ee0faa483f81bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3139ec5-7511-4624-8651-327266b98efc", "node_type": "1", "metadata": {"window": "We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults.  Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n", "original_text": "On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n"}, "hash": "a71ac33727aecf81093fd0c93b48ba2e890c190cd06e9aa8203ff543506f9d10", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $8.5 billion on a reported basis. ", "start_char_idx": 3001, "end_char_idx": 3049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3139ec5-7511-4624-8651-327266b98efc": {"__data__": {"id_": "a3139ec5-7511-4624-8651-327266b98efc", "embedding": null, "metadata": {"window": "We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults.  Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n", "original_text": "On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00d1c903-fe15-42a3-b67b-2abc4616edb3", "node_type": "1", "metadata": {"window": "The declines in February and March led to lower earnings contribution from COVID -19 tests \nin our fiscal fourth quarter.  We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults.  Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business. ", "original_text": "Revenues were $8.5 billion on a reported basis. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37b0d7de61024247667025f3d6db570a00f9a2c4ed281f36f1fc3226b5f9dba3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d55e2fd6-3e7c-4751-82e3-7b170afa19a2", "node_type": "1", "metadata": {"window": "Let me address our international r esults.  Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%. ", "original_text": "Operating profit increased 7% to $147 million. "}, "hash": "baadb89a72a043382041cd219c07ce77783bb5686837c3309b5171b3d40497e6", "class_name": "RelatedNodeInfo"}}, "text": "On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n", "start_char_idx": 3049, "end_char_idx": 3372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d55e2fd6-3e7c-4751-82e3-7b170afa19a2": {"__data__": {"id_": "d55e2fd6-3e7c-4751-82e3-7b170afa19a2", "embedding": null, "metadata": {"window": "Let me address our international r esults.  Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%. ", "original_text": "Operating profit increased 7% to $147 million. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3139ec5-7511-4624-8651-327266b98efc", "node_type": "1", "metadata": {"window": "We anticipate that the pace of C OVID test volume and vaccine demand will follow a \nsimilar fluctuating pattern in fiscal 2023, and we anticipate that fiscal 2023 COVID volume and earnings per share \ncontribution will be materially lower than fiscal 2022.  \n \n Let me address our international r esults.  Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n", "original_text": "On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d862fdb21b5360a22e987c3048b24a52757253028fe4b303bfa93414227e34c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77ab0a39-be1c-414a-9c57-b9dfe4a8c1b7", "node_type": "1", "metadata": {"window": "Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%.  During the \nquarter, mark -to-market valuations related to our equity investments within our McKesson Ventures portfolio \nresulted in net losses of approximately $6 million, compared to net gains of $44 million in fourth quarter of fiscal ", "original_text": "On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business. "}, "hash": "3037e418588bf25d6fe53667db30417308eb834494c082c5bd95feaaabd10b71", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit increased 7% to $147 million. ", "start_char_idx": 3372, "end_char_idx": 3419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77ab0a39-be1c-414a-9c57-b9dfe4a8c1b7": {"__data__": {"id_": "77ab0a39-be1c-414a-9c57-b9dfe4a8c1b7", "embedding": null, "metadata": {"window": "Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%.  During the \nquarter, mark -to-market valuations related to our equity investments within our McKesson Ventures portfolio \nresulted in net losses of approximately $6 million, compared to net gains of $44 million in fourth quarter of fiscal ", "original_text": "On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d55e2fd6-3e7c-4751-82e3-7b170afa19a2", "node_type": "1", "metadata": {"window": "Let me address our international r esults.  Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%. ", "original_text": "Operating profit increased 7% to $147 million. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9ecd68d4fd60c6b2d2f15caeb85d08965150f7a5028c37603fcb036cafd1165", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4f3c630-0cc2-4554-9136-454abbdb0f2b", "node_type": "1", "metadata": {"window": "On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%.  During the \nquarter, mark -to-market valuations related to our equity investments within our McKesson Ventures portfolio \nresulted in net losses of approximately $6 million, compared to net gains of $44 million in fourth quarter of fiscal ", "original_text": "For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n"}, "hash": "45cf1f1e37e3b797554b081221a1c04df32a433f41f40945085661b76c320dc1", "class_name": "RelatedNodeInfo"}}, "text": "On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business. ", "start_char_idx": 3419, "end_char_idx": 3659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4f3c630-0cc2-4554-9136-454abbdb0f2b": {"__data__": {"id_": "d4f3c630-0cc2-4554-9136-454abbdb0f2b", "embedding": null, "metadata": {"window": "On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%.  During the \nquarter, mark -to-market valuations related to our equity investments within our McKesson Ventures portfolio \nresulted in net losses of approximately $6 million, compared to net gains of $44 million in fourth quarter of fiscal ", "original_text": "For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77ab0a39-be1c-414a-9c57-b9dfe4a8c1b7", "node_type": "1", "metadata": {"window": "Revenues were $8.5 billion on a reported basis.  On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%.  During the \nquarter, mark -to-market valuations related to our equity investments within our McKesson Ventures portfolio \nresulted in net losses of approximately $6 million, compared to net gains of $44 million in fourth quarter of fiscal ", "original_text": "On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b70636a2e2c2a3090b541d6c119e89594750d4fc227efe74a537e76ed383a503", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "768b23b2-ac8c-4e72-891e-26846b74387e", "node_type": "1", "metadata": {"window": "Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%.  During the \nquarter, mark -to-market valuations related to our equity investments within our McKesson Ventures portfolio \nresulted in net losses of approximately $6 million, compared to net gains of $44 million in fourth quarter of fiscal ", "original_text": "And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%. "}, "hash": "da0f60363f1f0d5dac90c5e1d6bdef4be59727719aa4b134911d07ad7e79284b", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n", "start_char_idx": 3659, "end_char_idx": 3740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "768b23b2-ac8c-4e72-891e-26846b74387e": {"__data__": {"id_": "768b23b2-ac8c-4e72-891e-26846b74387e", "embedding": null, "metadata": {"window": "Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%.  During the \nquarter, mark -to-market valuations related to our equity investments within our McKesson Ventures portfolio \nresulted in net losses of approximately $6 million, compared to net gains of $44 million in fourth quarter of fiscal ", "original_text": "And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4f3c630-0cc2-4554-9136-454abbdb0f2b", "node_type": "1", "metadata": {"window": "On an FX adjusted \nbasis, revenues were $8.8 billion, an increase of 3%, driven by sales to new customers in the Canadian business \nand year -over-year volume recovery in our distribution businesses, par tially offset by the divestiture of our \nAustrian business, which closed during the fourth quarter of fiscal 2022.  \n \n Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%.  During the \nquarter, mark -to-market valuations related to our equity investments within our McKesson Ventures portfolio \nresulted in net losses of approximately $6 million, compared to net gains of $44 million in fourth quarter of fiscal ", "original_text": "For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "343333e013d7082172a06689a8a727306e870c2b149195844e46fab89fa4c93f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c70e09f-1931-4a71-8f2c-dc48ce59eec5", "node_type": "1", "metadata": {"window": "On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%.  During the \nquarter, mark -to-market valuations related to our equity investments within our McKesson Ventures portfolio \nresulted in net losses of approximately $6 million, compared to net gains of $44 million in fourth quarter of fiscal ", "original_text": "During the \nquarter, mark -to-market valuations related to our equity investments within our McKesson Ventures portfolio \nresulted in net losses of approximately $6 million, compared to net gains of $44 million in fourth quarter of fiscal "}, "hash": "6d38b66505838ff2f5a7f601c044e52e10937961da8810c6e50ecff4fca58c3f", "class_name": "RelatedNodeInfo"}}, "text": "And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%. ", "start_char_idx": 3740, "end_char_idx": 3834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c70e09f-1931-4a71-8f2c-dc48ce59eec5": {"__data__": {"id_": "4c70e09f-1931-4a71-8f2c-dc48ce59eec5", "embedding": null, "metadata": {"window": "On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%.  During the \nquarter, mark -to-market valuations related to our equity investments within our McKesson Ventures portfolio \nresulted in net losses of approximately $6 million, compared to net gains of $44 million in fourth quarter of fiscal ", "original_text": "During the \nquarter, mark -to-market valuations related to our equity investments within our McKesson Ventures portfolio \nresulted in net losses of approximately $6 million, compared to net gains of $44 million in fourth quarter of fiscal ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5de1a8ff1a91850db512fbed2e0bbaa1a50496d0002b9ce8360ba5ced4d91dc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "768b23b2-ac8c-4e72-891e-26846b74387e", "node_type": "1", "metadata": {"window": "Operating profit increased 7% to $147 million.  On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%.  During the \nquarter, mark -to-market valuations related to our equity investments within our McKesson Ventures portfolio \nresulted in net losses of approximately $6 million, compared to net gains of $44 million in fourth quarter of fiscal ", "original_text": "And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%. ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5aab3f0870c8d1650f2c16b2a479b1ca82640717a36e564976f21568d29d34a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6feeaf47-90a5-40c3-96e6-f59730bb4dc3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021.  Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share. ", "original_text": "McKesson Corp.  "}, "hash": "3ac1eff05a7d313381b93adef149941f154fe45e6c3798bad5ad836a7ef753c7", "class_name": "RelatedNodeInfo"}}, "text": "During the \nquarter, mark -to-market valuations related to our equity investments within our McKesson Ventures portfolio \nresulted in net losses of approximately $6 million, compared to net gains of $44 million in fourth quarter of fiscal ", "start_char_idx": 3834, "end_char_idx": 4073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6feeaf47-90a5-40c3-96e6-f59730bb4dc3": {"__data__": {"id_": "6feeaf47-90a5-40c3-96e6-f59730bb4dc3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021.  Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c70e09f-1931-4a71-8f2c-dc48ce59eec5", "node_type": "1", "metadata": {"window": "On an FX adjusted basis, operating profit increased 10% to $152 \nmillion due to the reduction o f depreciation and amortization on European assets under agreements to sell and \nincreased volumes in the pharmaceutical distribution business.  For the full year, operating profit on an FX -\nadjusted basis increased 40%.  \n \n And in our Corporate segment, expense s were $183 million in the quarter, an increase of 46%.  During the \nquarter, mark -to-market valuations related to our equity investments within our McKesson Ventures portfolio \nresulted in net losses of approximately $6 million, compared to net gains of $44 million in fourth quarter of fiscal ", "original_text": "During the \nquarter, mark -to-market valuations related to our equity investments within our McKesson Ventures portfolio \nresulted in net losses of approximately $6 million, compared to net gains of $44 million in fourth quarter of fiscal ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "439b79cbbec2e7969af717c9d7c52c9a83706078f06e4c41de857e4b808bcce5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d3f28b6-6ba4-4c7f-94a1-5be7be8cfb93", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021.  Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021. "}, "hash": "dd1af93ccef7fdf38476811dbf442aebea1e14ff939fef6e244c4c9778d5fac2", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d3f28b6-6ba4-4c7f-94a1-5be7be8cfb93": {"__data__": {"id_": "1d3f28b6-6ba4-4c7f-94a1-5be7be8cfb93", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021.  Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6feeaf47-90a5-40c3-96e6-f59730bb4dc3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021.  Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7be6703317f7152515c97b3bdacb805e6660ed695161011ee3ca64068a64eece", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a4ca8fc-c8a1-4928-8586-f7a09578116f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021.  Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n", "original_text": "Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n"}, "hash": "f208cff05e2bdf19848e28c9848ae31140aa3a34edecd47947ab47e8b10bee12", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021. ", "start_char_idx": 16, "end_char_idx": 187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a4ca8fc-c8a1-4928-8586-f7a09578116f": {"__data__": {"id_": "9a4ca8fc-c8a1-4928-8586-f7a09578116f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021.  Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n", "original_text": "Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d3f28b6-6ba4-4c7f-94a1-5be7be8cfb93", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021.  Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f605e7a58edae703493b7581c6d6e106311c0a1aaec9e3c9cf708063c8bf7b0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43f1af93-10d3-4af4-a3bd-914491f17183", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021.  Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter. ", "original_text": "In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share. "}, "hash": "9ae3ba9349f43a0a027316fb3906d76ba0e239a19e740dc49a5fc2cf00d43204", "class_name": "RelatedNodeInfo"}}, "text": "Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n", "start_char_idx": 187, "end_char_idx": 306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43f1af93-10d3-4af4-a3bd-914491f17183": {"__data__": {"id_": "43f1af93-10d3-4af4-a3bd-914491f17183", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021.  Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter. ", "original_text": "In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a4ca8fc-c8a1-4928-8586-f7a09578116f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021.  Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n", "original_text": "Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bba3e7cc24e026504b63e08ede5af674ef875aeb10ba8ff6a1cd41aba2794741", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f7b5f2b-7ad3-42a9-9e63-8ea1bc7801b5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021.  Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment. ", "original_text": "This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021. "}, "hash": "db17eb4e93d39a8df607c69166f97ea8356ec18d7de12a476db151eab33b907b", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share. ", "start_char_idx": 306, "end_char_idx": 469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f7b5f2b-7ad3-42a9-9e63-8ea1bc7801b5": {"__data__": {"id_": "3f7b5f2b-7ad3-42a9-9e63-8ea1bc7801b5", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021.  Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment. ", "original_text": "This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43f1af93-10d3-4af4-a3bd-914491f17183", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021.  Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter. ", "original_text": "In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0119c7ad44fc3339ded3c81cd1a92d0bdf6cb3291a10e26154a73a3afee6b9e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf40a5f7-e592-4d55-89a3-803f4b3a7007", "node_type": "1", "metadata": {"window": "Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur. ", "original_text": "As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n"}, "hash": "ce25e50c825486476b9a0e0dab038fbff7b745aa4289e3548ca3925d9b2e6bf1", "class_name": "RelatedNodeInfo"}}, "text": "This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021. ", "start_char_idx": 469, "end_char_idx": 570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf40a5f7-e592-4d55-89a3-803f4b3a7007": {"__data__": {"id_": "cf40a5f7-e592-4d55-89a3-803f4b3a7007", "embedding": null, "metadata": {"window": "Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur. ", "original_text": "As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f7b5f2b-7ad3-42a9-9e63-8ea1bc7801b5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021.  Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment. ", "original_text": "This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d17dc6d816c17edf074757a501252ebfb60a1aa3dff12a6dde0c6877a1f5078", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b617408-2b40-43f0-a743-f0a97af0ddb2", "node_type": "1", "metadata": {"window": "In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance. ", "original_text": "The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter. "}, "hash": "51d756df9978cb60664bb7941e8f774a765b1a0700b99399ddd3dc23e63a83a2", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n", "start_char_idx": 570, "end_char_idx": 793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b617408-2b40-43f0-a743-f0a97af0ddb2": {"__data__": {"id_": "0b617408-2b40-43f0-a743-f0a97af0ddb2", "embedding": null, "metadata": {"window": "In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance. ", "original_text": "The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf40a5f7-e592-4d55-89a3-803f4b3a7007", "node_type": "1", "metadata": {"window": "Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur. ", "original_text": "As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03de7e5ab384613f674ed59e078187ac83a6de77af702a592e3f534375c0d26e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1adeae0-276a-4275-bb30-6e9256b0bbfd", "node_type": "1", "metadata": {"window": "This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n", "original_text": "And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment. "}, "hash": "9166b6f5c0c5d76aa079d94cab364342e795e2cbe2b271bc7006f10aebf09f2d", "class_name": "RelatedNodeInfo"}}, "text": "The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter. ", "start_char_idx": 793, "end_char_idx": 924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1adeae0-276a-4275-bb30-6e9256b0bbfd": {"__data__": {"id_": "e1adeae0-276a-4275-bb30-6e9256b0bbfd", "embedding": null, "metadata": {"window": "This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n", "original_text": "And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b617408-2b40-43f0-a743-f0a97af0ddb2", "node_type": "1", "metadata": {"window": "In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share.  This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance. ", "original_text": "The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04479098df5dd56248a7f0a95617c6fa3e759ec6d261acded225ecb6f7001ec9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72050322-46e4-4848-ac79-0ccd13cfdd58", "node_type": "1", "metadata": {"window": "As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13. ", "original_text": "It's difficult to predict when gains and losses on our venture \nportfolio companies may occur. "}, "hash": "d15c26db797bea1bafd15c5d3f6644c678f92ecac40f860a87d99a55b5c601b7", "class_name": "RelatedNodeInfo"}}, "text": "And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment. ", "start_char_idx": 924, "end_char_idx": 1061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72050322-46e4-4848-ac79-0ccd13cfdd58": {"__data__": {"id_": "72050322-46e4-4848-ac79-0ccd13cfdd58", "embedding": null, "metadata": {"window": "As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13. ", "original_text": "It's difficult to predict when gains and losses on our venture \nportfolio companies may occur. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1adeae0-276a-4275-bb30-6e9256b0bbfd", "node_type": "1", "metadata": {"window": "This compares to net gains of approximately $132 million or \n$0.60 for the full year of fiscal 2021.  As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n", "original_text": "And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59b969d57e72a3376abad0fff98fe45a77f4b9b3d987a0da4ab2f15d599e00ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef97c86a-48fe-4d91-9941-1c9fab8e2803", "node_type": "1", "metadata": {"window": "The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures. ", "original_text": "And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance. "}, "hash": "9f337c01e9b7a50be169bbe422453594da1f42e3ad269d1015b1a444e3e35436", "class_name": "RelatedNodeInfo"}}, "text": "It's difficult to predict when gains and losses on our venture \nportfolio companies may occur. ", "start_char_idx": 1061, "end_char_idx": 1156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef97c86a-48fe-4d91-9941-1c9fab8e2803": {"__data__": {"id_": "ef97c86a-48fe-4d91-9941-1c9fab8e2803", "embedding": null, "metadata": {"window": "The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures. ", "original_text": "And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72050322-46e4-4848-ac79-0ccd13cfdd58", "node_type": "1", "metadata": {"window": "As a reminder, McKesson Ventures portfolio holds equity investments in \nseveral growth -stage di gital health and services companies, and we are pleased with the insights and the portfolio \nresults that we've obtained.  \n \n The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13. ", "original_text": "It's difficult to predict when gains and losses on our venture \nportfolio companies may occur. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "886e24f9ce1f1859de0f481cd6eee5590e851e6df534f0b5e3f97653c1c8799a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8a45a88-15d7-4c2f-b63f-a3973c55e4e2", "node_type": "1", "metadata": {"window": "And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders. ", "original_text": "And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n"}, "hash": "6e9925f539795453ea0873e6a5d75d767fbb5a9fd05b1021f808004e4b48fd4e", "class_name": "RelatedNodeInfo"}}, "text": "And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance. ", "start_char_idx": 1156, "end_char_idx": 1275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8a45a88-15d7-4c2f-b63f-a3973c55e4e2": {"__data__": {"id_": "a8a45a88-15d7-4c2f-b63f-a3973c55e4e2", "embedding": null, "metadata": {"window": "And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders. ", "original_text": "And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef97c86a-48fe-4d91-9941-1c9fab8e2803", "node_type": "1", "metadata": {"window": "The impacts for a consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures. ", "original_text": "And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a2453c55bb12de1caf52c6cf880dd48f87b1c167f57b79f7b588fcef7fbef28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc8dec21-3bb4-4383-8898-71a58cc275e4", "node_type": "1", "metadata": {"window": "It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends. ", "original_text": "Turning now to our cash position and capital deployment on slide 13. "}, "hash": "5230b90fef56770a9cf32a864875b1859c1e1bbbd7554383776c71bc6adbdf9e", "class_name": "RelatedNodeInfo"}}, "text": "And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n", "start_char_idx": 1275, "end_char_idx": 1438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc8dec21-3bb4-4383-8898-71a58cc275e4": {"__data__": {"id_": "dc8dec21-3bb4-4383-8898-71a58cc275e4", "embedding": null, "metadata": {"window": "It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends. ", "original_text": "Turning now to our cash position and capital deployment on slide 13. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8a45a88-15d7-4c2f-b63f-a3973c55e4e2", "node_type": "1", "metadata": {"window": "And a s a result, McKesson's investments may result in gains or losses, the timing and \nmagnitude of which can vary for each investment.  It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders. ", "original_text": "And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "532f4219374db05b0de5892d77649dfdc7d53ab1373975090af3f5ab16f9cc11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbdef979-468f-4324-a608-008860bf44ed", "node_type": "1", "metadata": {"window": "And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n", "original_text": "For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures. "}, "hash": "b2163fcd19fc504aaef11704eb250f92f30428b55606ac4df251f81f572427b2", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to our cash position and capital deployment on slide 13. ", "start_char_idx": 1438, "end_char_idx": 1507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbdef979-468f-4324-a608-008860bf44ed": {"__data__": {"id_": "dbdef979-468f-4324-a608-008860bf44ed", "embedding": null, "metadata": {"window": "And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n", "original_text": "For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc8dec21-3bb4-4383-8898-71a58cc275e4", "node_type": "1", "metadata": {"window": "It's difficult to predict when gains and losses on our venture \nportfolio companies may occur.  And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends. ", "original_text": "Turning now to our cash position and capital deployment on slide 13. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5215f588596cc3791673de359c695f9259fc03539e366e55dc218ee486f02ffc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "868c9160-e287-4a11-a9ef-f85c86634ea2", "node_type": "1", "metadata": {"window": "And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter. ", "original_text": "We continue to focus capital deployment to \ndrive value for our shareholders. "}, "hash": "548a48c1af6e2507054865d405d3de41d8e7cdb21af9795ca310021c9166bb5d", "class_name": "RelatedNodeInfo"}}, "text": "For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures. ", "start_char_idx": 1507, "end_char_idx": 1627, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "868c9160-e287-4a11-a9ef-f85c86634ea2": {"__data__": {"id_": "868c9160-e287-4a11-a9ef-f85c86634ea2", "embedding": null, "metadata": {"window": "And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter. ", "original_text": "We continue to focus capital deployment to \ndrive value for our shareholders. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbdef979-468f-4324-a608-008860bf44ed", "node_type": "1", "metadata": {"window": "And, therefore, our practice has  been and will continue to not include ventures \nportfolio estimates in our guidance.  And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n", "original_text": "For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "520ff337b581026493a578fe14bc56724a13df1f42f0eee8712edf1501df3b36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e9ff3b1-469b-49e2-9913-2dafc8023a8e", "node_type": "1", "metadata": {"window": "Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year. ", "original_text": "Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends. "}, "hash": "388f3c39eb4b66cfeb24cf1134ebfc7577f246665213b61b8aef365edac41199", "class_name": "RelatedNodeInfo"}}, "text": "We continue to focus capital deployment to \ndrive value for our shareholders. ", "start_char_idx": 1627, "end_char_idx": 1705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e9ff3b1-469b-49e2-9913-2dafc8023a8e": {"__data__": {"id_": "7e9ff3b1-469b-49e2-9913-2dafc8023a8e", "embedding": null, "metadata": {"window": "Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year. ", "original_text": "Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "868c9160-e287-4a11-a9ef-f85c86634ea2", "node_type": "1", "metadata": {"window": "And finally, in the fourth quarter, we incurred opioid related litigation expenses \nof $26 million and incurred $130 million for the full year of fiscal 2022.  \n \n Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter. ", "original_text": "We continue to focus capital deployment to \ndrive value for our shareholders. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a654563dd1f1b79ccdbd9a6b07e8d0f5d2e793f094642a4b40ff2128ec4c454a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42833547-fd87-4a50-a340-ac70f9037aa1", "node_type": "1", "metadata": {"window": "For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n", "original_text": "Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n"}, "hash": "908cb3df4b3f54810aeb68ea1ee1b19231403ac82359276349cc0b4dfa780410", "class_name": "RelatedNodeInfo"}}, "text": "Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends. ", "start_char_idx": 1705, "end_char_idx": 1815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42833547-fd87-4a50-a340-ac70f9037aa1": {"__data__": {"id_": "42833547-fd87-4a50-a340-ac70f9037aa1", "embedding": null, "metadata": {"window": "For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n", "original_text": "Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e9ff3b1-469b-49e2-9913-2dafc8023a8e", "node_type": "1", "metadata": {"window": "Turning now to our cash position and capital deployment on slide 13.  For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year. ", "original_text": "Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b43c19ce91013b3487d7834c34960cab85f7e240dc670f2cfaa3938eb4ded1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27be2a1b-61e9-437d-a943-b2ae46922962", "node_type": "1", "metadata": {"window": "We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n", "original_text": "In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter. "}, "hash": "0eed6517be9025545ceb82943f7f5ae954da71470bae3a0a8d65f65898a6e0bc", "class_name": "RelatedNodeInfo"}}, "text": "Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n", "start_char_idx": 1815, "end_char_idx": 1958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27be2a1b-61e9-437d-a943-b2ae46922962": {"__data__": {"id_": "27be2a1b-61e9-437d-a943-b2ae46922962", "embedding": null, "metadata": {"window": "We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n", "original_text": "In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42833547-fd87-4a50-a340-ac70f9037aa1", "node_type": "1", "metadata": {"window": "For the fiscal year, we generated $3.9 billion \nin free cash flow, which included $535 million of capital expenditures.  We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n", "original_text": "Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "336005569e2e1623e1740dd025ccc5b17837a46bc4fc7e7202a2d24081c4b480", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81f9114b-3024-41e3-b42d-a991a575da80", "node_type": "1", "metadata": {"window": "Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023. ", "original_text": "Additionally, we paid dividends of $277 million for the full year. "}, "hash": "55ab6330d014a9608dcce825454fa6d7854db84881df072a211708167a27f581", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter. ", "start_char_idx": 1958, "end_char_idx": 2081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81f9114b-3024-41e3-b42d-a991a575da80": {"__data__": {"id_": "81f9114b-3024-41e3-b42d-a991a575da80", "embedding": null, "metadata": {"window": "Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023. ", "original_text": "Additionally, we paid dividends of $277 million for the full year. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27be2a1b-61e9-437d-a943-b2ae46922962", "node_type": "1", "metadata": {"window": "We continue to focus capital deployment to \ndrive value for our shareholders.  Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n", "original_text": "In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b875759c0811a3d20c9651efcdecc5c9f5dc0b16094220afe4837c8d2e1ff490", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3949c318-49b4-413c-a937-d4551b45a20e", "node_type": "1", "metadata": {"window": "Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results. ", "original_text": "When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n"}, "hash": "5e94726713fb608cf515c6b516448012098813dac7ee35ae7feb972ad54a823f", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we paid dividends of $277 million for the full year. ", "start_char_idx": 2081, "end_char_idx": 2148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3949c318-49b4-413c-a937-d4551b45a20e": {"__data__": {"id_": "3949c318-49b4-413c-a937-d4551b45a20e", "embedding": null, "metadata": {"window": "Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results. ", "original_text": "When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81f9114b-3024-41e3-b42d-a991a575da80", "node_type": "1", "metadata": {"window": "Sin ce fiscal 2018, we returned $11 billion of cash to shareholders through share \nrepurchases and dividends.  Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023. ", "original_text": "Additionally, we paid dividends of $277 million for the full year. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cda5dbbdb87ba3473133ccd87488be488fbd6f80703ae82c3e515e6bab8f87ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9186b913-c183-4717-bc03-de19ac62ee20", "node_type": "1", "metadata": {"window": "In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance. ", "original_text": "Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n"}, "hash": "e85b16cb987ad107a599ad5dc20d142f8312d0f588eb8e747b92d21209c61feb", "class_name": "RelatedNodeInfo"}}, "text": "When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n", "start_char_idx": 2148, "end_char_idx": 2287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9186b913-c183-4717-bc03-de19ac62ee20": {"__data__": {"id_": "9186b913-c183-4717-bc03-de19ac62ee20", "embedding": null, "metadata": {"window": "In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance. ", "original_text": "Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3949c318-49b4-413c-a937-d4551b45a20e", "node_type": "1", "metadata": {"window": "Of this amount, over $9 billion has been returned through share repurchases, \nreducing our total average shares outstanding by nearly 31%.  \n \n In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results. ", "original_text": "When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b07137d6efa92baab6f38d3998a3672620dbeb632ebf0ac96fa9c6d1474b0b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9615b1c8-4552-484a-b2a2-1d062eb922da", "node_type": "1", "metadata": {"window": "Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n", "original_text": "Let me spend a few minutes now discussing our outlook for fiscal 2023. "}, "hash": "cb5fae8ca057c9b3a783c0ab665c4290070b2f96b2a45351252dac14a618165d", "class_name": "RelatedNodeInfo"}}, "text": "Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n", "start_char_idx": 2287, "end_char_idx": 2589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9615b1c8-4552-484a-b2a2-1d062eb922da": {"__data__": {"id_": "9615b1c8-4552-484a-b2a2-1d062eb922da", "embedding": null, "metadata": {"window": "Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n", "original_text": "Let me spend a few minutes now discussing our outlook for fiscal 2023. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9186b913-c183-4717-bc03-de19ac62ee20", "node_type": "1", "metadata": {"window": "In fiscal 20 22, we returned $3.5 billion through share repurchases, including $1.5 billion in the fiscal fourth \nquarter.  Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance. ", "original_text": "Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d74d1b74cf6d2078892fbd093490d0954bb6bb5b205acb83bd055ba9daaa28cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90e96a45-a254-4e61-9e29-40eb180f50a1", "node_type": "1", "metadata": {"window": "When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n", "original_text": "We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results. "}, "hash": "fda773a043e32eed97cb04f1a0f7a9239a05aac7c3f444fd412d9a5a37de9b09", "class_name": "RelatedNodeInfo"}}, "text": "Let me spend a few minutes now discussing our outlook for fiscal 2023. ", "start_char_idx": 2589, "end_char_idx": 2660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90e96a45-a254-4e61-9e29-40eb180f50a1": {"__data__": {"id_": "90e96a45-a254-4e61-9e29-40eb180f50a1", "embedding": null, "metadata": {"window": "When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n", "original_text": "We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9615b1c8-4552-484a-b2a2-1d062eb922da", "node_type": "1", "metadata": {"window": "Additionally, we paid dividends of $277 million for the full year.  When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n", "original_text": "Let me spend a few minutes now discussing our outlook for fiscal 2023. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1838432356c2193e9f6d340f6f3a9bec9c9d12f478077836eff55ab568b493b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e685cd4-7307-4a07-83ea-fd5c73cdddfa", "node_type": "1", "metadata": {"window": "Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems. ", "original_text": "Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance. "}, "hash": "c244f7a6c2e872c8528b281fe53a9676d5918280fc4be3326397cbc12b0509ed", "class_name": "RelatedNodeInfo"}}, "text": "We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results. ", "start_char_idx": 2660, "end_char_idx": 2751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e685cd4-7307-4a07-83ea-fd5c73cdddfa": {"__data__": {"id_": "6e685cd4-7307-4a07-83ea-fd5c73cdddfa", "embedding": null, "metadata": {"window": "Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems. ", "original_text": "Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90e96a45-a254-4e61-9e29-40eb180f50a1", "node_type": "1", "metadata": {"window": "When combining share repurchases with \ndividends paid, we returned approximately 97% of free cash flow to shareholders in fiscal 2022.  \n \n Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n", "original_text": "We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e05041cff36ed9c5d09bdc4ffc474f91683c6e0d35c5e068771e5775643b3be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74542ad2-a8b2-433c-9bcb-572a889956b6", "node_type": "1", "metadata": {"window": "Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n", "original_text": "A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n"}, "hash": "24972aefed61cc95a9694cefabb341e7c513527c5d84c0d214e3a81e9f8d2ce8", "class_name": "RelatedNodeInfo"}}, "text": "Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance. ", "start_char_idx": 2751, "end_char_idx": 2908, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74542ad2-a8b2-433c-9bcb-572a889956b6": {"__data__": {"id_": "74542ad2-a8b2-433c-9bcb-572a889956b6", "embedding": null, "metadata": {"window": "Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n", "original_text": "A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e685cd4-7307-4a07-83ea-fd5c73cdddfa", "node_type": "1", "metadata": {"window": "Our strong balance sheet and cash flow generation, along with disciplined capital allocation, continues to provide \nus with the financial flexibility to invest in our strategies, pursue strategic opport unities and return capital to \nshareholders, all while maintaining a strong capital structure.  \n \n Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems. ", "original_text": "Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5fd9aee51d27c6bea592d73c7cbc1b65da251cd91a6b015aaf5dd3f7d0c46742", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a7f2ed3-89a2-4400-8be2-e11680dcccc3", "node_type": "1", "metadata": {"window": "We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%. ", "original_text": "We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n"}, "hash": "f00aab349a308b437f34ec50a3a17105338433a4cf0c0670611062d2efce2e29", "class_name": "RelatedNodeInfo"}}, "text": "A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n", "start_char_idx": 2908, "end_char_idx": 3022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a7f2ed3-89a2-4400-8be2-e11680dcccc3": {"__data__": {"id_": "6a7f2ed3-89a2-4400-8be2-e11680dcccc3", "embedding": null, "metadata": {"window": "We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%. ", "original_text": "We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74542ad2-a8b2-433c-9bcb-572a889956b6", "node_type": "1", "metadata": {"window": "Let me spend a few minutes now discussing our outlook for fiscal 2023.  We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n", "original_text": "A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c3896de05ee9f1330fe940bff39b0c9166d56410d9a96f003602f8afefd3201", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efdd76e4-8a1b-4d41-8f6a-332c1322ed6f", "node_type": "1", "metadata": {"window": "Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n", "original_text": "We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems. "}, "hash": "4d915728bee6c96f0464725d59c5b5fdf53ceed977b72aee3e849b79d484ccfb", "class_name": "RelatedNodeInfo"}}, "text": "We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n", "start_char_idx": 3022, "end_char_idx": 3134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efdd76e4-8a1b-4d41-8f6a-332c1322ed6f": {"__data__": {"id_": "efdd76e4-8a1b-4d41-8f6a-332c1322ed6f", "embedding": null, "metadata": {"window": "Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n", "original_text": "We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a7f2ed3-89a2-4400-8be2-e11680dcccc3", "node_type": "1", "metadata": {"window": "We entered fiscal 2023 with solid \nmomentum, building upon the strong fiscal 2022 results.  Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%. ", "original_text": "We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee6c938260529d0ac5248f8c89b8622f2f88a868bd5c380a2df26019a8011240", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a679ff7-5db2-490e-a4b3-5e6942e3b6d2", "node_type": "1", "metadata": {"window": "A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities. ", "original_text": "Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n"}, "hash": "69c91974ff1d6b5501c964d46bd4ed942a2435b3d845bac57d9f46ecfbefe841", "class_name": "RelatedNodeInfo"}}, "text": "We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems. ", "start_char_idx": 3134, "end_char_idx": 3283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a679ff7-5db2-490e-a4b3-5e6942e3b6d2": {"__data__": {"id_": "4a679ff7-5db2-490e-a4b3-5e6942e3b6d2", "embedding": null, "metadata": {"window": "A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities. ", "original_text": "Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efdd76e4-8a1b-4d41-8f6a-332c1322ed6f", "node_type": "1", "metadata": {"window": "Rather than outlining each assumption, I'll instead walk \nyou through the key items, beginning with additional details of fiscal 2023 consolidated guidance.  A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n", "original_text": "We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9430761e37ebb6241dfbf06614f4c7fd2b5a1d3c306e7b28140e1609aa9a83a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5886313-a3ec-4166-8815-b085525a6126", "node_type": "1", "metadata": {"window": "We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities.  While we've reached a broad settlement, there are cases that remain o pen. ", "original_text": "Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%. "}, "hash": "9a1546e4585f659d4fcc29bad417ed204b633a01d92d0606d628f031bcef146c", "class_name": "RelatedNodeInfo"}}, "text": "Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n", "start_char_idx": 3283, "end_char_idx": 3420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5886313-a3ec-4166-8815-b085525a6126": {"__data__": {"id_": "a5886313-a3ec-4166-8815-b085525a6126", "embedding": null, "metadata": {"window": "We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities.  While we've reached a broad settlement, there are cases that remain o pen. ", "original_text": "Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a679ff7-5db2-490e-a4b3-5e6942e3b6d2", "node_type": "1", "metadata": {"window": "A full list of our \nassumptions can be found on slides 14 through 19 in our supplemental slide presen tation.  \n \n We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities. ", "original_text": "Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6cb466d544f39729a3087c3d7ffa34c3b809a8b17efca7c06ed33f2b030c1dcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34ec64b0-edd1-4a6e-9fe6-e05cb497499d", "node_type": "1", "metadata": {"window": "We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities.  While we've reached a broad settlement, there are cases that remain o pen.  As it relates to opioid \nlitigation expenses, we previously communicated that we anticipate a substantial reduction in fiscal year 2023 ", "original_text": "We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n"}, "hash": "7e3983d77a9feb4dd561f27bb78727f10cc0066a9d50e51016ac475149a656fc", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%. ", "start_char_idx": 3420, "end_char_idx": 3719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34ec64b0-edd1-4a6e-9fe6-e05cb497499d": {"__data__": {"id_": "34ec64b0-edd1-4a6e-9fe6-e05cb497499d", "embedding": null, "metadata": {"window": "We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities.  While we've reached a broad settlement, there are cases that remain o pen.  As it relates to opioid \nlitigation expenses, we previously communicated that we anticipate a substantial reduction in fiscal year 2023 ", "original_text": "We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5886313-a3ec-4166-8815-b085525a6126", "node_type": "1", "metadata": {"window": "We remain confident in the fundamentals of our North American healthcare services and distribution businesses. \n We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities.  While we've reached a broad settlement, there are cases that remain o pen. ", "original_text": "Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcbc2baa842577ac0a3a746b1dcc1f69bb0300089da95cdeb57043426e5aeeaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7c31bcb-cfbb-4d1a-8818-a6e9797e492f", "node_type": "1", "metadata": {"window": "Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities.  While we've reached a broad settlement, there are cases that remain o pen.  As it relates to opioid \nlitigation expenses, we previously communicated that we anticipate a substantial reduction in fiscal year 2023 ", "original_text": "In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities. "}, "hash": "2bc48798e92a5ec8b6177b9ccc1d79a133297de4be25fd77f1a7b6f80a2ab1dc", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n", "start_char_idx": 3719, "end_char_idx": 3858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7c31bcb-cfbb-4d1a-8818-a6e9797e492f": {"__data__": {"id_": "b7c31bcb-cfbb-4d1a-8818-a6e9797e492f", "embedding": null, "metadata": {"window": "Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities.  While we've reached a broad settlement, there are cases that remain o pen.  As it relates to opioid \nlitigation expenses, we previously communicated that we anticipate a substantial reduction in fiscal year 2023 ", "original_text": "In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34ec64b0-edd1-4a6e-9fe6-e05cb497499d", "node_type": "1", "metadata": {"window": "We'll continue to invest in innovative product offerings that further enhance our leading roles in the oncology and \nbiopharma services e cosystems.  Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities.  While we've reached a broad settlement, there are cases that remain o pen.  As it relates to opioid \nlitigation expenses, we previously communicated that we anticipate a substantial reduction in fiscal year 2023 ", "original_text": "We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "230d0c1a670ab346ee88f08e630d9d675998590dd5f42e8c5c3d3fe519f0daed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4db5f283-e360-42cb-a81b-bb71793a1d7d", "node_type": "1", "metadata": {"window": "Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities.  While we've reached a broad settlement, there are cases that remain o pen.  As it relates to opioid \nlitigation expenses, we previously communicated that we anticipate a substantial reduction in fiscal year 2023 ", "original_text": "While we've reached a broad settlement, there are cases that remain o pen. "}, "hash": "20e3b7a1903de39f4abec0a51d5d4f8910061513e3c88ab1db23150d45da62bd", "class_name": "RelatedNodeInfo"}}, "text": "In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities. ", "start_char_idx": 3858, "end_char_idx": 3987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4db5f283-e360-42cb-a81b-bb71793a1d7d": {"__data__": {"id_": "4db5f283-e360-42cb-a81b-bb71793a1d7d", "embedding": null, "metadata": {"window": "Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities.  While we've reached a broad settlement, there are cases that remain o pen.  As it relates to opioid \nlitigation expenses, we previously communicated that we anticipate a substantial reduction in fiscal year 2023 ", "original_text": "While we've reached a broad settlement, there are cases that remain o pen. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7c31bcb-cfbb-4d1a-8818-a6e9797e492f", "node_type": "1", "metadata": {"window": "Our fiscal 2023 guidance assumes flat to 4% reported revenue growth and 4% \nto 10% operating profit decline compared to fiscal 2022.  \n \n Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities.  While we've reached a broad settlement, there are cases that remain o pen.  As it relates to opioid \nlitigation expenses, we previously communicated that we anticipate a substantial reduction in fiscal year 2023 ", "original_text": "In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d6a510e25e20c6a7db091d1c965bfdd498ea0eb55e4a9bf953432ce3de7c077", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc43818d-eee8-4108-b964-c31b610c1da6", "node_type": "1", "metadata": {"window": "We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities.  While we've reached a broad settlement, there are cases that remain o pen.  As it relates to opioid \nlitigation expenses, we previously communicated that we anticipate a substantial reduction in fiscal year 2023 ", "original_text": "As it relates to opioid \nlitigation expenses, we previously communicated that we anticipate a substantial reduction in fiscal year 2023 "}, "hash": "76cb38fd44b0f7aaa62a80815ab611385b3803d5c0c12831f5d0083a30c20a61", "class_name": "RelatedNodeInfo"}}, "text": "While we've reached a broad settlement, there are cases that remain o pen. ", "start_char_idx": 3987, "end_char_idx": 4062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc43818d-eee8-4108-b964-c31b610c1da6": {"__data__": {"id_": "cc43818d-eee8-4108-b964-c31b610c1da6", "embedding": null, "metadata": {"window": "We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities.  While we've reached a broad settlement, there are cases that remain o pen.  As it relates to opioid \nlitigation expenses, we previously communicated that we anticipate a substantial reduction in fiscal year 2023 ", "original_text": "As it relates to opioid \nlitigation expenses, we previously communicated that we anticipate a substantial reduction in fiscal year 2023 ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "838456a8d5cdfdbe3af11be37b73679d386629e3b68ff4d12d8a5532d01130b6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4db5f283-e360-42cb-a81b-bb71793a1d7d", "node_type": "1", "metadata": {"window": "Excluding the impacts related to the US government's centralized COVID -19 vaccine and kitting distribution \nprogr ams, COVID -19 tests and net gains associated with McKesson Ventures' equity investments which were \nrecorded in fiscal year 2022, we anticipate operating profit to increase 3% to 9%.  We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities.  While we've reached a broad settlement, there are cases that remain o pen.  As it relates to opioid \nlitigation expenses, we previously communicated that we anticipate a substantial reduction in fiscal year 2023 ", "original_text": "While we've reached a broad settlement, there are cases that remain o pen. ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33379b0d65118f816536682d229a8a51000c5e09e544e32a9a055d07afa5ad2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfbcaa48-02bd-4ecc-ba69-9c044f3923c0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement.  For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23. ", "original_text": "McKesson Corp.  "}, "hash": "4921808d9a2d08aa7b4d4f0b504b059d9ef4a4114c27529fd50b4c8b39fa89f3", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to opioid \nlitigation expenses, we previously communicated that we anticipate a substantial reduction in fiscal year 2023 ", "start_char_idx": 4062, "end_char_idx": 4198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfbcaa48-02bd-4ecc-ba69-9c044f3923c0": {"__data__": {"id_": "dfbcaa48-02bd-4ecc-ba69-9c044f3923c0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement.  For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc43818d-eee8-4108-b964-c31b610c1da6", "node_type": "1", "metadata": {"window": "We anticipate a full year tax rate \nof approximately 18% to 20%, and corpor ate expenses in the range of $520 million to $590 million.  \n \n In the fourth quarter of fiscal 2022, we finalized the broad settlement of opioid -related claims of states and \nmunicipalities.  While we've reached a broad settlement, there are cases that remain o pen.  As it relates to opioid \nlitigation expenses, we previously communicated that we anticipate a substantial reduction in fiscal year 2023 ", "original_text": "As it relates to opioid \nlitigation expenses, we previously communicated that we anticipate a substantial reduction in fiscal year 2023 ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "520d86efa360f3e912afb3006cd284767bc54f80f1fb284e434fca29d8c6c246", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ec72c84-e69c-4a18-be91-ff794f2773c7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement.  For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement. "}, "hash": "fc8184b8f1f7916d1d1018eea965ae9a95ac0294be24be8ad005797e74e4101c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ec72c84-e69c-4a18-be91-ff794f2773c7": {"__data__": {"id_": "9ec72c84-e69c-4a18-be91-ff794f2773c7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement.  For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfbcaa48-02bd-4ecc-ba69-9c044f3923c0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement.  For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de5c0db42af5cdd8257e66fd3fb9c39f12674a09f9bd945d6318948baf58fbee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bad1ab8-3d00-4cbb-a47f-7be609e60789", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement.  For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year. ", "original_text": "For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n"}, "hash": "e21e47df2d0fa4a54ccd2861ee83a66d097f280de4be3d621f30188e64f52aee", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement. ", "start_char_idx": 16, "end_char_idx": 212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bad1ab8-3d00-4cbb-a47f-7be609e60789": {"__data__": {"id_": "2bad1ab8-3d00-4cbb-a47f-7be609e60789", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement.  For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year. ", "original_text": "For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ec72c84-e69c-4a18-be91-ff794f2773c7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement.  For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89c22b783d4f1cffcdfe030bd3cc34e006f257ae114145a679c6ad5540df9241", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fb99197-bfc0-4a24-af82-f2a11f1cecec", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement.  For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n", "original_text": "Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23. "}, "hash": "09719015e8dc1587c6c3b0dcde177abfbd79929450054a15dba963485570ae35", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n", "start_char_idx": 212, "end_char_idx": 453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fb99197-bfc0-4a24-af82-f2a11f1cecec": {"__data__": {"id_": "5fb99197-bfc0-4a24-af82-f2a11f1cecec", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement.  For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n", "original_text": "Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bad1ab8-3d00-4cbb-a47f-7be609e60789", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement.  For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year. ", "original_text": "For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51244577b669402f4a339c47568a46f978b19cc37343dbf3c924a772390baa0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61a9786a-26b8-473a-9504-6bd53d840275", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement.  For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments. ", "original_text": "60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n"}, "hash": "9220d099fcc6ae48057b2ffc3607cd0c7cfbf863ad4d684d545872c45c1f6147", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23. ", "start_char_idx": 453, "end_char_idx": 561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61a9786a-26b8-473a-9504-6bd53d840275": {"__data__": {"id_": "61a9786a-26b8-473a-9504-6bd53d840275", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement.  For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments. ", "original_text": "60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fb99197-bfc0-4a24-af82-f2a11f1cecec", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement.  For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n", "original_text": "Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15fcf0654f02724c8221b8679b6448ce74710f4e85b926e457ef25e6c0836b8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdeb5b83-2839-46ad-8ed7-b07bd510726c", "node_type": "1", "metadata": {"window": "For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem. ", "original_text": "Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year. "}, "hash": "6b2ec53e9d06ca26f3e00e6ebbaf24d6e6f749f6d54edaffd90d7ba713377794", "class_name": "RelatedNodeInfo"}}, "text": "60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n", "start_char_idx": 561, "end_char_idx": 877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdeb5b83-2839-46ad-8ed7-b07bd510726c": {"__data__": {"id_": "cdeb5b83-2839-46ad-8ed7-b07bd510726c", "embedding": null, "metadata": {"window": "For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem. ", "original_text": "Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61a9786a-26b8-473a-9504-6bd53d840275", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement.  For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments. ", "original_text": "60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68d8781e89146e2d46be788f1b2834883ed5e8dbfa62f9cc25e68f5bc1df2c9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f31db4d-bb3c-4862-b8e7-f8432228641a", "node_type": "1", "metadata": {"window": "Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year. ", "original_text": "This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n"}, "hash": "e7e6da6a8a4576d6224b127b10b0a15c9997f21fafa85143f92b1e944708d6a7", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year. ", "start_char_idx": 877, "end_char_idx": 1181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f31db4d-bb3c-4862-b8e7-f8432228641a": {"__data__": {"id_": "0f31db4d-bb3c-4862-b8e7-f8432228641a", "embedding": null, "metadata": {"window": "Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year. ", "original_text": "This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdeb5b83-2839-46ad-8ed7-b07bd510726c", "node_type": "1", "metadata": {"window": "For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem. ", "original_text": "Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0076732d75eecd07a953377def14cabc592981f8d85d334cf21339e7ea2289d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2caef75-0f6e-4c7f-ab60-515bb67da8bb", "node_type": "1", "metadata": {"window": "60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government. ", "original_text": "Moving now to our segments. "}, "hash": "8ef06a4b22b97a3642ecf319aa7baf9c2693df153d9d3fc775c2d6286508678b", "class_name": "RelatedNodeInfo"}}, "text": "This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n", "start_char_idx": 1181, "end_char_idx": 1503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2caef75-0f6e-4c7f-ab60-515bb67da8bb": {"__data__": {"id_": "b2caef75-0f6e-4c7f-ab60-515bb67da8bb", "embedding": null, "metadata": {"window": "60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government. ", "original_text": "Moving now to our segments. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f31db4d-bb3c-4862-b8e7-f8432228641a", "node_type": "1", "metadata": {"window": "Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23.  60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year. ", "original_text": "This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "210c8ff70c2a0baf8534e71c9e58363c5e050ca15e32f4c3fbc8d516cd902ba6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6f9ffd9-cee1-4031-a7bc-451904f2310f", "node_type": "1", "metadata": {"window": "Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022. ", "original_text": "In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem. "}, "hash": "5c77de8737c52b9738e861c39767c5449609c967aa2ded92d68a253469c18b79", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to our segments. ", "start_char_idx": 1503, "end_char_idx": 1531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6f9ffd9-cee1-4031-a7bc-451904f2310f": {"__data__": {"id_": "f6f9ffd9-cee1-4031-a7bc-451904f2310f", "embedding": null, "metadata": {"window": "Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022. ", "original_text": "In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2caef75-0f6e-4c7f-ab60-515bb67da8bb", "node_type": "1", "metadata": {"window": "60, \nwhich includes $0.20 to $0.60 of contribution attributable to the following COVID -19-related items: $0.05 to $0.20 \nrelated to the US government's vaccine distribution; less than $0.05 related to the kitting, storage and distribution \nof ancillary suppli es; and $0.15 to $0.35 related to COVID -19 tests.  \n \n Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government. ", "original_text": "Moving now to our segments. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e412abd46c228802da124c02fff04e48325b636bc17ac40e7da94c99ce7c17d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "539defe2-e5a6-42c0-86af-4b4f19020094", "node_type": "1", "metadata": {"window": "This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n", "original_text": "We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year. "}, "hash": "1a45cb9ef19961167d6af1f758bee7231f56f3df81897f7f2b07d5e056b52752", "class_name": "RelatedNodeInfo"}}, "text": "In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem. ", "start_char_idx": 1531, "end_char_idx": 1703, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "539defe2-e5a6-42c0-86af-4b4f19020094": {"__data__": {"id_": "539defe2-e5a6-42c0-86af-4b4f19020094", "embedding": null, "metadata": {"window": "This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n", "original_text": "We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6f9ffd9-cee1-4031-a7bc-451904f2310f", "node_type": "1", "metadata": {"window": "Excluding the impacts of these COVID -19 related items from both fiscal 2023 guidance and fiscal 2022 results \nand the $0.47 related to net gains associated with the McKesson Ventures' equity investments in FY 2022, our \nfiscal 2023 guidance indicates approximately 9% to 14% growth over the prior year.  This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022. ", "original_text": "In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98e70026c76bb07f1555c308432e6c915ac6df95421110095e427c14c498d1b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33705577-5b64-4adf-a8e6-2956c674d6a8", "node_type": "1", "metadata": {"window": "Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%. ", "original_text": "Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government. "}, "hash": "17bc5aa7d35851ab7b3915f5be094f09ccfbaa609363668bfa7d4f462d382ff9", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year. ", "start_char_idx": 1703, "end_char_idx": 1834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33705577-5b64-4adf-a8e6-2956c674d6a8": {"__data__": {"id_": "33705577-5b64-4adf-a8e6-2956c674d6a8", "embedding": null, "metadata": {"window": "Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%. ", "original_text": "Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "539defe2-e5a6-42c0-86af-4b4f19020094", "node_type": "1", "metadata": {"window": "This estimated year -over-\nyear growth is consistent with the long -term financial targets that we provided at our December Investor Day \nevent and represents solid  organic growth in our underlying businesses, disciplined capital deployment and \ncontinued expansion of our oncology and biopharma services ecosystems.  \n \n Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n", "original_text": "We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d68c0a913487454bda989010063c86a47620facbc304b25256fe0c49aa0cfede", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3164538-6719-4b3e-a397-453da29e823a", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n", "original_text": "This compares to $0.89 in full year fiscal 2022. "}, "hash": "d733e2acd57aa48ff6b0c0eb031eeb2ea96028d55f06699efffa47b8a4336f59", "class_name": "RelatedNodeInfo"}}, "text": "Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government. ", "start_char_idx": 1834, "end_char_idx": 2113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3164538-6719-4b3e-a397-453da29e823a": {"__data__": {"id_": "a3164538-6719-4b3e-a397-453da29e823a", "embedding": null, "metadata": {"window": "In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n", "original_text": "This compares to $0.89 in full year fiscal 2022. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33705577-5b64-4adf-a8e6-2956c674d6a8", "node_type": "1", "metadata": {"window": "Moving now to our segments.  In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%. ", "original_text": "Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a9f9fc70f72923436c16bd1aef2c73fc3cb699185858fdbf33de15f7261797a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e05d07b-82ae-4b26-898e-0aeb843f96ef", "node_type": "1", "metadata": {"window": "We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%. ", "original_text": "When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n"}, "hash": "dcd34ed1b02bd7609a25f5637b74d4fac636d1339bcd849ce72240e9148ffcc7", "class_name": "RelatedNodeInfo"}}, "text": "This compares to $0.89 in full year fiscal 2022. ", "start_char_idx": 2113, "end_char_idx": 2162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e05d07b-82ae-4b26-898e-0aeb843f96ef": {"__data__": {"id_": "4e05d07b-82ae-4b26-898e-0aeb843f96ef", "embedding": null, "metadata": {"window": "We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%. ", "original_text": "When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3164538-6719-4b3e-a397-453da29e823a", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical segment, our outlook reflects the efficiency and d urability \nof our core distribution platform and continued expansion of our oncology ecosystem.  We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n", "original_text": "This compares to $0.89 in full year fiscal 2022. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f92cd1aeb87fc74794e874fcf8f4f43b76e7f11958f73ec69952c3d320a6d52d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "682ec1d8-8ab8-4aa2-a007-5739d696faea", "node_type": "1", "metadata": {"window": "Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government. ", "original_text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%. "}, "hash": "bba13e91a4e1958e1adf3cf5bf980af5dfdbd03e2e0f868597897aa0dcb9891a", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n", "start_char_idx": 2162, "end_char_idx": 2434, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "682ec1d8-8ab8-4aa2-a007-5739d696faea": {"__data__": {"id_": "682ec1d8-8ab8-4aa2-a007-5739d696faea", "embedding": null, "metadata": {"window": "Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government. ", "original_text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e05d07b-82ae-4b26-898e-0aeb843f96ef", "node_type": "1", "metadata": {"window": "We anticipate reported \nrevenue to increase 7% to 10% and operating profit to approximately be flat to 4% decline year -over-year.  Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%. ", "original_text": "When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9dbbf6a93bdccb2bdf8de4d34ed7f62f20c48cf8da89fdf8e41ccf12fa3bd385", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97a83009-22e0-4f32-a771-f3643c06223c", "node_type": "1", "metadata": {"window": "This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022. ", "original_text": "This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n"}, "hash": "bd0ddc4ad9630ee366fc47ea59a6a3135f7ee2c86058f6786c63ae1c07e4f0f5", "class_name": "RelatedNodeInfo"}}, "text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%. ", "start_char_idx": 2434, "end_char_idx": 2571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97a83009-22e0-4f32-a771-f3643c06223c": {"__data__": {"id_": "97a83009-22e0-4f32-a771-f3643c06223c", "embedding": null, "metadata": {"window": "This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022. ", "original_text": "This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "682ec1d8-8ab8-4aa2-a007-5739d696faea", "node_type": "1", "metadata": {"window": "Our \noutlook includes approximate ly $0.05 to $0.20 related to COVID -19 vaccine distribution for the US government in \nthe first quarter of fiscal 2023, which is aligned to the current contract timing and volume distribution schedule \nprovided by the CDC and the US government.  This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government. ", "original_text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ed4c322feaf6df5944706050b83cec2eef80abe813eb0f26164e1190626bcf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d1bddb9-c5f4-490a-ab09-4d1fd4df08e4", "node_type": "1", "metadata": {"window": "When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022. ", "original_text": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%. "}, "hash": "f4d4224109e66807498fe5ed8400f7b1510234a1a789ff4bcf153cefb1bfadd8", "class_name": "RelatedNodeInfo"}}, "text": "This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n", "start_char_idx": 2571, "end_char_idx": 2824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d1bddb9-c5f4-490a-ab09-4d1fd4df08e4": {"__data__": {"id_": "2d1bddb9-c5f4-490a-ab09-4d1fd4df08e4", "embedding": null, "metadata": {"window": "When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022. ", "original_text": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97a83009-22e0-4f32-a771-f3643c06223c", "node_type": "1", "metadata": {"window": "This compares to $0.89 in full year fiscal 2022.  When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022. ", "original_text": "This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bbb4d85590d93908b78a907d3338ca3b7400254d49ec050e6d3da045ae9d96b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58c7c553-0b7c-4884-82a3-f7d793998bcc", "node_type": "1", "metadata": {"window": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023. ", "original_text": "Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government. "}, "hash": "a5b6fc73275b3db9f86bb230d8fd4844118bb4c59e30fd2ca3e2c2ea9f5aa246", "class_name": "RelatedNodeInfo"}}, "text": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%. ", "start_char_idx": 2824, "end_char_idx": 2969, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58c7c553-0b7c-4884-82a3-f7d793998bcc": {"__data__": {"id_": "58c7c553-0b7c-4884-82a3-f7d793998bcc", "embedding": null, "metadata": {"window": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023. ", "original_text": "Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d1bddb9-c5f4-490a-ab09-4d1fd4df08e4", "node_type": "1", "metadata": {"window": "When excluding the \nimpact of COVID -19 vaccine distribution for the US government, we anticipate 3% to 5% operating profit growth, \nwhich is consistent with the long -term growth target we provided for the US Pharmaceutical segment at our recent \nInvestor Day event.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022. ", "original_text": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b686ef1213ddcf4b6d410fec4a704dfa51a477987008271d8038167f948ff602", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a33ae062-b237-4c31-87a2-8bb01c49b7cf", "node_type": "1", "metadata": {"window": "This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business. ", "original_text": "And this compares to $0.90 in fiscal 2022. "}, "hash": "7235911de4ac5d992ed94fec25be33b949a3461822d7d9fcb6969a8074211c6c", "class_name": "RelatedNodeInfo"}}, "text": "Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government. ", "start_char_idx": 2969, "end_char_idx": 3111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a33ae062-b237-4c31-87a2-8bb01c49b7cf": {"__data__": {"id_": "a33ae062-b237-4c31-87a2-8bb01c49b7cf", "embedding": null, "metadata": {"window": "This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business. ", "original_text": "And this compares to $0.90 in fiscal 2022. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58c7c553-0b7c-4884-82a3-f7d793998bcc", "node_type": "1", "metadata": {"window": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 17% to 23% and operating \nprofit growth of 14% to 20%.  This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023. ", "original_text": "Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a14678b3e163f239d38baf8ded26603d81a1686550e9ca99d6aaf307dbaa64d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d71fea52-4d1e-46ec-bc53-9a4efdc398ac", "node_type": "1", "metadata": {"window": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n", "original_text": "As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022. "}, "hash": "817035ced87e8ad72f27d4c6d162b8f0eeda7488ba7c4d4c6087105514e625c7", "class_name": "RelatedNodeInfo"}}, "text": "And this compares to $0.90 in fiscal 2022. ", "start_char_idx": 3111, "end_char_idx": 3154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d71fea52-4d1e-46ec-bc53-9a4efdc398ac": {"__data__": {"id_": "d71fea52-4d1e-46ec-bc53-9a4efdc398ac", "embedding": null, "metadata": {"window": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n", "original_text": "As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a33ae062-b237-4c31-87a2-8bb01c49b7cf", "node_type": "1", "metadata": {"window": "This outlook reflects momentum of organic growth across our solutions and ser vices \nas we expand partnerships with biopharma manufacturers, generate higher transaction volume and increase the \nnumber of brands under access and adherence platforms.  \n \n In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business. ", "original_text": "And this compares to $0.90 in fiscal 2022. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "847f350eb3f704a2ec464a7cd57809625c84688cdf0b137d2712ab805f1dc481", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "128a5a41-a728-4122-9518-1ad7b5cb93cf", "node_type": "1", "metadata": {"window": "Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%. ", "original_text": "We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023. "}, "hash": "f74c875757e2841651c16e93ffa133de6a03cdd6240534d389e70f257ca260e1", "class_name": "RelatedNodeInfo"}}, "text": "As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022. ", "start_char_idx": 3154, "end_char_idx": 3246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "128a5a41-a728-4122-9518-1ad7b5cb93cf": {"__data__": {"id_": "128a5a41-a728-4122-9518-1ad7b5cb93cf", "embedding": null, "metadata": {"window": "Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%. ", "original_text": "We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d71fea52-4d1e-46ec-bc53-9a4efdc398ac", "node_type": "1", "metadata": {"window": "In the Medical -Surgical Solutions segment, we anticipate reported revenues to decrease  7% to 11% and \noperating profit to decrease 15% to 21%.  Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n", "original_text": "As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "977383f70303256900cd0515ff6ffcdefdd67184c214b0a8a2ab42863263f763", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be4ea1f5-984b-449d-b8fb-752b2b6bd76a", "node_type": "1", "metadata": {"window": "And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023. ", "original_text": "Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business. "}, "hash": "21dca1c3a47c0c46c82a5bc1d5b95d7967f137d80f0af77d2fe2c44e3402b641", "class_name": "RelatedNodeInfo"}}, "text": "We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023. ", "start_char_idx": 3246, "end_char_idx": 3338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be4ea1f5-984b-449d-b8fb-752b2b6bd76a": {"__data__": {"id_": "be4ea1f5-984b-449d-b8fb-752b2b6bd76a", "embedding": null, "metadata": {"window": "And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023. ", "original_text": "Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "128a5a41-a728-4122-9518-1ad7b5cb93cf", "node_type": "1", "metadata": {"window": "Our outlook includes approximately less than $0.05 related to kitting, \nstorage and distribution of ancillary supplies for the US government.  And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%. ", "original_text": "We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7eee01e8c78eb9728db0fadd2e50577840c0fa83a69d45119dc1b92d88d05ada", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "693ba4d1-d740-4c76-8aaf-63ec1e8f7c5e", "node_type": "1", "metadata": {"window": "As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023.  In Canada, we \nhave a strong position as the leader in healthcare distribution. ", "original_text": "The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n"}, "hash": "10a61187a8f75fc5b4664f02fc96f985529dd92924d029679b57dd2d138576fb", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business. ", "start_char_idx": 3338, "end_char_idx": 3512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "693ba4d1-d740-4c76-8aaf-63ec1e8f7c5e": {"__data__": {"id_": "693ba4d1-d740-4c76-8aaf-63ec1e8f7c5e", "embedding": null, "metadata": {"window": "As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023.  In Canada, we \nhave a strong position as the leader in healthcare distribution. ", "original_text": "The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be4ea1f5-984b-449d-b8fb-752b2b6bd76a", "node_type": "1", "metadata": {"window": "And this compares to $0.90 in fiscal 2022.  As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023. ", "original_text": "Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ea1b85c92f40d05a4e834dfc6e437b3bb085cb1f660c89bd3a6e65ea93f329f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7f555eb-ed1b-41c9-9163-05bef43378bc", "node_type": "1", "metadata": {"window": "We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023.  In Canada, we \nhave a strong position as the leader in healthcare distribution.  We anticipate continued organic growth in our \npharmaceutical distribution b usiness, including strategic sourcing efforts.  \n ", "original_text": "Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%. "}, "hash": "60b691efdae27f14795268f50080b63e8ee3aad0462752d9d248f6c4bb89817a", "class_name": "RelatedNodeInfo"}}, "text": "The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n", "start_char_idx": 3512, "end_char_idx": 3733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7f555eb-ed1b-41c9-9163-05bef43378bc": {"__data__": {"id_": "f7f555eb-ed1b-41c9-9163-05bef43378bc", "embedding": null, "metadata": {"window": "We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023.  In Canada, we \nhave a strong position as the leader in healthcare distribution.  We anticipate continued organic growth in our \npharmaceutical distribution b usiness, including strategic sourcing efforts.  \n ", "original_text": "Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "693ba4d1-d740-4c76-8aaf-63ec1e8f7c5e", "node_type": "1", "metadata": {"window": "As \na reminder, o ur contracts with the US government are scheduled to end in July of 2022.  We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023.  In Canada, we \nhave a strong position as the leader in healthcare distribution. ", "original_text": "The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5a5388b10588822536fcb5d2bc112f85d5511c824e66aeb87fd55313dff1a73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e805506b-b139-4c1e-9034-3be7d42ab444", "node_type": "1", "metadata": {"window": "Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023.  In Canada, we \nhave a strong position as the leader in healthcare distribution.  We anticipate continued organic growth in our \npharmaceutical distribution b usiness, including strategic sourcing efforts.  \n ", "original_text": "This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023. "}, "hash": "c28b279e98017a0698a7c3940175ce36a9d079dd21cbb88b36731776df3db285", "class_name": "RelatedNodeInfo"}}, "text": "Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%. ", "start_char_idx": 3733, "end_char_idx": 3877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e805506b-b139-4c1e-9034-3be7d42ab444": {"__data__": {"id_": "e805506b-b139-4c1e-9034-3be7d42ab444", "embedding": null, "metadata": {"window": "Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023.  In Canada, we \nhave a strong position as the leader in healthcare distribution.  We anticipate continued organic growth in our \npharmaceutical distribution b usiness, including strategic sourcing efforts.  \n ", "original_text": "This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7f555eb-ed1b-41c9-9163-05bef43378bc", "node_type": "1", "metadata": {"window": "We also anticipate \napproximately $0.15 to $0.35 related to COVID -19 tests in fiscal 2023.  Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023.  In Canada, we \nhave a strong position as the leader in healthcare distribution.  We anticipate continued organic growth in our \npharmaceutical distribution b usiness, including strategic sourcing efforts.  \n ", "original_text": "Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb96e59c9febbd633faf85d7ab79c3a3bb543ec1e6dfc3e4d254324faf222619", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b71c2d34-3368-426b-9ac0-079daee37cec", "node_type": "1", "metadata": {"window": "The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023.  In Canada, we \nhave a strong position as the leader in healthcare distribution.  We anticipate continued organic growth in our \npharmaceutical distribution b usiness, including strategic sourcing efforts.  \n ", "original_text": "In Canada, we \nhave a strong position as the leader in healthcare distribution. "}, "hash": "66234bb3e8886b8f461e24c88a0233730a41894cf81cb15384b19d4bc2cdc88d", "class_name": "RelatedNodeInfo"}}, "text": "This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023. ", "start_char_idx": 3877, "end_char_idx": 4059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b71c2d34-3368-426b-9ac0-079daee37cec": {"__data__": {"id_": "b71c2d34-3368-426b-9ac0-079daee37cec", "embedding": null, "metadata": {"window": "The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023.  In Canada, we \nhave a strong position as the leader in healthcare distribution.  We anticipate continued organic growth in our \npharmaceutical distribution b usiness, including strategic sourcing efforts.  \n ", "original_text": "In Canada, we \nhave a strong position as the leader in healthcare distribution. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e805506b-b139-4c1e-9034-3be7d42ab444", "node_type": "1", "metadata": {"window": "Excluding the impact of these COVID -19-\nrelated items, we anticipate operating profit to incr ease 8% to 14%, primarily as a result of growth in the primary \ncare business.  The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023.  In Canada, we \nhave a strong position as the leader in healthcare distribution.  We anticipate continued organic growth in our \npharmaceutical distribution b usiness, including strategic sourcing efforts.  \n ", "original_text": "This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6be8e0b354770bab955e64cc784f9f49c5561b27a5de8b1c0fa79293cad738e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ec11ad0-ad6b-4649-a53f-0df8b7fef47b", "node_type": "1", "metadata": {"window": "Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023.  In Canada, we \nhave a strong position as the leader in healthcare distribution.  We anticipate continued organic growth in our \npharmaceutical distribution b usiness, including strategic sourcing efforts.  \n ", "original_text": "We anticipate continued organic growth in our \npharmaceutical distribution b usiness, including strategic sourcing efforts.  \n "}, "hash": "e08895817ba6b210494165aa11f3f4050819007fa2a63d659b0b0454f07183cb", "class_name": "RelatedNodeInfo"}}, "text": "In Canada, we \nhave a strong position as the leader in healthcare distribution. ", "start_char_idx": 4059, "end_char_idx": 4139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ec11ad0-ad6b-4649-a53f-0df8b7fef47b": {"__data__": {"id_": "2ec11ad0-ad6b-4649-a53f-0df8b7fef47b", "embedding": null, "metadata": {"window": "Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023.  In Canada, we \nhave a strong position as the leader in healthcare distribution.  We anticipate continued organic growth in our \npharmaceutical distribution b usiness, including strategic sourcing efforts.  \n ", "original_text": "We anticipate continued organic growth in our \npharmaceutical distribution b usiness, including strategic sourcing efforts.  \n ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5dee6194-accf-44d6-83cd-5a00f361089d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffa18e12dd193b3e3516a2bcc5fad27df1587d853bad8f70728b8a99eda442", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b71c2d34-3368-426b-9ac0-079daee37cec", "node_type": "1", "metadata": {"window": "The Medical -Surgical business remains well -positioned to leverage the breadth and depth of its \nservices throughout the alternate site market, including growth from laboratory sol utions and the government \nsector.  \n \n Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023.  In Canada, we \nhave a strong position as the leader in healthcare distribution.  We anticipate continued organic growth in our \npharmaceutical distribution b usiness, including strategic sourcing efforts.  \n ", "original_text": "In Canada, we \nhave a strong position as the leader in healthcare distribution. ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a8b4960172b67062807201c7b7388b7f4d1087092dff8608a65ee826c24692f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73a5999f-7e02-4f3e-a52a-8a40f5739277", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility. ", "original_text": "McKesson Corp.  "}, "hash": "4e4ad73e5f71b57833a257d6fc79f0cd5ebf04d98f2410b4ca7bd00c2374569c", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate continued organic growth in our \npharmaceutical distribution b usiness, including strategic sourcing efforts.  \n ", "start_char_idx": 4139, "end_char_idx": 4266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73a5999f-7e02-4f3e-a52a-8a40f5739277": {"__data__": {"id_": "73a5999f-7e02-4f3e-a52a-8a40f5739277", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ec11ad0-ad6b-4649-a53f-0df8b7fef47b", "node_type": "1", "metadata": {"window": "Finally, in the International segment, we anticipate reported revenues to decline by 34% to 38% and operating \nprofit to decline by 22% to 28%.  This year -over-year decrease includes a loss of operating profit contribution from \nbusinesses and transactions we've closed to date and that we expect to close during fiscal 2023.  In Canada, we \nhave a strong position as the leader in healthcare distribution.  We anticipate continued organic growth in our \npharmaceutical distribution b usiness, including strategic sourcing efforts.  \n ", "original_text": "We anticipate continued organic growth in our \npharmaceutical distribution b usiness, including strategic sourcing efforts.  \n ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "add794ee223817fbffd4a75703deb91a8567677f6c21d7fbd2b8ab00d26668dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25baa248-260a-4976-a94d-c930db8e6d94", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment. "}, "hash": "67417a5066639aa8e94353da5cd0f35ba17218575d0cca4f9a276b7a80e4ebff", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25baa248-260a-4976-a94d-c930db8e6d94": {"__data__": {"id_": "25baa248-260a-4976-a94d-c930db8e6d94", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73a5999f-7e02-4f3e-a52a-8a40f5739277", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68f301012760d178efffe299c7a3c20e786f014d6a8b4de086bd4dc6846c42a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f847d14-11a7-4b9b-9bbc-19bd572d1d1f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses. ", "original_text": "As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend. "}, "hash": "24a828da1e4b30bdf8c83133dfd0ea7603bb8851299cd1d78281647446ec3c09", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment. ", "start_char_idx": 16, "end_char_idx": 278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f847d14-11a7-4b9b-9bbc-19bd572d1d1f": {"__data__": {"id_": "0f847d14-11a7-4b9b-9bbc-19bd572d1d1f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses. ", "original_text": "As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25baa248-260a-4976-a94d-c930db8e6d94", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62502240808350984f1607d96d8ec3b7eea1b1fbe34a950a69d09ee0c4541b4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7972863-9294-4440-820e-efe2381940bc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity. ", "original_text": "Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility. "}, "hash": "833c12d5ce96cfb7c806a3bd2639be66e118822da16b247da47ffae0a9f868a5", "class_name": "RelatedNodeInfo"}}, "text": "As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend. ", "start_char_idx": 278, "end_char_idx": 495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7972863-9294-4440-820e-efe2381940bc": {"__data__": {"id_": "f7972863-9294-4440-820e-efe2381940bc", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity. ", "original_text": "Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f847d14-11a7-4b9b-9bbc-19bd572d1d1f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses. ", "original_text": "As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9fd136ebf3e38402cc8e6fb46b3960c3df6f0d72eb287607e33885d26717b7b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7bc2251-34f1-4d9d-89af-08784cd75ccc", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n", "original_text": "This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n"}, "hash": "bd7d74f4ca7975fa08ed4043eea02014bc3f5025cd1d208d2c9255d4abdb2346", "class_name": "RelatedNodeInfo"}}, "text": "Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility. ", "start_char_idx": 495, "end_char_idx": 592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7bc2251-34f1-4d9d-89af-08784cd75ccc": {"__data__": {"id_": "f7bc2251-34f1-4d9d-89af-08784cd75ccc", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n", "original_text": "This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7972863-9294-4440-820e-efe2381940bc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity. ", "original_text": "Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98f4376914f2f935bd81fbd7289efcf902cb4bb11f87333ff09c5ec502a0bfc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "174cba22-54b3-47d9-a479-2615e13cd6f1", "node_type": "1", "metadata": {"window": "As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares. ", "original_text": "In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses. "}, "hash": "257fb67dc8581cdea379a1be176464378dd09f60f1bab8f3b1cb9a0ece1e861d", "class_name": "RelatedNodeInfo"}}, "text": "This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n", "start_char_idx": 592, "end_char_idx": 712, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "174cba22-54b3-47d9-a479-2615e13cd6f1": {"__data__": {"id_": "174cba22-54b3-47d9-a479-2615e13cd6f1", "embedding": null, "metadata": {"window": "As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares. ", "original_text": "In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7bc2251-34f1-4d9d-89af-08784cd75ccc", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n", "original_text": "This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c93df9c07d73ccacbddea3b959fba36d1060b5516db85280de1ff9b9bc28a0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "992b6198-99bf-41b9-b128-c6818414a61a", "node_type": "1", "metadata": {"window": "Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures. ", "original_text": "As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity. "}, "hash": "1fbf689c094a25a8602de89a8a9a12d7431ed486e190d80ad9adb4e150e26345", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses. ", "start_char_idx": 712, "end_char_idx": 878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "992b6198-99bf-41b9-b128-c6818414a61a": {"__data__": {"id_": "992b6198-99bf-41b9-b128-c6818414a61a", "embedding": null, "metadata": {"window": "Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures. ", "original_text": "As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "174cba22-54b3-47d9-a479-2615e13cd6f1", "node_type": "1", "metadata": {"window": "As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares. ", "original_text": "In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aef9bd81fcc8aeea3ec4850342aa3d599756052a517be4a5f0b08f91cd523a29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c80c9c6-1ea9-45df-a56c-8e36418803db", "node_type": "1", "metadata": {"window": "This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n", "original_text": "As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n"}, "hash": "3100fa957e38d925d672a9377779536625e3ffa305635b3cbf096b329beea760", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity. ", "start_char_idx": 878, "end_char_idx": 1072, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c80c9c6-1ea9-45df-a56c-8e36418803db": {"__data__": {"id_": "8c80c9c6-1ea9-45df-a56c-8e36418803db", "embedding": null, "metadata": {"window": "This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n", "original_text": "As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "992b6198-99bf-41b9-b128-c6818414a61a", "node_type": "1", "metadata": {"window": "Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility.  This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures. ", "original_text": "As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b136a03cca96195adab8050c0bfdd436844a9f59d39a766c98d27985b392819f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14001324-03d3-4f26-9618-42f00c835a64", "node_type": "1", "metadata": {"window": "In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow. ", "original_text": "As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares. "}, "hash": "12a1ecb57a22c284465e9455b93470638fcf25f26efe56892f455a89a42d42d1", "class_name": "RelatedNodeInfo"}}, "text": "As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n", "start_char_idx": 1072, "end_char_idx": 1202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14001324-03d3-4f26-9618-42f00c835a64": {"__data__": {"id_": "14001324-03d3-4f26-9618-42f00c835a64", "embedding": null, "metadata": {"window": "In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow. ", "original_text": "As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c80c9c6-1ea9-45df-a56c-8e36418803db", "node_type": "1", "metadata": {"window": "This flexibility positions us \nfor the continuation of sust ainable long -term value creation for our shareholders.  \n \n In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n", "original_text": "As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9b6a81dd1507753cb093ac0c341606feb82ccefffaea48f6d958a4c3dd5c0ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53d95df9-c9c4-4040-be86-0bc0a7074714", "node_type": "1", "metadata": {"window": "As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n", "original_text": "A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures. "}, "hash": "a745e94ca4526b290021bb9209e4c4613cd62c83a953d1dcdd92887b25073760", "class_name": "RelatedNodeInfo"}}, "text": "As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares. ", "start_char_idx": 1202, "end_char_idx": 1324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53d95df9-c9c4-4040-be86-0bc0a7074714": {"__data__": {"id_": "53d95df9-c9c4-4040-be86-0bc0a7074714", "embedding": null, "metadata": {"window": "As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n", "original_text": "A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14001324-03d3-4f26-9618-42f00c835a64", "node_type": "1", "metadata": {"window": "In fiscal 2023, we anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property \nacquisitions and capitalized software expenses.  As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow. ", "original_text": "As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a0595ace31b899a69357ed66f0630fd155159fb60cd7e67cd4681b1dbbf642d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3ead74d-1c0f-4102-af5f-02f75752f04d", "node_type": "1", "metadata": {"window": "As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson. ", "original_text": "As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n"}, "hash": "af9579c2e59484073098863a470959cfb7460e20ac03d84bbc7ac883c0860157", "class_name": "RelatedNodeInfo"}}, "text": "A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures. ", "start_char_idx": 1324, "end_char_idx": 1463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3ead74d-1c0f-4102-af5f-02f75752f04d": {"__data__": {"id_": "c3ead74d-1c0f-4102-af5f-02f75752f04d", "embedding": null, "metadata": {"window": "As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson. ", "original_text": "As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53d95df9-c9c4-4040-be86-0bc0a7074714", "node_type": "1", "metadata": {"window": "As a reminder, our working capital metrics and resulting cash \nflows vary from quarter -to-quarter, impacted by timing, which could include the timing of planned European \ndivestiture activity.  As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n", "original_text": "A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02afbffb9ca2470c5bfef13c7d3d2c9d4045386fe65b5e2cfb69c212e46d8df3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a202afdc-50ef-4fcc-89a0-001595c525c4", "node_type": "1", "metadata": {"window": "As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n", "original_text": "The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow. "}, "hash": "8cb362935396ce08e99f561b045c4efe011e7f5d6c083a8e96d738ae56190775", "class_name": "RelatedNodeInfo"}}, "text": "As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n", "start_char_idx": 1463, "end_char_idx": 1650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a202afdc-50ef-4fcc-89a0-001595c525c4": {"__data__": {"id_": "a202afdc-50ef-4fcc-89a0-001595c525c4", "embedding": null, "metadata": {"window": "As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n", "original_text": "The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3ead74d-1c0f-4102-af5f-02f75752f04d", "node_type": "1", "metadata": {"window": "As discussed at Investor Day, we intend to offset the dilution related to our European \ndivestitures with capital deployment.  \n \n As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson. ", "original_text": "As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c3be388c4126f2d4a635427a9c3aa28fae0f3d244ad5300f01c83c2ef252317", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66d3fb9a-ea36-420e-b8c2-ce8953076b12", "node_type": "1", "metadata": {"window": "A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders. ", "original_text": "This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n"}, "hash": "1d58161bbcfbe4e040b35dd7723c7cb4b318c3ca0bea131c534c59841ba40694", "class_name": "RelatedNodeInfo"}}, "text": "The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow. ", "start_char_idx": 1650, "end_char_idx": 1795, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66d3fb9a-ea36-420e-b8c2-ce8953076b12": {"__data__": {"id_": "66d3fb9a-ea36-420e-b8c2-ce8953076b12", "embedding": null, "metadata": {"window": "A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders. ", "original_text": "This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a202afdc-50ef-4fcc-89a0-001595c525c4", "node_type": "1", "metadata": {"window": "As indicated on slide 18, our fiscal 2023 outlook incorporates plans to repurchase approximately $3.5 billion of \nshares.  A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n", "original_text": "The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6742377ae5a7e65d79580ba7293ca0d3a0adadc318a0afad35b8a8c159d16cba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b63ba14-b069-4562-9e94-8ff59e514131", "node_type": "1", "metadata": {"window": "As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n", "original_text": "In closing, fiscal 2022 was another strong year for McKesson. "}, "hash": "2b26ce894978ba97266cb00a1aecca2af06f22974da1f0fc859be079cf1c5cd1", "class_name": "RelatedNodeInfo"}}, "text": "This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n", "start_char_idx": 1795, "end_char_idx": 2005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b63ba14-b069-4562-9e94-8ff59e514131": {"__data__": {"id_": "9b63ba14-b069-4562-9e94-8ff59e514131", "embedding": null, "metadata": {"window": "As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n", "original_text": "In closing, fiscal 2022 was another strong year for McKesson. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66d3fb9a-ea36-420e-b8c2-ce8953076b12", "node_type": "1", "metadata": {"window": "A significant portion of the share buyback assumption is associated with offsetting the year -over-year \nimpact  of European divestitures.  As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders. ", "original_text": "This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f79bd350512cc11f1dcec250bf3d28ff50bb7e45de9fde6465d76ab3acb67fbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9eacd4c-410c-4bda-bf5f-f38f0264f75f", "node_type": "1", "metadata": {"window": "The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook. ", "original_text": "We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n"}, "hash": "900238433c2800a31c21c28e9c64908b219c20cdcbd523d4bd8436ce2a6c424c", "class_name": "RelatedNodeInfo"}}, "text": "In closing, fiscal 2022 was another strong year for McKesson. ", "start_char_idx": 2005, "end_char_idx": 2067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9eacd4c-410c-4bda-bf5f-f38f0264f75f": {"__data__": {"id_": "a9eacd4c-410c-4bda-bf5f-f38f0264f75f", "embedding": null, "metadata": {"window": "The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook. ", "original_text": "We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b63ba14-b069-4562-9e94-8ff59e514131", "node_type": "1", "metadata": {"window": "As a result of the share repurchase activity, we estimate weighted average \ndiluted shares outstanding for fiscal 2023 to be in the range of approximately 142 million to 144 million.  \n \n The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n", "original_text": "In closing, fiscal 2022 was another strong year for McKesson. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2478451ba334dbca5bdf2601a11cf8ac9a90bfcdafa2af3e3e995a27caf6e121", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7a7acfc-8c85-4ffe-8989-c380b677727a", "node_type": "1", "metadata": {"window": "This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation. ", "original_text": "Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders. "}, "hash": "91e8b591e5e4912843cf1e243e617854469c21448f89a2190ae350f662bf2651", "class_name": "RelatedNodeInfo"}}, "text": "We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n", "start_char_idx": 2067, "end_char_idx": 2306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7a7acfc-8c85-4ffe-8989-c380b677727a": {"__data__": {"id_": "a7a7acfc-8c85-4ffe-8989-c380b677727a", "embedding": null, "metadata": {"window": "This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation. ", "original_text": "Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9eacd4c-410c-4bda-bf5f-f38f0264f75f", "node_type": "1", "metadata": {"window": "The progress we're making across our strategic  priorities, including our commitment to streamline the business, \nsupports our strong cash flow.  This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook. ", "original_text": "We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ac3efb16c2b5504bf78662da6f0025d14b294945af02aff57dadf9e8a23c9ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0389721-b9c3-4bd9-842c-ba7b3ea57fc4", "node_type": "1", "metadata": {"window": "In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n", "original_text": "We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n"}, "hash": "6b8ddbc8223ecea8c31d23cec017cd7905d7a3ce05c28a9acfdf884f0335bfe2", "class_name": "RelatedNodeInfo"}}, "text": "Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders. ", "start_char_idx": 2306, "end_char_idx": 2415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0389721-b9c3-4bd9-842c-ba7b3ea57fc4": {"__data__": {"id_": "a0389721-b9c3-4bd9-842c-ba7b3ea57fc4", "embedding": null, "metadata": {"window": "In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n", "original_text": "We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7a7acfc-8c85-4ffe-8989-c380b677727a", "node_type": "1", "metadata": {"window": "This cash flow provides us with the flexibility to deploy capital through organic and \ninorganic investments in our business and returning capital to shareholde rs through share repurchases and \ndividends.  \n \n In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation. ", "original_text": "Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d33145a800bfbe91a90fffd6dc13877a8b0218cf99da921bde05bc6c7ee5d0b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ffd4f07-da0d-44d7-9a30-b34c835c2d6a", "node_type": "1", "metadata": {"window": "We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n Thank you. ", "original_text": "We have a strong financial outlook. "}, "hash": "1b3bdc19434cf453152f3bd2cfb103179bd566e89b33f2b9c1fbf8980f2b85a0", "class_name": "RelatedNodeInfo"}}, "text": "We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n", "start_char_idx": 2415, "end_char_idx": 2534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ffd4f07-da0d-44d7-9a30-b34c835c2d6a": {"__data__": {"id_": "6ffd4f07-da0d-44d7-9a30-b34c835c2d6a", "embedding": null, "metadata": {"window": "We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n Thank you. ", "original_text": "We have a strong financial outlook. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0389721-b9c3-4bd9-842c-ba7b3ea57fc4", "node_type": "1", "metadata": {"window": "In closing, fiscal 2022 was another strong year for McKesson.  We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n", "original_text": "We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d405f12fd7421e05f440f2b7af0fb2165590ff069a79b23c346f577c49e23b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4764c91-e475-4d6a-b58e-0a2c08e09b49", "node_type": "1", "metadata": {"window": "Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n Thank you.  And with that, I'll turn it over to the operator for Q&A.  \n  ", "original_text": "And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation. "}, "hash": "fb26a8b2a1642779034acac774c4b2d632986e0627b0fe84bd7cf758bd0f5a96", "class_name": "RelatedNodeInfo"}}, "text": "We have a strong financial outlook. ", "start_char_idx": 2534, "end_char_idx": 2570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4764c91-e475-4d6a-b58e-0a2c08e09b49": {"__data__": {"id_": "e4764c91-e475-4d6a-b58e-0a2c08e09b49", "embedding": null, "metadata": {"window": "Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n Thank you.  And with that, I'll turn it over to the operator for Q&A.  \n  ", "original_text": "And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ffd4f07-da0d-44d7-9a30-b34c835c2d6a", "node_type": "1", "metadata": {"window": "We continue to make great progress on our \ntransformative journey, from a distribution -focused company to a leading diversified health care services \ncompany, accelerating and expanding our oncology and biopharma services ecosystems.  \n \n Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n Thank you. ", "original_text": "We have a strong financial outlook. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9856936772ab16108e10fca703222a28819264b5d387af38c19852f9e61ed093", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ba60662-3a6a-48a9-8eb2-00b41f896b26", "node_type": "1", "metadata": {"window": "We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n Thank you.  And with that, I'll turn it over to the operator for Q&A.  \n  ", "original_text": "We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n"}, "hash": "b027c531f9fe0b17b77eace6a309179f744575cc1828b4150f9d385d1efca0ec", "class_name": "RelatedNodeInfo"}}, "text": "And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation. ", "start_char_idx": 2570, "end_char_idx": 2706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ba60662-3a6a-48a9-8eb2-00b41f896b26": {"__data__": {"id_": "7ba60662-3a6a-48a9-8eb2-00b41f896b26", "embedding": null, "metadata": {"window": "We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n Thank you.  And with that, I'll turn it over to the operator for Q&A.  \n  ", "original_text": "We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4764c91-e475-4d6a-b58e-0a2c08e09b49", "node_type": "1", "metadata": {"window": "Our strategies are working, and we're delivering for our customers, partners, patients and our shareholders.  We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n Thank you.  And with that, I'll turn it over to the operator for Q&A.  \n  ", "original_text": "And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b25cfad5386dacf8e4afd220f2e06d9785c63cdf2ee5d9e745a99a8434644f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7994167b-a1f7-487e-a319-8abde81cb7dc", "node_type": "1", "metadata": {"window": "We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n Thank you.  And with that, I'll turn it over to the operator for Q&A.  \n  ", "original_text": "Thank you. "}, "hash": "04751b6020fdae6e5aad221eb219c5967fb8d0ca15f1054fde479379e4b06b7f", "class_name": "RelatedNodeInfo"}}, "text": "We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n", "start_char_idx": 2706, "end_char_idx": 2800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7994167b-a1f7-487e-a319-8abde81cb7dc": {"__data__": {"id_": "7994167b-a1f7-487e-a319-8abde81cb7dc", "embedding": null, "metadata": {"window": "We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n Thank you.  And with that, I'll turn it over to the operator for Q&A.  \n  ", "original_text": "Thank you. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ba60662-3a6a-48a9-8eb2-00b41f896b26", "node_type": "1", "metadata": {"window": "We \nare well positioned to capture the vast opportunities in the  growing markets of oncology and biopharma services. \n We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n Thank you.  And with that, I'll turn it over to the operator for Q&A.  \n  ", "original_text": "We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33c828923b8f60fd042ac6e7e39ed8fafb0e4932b62eee4e8a0db78f709fb4fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eac2d26e-d04a-4a97-a42e-2633aa8d6134", "node_type": "1", "metadata": {"window": "And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n Thank you.  And with that, I'll turn it over to the operator for Q&A.  \n  ", "original_text": "And with that, I'll turn it over to the operator for Q&A.  \n  "}, "hash": "bd54a600490febea4e55a71c46f05918f61007230883df96c85292741c92f062", "class_name": "RelatedNodeInfo"}}, "text": "Thank you. ", "start_char_idx": 2800, "end_char_idx": 2811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eac2d26e-d04a-4a97-a42e-2633aa8d6134": {"__data__": {"id_": "eac2d26e-d04a-4a97-a42e-2633aa8d6134", "embedding": null, "metadata": {"window": "And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n Thank you.  And with that, I'll turn it over to the operator for Q&A.  \n  ", "original_text": "And with that, I'll turn it over to the operator for Q&A.  \n  ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f93ac1981d88bd2a81eab79c5a9d48fa4f74972184d97c8f4f093f9dfa3a9695", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7994167b-a1f7-487e-a319-8abde81cb7dc", "node_type": "1", "metadata": {"window": "We have a strong financial outlook.  And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n Thank you.  And with that, I'll turn it over to the operator for Q&A.  \n  ", "original_text": "Thank you. ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "235d51b1a2f1c24a817e5922c2f58ee1a464991c5a18f1ee5fc394d05f6f65e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29be148c-810f-4a67-846d-9486f1af6475", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "McKesson Corp.  "}, "hash": "9c136c254304b2c6ea0367287de3a84a0208f54ee055cf99102c6265e470cb99", "class_name": "RelatedNodeInfo"}}, "text": "And with that, I'll turn it over to the operator for Q&A.  \n  ", "start_char_idx": 2811, "end_char_idx": 2873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29be148c-810f-4a67-846d-9486f1af6475": {"__data__": {"id_": "29be148c-810f-4a67-846d-9486f1af6475", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eac2d26e-d04a-4a97-a42e-2633aa8d6134", "node_type": "1", "metadata": {"window": "And our financial framework and execution position us to deliver sustainable \nprofit growth, cash flows and shareholder value creation.  We have great confidence in our teams, in our products \nand services and in our strategy.  \n \n Thank you.  And with that, I'll turn it over to the operator for Q&A.  \n  ", "original_text": "And with that, I'll turn it over to the operator for Q&A.  \n  ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "243f752e0420a7b4730f4bee3671e2b926eced715781f87a7ccbad38ea5fc600", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75b4a0fc-81e8-4912-ace5-90c0155ad0e3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. "}, "hash": "3a758130f94b6b3f77466aa856b7b9c9581b6b283f9e78990f4a81c7735e9605", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75b4a0fc-81e8-4912-ace5-90c0155ad0e3": {"__data__": {"id_": "75b4a0fc-81e8-4912-ace5-90c0155ad0e3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29be148c-810f-4a67-846d-9486f1af6475", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40ab32799628ff21a2359e9071f34e78fb7055abdebd7d5e075466b365b7ca7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e564716b-242d-40c0-97c0-6bd418914c8b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure. ", "original_text": "[Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n "}, "hash": "5eead637701f7042a9edd8c8f848f54536399b89ffff451afff0daa772390b42", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "start_char_idx": 16, "end_char_idx": 238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e564716b-242d-40c0-97c0-6bd418914c8b": {"__data__": {"id_": "e564716b-242d-40c0-97c0-6bd418914c8b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure. ", "original_text": "[Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75b4a0fc-81e8-4912-ace5-90c0155ad0e3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dacfec0e32d2f9188639b86afde9cb5cfd10d3a718a4145e786d99cfd69dc7a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b152da9-3f39-4552-be03-c07fd0497b23", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  "}, "hash": "b7c2ae54393da174b8fb26237a71b1026267d840721993674b637940089a69bf", "class_name": "RelatedNodeInfo"}}, "text": "[Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n ", "start_char_idx": 238, "end_char_idx": 337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b152da9-3f39-4552-be03-c07fd0497b23": {"__data__": {"id_": "4b152da9-3f39-4552-be03-c07fd0497b23", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e564716b-242d-40c0-97c0-6bd418914c8b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure. ", "original_text": "[Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fede1609967044973bdb1a5c0bbb7c3ad9cab0a4ee803dc2981cc2ab4a42e4a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f068dbe-115c-4dfc-9472-66a54f0c27ea", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n ", "original_text": "Q \nGood afternoon, and thanks for, obviously, a ton of details. "}, "hash": "c28552fbdc382400e93629114726d013b9d9887d546f40b0d0f2bf4ff89ad1cf", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 337, "end_char_idx": 658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f068dbe-115c-4dfc-9472-66a54f0c27ea": {"__data__": {"id_": "2f068dbe-115c-4dfc-9472-66a54f0c27ea", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n ", "original_text": "Q \nGood afternoon, and thanks for, obviously, a ton of details. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b152da9-3f39-4552-be03-c07fd0497b23", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ea05f644e35532840b85345f24325c3cc64b9f62ea4e8d614f2994f641310e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e98418b-776c-43a2-ad59-873f656f9850", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure. "}, "hash": "af8db10e49b84b6af8eff8ac58fe2a6ba0778b2a3742999045c020a1cc43e7b5", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGood afternoon, and thanks for, obviously, a ton of details. ", "start_char_idx": 658, "end_char_idx": 722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e98418b-776c-43a2-ad59-873f656f9850": {"__data__": {"id_": "5e98418b-776c-43a2-ad59-873f656f9850", "embedding": null, "metadata": {"window": "[Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f068dbe-115c-4dfc-9472-66a54f0c27ea", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n ", "original_text": "Q \nGood afternoon, and thanks for, obviously, a ton of details. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba4acaa7ab636cadfdcdc16fff2814e214323a5290363cc099ec8b1701294060", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a3db9ca-8dc3-4fdc-aca8-43b7f15642e9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year? "}, "hash": "0f54cbf9ce330d336f031d4d78670e64c42a0c99dd7a60842d8f01ff4df210c3", "class_name": "RelatedNodeInfo"}}, "text": "So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure. ", "start_char_idx": 722, "end_char_idx": 824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a3db9ca-8dc3-4fdc-aca8-43b7f15642e9": {"__data__": {"id_": "2a3db9ca-8dc3-4fdc-aca8-43b7f15642e9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year? ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e98418b-776c-43a2-ad59-873f656f9850", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06675ebcd3eaa4ca5a9731d4f50f86f0383b12c6389c38849b095b0beb483542", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19dc97dd-deb2-4c54-9f26-511b66581860", "node_type": "1", "metadata": {"window": "Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Mike. ", "original_text": "And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n "}, "hash": "13aa0da67fca42de3fe8c9e78dbf0b0545e2cbd9fc3a9793e29ffd2ca4447977", "class_name": "RelatedNodeInfo"}}, "text": "Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year? ", "start_char_idx": 824, "end_char_idx": 956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19dc97dd-deb2-4c54-9f26-511b66581860": {"__data__": {"id_": "19dc97dd-deb2-4c54-9f26-511b66581860", "embedding": null, "metadata": {"window": "Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Mike. ", "original_text": "And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a3db9ca-8dc3-4fdc-aca8-43b7f15642e9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year? ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "545c796bcf7c0c0e162339790460c7d027473af1dc4de513fb10baaf80096646", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8543e6b-0e95-4774-935e-286b323a5bfa", "node_type": "1", "metadata": {"window": "So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "11a604a262a47baf34f33db87056687137e6def3f7aeb794c65d11595bf01af6", "class_name": "RelatedNodeInfo"}}, "text": "And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n ", "start_char_idx": 956, "end_char_idx": 1160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8543e6b-0e95-4774-935e-286b323a5bfa": {"__data__": {"id_": "c8543e6b-0e95-4774-935e-286b323a5bfa", "embedding": null, "metadata": {"window": "So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19dc97dd-deb2-4c54-9f26-511b66581860", "node_type": "1", "metadata": {"window": "Q \nGood afternoon, and thanks for, obviously, a ton of details.  So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Mike. ", "original_text": "And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8eed47df183059411ae151669fde36a0f9c49597161740cadd0c567234ccba2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b7063ac-4714-4b2f-a2ce-8170a431f038", "node_type": "1", "metadata": {"window": "Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022. ", "original_text": "A \nYeah. "}, "hash": "22e72aec22a9c90719deebdfa57bba203ad9f15d556309c5b29055087a0a7084", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1160, "end_char_idx": 1517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b7063ac-4714-4b2f-a2ce-8170a431f038": {"__data__": {"id_": "5b7063ac-4714-4b2f-a2ce-8170a431f038", "embedding": null, "metadata": {"window": "Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022. ", "original_text": "A \nYeah. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8543e6b-0e95-4774-935e-286b323a5bfa", "node_type": "1", "metadata": {"window": "So I want to think about just the cadence of the year, if \nI can, a little bridge, just to make sure.  Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8040dcdcf45a0affbe64193d0d0ade09a92f063962bc539d25739aa24d8eb09d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5f6e4a9-a26b-45fd-9291-a3c2f25076e3", "node_type": "1", "metadata": {"window": "And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution. ", "original_text": "Thanks for that question, Mike. "}, "hash": "610d2547ac1128aeb4da988c09fa09e6f94fe6fff781a969455d89edd55fbe04", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 1517, "end_char_idx": 1526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5f6e4a9-a26b-45fd-9291-a3c2f25076e3": {"__data__": {"id_": "e5f6e4a9-a26b-45fd-9291-a3c2f25076e3", "embedding": null, "metadata": {"window": "And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution. ", "original_text": "Thanks for that question, Mike. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b7063ac-4714-4b2f-a2ce-8170a431f038", "node_type": "1", "metadata": {"window": "Should we assume, bas ed on the timing of the CDC contract, that pharma \ngrowth should be heavier in the first quarter of the year?  And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022. ", "original_text": "A \nYeah. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7a96f852a4f3bbd473f564021063c142d4e19c29ffbb8c1ffd0f22dcc8d67ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2920c459-9ce6-4cad-b844-2ae2c633659e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n ", "original_text": "As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n"}, "hash": "30883ceb6daff28d36b61d8c981d9bb593072815ae31cf4882b4e60f07478535", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for that question, Mike. ", "start_char_idx": 1526, "end_char_idx": 1558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2920c459-9ce6-4cad-b844-2ae2c633659e": {"__data__": {"id_": "2920c459-9ce6-4cad-b844-2ae2c633659e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n ", "original_text": "As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5f6e4a9-a26b-45fd-9291-a3c2f25076e3", "node_type": "1", "metadata": {"window": "And how should we think about any other components of \ncadence and how it should filter through the year relative to some of the more identifiable i tems like the COVID \nbenefits and other components?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution. ", "original_text": "Thanks for that question, Mike. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b278f981f329f9f987ca57a904ab26bacc1c1b141ad490ebd25c9b6c367beb60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecc14e03-d47d-469b-8850-1d61d1658053", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022. "}, "hash": "3f768fc8c664ce92bbd14442087e9412d1b08349b458322a1aadc5d4e649358f", "class_name": "RelatedNodeInfo"}}, "text": "As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n", "start_char_idx": 1558, "end_char_idx": 1831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecc14e03-d47d-469b-8850-1d61d1658053": {"__data__": {"id_": "ecc14e03-d47d-469b-8850-1d61d1658053", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2920c459-9ce6-4cad-b844-2ae2c633659e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n ", "original_text": "As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e151f49b290b576524d1e062864fa537a79fcc3123b53095487b9149ce1c5bf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddc5d9db-52e5-4bfa-a6e1-716beaee1972", "node_type": "1", "metadata": {"window": "Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution. "}, "hash": "f20d8661a377b008b5bd9d7c15c58ef3560f31d3202b6e92fd123fac5c6501da", "class_name": "RelatedNodeInfo"}}, "text": "As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022. ", "start_char_idx": 1831, "end_char_idx": 1957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddc5d9db-52e5-4bfa-a6e1-716beaee1972": {"__data__": {"id_": "ddc5d9db-52e5-4bfa-a6e1-716beaee1972", "embedding": null, "metadata": {"window": "Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecc14e03-d47d-469b-8850-1d61d1658053", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "309a3e8852d76054f5a3b65438b92766b917bd50647e9c0f5a100ca8adb1019d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68d58b73-43ca-49ff-a54b-f40d3ff1e9ff", "node_type": "1", "metadata": {"window": "As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research. ", "original_text": "So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n "}, "hash": "c5f9bd2aedbdd5bc651ecbad7b36b4840985fc70c7e2abbab0fe2364cd5581b7", "class_name": "RelatedNodeInfo"}}, "text": "And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution. ", "start_char_idx": 1957, "end_char_idx": 2075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68d58b73-43ca-49ff-a54b-f40d3ff1e9ff": {"__data__": {"id_": "68d58b73-43ca-49ff-a54b-f40d3ff1e9ff", "embedding": null, "metadata": {"window": "As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research. ", "original_text": "So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddc5d9db-52e5-4bfa-a6e1-716beaee1972", "node_type": "1", "metadata": {"window": "Thanks for that question, Mike.  As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c1c6fd757398c2825e8c33e9fafc1a2505d16b09309ff5eadac8040c4d344e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "386870ee-d3d7-4522-a807-871e092e6b8a", "node_type": "1", "metadata": {"window": "As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n "}, "hash": "d8efb28dbf5c16f412ed2cf26f2bbf7ac8184cd762b2ed3a0506aee3e5ca9557", "class_name": "RelatedNodeInfo"}}, "text": "So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n ", "start_char_idx": 2075, "end_char_idx": 2288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "386870ee-d3d7-4522-a807-871e092e6b8a": {"__data__": {"id_": "386870ee-d3d7-4522-a807-871e092e6b8a", "embedding": null, "metadata": {"window": "As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68d58b73-43ca-49ff-a54b-f40d3ff1e9ff", "node_type": "1", "metadata": {"window": "As we didn't really outline it, we don't talk about quarterly guidance, but I \ncan indicate for you that on a consolidated basis, what we would expect is that our earnings growth will be heavier \nin the second half of the year as opposed to the first half of the year.  \n \n As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research. ", "original_text": "So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e3491bbb097be3dd10234ff78f1c1c2c265a3edf12300f89f716166b2aa1e90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20ae6df3-08e3-4138-85db-38a5f6578216", "node_type": "1", "metadata": {"window": "And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. "}, "hash": "a6b7d87911caf29d5b8a04ac8da191ea2128614198ee8cb387a7cfd6fdc7cf8a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "start_char_idx": 2288, "end_char_idx": 2651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20ae6df3-08e3-4138-85db-38a5f6578216": {"__data__": {"id_": "20ae6df3-08e3-4138-85db-38a5f6578216", "embedding": null, "metadata": {"window": "And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "386870ee-d3d7-4522-a807-871e092e6b8a", "node_type": "1", "metadata": {"window": "As I laid out in my comments, we have less contribution from COVID  related items in fiscal 2023 than we did in \nfiscal 2022.  And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ceb0c32d5ff9df39715f7d370e742d7e18888b5e1bee57a770fdd48ec17f8495", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b04a07ac-7e7b-4ae6-8ce1-1bfe65fa1e16", "node_type": "1", "metadata": {"window": "So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance. ", "original_text": "We'll take our nex t question from Eric Percher with Nephron Research. "}, "hash": "8824063d7a066c217dcc69947a023b5ea4f19741b9c5d9aa4fd8186775019481", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "start_char_idx": 2651, "end_char_idx": 2947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b04a07ac-7e7b-4ae6-8ce1-1bfe65fa1e16": {"__data__": {"id_": "b04a07ac-7e7b-4ae6-8ce1-1bfe65fa1e16", "embedding": null, "metadata": {"window": "So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance. ", "original_text": "We'll take our nex t question from Eric Percher with Nephron Research. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20ae6df3-08e3-4138-85db-38a5f6578216", "node_type": "1", "metadata": {"window": "And in fact, in all cases, across both pharma and our medical segment, we have declining COVID \nrelated contribution.  So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1aa9a599b0ba9034ba689bee096abba7ff993dad9c6dcbf5589bd6f3085d40b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "121e0bb1-6e58-49ef-8aa5-5e78ebd2ba69", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID. ", "original_text": "Please go ahead.  \n "}, "hash": "4a9ac56fbbf5a6c437d25f458a0377455fe2c8228bfdabd030cde1ed8360479a", "class_name": "RelatedNodeInfo"}}, "text": "We'll take our nex t question from Eric Percher with Nephron Research. ", "start_char_idx": 2947, "end_char_idx": 3018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "121e0bb1-6e58-49ef-8aa5-5e78ebd2ba69": {"__data__": {"id_": "121e0bb1-6e58-49ef-8aa5-5e78ebd2ba69", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID. ", "original_text": "Please go ahead.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b04a07ac-7e7b-4ae6-8ce1-1bfe65fa1e16", "node_type": "1", "metadata": {"window": "So what we do expect is that we would indicate to you expect a heavier proportion  of \nearnings in the second half of the year, a modestly heavier proportion in the second half of the year than the first \nhalf. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance. ", "original_text": "We'll take our nex t question from Eric Percher with Nephron Research. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c3c3ba17f18529f6acd88467d8140bdea7db2272edcc266766c7f442ddfc42c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e2ce2f9-76c0-4b9b-b936-61e72f2537db", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. "}, "hash": "ce8fb89d210429e15021db09617a1cab122aad4ecef3eb90af787c8ded6ea4e5", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 3018, "end_char_idx": 3038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e2ce2f9-76c0-4b9b-b936-61e72f2537db": {"__data__": {"id_": "2e2ce2f9-76c0-4b9b-b936-61e72f2537db", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "121e0bb1-6e58-49ef-8aa5-5e78ebd2ba69", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID. ", "original_text": "Please go ahead.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76d2beb8268a8a9d9b4939a86d81f0dbc3e5676c690600d288109fb3c09e4636", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7365184-8b45-4fd2-9058-652fbbd4af8b", "node_type": "1", "metadata": {"window": "We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Brian and Britt, kind of, a standard question on initial guidance. "}, "hash": "6385a99d81588bede960f588022b753783849eae53f05ed5515d2e702fed022f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "start_char_idx": 3038, "end_char_idx": 3370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7365184-8b45-4fd2-9058-652fbbd4af8b": {"__data__": {"id_": "e7365184-8b45-4fd2-9058-652fbbd4af8b", "embedding": null, "metadata": {"window": "We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Brian and Britt, kind of, a standard question on initial guidance. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e2ce2f9-76c0-4b9b-b936-61e72f2537db", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1abd6ede5e308999dc750105fe478413231ef07e3eb86c313881f184df7cb5c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec0cbcfd-02cc-48fe-8b87-e2aaf0fe91da", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric. ", "original_text": "As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID. "}, "hash": "5844032a8d2d0786af737a9e598ca16a58ece3a5fbb55df80189df151565b554", "class_name": "RelatedNodeInfo"}}, "text": "Brian and Britt, kind of, a standard question on initial guidance. ", "start_char_idx": 3370, "end_char_idx": 3437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec0cbcfd-02cc-48fe-8b87-e2aaf0fe91da": {"__data__": {"id_": "ec0cbcfd-02cc-48fe-8b87-e2aaf0fe91da", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric. ", "original_text": "As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7365184-8b45-4fd2-9058-652fbbd4af8b", "node_type": "1", "metadata": {"window": "We'll take our nex t question from Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Brian and Britt, kind of, a standard question on initial guidance. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b70bb17bbfa1135ebe27fcbb1912c0ced28c46a6cc4a6fca7b84351942643c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c96c59e-cb45-4bd9-ad8f-32fa08d44e3f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on. ", "original_text": "So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n "}, "hash": "faa22aa52e48840ed8a69e01e4d816c67fa5d6324c7d4c23983499aab4f365c3", "class_name": "RelatedNodeInfo"}}, "text": "As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID. ", "start_char_idx": 3437, "end_char_idx": 3650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c96c59e-cb45-4bd9-ad8f-32fa08d44e3f": {"__data__": {"id_": "7c96c59e-cb45-4bd9-ad8f-32fa08d44e3f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on. ", "original_text": "So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec0cbcfd-02cc-48fe-8b87-e2aaf0fe91da", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric. ", "original_text": "As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4abb9b6534276c8f42dd8f968c69224638ca50cd40df38e6b99125c11d74b36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ec743f4-7892-45f9-b74d-4063eaef8729", "node_type": "1", "metadata": {"window": "Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "b77ca8f81198798ccd545e7dfdd492153ef20aca3b153b2abd900c6bbdf28b6e", "class_name": "RelatedNodeInfo"}}, "text": "So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n ", "start_char_idx": 3650, "end_char_idx": 3772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ec743f4-7892-45f9-b74d-4063eaef8729": {"__data__": {"id_": "6ec743f4-7892-45f9-b74d-4063eaef8729", "embedding": null, "metadata": {"window": "Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c96c59e-cb45-4bd9-ad8f-32fa08d44e3f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on. ", "original_text": "So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6dc4130ccc76429bdbf7bb09cbb4f3dece6a58eebc436f8f3db7a15c37e557b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7f91d9d-5305-4d44-9bbf-54201da34ec9", "node_type": "1", "metadata": {"window": "As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests.  So that could \nbe a risk. ", "original_text": "A \nThanks for the question, Eric. "}, "hash": "6a06e0274d89fbe81cec1c466bca72a09759b72c9022fcd14ec4b931551b9870", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1160, "end_char_idx": 1517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7f91d9d-5305-4d44-9bbf-54201da34ec9": {"__data__": {"id_": "a7f91d9d-5305-4d44-9bbf-54201da34ec9", "embedding": null, "metadata": {"window": "As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests.  So that could \nbe a risk. ", "original_text": "A \nThanks for the question, Eric. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ec743f4-7892-45f9-b74d-4063eaef8729", "node_type": "1", "metadata": {"window": "Brian and Britt, kind of, a standard question on initial guidance.  As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8943ff3aa6ef3bc1dd84aef165b5699b1d26c3e6b582e39a61617d8c5ecc4e81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfb2ea87-9fc7-47d4-9a5c-4d875141065c", "node_type": "1", "metadata": {"window": "So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests.  So that could \nbe a risk.  It could be a positive or a negative.  ", "original_text": "I'll start, and then, certainly, Brian can add on. "}, "hash": "658c4f4fe962e490824b2cf9daedbf7ff1f6825a80c184d238e2446de70d0e3a", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for the question, Eric. ", "start_char_idx": 4129, "end_char_idx": 4163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfb2ea87-9fc7-47d4-9a5c-4d875141065c": {"__data__": {"id_": "bfb2ea87-9fc7-47d4-9a5c-4d875141065c", "embedding": null, "metadata": {"window": "So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests.  So that could \nbe a risk.  It could be a positive or a negative.  ", "original_text": "I'll start, and then, certainly, Brian can add on. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7f91d9d-5305-4d44-9bbf-54201da34ec9", "node_type": "1", "metadata": {"window": "As you've looked at your budget for \nthe year, I'd be interested to hear what the risks and opportunities look like, recognizing you have a $0.70 range \non $23 and potentially $0.40 of that attributable to COVID.  So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests.  So that could \nbe a risk. ", "original_text": "A \nThanks for the question, Eric. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6eee74a8d8a94768d67d22c75ee0058d086be07e33bb0c3f285dd089dcf8d4b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bddd7c4a-2f05-44ea-bd4f-53cc04363430", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests.  So that could \nbe a risk.  It could be a positive or a negative.  ", "original_text": "I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests. "}, "hash": "209ce2a5bb5ec4a349a490dbf59c29df93b93b1ad275a01993ba539872bb3134", "class_name": "RelatedNodeInfo"}}, "text": "I'll start, and then, certainly, Brian can add on. ", "start_char_idx": 4163, "end_char_idx": 4214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bddd7c4a-2f05-44ea-bd4f-53cc04363430": {"__data__": {"id_": "bddd7c4a-2f05-44ea-bd4f-53cc04363430", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests.  So that could \nbe a risk.  It could be a positive or a negative.  ", "original_text": "I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfb2ea87-9fc7-47d4-9a5c-4d875141065c", "node_type": "1", "metadata": {"window": "So you're feeling that there's relatively little variance \nand what are the factors that would driv e you high or low?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests.  So that could \nbe a risk.  It could be a positive or a negative.  ", "original_text": "I'll start, and then, certainly, Brian can add on. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7fb443b8020093a3c5e53a1f623dcdc40939430c03ae596f30715310a688f412", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dac15da0-98af-4e41-85b8-3ba13d415c68", "node_type": "1", "metadata": {"window": "A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests.  So that could \nbe a risk.  It could be a positive or a negative.  ", "original_text": "So that could \nbe a risk. "}, "hash": "8093a76f28811ba1353a43a7f39b4e628220345f1dd9f7fff0209a29cc50a7c1", "class_name": "RelatedNodeInfo"}}, "text": "I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests. ", "start_char_idx": 4214, "end_char_idx": 4477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dac15da0-98af-4e41-85b8-3ba13d415c68": {"__data__": {"id_": "dac15da0-98af-4e41-85b8-3ba13d415c68", "embedding": null, "metadata": {"window": "A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests.  So that could \nbe a risk.  It could be a positive or a negative.  ", "original_text": "So that could \nbe a risk. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bddd7c4a-2f05-44ea-bd4f-53cc04363430", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests.  So that could \nbe a risk.  It could be a positive or a negative.  ", "original_text": "I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ddab1cdea78768bd8bd857230eb99b684d1c0b223cbc934c5c8a4a08f9f2ae9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d16eb41-a5d7-4df4-82ec-2c2c449bf047", "node_type": "1", "metadata": {"window": "I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests.  So that could \nbe a risk.  It could be a positive or a negative.  ", "original_text": "It could be a positive or a negative.  "}, "hash": "11fd5f245a805a9f1fcd98ff4a17daa133526f6974dbdad3c42275f78fa56c6b", "class_name": "RelatedNodeInfo"}}, "text": "So that could \nbe a risk. ", "start_char_idx": 4477, "end_char_idx": 4503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d16eb41-a5d7-4df4-82ec-2c2c449bf047": {"__data__": {"id_": "1d16eb41-a5d7-4df4-82ec-2c2c449bf047", "embedding": null, "metadata": {"window": "I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests.  So that could \nbe a risk.  It could be a positive or a negative.  ", "original_text": "It could be a positive or a negative.  ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8076c054-5391-4925-b7fa-253b49ee3670", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b13ff14731adc2081bf22a3a7e204953405f0483bc381d2e6158a74fbe276047", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dac15da0-98af-4e41-85b8-3ba13d415c68", "node_type": "1", "metadata": {"window": "A \nThanks for the question, Eric.  I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests.  So that could \nbe a risk.  It could be a positive or a negative.  ", "original_text": "So that could \nbe a risk. ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "711dc9665e15ad5fd4b4a5b285aa4abe61779dd9d860a808daa3824af4359692", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75eae37e-e1d9-4a1c-9d7d-0a4492ae1eae", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase.  And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital. ", "original_text": "McKesson Corp.  "}, "hash": "5f5dbb5cd83d488c2e6dcb50c53ef40646241ea80ce7b7aef306ddbc644e3f89", "class_name": "RelatedNodeInfo"}}, "text": "It could be a positive or a negative.  ", "start_char_idx": 4503, "end_char_idx": 4542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75eae37e-e1d9-4a1c-9d7d-0a4492ae1eae": {"__data__": {"id_": "75eae37e-e1d9-4a1c-9d7d-0a4492ae1eae", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase.  And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d16eb41-a5d7-4df4-82ec-2c2c449bf047", "node_type": "1", "metadata": {"window": "I'll start, and then, certainly, Brian can add on.  I think one thing for sure as we think \nabout this is, we talked abou t the variability that we've seen in COVID and, sort of, the pace of COVID is certainly \none that we'll watch for and that certainly can go up or down, particularly in the case of COVID tests.  So that could \nbe a risk.  It could be a positive or a negative.  ", "original_text": "It could be a positive or a negative.  ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e2dfcfeb5ab92b09bdb966b7814278ffe91aa57a5ea1e7827d23567ab6bb3f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "baeafd69-3236-4475-bb36-da271c9a02bc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase.  And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase. "}, "hash": "713258af5b0912a57b42447558466ee5cbbd9f523da8d984b9814bab3f2a980d", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "baeafd69-3236-4475-bb36-da271c9a02bc": {"__data__": {"id_": "baeafd69-3236-4475-bb36-da271c9a02bc", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase.  And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75eae37e-e1d9-4a1c-9d7d-0a4492ae1eae", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase.  And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36d0d29f731d96c749f19fb5110a9607ef2b960e9e5bd22d57b481df3ec66b83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffdc542f-3d1c-43f8-861c-044c7c50ad0d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase.  And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.  ", "original_text": "And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well. "}, "hash": "8b42367adae303ab5b0ca18fc408ac0291cb94e12a2b055ee6fc9de16433e0cf", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase. ", "start_char_idx": 16, "end_char_idx": 333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffdc542f-3d1c-43f8-861c-044c7c50ad0d": {"__data__": {"id_": "ffdc542f-3d1c-43f8-861c-044c7c50ad0d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase.  And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.  ", "original_text": "And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "baeafd69-3236-4475-bb36-da271c9a02bc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase.  And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1996e568300ea6145fa970ec06840feac959b7538709cc8d683d22256e7e940", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c80351f-7d37-4e24-af04-5bee454e1fca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase.  And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n ", "original_text": "We certainly have the oppor tunity to deploy capital. "}, "hash": "e34252d3d8cf68e28521f265e6759747dda9b9e409dae70ee8bf447214f38102", "class_name": "RelatedNodeInfo"}}, "text": "And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well. ", "start_char_idx": 333, "end_char_idx": 673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c80351f-7d37-4e24-af04-5bee454e1fca": {"__data__": {"id_": "6c80351f-7d37-4e24-af04-5bee454e1fca", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase.  And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n ", "original_text": "We certainly have the oppor tunity to deploy capital. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffdc542f-3d1c-43f8-861c-044c7c50ad0d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase.  And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.  ", "original_text": "And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67007e60312f9ddc7207d526bc19763f3932ec900cdc1ce6ac2ab97c145770ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf4f5744-1e32-4850-88a8-a63fe0528fcb", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase.  And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n"}, "hash": "e5454c3f8e6f94988e7ea1f5dd40e090c0911098093f3f79290ce70b64db9b25", "class_name": "RelatedNodeInfo"}}, "text": "We certainly have the oppor tunity to deploy capital. ", "start_char_idx": 673, "end_char_idx": 727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf4f5744-1e32-4850-88a8-a63fe0528fcb": {"__data__": {"id_": "bf4f5744-1e32-4850-88a8-a63fe0528fcb", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase.  And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c80351f-7d37-4e24-af04-5bee454e1fca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase.  And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n ", "original_text": "We certainly have the oppor tunity to deploy capital. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "482ad3d6be2d92f4d74de2381e5b7996c025224b873d4052ccd78f73004a732b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba0182bf-e3a5-4a72-8513-dbbb747dea99", "node_type": "1", "metadata": {"window": "And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "And the other what I would point out to you is really the timing around our European divestitures.  "}, "hash": "76604bfdd0227591d56ea73f3276483eb84b5005ffe14970a735caf29a4b3aa4", "class_name": "RelatedNodeInfo"}}, "text": "We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n", "start_char_idx": 727, "end_char_idx": 864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba0182bf-e3a5-4a72-8513-dbbb747dea99": {"__data__": {"id_": "ba0182bf-e3a5-4a72-8513-dbbb747dea99", "embedding": null, "metadata": {"window": "And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "And the other what I would point out to you is really the timing around our European divestitures.  ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf4f5744-1e32-4850-88a8-a63fe0528fcb", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase.  And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a092cc3e322a04e446af544dc8c481748502e279f3ab9f6aedad5e73dc4ba288", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c8b268c-9037-49f9-b232-b350b0a4c6c2", "node_type": "1", "metadata": {"window": "We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n ", "original_text": "We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n "}, "hash": "3976c4fdc7c74fc394d6a536cd04ddbe7c790c25f7dfa2f2ce5046f2a2c6703a", "class_name": "RelatedNodeInfo"}}, "text": "And the other what I would point out to you is really the timing around our European divestitures.  ", "start_char_idx": 864, "end_char_idx": 964, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c8b268c-9037-49f9-b232-b350b0a4c6c2": {"__data__": {"id_": "1c8b268c-9037-49f9-b232-b350b0a4c6c2", "embedding": null, "metadata": {"window": "We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n ", "original_text": "We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba0182bf-e3a5-4a72-8513-dbbb747dea99", "node_type": "1", "metadata": {"window": "And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "And the other what I would point out to you is really the timing around our European divestitures.  ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "094bc2e1165303dcdd52d5c37a438d02984380944132fa1300aba6384669ad74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce481a93-71dd-4d2f-99b4-bff9c8d8f323", "node_type": "1", "metadata": {"window": "We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n "}, "hash": "c11a1a5037e6c31e4eeada199609c787ab5c6d47447aea0bd51e7d66506861ac", "class_name": "RelatedNodeInfo"}}, "text": "We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n ", "start_char_idx": 964, "end_char_idx": 1175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce481a93-71dd-4d2f-99b4-bff9c8d8f323": {"__data__": {"id_": "ce481a93-71dd-4d2f-99b4-bff9c8d8f323", "embedding": null, "metadata": {"window": "We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c8b268c-9037-49f9-b232-b350b0a4c6c2", "node_type": "1", "metadata": {"window": "We certainly have the oppor tunity to deploy capital.  We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n ", "original_text": "We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4eb6144cdfbc6018ba44a0c9d5ece343c54a1dca6ede86c84e35211f8d90af18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c1abde4-ed70-4f1a-9ebd-7c308cfb5f0b", "node_type": "1", "metadata": {"window": "And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. "}, "hash": "88d9c37a33577c5c0e5ec0876ffa9e5832b7bacca6edeb882fe5d96d36846f0e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "start_char_idx": 1175, "end_char_idx": 1538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c1abde4-ed70-4f1a-9ebd-7c308cfb5f0b": {"__data__": {"id_": "8c1abde4-ed70-4f1a-9ebd-7c308cfb5f0b", "embedding": null, "metadata": {"window": "And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce481a93-71dd-4d2f-99b4-bff9c8d8f323", "node_type": "1", "metadata": {"window": "We've laid out \nfor you our assumptions around capital deployment, but we have a lot of flexibility and a good financial \nframework.  \n \n And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da185ef52e03e792f1b8619706e74a418fd36550e7bfcfe476e16b88f714fca5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d041f137-a26a-41a3-a80b-e9494230f692", "node_type": "1", "metadata": {"window": "We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question. ", "original_text": "Our next question comes from Charles Rhyee with Cowen.  \n "}, "hash": "470c74127766eab89930d505660ad750e2081cdf08f540fec73bbe0a0d1660da", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "start_char_idx": 1538, "end_char_idx": 1834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d041f137-a26a-41a3-a80b-e9494230f692": {"__data__": {"id_": "d041f137-a26a-41a3-a80b-e9494230f692", "embedding": null, "metadata": {"window": "We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question. ", "original_text": "Our next question comes from Charles Rhyee with Cowen.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c1abde4-ed70-4f1a-9ebd-7c308cfb5f0b", "node_type": "1", "metadata": {"window": "And the other what I would point out to you is really the timing around our European divestitures.   We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b26beda6a47581146db74031c4d12e5dc3e6ded510d44b1fd0af79bd5b015ac1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17d145ed-bfd6-4932-b4bb-22ae74437964", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "f8a97422f5af101e9e0b01beda8c190607b5850902eafdc9bd5363113e49c651", "class_name": "RelatedNodeInfo"}}, "text": "Our next question comes from Charles Rhyee with Cowen.  \n ", "start_char_idx": 1834, "end_char_idx": 1892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17d145ed-bfd6-4932-b4bb-22ae74437964": {"__data__": {"id_": "17d145ed-bfd6-4932-b4bb-22ae74437964", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d041f137-a26a-41a3-a80b-e9494230f692", "node_type": "1", "metadata": {"window": "We've laid out \nfor you that we would expect the transaction with the PHOENIX Group to be in the second half of the year, but \nclearly, that timing could move as we continue to move through that transaction.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question. ", "original_text": "Our next question comes from Charles Rhyee with Cowen.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f3660d4646e4626e1a7cbe66f429f8eec32a6a73d1e3df588370db2cbdb49a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9afe32fb-c3da-4e5d-a132-3cae5c727993", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing. ", "original_text": "LLC  Q \nYeah. "}, "hash": "b88e40947cc28fcfeb68f53148026c294ba0b7c0d5dd0c1d17a9201c9a29714e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 1892, "end_char_idx": 2201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9afe32fb-c3da-4e5d-a132-3cae5c727993": {"__data__": {"id_": "9afe32fb-c3da-4e5d-a132-3cae5c727993", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing. ", "original_text": "LLC  Q \nYeah. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17d145ed-bfd6-4932-b4bb-22ae74437964", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6592d3ce8b1730bce0d9c411a488040d5d4efc77d19e5a6d0a071d11aa375fd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a045860d-2360-4e3b-b517-b19607006405", "node_type": "1", "metadata": {"window": "Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n", "original_text": "Thanks for taking the question. "}, "hash": "3313d8c4da9227c5d7e9d909678b4824519aeb09912dc21ea76d1cbce1b86ef6", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah. ", "start_char_idx": 2201, "end_char_idx": 2215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a045860d-2360-4e3b-b517-b19607006405": {"__data__": {"id_": "a045860d-2360-4e3b-b517-b19607006405", "embedding": null, "metadata": {"window": "Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n", "original_text": "Thanks for taking the question. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9afe32fb-c3da-4e5d-a132-3cae5c727993", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing. ", "original_text": "LLC  Q \nYeah. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b628e176b031b39e6ec042b44407b3766fdba371ba093a8ed170cea06f78c9db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b562bcd-ca65-4125-9201-108104654752", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently. ", "original_text": "Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country. "}, "hash": "b333a915fb9619c73755dc94461b87a8b795dfb8c9050c8b3a6aba92830b07de", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 2215, "end_char_idx": 2247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b562bcd-ca65-4125-9201-108104654752": {"__data__": {"id_": "6b562bcd-ca65-4125-9201-108104654752", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently. ", "original_text": "Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a045860d-2360-4e3b-b517-b19607006405", "node_type": "1", "metadata": {"window": "Our next question comes from Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n", "original_text": "Thanks for taking the question. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf38320986325be7ad973ab8e7d9892ad3b6ad7a8d53f85ebf53c9ea267fd2ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e264200b-9a48-4023-b6f8-58fa4889e140", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like? ", "original_text": "We are seeing cases rise, at least today, that's what the data seems \nto be showing. "}, "hash": "8e9fc6ad6aa82fb0d698fe6e42ba0bf4837368cce28d830da8c15922b3ff4f3e", "class_name": "RelatedNodeInfo"}}, "text": "Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country. ", "start_char_idx": 2247, "end_char_idx": 2366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e264200b-9a48-4023-b6f8-58fa4889e140": {"__data__": {"id_": "e264200b-9a48-4023-b6f8-58fa4889e140", "embedding": null, "metadata": {"window": "LLC  Q \nYeah.  Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like? ", "original_text": "We are seeing cases rise, at least today, that's what the data seems \nto be showing. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b562bcd-ca65-4125-9201-108104654752", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently. ", "original_text": "Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "efcd46218faa692e74b4fce74dd063fc52b94387c40d2d17ca6872805fbc8d67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "912c769e-da7c-4cc5-abb8-62e60e279b5e", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID? ", "original_text": "But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n"}, "hash": "15ac0b1c12f70ca5dbbd2cc5ff4928ecb287fb198dbd71c3e258e07c8a55e1c0", "class_name": "RelatedNodeInfo"}}, "text": "We are seeing cases rise, at least today, that's what the data seems \nto be showing. ", "start_char_idx": 2366, "end_char_idx": 2451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "912c769e-da7c-4cc5-abb8-62e60e279b5e": {"__data__": {"id_": "912c769e-da7c-4cc5-abb8-62e60e279b5e", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID? ", "original_text": "But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e264200b-9a48-4023-b6f8-58fa4889e140", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like? ", "original_text": "We are seeing cases rise, at least today, that's what the data seems \nto be showing. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64da260c68f7410130be4285d3b09f48f5aaa751244034c0b8c3b23ac4b23613", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93640f74-ffc2-446e-9321-e583295650c2", "node_type": "1", "metadata": {"window": "Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n ", "original_text": "Maybe you can  talk about maybe trends that you're seeing currently. "}, "hash": "27ff5d74a139536c2e2acc25a94bfec9cf4a9fcb066fde7c783e97e297d416b2", "class_name": "RelatedNodeInfo"}}, "text": "But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n", "start_char_idx": 2451, "end_char_idx": 2550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93640f74-ffc2-446e-9321-e583295650c2": {"__data__": {"id_": "93640f74-ffc2-446e-9321-e583295650c2", "embedding": null, "metadata": {"window": "Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n ", "original_text": "Maybe you can  talk about maybe trends that you're seeing currently. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "912c769e-da7c-4cc5-abb8-62e60e279b5e", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID? ", "original_text": "But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9362d173f01ceb52d9ba38127cc8334ff064afd851ba9a22cda8eca857e53d1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73b949f8-7def-4a3b-9a1f-8c26073300db", "node_type": "1", "metadata": {"window": "We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.  ", "original_text": "And what does an endemic phase of COVID \nlook like? "}, "hash": "235d473ae0860314a9361b3b49630a68d14d64a7276df2c08d08622530407914", "class_name": "RelatedNodeInfo"}}, "text": "Maybe you can  talk about maybe trends that you're seeing currently. ", "start_char_idx": 2550, "end_char_idx": 2619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73b949f8-7def-4a3b-9a1f-8c26073300db": {"__data__": {"id_": "73b949f8-7def-4a3b-9a1f-8c26073300db", "embedding": null, "metadata": {"window": "We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.  ", "original_text": "And what does an endemic phase of COVID \nlook like? ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93640f74-ffc2-446e-9321-e583295650c2", "node_type": "1", "metadata": {"window": "Britt, you talked about how your COVID -related business es really tracks \nwith the incidence of COVID in the country.  We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n ", "original_text": "Maybe you can  talk about maybe trends that you're seeing currently. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a47f41687e883066ff545bdae7faa8dca72d26aac448402e9b745d97911320ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d68c7eed-f39e-4827-9230-d265f3bcd91f", "node_type": "1", "metadata": {"window": "But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles. ", "original_text": "Or how are you guys thinking about that if we move into an endemic phase for COVID? "}, "hash": "98103e12df1d73c961b12c4d0d25c6937b82102513155d30f2d6c16f58073067", "class_name": "RelatedNodeInfo"}}, "text": "And what does an endemic phase of COVID \nlook like? ", "start_char_idx": 2619, "end_char_idx": 2671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d68c7eed-f39e-4827-9230-d265f3bcd91f": {"__data__": {"id_": "d68c7eed-f39e-4827-9230-d265f3bcd91f", "embedding": null, "metadata": {"window": "But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles. ", "original_text": "Or how are you guys thinking about that if we move into an endemic phase for COVID? ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73b949f8-7def-4a3b-9a1f-8c26073300db", "node_type": "1", "metadata": {"window": "We are seeing cases rise, at least today, that's what the data seems \nto be showing.  But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.  ", "original_text": "And what does an endemic phase of COVID \nlook like? ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10217ba41a98765be1724ff489e603326feb98490c03b39d5d3242986b6e51df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb0258d9-cbb1-4057-bcec-33d55c16c6a2", "node_type": "1", "metadata": {"window": "Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years. ", "original_text": "Thanks.  \n "}, "hash": "e0924019763cdd2db9d2e6adb321fc5d84b547536a779932db3c42c86da8931b", "class_name": "RelatedNodeInfo"}}, "text": "Or how are you guys thinking about that if we move into an endemic phase for COVID? ", "start_char_idx": 2671, "end_char_idx": 2755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb0258d9-cbb1-4057-bcec-33d55c16c6a2": {"__data__": {"id_": "fb0258d9-cbb1-4057-bcec-33d55c16c6a2", "embedding": null, "metadata": {"window": "Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years. ", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d68c7eed-f39e-4827-9230-d265f3bcd91f", "node_type": "1", "metadata": {"window": "But at the same time, right, it seems like there's overall less testing, sort of a less emphasis. \n Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles. ", "original_text": "Or how are you guys thinking about that if we move into an endemic phase for COVID? ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e67b9f56f5efe6658647de93bf19384d1bf04a8aecc2d3783915220fa43f326a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fde5a5a4-d297-4c36-8445-d6f046347e9c", "node_type": "1", "metadata": {"window": "And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.  "}, "hash": "98a9864874f88542112f84b3cd570fdb549b49e321b68845047c0218df6c7aa8", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2755, "end_char_idx": 2766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fde5a5a4-d297-4c36-8445-d6f046347e9c": {"__data__": {"id_": "fde5a5a4-d297-4c36-8445-d6f046347e9c", "embedding": null, "metadata": {"window": "And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb0258d9-cbb1-4057-bcec-33d55c16c6a2", "node_type": "1", "metadata": {"window": "Maybe you can  talk about maybe trends that you're seeing currently.  And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years. ", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7323e42e1745d9be373dce49cabe080af1e34da03d78f0029f9b23074c2ffa2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d39bda84-291e-45c3-bdd4-e7520d36ff2d", "node_type": "1", "metadata": {"window": "Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then. ", "original_text": "A \nThanks, Charles. "}, "hash": "29184061ebc1c4a052ee3c0d5cdd6e75f2c84a27075e2faf227cf7bb7a6dcb26", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.  ", "start_char_idx": 2766, "end_char_idx": 3108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d39bda84-291e-45c3-bdd4-e7520d36ff2d": {"__data__": {"id_": "d39bda84-291e-45c3-bdd4-e7520d36ff2d", "embedding": null, "metadata": {"window": "Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then. ", "original_text": "A \nThanks, Charles. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fde5a5a4-d297-4c36-8445-d6f046347e9c", "node_type": "1", "metadata": {"window": "And what does an endemic phase of COVID \nlook like?  Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9acdf4aaf4097fd83ed890fe68634b26ffbab2df8c5608d69eb9fd8bd169472", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8937c1d1-1a35-4b5f-8372-404e4ce977c6", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating. ", "original_text": "Obviously, it's been a little bit hard to predict over the last two years. "}, "hash": "59fd2f69951211623358ca7d991925d20cff2374db5eaa6cc44663b5d7494b15", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks, Charles. ", "start_char_idx": 3108, "end_char_idx": 3128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8937c1d1-1a35-4b5f-8372-404e4ce977c6": {"__data__": {"id_": "8937c1d1-1a35-4b5f-8372-404e4ce977c6", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating. ", "original_text": "Obviously, it's been a little bit hard to predict over the last two years. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d39bda84-291e-45c3-bdd4-e7520d36ff2d", "node_type": "1", "metadata": {"window": "Or how are you guys thinking about that if we move into an endemic phase for COVID?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then. ", "original_text": "A \nThanks, Charles. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "712b72b93960d9b7e2e68ab479ef9cfa5fe16c96c6c3b14adb053498f0f1aa11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfc9b694-6729-4715-8c3b-285e70162c0d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant. ", "original_text": "We saw our last, sort of, \nspike in testing really hit us in January of this year. "}, "hash": "8e09188d4a24594e43c9ea98bd20c498723d7c3bee5b97c33a0482683cd86bfd", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, it's been a little bit hard to predict over the last two years. ", "start_char_idx": 3128, "end_char_idx": 3203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfc9b694-6729-4715-8c3b-285e70162c0d": {"__data__": {"id_": "dfc9b694-6729-4715-8c3b-285e70162c0d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant. ", "original_text": "We saw our last, sort of, \nspike in testing really hit us in January of this year. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8937c1d1-1a35-4b5f-8372-404e4ce977c6", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating. ", "original_text": "Obviously, it's been a little bit hard to predict over the last two years. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a4ba0e66a53ef464a46b64c997b742866681f92c228d4a2725781945e10f7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92b3f5fa-ce72-484e-9a68-b5b77cfe10fa", "node_type": "1", "metadata": {"window": "A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior. ", "original_text": "And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then. "}, "hash": "1a7b0bc2bc5ad3d6569256380101ea639d77a284d017c9e1f0048fc7fa0c673a", "class_name": "RelatedNodeInfo"}}, "text": "We saw our last, sort of, \nspike in testing really hit us in January of this year. ", "start_char_idx": 3203, "end_char_idx": 3286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92b3f5fa-ce72-484e-9a68-b5b77cfe10fa": {"__data__": {"id_": "92b3f5fa-ce72-484e-9a68-b5b77cfe10fa", "embedding": null, "metadata": {"window": "A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior. ", "original_text": "And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfc9b694-6729-4715-8c3b-285e70162c0d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant. ", "original_text": "We saw our last, sort of, \nspike in testing really hit us in January of this year. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "026551f3c129d5ffa90681c04ea2df2528f9bbbf66b01d5d727ed575c34068fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f488a4d5-8796-47df-acc9-c43a2c61f794", "node_type": "1", "metadata": {"window": "Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior.  Do people get into routine testing? ", "original_text": "There is a new variant circulating. "}, "hash": "608caeb2445756181f32ef55470dd8d6dd9020ff60e32a841fd67bd4f88d047b", "class_name": "RelatedNodeInfo"}}, "text": "And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then. ", "start_char_idx": 3286, "end_char_idx": 3372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f488a4d5-8796-47df-acc9-c43a2c61f794": {"__data__": {"id_": "f488a4d5-8796-47df-acc9-c43a2c61f794", "embedding": null, "metadata": {"window": "Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior.  Do people get into routine testing? ", "original_text": "There is a new variant circulating. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92b3f5fa-ce72-484e-9a68-b5b77cfe10fa", "node_type": "1", "metadata": {"window": "A \nThanks, Charles.  Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior. ", "original_text": "And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18691770369c178b58707c88e3d0f0364dcb93d38d30b90956971b12a249a45d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b05413a5-261b-4fab-8765-659ba0aad766", "node_type": "1", "metadata": {"window": "We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior.  Do people get into routine testing?  Do \nthey feel the need to  routinely test? ", "original_text": "Initial indications are, it has probably the same medical \nprofile as the previous variant. "}, "hash": "7e20abfbb026f5ce56828ef6b3d4e315283f13c2692adf435f01301f47d8103b", "class_name": "RelatedNodeInfo"}}, "text": "There is a new variant circulating. ", "start_char_idx": 3372, "end_char_idx": 3408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b05413a5-261b-4fab-8765-659ba0aad766": {"__data__": {"id_": "b05413a5-261b-4fab-8765-659ba0aad766", "embedding": null, "metadata": {"window": "We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior.  Do people get into routine testing?  Do \nthey feel the need to  routinely test? ", "original_text": "Initial indications are, it has probably the same medical \nprofile as the previous variant. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f488a4d5-8796-47df-acc9-c43a2c61f794", "node_type": "1", "metadata": {"window": "Obviously, it's been a little bit hard to predict over the last two years.  We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior.  Do people get into routine testing? ", "original_text": "There is a new variant circulating. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b79f0e5f1e7316a9e458b5e2c09c8012b994e9cd2d381175717b4857d0eac22d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a621744f-55af-49c7-b666-153fbb9e845b", "node_type": "1", "metadata": {"window": "And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior.  Do people get into routine testing?  Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back? ", "original_text": "But the wildcard will be patient behavior. "}, "hash": "040d9cb21d81c483169fad3ef8900349f2c38cd90e6aa88e63dcbf47e51aa4ee", "class_name": "RelatedNodeInfo"}}, "text": "Initial indications are, it has probably the same medical \nprofile as the previous variant. ", "start_char_idx": 3408, "end_char_idx": 3500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a621744f-55af-49c7-b666-153fbb9e845b": {"__data__": {"id_": "a621744f-55af-49c7-b666-153fbb9e845b", "embedding": null, "metadata": {"window": "And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior.  Do people get into routine testing?  Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back? ", "original_text": "But the wildcard will be patient behavior. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b05413a5-261b-4fab-8765-659ba0aad766", "node_type": "1", "metadata": {"window": "We saw our last, sort of, \nspike in testing really hit us in January of this year.  And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior.  Do people get into routine testing?  Do \nthey feel the need to  routinely test? ", "original_text": "Initial indications are, it has probably the same medical \nprofile as the previous variant. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba0f28986492a7408fc77830f18d35dbe57801fc2bef55a9866d5035039d6c86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5852b25f-59d3-4161-acc5-5281c687a80a", "node_type": "1", "metadata": {"window": "There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior.  Do people get into routine testing?  Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast. ", "original_text": "Do people get into routine testing? "}, "hash": "9cdf69a9b2295a19d509bf480de31f06ba4dbf60b4011508f848ef3d067e29ac", "class_name": "RelatedNodeInfo"}}, "text": "But the wildcard will be patient behavior. ", "start_char_idx": 3500, "end_char_idx": 3543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5852b25f-59d3-4161-acc5-5281c687a80a": {"__data__": {"id_": "5852b25f-59d3-4161-acc5-5281c687a80a", "embedding": null, "metadata": {"window": "There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior.  Do people get into routine testing?  Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast. ", "original_text": "Do people get into routine testing? ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a621744f-55af-49c7-b666-153fbb9e845b", "node_type": "1", "metadata": {"window": "And then we've seen COVID test kit volumes fall off pretty \nsignificantly since then.  There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior.  Do people get into routine testing?  Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back? ", "original_text": "But the wildcard will be patient behavior. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eba2cd0c14626ae054277865a19de8e2decf6ed0c3768c910cdef641cf7cdb27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b74451a-3cd7-4af7-90b9-498485dbc43c", "node_type": "1", "metadata": {"window": "Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior.  Do people get into routine testing?  Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n ", "original_text": "Do \nthey feel the need to  routinely test? "}, "hash": "fe8b5cf269f0a1184496c4e90086b1be181c714653269d0612b6f642063e1590", "class_name": "RelatedNodeInfo"}}, "text": "Do people get into routine testing? ", "start_char_idx": 3543, "end_char_idx": 3579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b74451a-3cd7-4af7-90b9-498485dbc43c": {"__data__": {"id_": "8b74451a-3cd7-4af7-90b9-498485dbc43c", "embedding": null, "metadata": {"window": "Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior.  Do people get into routine testing?  Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n ", "original_text": "Do \nthey feel the need to  routinely test? ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5852b25f-59d3-4161-acc5-5281c687a80a", "node_type": "1", "metadata": {"window": "There is a new variant circulating.  Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior.  Do people get into routine testing?  Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast. ", "original_text": "Do people get into routine testing? ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9377e7bd6d5abe5af4707ddaf951506b8e7e8e0b4d46912b0b30ed78ccd01591", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2baa29f4-6bae-435a-b4af-24fb58d6c556", "node_type": "1", "metadata": {"window": "But the wildcard will be patient behavior.  Do people get into routine testing?  Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "original_text": "Do employers test, as they bring people back? "}, "hash": "86a68afa54df3cb3a488edf6d7eac67737206a30cc2bd3f0e441c0687854a61f", "class_name": "RelatedNodeInfo"}}, "text": "Do \nthey feel the need to  routinely test? ", "start_char_idx": 3579, "end_char_idx": 3622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2baa29f4-6bae-435a-b4af-24fb58d6c556": {"__data__": {"id_": "2baa29f4-6bae-435a-b4af-24fb58d6c556", "embedding": null, "metadata": {"window": "But the wildcard will be patient behavior.  Do people get into routine testing?  Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "original_text": "Do employers test, as they bring people back? ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b74451a-3cd7-4af7-90b9-498485dbc43c", "node_type": "1", "metadata": {"window": "Initial indications are, it has probably the same medical \nprofile as the previous variant.  But the wildcard will be patient behavior.  Do people get into routine testing?  Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n ", "original_text": "Do \nthey feel the need to  routinely test? ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4ff580cb8e07aa8c2c867794d0a6fe8c72be292d2012924630cd6ef1457653e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e40129f2-cb93-4160-9d7d-de67a14ec151", "node_type": "1", "metadata": {"window": "Do people get into routine testing?  Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.  ", "original_text": "And that's a little bit difficult to \nforecast. "}, "hash": "1b83977379fd9f664ea67d094876fb4c262d78fd74d2e1daf9c07cea6dbf8ab4", "class_name": "RelatedNodeInfo"}}, "text": "Do employers test, as they bring people back? ", "start_char_idx": 3622, "end_char_idx": 3668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e40129f2-cb93-4160-9d7d-de67a14ec151": {"__data__": {"id_": "e40129f2-cb93-4160-9d7d-de67a14ec151", "embedding": null, "metadata": {"window": "Do people get into routine testing?  Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.  ", "original_text": "And that's a little bit difficult to \nforecast. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2baa29f4-6bae-435a-b4af-24fb58d6c556", "node_type": "1", "metadata": {"window": "But the wildcard will be patient behavior.  Do people get into routine testing?  Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "original_text": "Do employers test, as they bring people back? ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a09c8c26d22cb9122cb0f4c40ccece6f76721a09dfe6ab805129e18f30029521", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d27c988b-97a3-41e7-bba3-9e8624c3d29c", "node_type": "1", "metadata": {"window": "Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing. ", "original_text": "So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n "}, "hash": "f1949d5832169b24f77a0abaab92b71fa52b9759a400c536a4fe57b21324aa73", "class_name": "RelatedNodeInfo"}}, "text": "And that's a little bit difficult to \nforecast. ", "start_char_idx": 3668, "end_char_idx": 3716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d27c988b-97a3-41e7-bba3-9e8624c3d29c": {"__data__": {"id_": "d27c988b-97a3-41e7-bba3-9e8624c3d29c", "embedding": null, "metadata": {"window": "Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing. ", "original_text": "So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e40129f2-cb93-4160-9d7d-de67a14ec151", "node_type": "1", "metadata": {"window": "Do people get into routine testing?  Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.  ", "original_text": "And that's a little bit difficult to \nforecast. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7771017a0997d1fe12001a9999b64ab6eca0810a805c1baf143f69d5a06373ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe966659-ebcd-4625-b0e9-f7818fbd306f", "node_type": "1", "metadata": {"window": "Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  "}, "hash": "4f776b8c2e3bbbe29f164293cb37ac0ccb73637834e3289905637be8054f524f", "class_name": "RelatedNodeInfo"}}, "text": "So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n ", "start_char_idx": 3716, "end_char_idx": 3816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe966659-ebcd-4625-b0e9-f7818fbd306f": {"__data__": {"id_": "fe966659-ebcd-4625-b0e9-f7818fbd306f", "embedding": null, "metadata": {"window": "Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d27c988b-97a3-41e7-bba3-9e8624c3d29c", "node_type": "1", "metadata": {"window": "Do \nthey feel the need to  routinely test?  Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing. ", "original_text": "So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "12db1bc27ba5c02e3e5e098576aa7261f1d95956441eba95ffa031c59ce8c4d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3437d41a-cb2e-461d-8d55-4689becfb834", "node_type": "1", "metadata": {"window": "And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for.  And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n ", "original_text": "A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.  "}, "hash": "a6aa99d18f9765be95e77ef34a5d230e9b0da44733f74fea84bf2d0f593efe82", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "start_char_idx": 3816, "end_char_idx": 4174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3437d41a-cb2e-461d-8d55-4689becfb834": {"__data__": {"id_": "3437d41a-cb2e-461d-8d55-4689becfb834", "embedding": null, "metadata": {"window": "And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for.  And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n ", "original_text": "A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.  ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe966659-ebcd-4625-b0e9-f7818fbd306f", "node_type": "1", "metadata": {"window": "Do employers test, as they bring people back?  And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bef726941415e616d189278ae67fa51cf0ce2bd63e31c1c1986535610d346c48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86ff5e44-afe6-4d47-a782-8ed83c801d79", "node_type": "1", "metadata": {"window": "So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for.  And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing. "}, "hash": "4fc8b35191d3d77d154ded398c4b26e0dc6b5d92aa2262c16846e9deabc5e70e", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.  ", "start_char_idx": 4174, "end_char_idx": 4398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86ff5e44-afe6-4d47-a782-8ed83c801d79": {"__data__": {"id_": "86ff5e44-afe6-4d47-a782-8ed83c801d79", "embedding": null, "metadata": {"window": "So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for.  And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3437d41a-cb2e-461d-8d55-4689becfb834", "node_type": "1", "metadata": {"window": "And that's a little bit difficult to \nforecast.  So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for.  And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n ", "original_text": "A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.  ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79d47badcfffd0dc79342f75ad8dfe3824002e50310751d03a849cf1079413cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6bbb18c-5c37-424c-81cb-623bcf7fb5e9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for.  And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for. "}, "hash": "868d63976dd536ee01fc4155f2b0775bfff3d5cd11d0e030f54a90dd44a953b3", "class_name": "RelatedNodeInfo"}}, "text": "We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing. ", "start_char_idx": 4398, "end_char_idx": 4553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6bbb18c-5c37-424c-81cb-623bcf7fb5e9": {"__data__": {"id_": "f6bbb18c-5c37-424c-81cb-623bcf7fb5e9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for.  And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86ff5e44-afe6-4d47-a782-8ed83c801d79", "node_type": "1", "metadata": {"window": "So what we've given you is a guide in FY 2023, based on our best and current view of the market.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for.  And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ab94cdc962cc8a172e875573d8c1d0574f778b8223b2b15a2894f0863fd5ead", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13aee707-6f14-4919-bc18-83d853b037dc", "node_type": "1", "metadata": {"window": "A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for.  And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n "}, "hash": "d212d90a68af89fa055e82904e99f62213670db7f25bb54831bd7f67069c2efb", "class_name": "RelatedNodeInfo"}}, "text": "But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for. ", "start_char_idx": 4553, "end_char_idx": 4679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13aee707-6f14-4919-bc18-83d853b037dc": {"__data__": {"id_": "13aee707-6f14-4919-bc18-83d853b037dc", "embedding": null, "metadata": {"window": "A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for.  And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6bbb18c-5c37-424c-81cb-623bcf7fb5e9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for.  And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for. ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4813b6196b9ce13cb5fcdfcd4c40ee9b1158a2c8f5c971c0cf584792c3f577dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c90306a6-0db1-4873-b599-15a769020908", "node_type": "1", "metadata": {"window": "We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for.  And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "0c8fe4bab0045f4c501777b83c87e72f69d4dd2d3827ba0c967e10b68ca59df8", "class_name": "RelatedNodeInfo"}}, "text": "And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n ", "start_char_idx": 4679, "end_char_idx": 4764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c90306a6-0db1-4873-b599-15a769020908": {"__data__": {"id_": "c90306a6-0db1-4873-b599-15a769020908", "embedding": null, "metadata": {"window": "We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for.  And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc1097bf71394eae580b7841df8400930daaffb5b4aa01746dbeae937fe5ba1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13aee707-6f14-4919-bc18-83d853b037dc", "node_type": "1", "metadata": {"window": "A \nAnd, Charles, maybe just getting back to the question that Eric asked, as we think about the year, things that \ncould get us to the high or the low end of the range, clearly, COVID test has a lot of variability in that.   We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for.  And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a30772bf4772cf43b0f4449961d34c0d84bd9706857e9d868f728b72ef5a6ab8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b071f51-7392-4b71-9136-47b8bcb063b4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan. ", "original_text": "McKesson Corp.  "}, "hash": "ac6245ab96c03114ef7886f669d9cb2dc01002b2d9537c3d6cd1944a2fae6ee9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 1175, "end_char_idx": 1446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b071f51-7392-4b71-9136-47b8bcb063b4": {"__data__": {"id_": "9b071f51-7392-4b71-9136-47b8bcb063b4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c90306a6-0db1-4873-b599-15a769020908", "node_type": "1", "metadata": {"window": "We've given \nyou our best estimate based on the trends that we've seen, which is really, as Brian talked about, that declining \nlevel of cases in testing.  But, certainly, if a variant does come back and cases begin to rise again, that would be \nsomething tha t we would watch for.  And we would anticipate that COVID testing would follow the trajectory of \ncases.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7b2ca06709c3ab85b41b1cf3673f2a2e812fcfa6dbccf5bb8d5f34f16df4df6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8041f740-19ca-4b22-9ee8-56614b98db18", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan.  Ms. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n "}, "hash": "1e2c333cf378881572010478cdb42b4655e3f5218b48a90e77b613a7df3ca11b", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8041f740-19ca-4b22-9ee8-56614b98db18": {"__data__": {"id_": "8041f740-19ca-4b22-9ee8-56614b98db18", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan.  Ms. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b071f51-7392-4b71-9136-47b8bcb063b4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2708613ee8526b3a8a4fb5a5f042de717e0dc0a49c234e37981ebf0f0669d09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b583e0de-ee08-48b8-8af2-e6f330e8e6c3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan.  Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. "}, "hash": "7612916ee312586a9eb3b684d3dde0ac5644245f4ef2c80e89f90c3dc463ea55", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "start_char_idx": 16, "end_char_idx": 272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b583e0de-ee08-48b8-8af2-e6f330e8e6c3": {"__data__": {"id_": "b583e0de-ee08-48b8-8af2-e6f330e8e6c3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan.  Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8041f740-19ca-4b22-9ee8-56614b98db18", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan.  Ms. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "976bdb1bc3157b7f0246c84aa7f498c7830387876ffab1a0728568dcdfc0277e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80147a08-ced5-4245-aec5-cdcc659b5000", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan.  Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa. ", "original_text": "Our next question comes from Lisa Gill with JPMorgan. "}, "hash": "78ce4dcc6fb1e8d1bf615bf7a177af16badbd9c46f59c6b78353c3d9ebf618be", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "start_char_idx": 272, "end_char_idx": 568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80147a08-ced5-4245-aec5-cdcc659b5000": {"__data__": {"id_": "80147a08-ced5-4245-aec5-cdcc659b5000", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan.  Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa. ", "original_text": "Our next question comes from Lisa Gill with JPMorgan. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b583e0de-ee08-48b8-8af2-e6f330e8e6c3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan.  Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "496fb486ffda06f90038b10cca2f78f69842b2ac879afd88268c31474bb84408", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d85a4a64-296e-449d-96fb-7664fdd14c9a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan.  Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa.  Are you there?  \n ", "original_text": "Ms. "}, "hash": "409b8bb1cd4f4f2246769bad5b1f982ae857420f9e9c3cd90663439e35732a5c", "class_name": "RelatedNodeInfo"}}, "text": "Our next question comes from Lisa Gill with JPMorgan. ", "start_char_idx": 568, "end_char_idx": 622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d85a4a64-296e-449d-96fb-7664fdd14c9a": {"__data__": {"id_": "d85a4a64-296e-449d-96fb-7664fdd14c9a", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan.  Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa.  Are you there?  \n ", "original_text": "Ms. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80147a08-ced5-4245-aec5-cdcc659b5000", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan.  Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa. ", "original_text": "Our next question comes from Lisa Gill with JPMorgan. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c818b7d75aa1b037364df4c95ade7eb6330ac090a84b4d5d99d329373542b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b4e0f5d-47cc-4b7d-9b55-af0640563bbb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan.  Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa.  Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here. ", "original_text": "Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "6af58224bfc9fab708df03d6fba32fdac77007b4d6b9725154884f01f90a076a", "class_name": "RelatedNodeInfo"}}, "text": "Ms. ", "start_char_idx": 622, "end_char_idx": 626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b4e0f5d-47cc-4b7d-9b55-af0640563bbb": {"__data__": {"id_": "5b4e0f5d-47cc-4b7d-9b55-af0640563bbb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan.  Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa.  Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here. ", "original_text": "Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d85a4a64-296e-449d-96fb-7664fdd14c9a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan.  Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa.  Are you there?  \n ", "original_text": "Ms. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40a40187fc2c01740e71b1229843cbbff4e594380d75710469d538d871c27806", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "001ee631-e42c-4f13-ac62-423d06193080", "node_type": "1", "metadata": {"window": "Our next question comes from Lisa Gill with JPMorgan.  Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa.  Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail. ", "original_text": "A \nHi, Lisa. "}, "hash": "389b9e80d2e270ce67fe8e8085a2d7691a49b5a72371bcebf598696f725781fe", "class_name": "RelatedNodeInfo"}}, "text": "Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 626, "end_char_idx": 1018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "001ee631-e42c-4f13-ac62-423d06193080": {"__data__": {"id_": "001ee631-e42c-4f13-ac62-423d06193080", "embedding": null, "metadata": {"window": "Our next question comes from Lisa Gill with JPMorgan.  Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa.  Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail. ", "original_text": "A \nHi, Lisa. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b4e0f5d-47cc-4b7d-9b55-af0640563bbb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan.  Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa.  Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here. ", "original_text": "Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "14dfd3e0814cee957f67a183651b8eabc76b41fa4c1d6954d2efd39f2c74768c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6e54d2b-395c-4f7a-8bec-2eb17a8ae656", "node_type": "1", "metadata": {"window": "Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa.  Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance. ", "original_text": "Are you there?  \n "}, "hash": "2fa4c613bb21bd5e824725740de08c8ea1f1b440d84595dbc3118661b5697832", "class_name": "RelatedNodeInfo"}}, "text": "A \nHi, Lisa. ", "start_char_idx": 1018, "end_char_idx": 1031, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6e54d2b-395c-4f7a-8bec-2eb17a8ae656": {"__data__": {"id_": "e6e54d2b-395c-4f7a-8bec-2eb17a8ae656", "embedding": null, "metadata": {"window": "Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa.  Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance. ", "original_text": "Are you there?  \n ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "001ee631-e42c-4f13-ac62-423d06193080", "node_type": "1", "metadata": {"window": "Our next question comes from Lisa Gill with JPMorgan.  Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa.  Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail. ", "original_text": "A \nHi, Lisa. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9758ee07d58b736ca324187546cd5478396866273024a83bc2e941f5106d9f6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81396d50-913c-4f33-927e-9e0fcf134a9d", "node_type": "1", "metadata": {"window": "Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa.  Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here. "}, "hash": "49c5ef9ddb783c84e5e730a0cc4fbdf9b008f7c62a36a215fd52f0124c105691", "class_name": "RelatedNodeInfo"}}, "text": "Are you there?  \n ", "start_char_idx": 1031, "end_char_idx": 1049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81396d50-913c-4f33-927e-9e0fcf134a9d": {"__data__": {"id_": "81396d50-913c-4f33-927e-9e0fcf134a9d", "embedding": null, "metadata": {"window": "Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa.  Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6e54d2b-395c-4f7a-8bec-2eb17a8ae656", "node_type": "1", "metadata": {"window": "Ms.  Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa.  Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance. ", "original_text": "Are you there?  \n ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8781598de3c92272f906aae186a08e3646499b3c652c7e2c6df320b4b28274", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c13eb7e3-c12b-41e0-9c07-1e3fdb5f3d65", "node_type": "1", "metadata": {"window": "A \nHi, Lisa.  Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis? ", "original_text": "Thank you very much for al l the detail. "}, "hash": "882d2466d89478391380162b0a6a0cf97ad73ef2ab8395f302631f8f2e5bc91a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here. ", "start_char_idx": 1049, "end_char_idx": 1390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c13eb7e3-c12b-41e0-9c07-1e3fdb5f3d65": {"__data__": {"id_": "c13eb7e3-c12b-41e0-9c07-1e3fdb5f3d65", "embedding": null, "metadata": {"window": "A \nHi, Lisa.  Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis? ", "original_text": "Thank you very much for al l the detail. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81396d50-913c-4f33-927e-9e0fcf134a9d", "node_type": "1", "metadata": {"window": "Gill, please check your mute \nbutton on your...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nHi, Lisa.  Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72ff5314e581dc4e201734922d829088ba5f4301400aa6492b812f4b08264f9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "471046f8-f35f-4920-9a84-c61e0f985943", "node_type": "1", "metadata": {"window": "Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia. ", "original_text": "I just really wanted to understand a couple of things, as we \nthink about the guidance. "}, "hash": "c1b720aa588f7ebcb778d76341da03f820d305356221f930a63c4d4c0e1b57e6", "class_name": "RelatedNodeInfo"}}, "text": "Thank you very much for al l the detail. ", "start_char_idx": 1390, "end_char_idx": 1431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "471046f8-f35f-4920-9a84-c61e0f985943": {"__data__": {"id_": "471046f8-f35f-4920-9a84-c61e0f985943", "embedding": null, "metadata": {"window": "Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia. ", "original_text": "I just really wanted to understand a couple of things, as we \nthink about the guidance. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c13eb7e3-c12b-41e0-9c07-1e3fdb5f3d65", "node_type": "1", "metadata": {"window": "A \nHi, Lisa.  Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis? ", "original_text": "Thank you very much for al l the detail. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7f6dc0cd73b20c6c956505e4a7b48dd3b1454588bb6b45ae3bada519b0ad7ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eba3b6de-e9cc-4c30-95c2-5774275e3bf4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n ", "original_text": "One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance. "}, "hash": "1efc5b7d9ef7236ae31cc6e5763128288b6f18c67d9847eeb6f34b6cbde369de", "class_name": "RelatedNodeInfo"}}, "text": "I just really wanted to understand a couple of things, as we \nthink about the guidance. ", "start_char_idx": 1431, "end_char_idx": 1519, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eba3b6de-e9cc-4c30-95c2-5774275e3bf4": {"__data__": {"id_": "eba3b6de-e9cc-4c30-95c2-5774275e3bf4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n ", "original_text": "One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "471046f8-f35f-4920-9a84-c61e0f985943", "node_type": "1", "metadata": {"window": "Are you there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia. ", "original_text": "I just really wanted to understand a couple of things, as we \nthink about the guidance. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d37dcd72511c3fa4a4765b86254e9420792a1c82a00c52d7a056716f7f761b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bf37985-fa9d-4d67-9e6f-03f4c8ef3de5", "node_type": "1", "metadata": {"window": "Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis? "}, "hash": "9a5046f08a613cc54fc9882e895b3687711aebe51ba35d568927ce337c26b7b1", "class_name": "RelatedNodeInfo"}}, "text": "One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance. ", "start_char_idx": 1519, "end_char_idx": 1661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bf37985-fa9d-4d67-9e6f-03f4c8ef3de5": {"__data__": {"id_": "7bf37985-fa9d-4d67-9e6f-03f4c8ef3de5", "embedding": null, "metadata": {"window": "Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis? ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eba3b6de-e9cc-4c30-95c2-5774275e3bf4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nSorry, I'm here.  Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n ", "original_text": "One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31a698f234232c65f4825e3d295b60418ae583ecc595b00da479e5ba449b01f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8ab246d-4107-4a08-bd41-cfc1e9bd38ec", "node_type": "1", "metadata": {"window": "I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question. ", "original_text": "And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia. "}, "hash": "f5363a00f6b1e79a2622cb4f89b8d20f02c592adcd2e3c350426ed5ca74af519", "class_name": "RelatedNodeInfo"}}, "text": "You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis? ", "start_char_idx": 1661, "end_char_idx": 1789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8ab246d-4107-4a08-bd41-cfc1e9bd38ec": {"__data__": {"id_": "b8ab246d-4107-4a08-bd41-cfc1e9bd38ec", "embedding": null, "metadata": {"window": "I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question. ", "original_text": "And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bf37985-fa9d-4d67-9e6f-03f4c8ef3de5", "node_type": "1", "metadata": {"window": "Thank you very much for al l the detail.  I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis? ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbf3a92294e441e2c8278ee9550ae2298b0ec5bca06d7e9b27c6127b36aa6143", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35a86a96-2e30-4076-93b8-f3695cd8c0c0", "node_type": "1", "metadata": {"window": "One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like. ", "original_text": "So has there been any impact due to supply constraints on that side of the business?  \n "}, "hash": "7479bce7111a6e80f8bca5d0798ecd2b6d4999f4317d835488a655fe7801d7b6", "class_name": "RelatedNodeInfo"}}, "text": "And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia. ", "start_char_idx": 1789, "end_char_idx": 1962, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35a86a96-2e30-4076-93b8-f3695cd8c0c0": {"__data__": {"id_": "35a86a96-2e30-4076-93b8-f3695cd8c0c0", "embedding": null, "metadata": {"window": "One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like. ", "original_text": "So has there been any impact due to supply constraints on that side of the business?  \n ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8ab246d-4107-4a08-bd41-cfc1e9bd38ec", "node_type": "1", "metadata": {"window": "I just really wanted to understand a couple of things, as we \nthink about the guidance.  One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question. ", "original_text": "And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df24e9ae819f92960b469d356c80c862d4cef1130677c1f990e9fe7810cea06b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c2123a0-73e4-407d-895c-9b9a67c7bef9", "node_type": "1", "metadata": {"window": "You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "394e034018cf67ce6d4f8632ea259cac134775e26f9b434699e40f46ec949899", "class_name": "RelatedNodeInfo"}}, "text": "So has there been any impact due to supply constraints on that side of the business?  \n ", "start_char_idx": 1962, "end_char_idx": 2050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c2123a0-73e4-407d-895c-9b9a67c7bef9": {"__data__": {"id_": "9c2123a0-73e4-407d-895c-9b9a67c7bef9", "embedding": null, "metadata": {"window": "You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35a86a96-2e30-4076-93b8-f3695cd8c0c0", "node_type": "1", "metadata": {"window": "One, I know you made a comment earlier on when we think about supply chain and \ninflation that you have some things built into your guidance.  You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like. ", "original_text": "So has there been any impact due to supply constraints on that side of the business?  \n ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9356fc09cabb3750d02e0afae4c8f13512bba8e8fe360008127e6d8bd3503994", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7dc381e-cc46-426d-b6df-a3ad995f7e46", "node_type": "1", "metadata": {"window": "And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n", "original_text": "A \nThanks for the question. "}, "hash": "0b2fa4d8b53f20aaa70256ba57931fda3df9397d7bbc1563baf17411f3f39d0e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 677, "end_char_idx": 1018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7dc381e-cc46-426d-b6df-a3ad995f7e46": {"__data__": {"id_": "d7dc381e-cc46-426d-b6df-a3ad995f7e46", "embedding": null, "metadata": {"window": "And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n", "original_text": "A \nThanks for the question. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c2123a0-73e4-407d-895c-9b9a67c7bef9", "node_type": "1", "metadata": {"window": "You talked abo ut the inflation on the side of wage \ninflation, one, did you carry that through into 2023 on a permanent basis?  And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6edfa2d7f0e97e54f254029dd76c7451d2170faf45846b2438330ce12b2c4c79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76b87cc6-c1af-4ecb-96db-038a9fbb9167", "node_type": "1", "metadata": {"window": "So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business. ", "original_text": "I'll kick it off, and Britt can add whatever additional comments he'd like. "}, "hash": "d9b79e1438a911fb3defc39c3949e76124217fe31ac8611cf2ab3d5f52502d1e", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for the question. ", "start_char_idx": 2391, "end_char_idx": 2419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76b87cc6-c1af-4ecb-96db-038a9fbb9167": {"__data__": {"id_": "76b87cc6-c1af-4ecb-96db-038a9fbb9167", "embedding": null, "metadata": {"window": "So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business. ", "original_text": "I'll kick it off, and Britt can add whatever additional comments he'd like. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7dc381e-cc46-426d-b6df-a3ad995f7e46", "node_type": "1", "metadata": {"window": "And then, secondly, if I think about your \nmedical supply business, you have historically had a private label product that was coming, if I remem ber \ncorrectly, from Asia.  So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n", "original_text": "A \nThanks for the question. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35b5515141863784135123b3196ccbbc704a8ac283096a54dc1f464e26732d48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6834afbd-6810-4714-8739-94dd7916cddb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday. ", "original_text": "I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market. "}, "hash": "606f803d6ad10a387aab435ea142f9afa24a21a69ecb3bbd67679054d0213b35", "class_name": "RelatedNodeInfo"}}, "text": "I'll kick it off, and Britt can add whatever additional comments he'd like. ", "start_char_idx": 2419, "end_char_idx": 2495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6834afbd-6810-4714-8739-94dd7916cddb": {"__data__": {"id_": "6834afbd-6810-4714-8739-94dd7916cddb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday. ", "original_text": "I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76b87cc6-c1af-4ecb-96db-038a9fbb9167", "node_type": "1", "metadata": {"window": "So has there been any impact due to supply constraints on that side of the business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business. ", "original_text": "I'll kick it off, and Britt can add whatever additional comments he'd like. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b435debffa24c2368d3e84d89022bc6b56dfda7ad3641546ff956297fe46388", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d07dd57e-1180-4b36-be02-cb4a7f7622af", "node_type": "1", "metadata": {"window": "A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track. ", "original_text": "We think of it as micro markets around where we have locations and facilities.  \n \n"}, "hash": "e38b0fbbf8bb525eacfdc4678fb3a27955bf970dbe1c90fec96a34c1f1ec7e46", "class_name": "RelatedNodeInfo"}}, "text": "I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market. ", "start_char_idx": 2495, "end_char_idx": 2644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d07dd57e-1180-4b36-be02-cb4a7f7622af": {"__data__": {"id_": "d07dd57e-1180-4b36-be02-cb4a7f7622af", "embedding": null, "metadata": {"window": "A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track. ", "original_text": "We think of it as micro markets around where we have locations and facilities.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6834afbd-6810-4714-8739-94dd7916cddb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday. ", "original_text": "I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d25b617c332c89aa26c1125968591f7f10776e087eed15444e1f120017e4f911", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2d06df2-b4b2-4e4b-873a-01ff3c62ae1e", "node_type": "1", "metadata": {"window": "I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track.  I mean, I think, McKesson is a great place to work. ", "original_text": "We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business. "}, "hash": "4898473f8ad55db85159eeeaf749413595e2877da0c0a199d3f1454372850dbf", "class_name": "RelatedNodeInfo"}}, "text": "We think of it as micro markets around where we have locations and facilities.  \n \n", "start_char_idx": 2644, "end_char_idx": 2727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2d06df2-b4b2-4e4b-873a-01ff3c62ae1e": {"__data__": {"id_": "b2d06df2-b4b2-4e4b-873a-01ff3c62ae1e", "embedding": null, "metadata": {"window": "I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track.  I mean, I think, McKesson is a great place to work. ", "original_text": "We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d07dd57e-1180-4b36-be02-cb4a7f7622af", "node_type": "1", "metadata": {"window": "A \nThanks for the question.  I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track. ", "original_text": "We think of it as micro markets around where we have locations and facilities.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2ec39bcad77cb60cbdee2ecf383de703f14d233ee9d83e495f64b53d83a07e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b110948-ea1f-4996-aacf-18f1ec13611f", "node_type": "1", "metadata": {"window": "I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track.  I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it. ", "original_text": "And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday. "}, "hash": "a3cc4fff22bbf8db9e8f7925c5ed9ada3df002503ed5f97968d32d167408ed24", "class_name": "RelatedNodeInfo"}}, "text": "We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business. ", "start_char_idx": 2727, "end_char_idx": 2832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b110948-ea1f-4996-aacf-18f1ec13611f": {"__data__": {"id_": "0b110948-ea1f-4996-aacf-18f1ec13611f", "embedding": null, "metadata": {"window": "I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track.  I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it. ", "original_text": "And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2d06df2-b4b2-4e4b-873a-01ff3c62ae1e", "node_type": "1", "metadata": {"window": "I'll kick it off, and Britt can add whatever additional comments he'd like.  I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track.  I mean, I think, McKesson is a great place to work. ", "original_text": "We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b95a33e8e4683ca363cd1a04ab151d23e817acb9b25f789776c92d0b82e369f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8c360aa-a2c6-40f7-9ff3-d319c6fadfa9", "node_type": "1", "metadata": {"window": "We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track.  I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n", "original_text": "That's something we'll continue to track. "}, "hash": "bc082d40bf937aec4d8864a0026e7ab3feebe1e184f8f15eb7d65ea95b9bb1b2", "class_name": "RelatedNodeInfo"}}, "text": "And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday. ", "start_char_idx": 2832, "end_char_idx": 3071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8c360aa-a2c6-40f7-9ff3-d319c6fadfa9": {"__data__": {"id_": "f8c360aa-a2c6-40f7-9ff3-d319c6fadfa9", "embedding": null, "metadata": {"window": "We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track.  I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n", "original_text": "That's something we'll continue to track. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b110948-ea1f-4996-aacf-18f1ec13611f", "node_type": "1", "metadata": {"window": "I mean, starting \non the labor cost front, it's obviously been a pretty dynamic labor market, and we don't actually think of it as a \nsingle market.  We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track.  I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it. ", "original_text": "And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "663e4c1a162310d1d67d2620760c8846f20a13768161a72c8c637552151e4394", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7224e92e-cfaa-47a7-aeb5-57fe4df862dc", "node_type": "1", "metadata": {"window": "We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track.  I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient. ", "original_text": "I mean, I think, McKesson is a great place to work. "}, "hash": "57da1818374c48d6ebcdef8d96bff41f18f8110e3eabd0cc68448cd44ada4e80", "class_name": "RelatedNodeInfo"}}, "text": "That's something we'll continue to track. ", "start_char_idx": 3071, "end_char_idx": 3113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7224e92e-cfaa-47a7-aeb5-57fe4df862dc": {"__data__": {"id_": "7224e92e-cfaa-47a7-aeb5-57fe4df862dc", "embedding": null, "metadata": {"window": "We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track.  I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient. ", "original_text": "I mean, I think, McKesson is a great place to work. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8c360aa-a2c6-40f7-9ff3-d319c6fadfa9", "node_type": "1", "metadata": {"window": "We think of it as micro markets around where we have locations and facilities.  \n \n We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track.  I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n", "original_text": "That's something we'll continue to track. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "749d680883a2d05cbbcfce7015560ba06dadff1e8e43581945bd22862d489835", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07d7b056-f88c-4eff-9dc2-a88a8f15c43e", "node_type": "1", "metadata": {"window": "And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track.  I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023. ", "original_text": "We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it. "}, "hash": "2ab0ab11aac877026aec1c224d406bf520019ddbaf18117782feed35c6be1c50", "class_name": "RelatedNodeInfo"}}, "text": "I mean, I think, McKesson is a great place to work. ", "start_char_idx": 3113, "end_char_idx": 3165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07d7b056-f88c-4eff-9dc2-a88a8f15c43e": {"__data__": {"id_": "07d7b056-f88c-4eff-9dc2-a88a8f15c43e", "embedding": null, "metadata": {"window": "And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track.  I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023. ", "original_text": "We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7224e92e-cfaa-47a7-aeb5-57fe4df862dc", "node_type": "1", "metadata": {"window": "We did make investments largely into our frontline teams in our Medical and our Pharmaceutical business.  And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track.  I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient. ", "original_text": "I mean, I think, McKesson is a great place to work. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7e09d3a422fde73183754a401dcda16e1c99ff8ec77211a7193f32a4a7865d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2eae8e68-ec14-455f-8b49-61d12ee25fec", "node_type": "1", "metadata": {"window": "That's something we'll continue to track.  I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source. ", "original_text": "So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n"}, "hash": "0dbe21101e22450626709be1a41bf6afb2400f6af846633da734b94bb8744ff2", "class_name": "RelatedNodeInfo"}}, "text": "We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it. ", "start_char_idx": 3165, "end_char_idx": 3371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2eae8e68-ec14-455f-8b49-61d12ee25fec": {"__data__": {"id_": "2eae8e68-ec14-455f-8b49-61d12ee25fec", "embedding": null, "metadata": {"window": "That's something we'll continue to track.  I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source. ", "original_text": "So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07d7b056-f88c-4eff-9dc2-a88a8f15c43e", "node_type": "1", "metadata": {"window": "And \nthe back half of our last fiscal year, we've talked about that, and we have contemplated some labor investments in \nour FY 2023 outlook, based on the status of the market today and the behaviors and the indicators that we see \ntoday.  That's something we'll continue to track.  I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023. ", "original_text": "We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1bd834c904c8044959c5b2927ce39e33b93532769171313c4d160ab0e6a11bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3543f29-c17a-4b62-a101-aafe368caa06", "node_type": "1", "metadata": {"window": "I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply. ", "original_text": "On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient. "}, "hash": "ff2f0132799fd8f44424db1a0005bd68d871db8ae52ec7a941e33a3c0724c3dd", "class_name": "RelatedNodeInfo"}}, "text": "So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n", "start_char_idx": 3371, "end_char_idx": 3597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3543f29-c17a-4b62-a101-aafe368caa06": {"__data__": {"id_": "a3543f29-c17a-4b62-a101-aafe368caa06", "embedding": null, "metadata": {"window": "I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply. ", "original_text": "On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2eae8e68-ec14-455f-8b49-61d12ee25fec", "node_type": "1", "metadata": {"window": "That's something we'll continue to track.  I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source. ", "original_text": "So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8affd9fb3eed34df9f41764dd363030752214fdbebb3d6a7cfb572d2873727c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da164256-8dd8-465c-b3b9-2cbd7e2c3a3d", "node_type": "1", "metadata": {"window": "We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n ", "original_text": "We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023. "}, "hash": "43df91f9b85f924c1267b05cb3b6ef09c885e8ca553d49f0168b0fe90c01b29e", "class_name": "RelatedNodeInfo"}}, "text": "On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient. ", "start_char_idx": 3597, "end_char_idx": 3825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da164256-8dd8-465c-b3b9-2cbd7e2c3a3d": {"__data__": {"id_": "da164256-8dd8-465c-b3b9-2cbd7e2c3a3d", "embedding": null, "metadata": {"window": "We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n ", "original_text": "We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3543f29-c17a-4b62-a101-aafe368caa06", "node_type": "1", "metadata": {"window": "I mean, I think, McKesson is a great place to work.  We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply. ", "original_text": "On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49e6d12a5dc4fbe6611334784743aebef2b64a93cec0750ea32ad499eb3ce76d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89e50121-c273-47cb-93bb-681b2a138108", "node_type": "1", "metadata": {"window": "So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.  ", "original_text": "Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source. "}, "hash": "23443c96fb069d683a8000b572d21ce7e06cc8360356da177e604f546189074c", "class_name": "RelatedNodeInfo"}}, "text": "We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023. ", "start_char_idx": 3825, "end_char_idx": 3910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89e50121-c273-47cb-93bb-681b2a138108": {"__data__": {"id_": "89e50121-c273-47cb-93bb-681b2a138108", "embedding": null, "metadata": {"window": "So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.  ", "original_text": "Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da164256-8dd8-465c-b3b9-2cbd7e2c3a3d", "node_type": "1", "metadata": {"window": "We have a \nreally strong employee value proposition that includes competitiv e wages, but benefits and development and \ncareer progression and mean \u2013 and work that has really meaning and purpose behind it.  So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n ", "original_text": "We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae60014ed74782f2e7b9072c60dc1e1f1c9b5bbf6abf975b7af5ba53f27f39bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a73e036-4e5a-41c9-9100-e5e36856ba0f", "node_type": "1", "metadata": {"window": "On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries. ", "original_text": "And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply. "}, "hash": "2506151ea6572894851f015ff123026da857b0f874642ab3d7b0b13d9742cd4a", "class_name": "RelatedNodeInfo"}}, "text": "Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source. ", "start_char_idx": 3910, "end_char_idx": 4029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a73e036-4e5a-41c9-9100-e5e36856ba0f": {"__data__": {"id_": "5a73e036-4e5a-41c9-9100-e5e36856ba0f", "embedding": null, "metadata": {"window": "On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries. ", "original_text": "And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89e50121-c273-47cb-93bb-681b2a138108", "node_type": "1", "metadata": {"window": "So I think we feel good \nabout where we stand as we enter the year, but it's certainly the last several months have been, labor m arkets \nlike most of us have not seen, so we'll continue to monitor and track that closely.  \n \n On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.  ", "original_text": "Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84f38160cdc362d03572ca870e0383fdfc5821d4c840670c5cfa27a65ce2cd49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98c27877-ecec-46c6-8631-233e42d1eed9", "node_type": "1", "metadata": {"window": "We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries.  And one of the things that we're really proud ", "original_text": "And thus \nfar, we've been able to maintain very good inventory positions.  \n "}, "hash": "0441f4f9979fd36c05c229cb6fc6ff934d06c8ad50076aee643b8c0444a41008", "class_name": "RelatedNodeInfo"}}, "text": "And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply. ", "start_char_idx": 4029, "end_char_idx": 4151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98c27877-ecec-46c6-8631-233e42d1eed9": {"__data__": {"id_": "98c27877-ecec-46c6-8631-233e42d1eed9", "embedding": null, "metadata": {"window": "We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries.  And one of the things that we're really proud ", "original_text": "And thus \nfar, we've been able to maintain very good inventory positions.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a73e036-4e5a-41c9-9100-e5e36856ba0f", "node_type": "1", "metadata": {"window": "On the supply chain front, I think our supply chains have been remarkably resilient in Medical and Pharmaceutical \nover the many, many twists and turns of the last t wo years, and I would say that they continue to be resilient.  We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries. ", "original_text": "And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8f769d17f34a4865d0ef78708dad8672428dcd4a31e8858578e826e2d3b40af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f408f4e1-80b0-4a28-885b-98a53a5d2d62", "node_type": "1", "metadata": {"window": "Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries.  And one of the things that we're really proud ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.  "}, "hash": "c5b922a3ffe90abc1a916f646b30d18d3c544a4268930d748201a82bfb7740cc", "class_name": "RelatedNodeInfo"}}, "text": "And thus \nfar, we've been able to maintain very good inventory positions.  \n ", "start_char_idx": 4151, "end_char_idx": 4228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f408f4e1-80b0-4a28-885b-98a53a5d2d62": {"__data__": {"id_": "f408f4e1-80b0-4a28-885b-98a53a5d2d62", "embedding": null, "metadata": {"window": "Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries.  And one of the things that we're really proud ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98c27877-ecec-46c6-8631-233e42d1eed9", "node_type": "1", "metadata": {"window": "We \nwould anticipate very modest levels of disruption and cost inflation in FY 2023.  Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries.  And one of the things that we're really proud ", "original_text": "And thus \nfar, we've been able to maintain very good inventory positions.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba2c6e976db7d63866ec9b7b8ee607965919b7fb54863638067e7b5e39780dcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63af9404-a88a-4fa3-8f19-af8c444ce061", "node_type": "1", "metadata": {"window": "And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries.  And one of the things that we're really proud ", "original_text": "A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries. "}, "hash": "e0e4a59c797dd0cf84d36122e2600d2655eee8915dfa75c3fda6058675eac9ba", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.  ", "start_char_idx": 4228, "end_char_idx": 4586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63af9404-a88a-4fa3-8f19-af8c444ce061": {"__data__": {"id_": "63af9404-a88a-4fa3-8f19-af8c444ce061", "embedding": null, "metadata": {"window": "And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries.  And one of the things that we're really proud ", "original_text": "A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f408f4e1-80b0-4a28-885b-98a53a5d2d62", "node_type": "1", "metadata": {"window": "Our private brand program, as you \nmight recall, we don't own physical plant and equipment and manufacture, we source.  And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries.  And one of the things that we're really proud ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36f14c47d93854194e9cbcfe401cd01a26a479f0e194c957e3ce9a3410e07c5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24bc2aca-5e06-4a12-8d36-3b18ba3bee70", "node_type": "1", "metadata": {"window": "And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries.  And one of the things that we're really proud ", "original_text": "And one of the things that we're really proud "}, "hash": "7f5d4734440da9d7585a3dc57a778fd1b9cf65a2bc0751b604a804daffbac745", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries. ", "start_char_idx": 4586, "end_char_idx": 4765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24bc2aca-5e06-4a12-8d36-3b18ba3bee70": {"__data__": {"id_": "24bc2aca-5e06-4a12-8d36-3b18ba3bee70", "embedding": null, "metadata": {"window": "And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries.  And one of the things that we're really proud ", "original_text": "And one of the things that we're really proud ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fbbb9e1fc1f3bfac240a60f20122a742ac4dbdafbb0c9f83ff935e93a9f5547", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63af9404-a88a-4fa3-8f19-af8c444ce061", "node_type": "1", "metadata": {"window": "And so our teams have \nbeen very aggressively thinking about expanding and broadening and rotating our sources of supply.  And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries.  And one of the things that we're really proud ", "original_text": "A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries. ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1959ac42ebf7ca4806181715aa6740547da2f3af8998b36c9bdad02bc797d9d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a54f700a-921b-44bd-993c-a235238820cc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing.  And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n ", "original_text": "McKesson Corp.  "}, "hash": "3889774149a525e42bc880ff2960f10dbcf43607bbbae5936c9c49873ec73a33", "class_name": "RelatedNodeInfo"}}, "text": "And one of the things that we're really proud ", "start_char_idx": 4765, "end_char_idx": 4811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a54f700a-921b-44bd-993c-a235238820cc": {"__data__": {"id_": "a54f700a-921b-44bd-993c-a235238820cc", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing.  And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24bc2aca-5e06-4a12-8d36-3b18ba3bee70", "node_type": "1", "metadata": {"window": "And thus \nfar, we've been able to maintain very good inventory positions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive V ice President, McKesson Corp.   A \nAnd maybe just, Lisa, I'd just add on, we have a very comprehensive sourcing strategy and we source our \nproducts really in a very diverse way across many different countries.  And one of the things that we're really proud ", "original_text": "And one of the things that we're really proud ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4d557a0f41cb73d2d72c80f03b584d86c22da8ae5423a80fd3aa1b534e2ac41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0de4c3ac-8914-4709-b901-f4678d4ff008", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing.  And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing. "}, "hash": "7d833041032d56a9963319911a0188e769515f3118cd53b918d5aed6c321dec1", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0de4c3ac-8914-4709-b901-f4678d4ff008": {"__data__": {"id_": "0de4c3ac-8914-4709-b901-f4678d4ff008", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing.  And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a54f700a-921b-44bd-993c-a235238820cc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing.  And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "613e5b97ee50744d7c785bea19a3ee4df2f2830347776bc7bf7ddd5bdf8e4d88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d93bafa4-9887-4f60-98a4-16021ecea556", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing.  And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n ", "original_text": "And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve. "}, "hash": "1789c7f603640d9b4e4cd14030b1775ce7625df7255b712600e50f2e05c7ea68", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing. ", "start_char_idx": 16, "end_char_idx": 259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d93bafa4-9887-4f60-98a4-16021ecea556": {"__data__": {"id_": "d93bafa4-9887-4f60-98a4-16021ecea556", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing.  And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n ", "original_text": "And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0de4c3ac-8914-4709-b901-f4678d4ff008", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing.  And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e20ac61d7dd1c09c4ec3a23b3a188c6f0d6e213387459cb7781222e177b791a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37d2f94c-1e26-45c7-b320-38e883cf9724", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing.  And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n "}, "hash": "b3846acad7150bec066ad7241467a4a789726ef007dc0732dacfa93daa069203", "class_name": "RelatedNodeInfo"}}, "text": "And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve. ", "start_char_idx": 259, "end_char_idx": 384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37d2f94c-1e26-45c7-b320-38e883cf9724": {"__data__": {"id_": "37d2f94c-1e26-45c7-b320-38e883cf9724", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing.  And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d93bafa4-9887-4f60-98a4-16021ecea556", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing.  And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n ", "original_text": "And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61de1dba16d30bbb05a2da20a681e3b6c69fa7f7af85ddd85e41d61636f0812b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18699c98-04ba-4eda-b757-2422a721ce30", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing.  And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n "}, "hash": "7d516de50ec5e3a5a8165e46e5c396d5db96004af868fc700b363d7a4932dcff", "class_name": "RelatedNodeInfo"}}, "text": "So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n ", "start_char_idx": 384, "end_char_idx": 489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18699c98-04ba-4eda-b757-2422a721ce30": {"__data__": {"id_": "18699c98-04ba-4eda-b757-2422a721ce30", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing.  And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37d2f94c-1e26-45c7-b320-38e883cf9724", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing.  And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a273869c613e499c7611444f45793eba5b69a965599a9dd0e301977db3adf844", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "201f319f-d1c5-4ad3-b8a8-fdc8bb6c6eab", "node_type": "1", "metadata": {"window": "And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n "}, "hash": "7c386143d466a2c780298928d07b9a2c44b45bc401f6e470183e5f29f94730e8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "start_char_idx": 489, "end_char_idx": 852, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "201f319f-d1c5-4ad3-b8a8-fdc8bb6c6eab": {"__data__": {"id_": "201f319f-d1c5-4ad3-b8a8-fdc8bb6c6eab", "embedding": null, "metadata": {"window": "And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18699c98-04ba-4eda-b757-2422a721ce30", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing.  And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "184312a710cde0665cdad3330f4f804ebff813640eeda6f9bd435d91a78b88b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69dd2a4b-ce9a-4ca7-ac06-3163f83e3db5", "node_type": "1", "metadata": {"window": "So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  "}, "hash": "7dff4694134395187828f2bee7a9b7d084e94924299e3b3ac86568e2fcf6ba5d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n ", "start_char_idx": 852, "end_char_idx": 1206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69dd2a4b-ce9a-4ca7-ac06-3163f83e3db5": {"__data__": {"id_": "69dd2a4b-ce9a-4ca7-ac06-3163f83e3db5", "embedding": null, "metadata": {"window": "So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "201f319f-d1c5-4ad3-b8a8-fdc8bb6c6eab", "node_type": "1", "metadata": {"window": "And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b089d259bced6e5381ecfe9d3b8f51b8618c9dbfee17d7b6ca3bbcbacf6f290", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1fc67a6-829f-438c-a194-eb93875f5329", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year? ", "original_text": "Q \nThanks. "}, "hash": "a5b4cfe543167bc169704e799eacffbeffcda9b64c98d8d88fce259144d706c6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "start_char_idx": 1206, "end_char_idx": 1533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1fc67a6-829f-438c-a194-eb93875f5329": {"__data__": {"id_": "a1fc67a6-829f-438c-a194-eb93875f5329", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year? ", "original_text": "Q \nThanks. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69dd2a4b-ce9a-4ca7-ac06-3163f83e3db5", "node_type": "1", "metadata": {"window": "So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2340e9761e08346b9336e268cad294d7cb13afdf595349d9227a22b78dd41fea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0fe2c25-8ae1-4a0e-a011-fbbcfce44db0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024? ", "original_text": "Good afternoon, everybody. "}, "hash": "bc5a22424689c7922600b0c0a3ddb1a5e8ca262d2d434239ea3e6e4f111063c6", "class_name": "RelatedNodeInfo"}}, "text": "Q \nThanks. ", "start_char_idx": 1533, "end_char_idx": 1544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0fe2c25-8ae1-4a0e-a011-fbbcfce44db0": {"__data__": {"id_": "c0fe2c25-8ae1-4a0e-a011-fbbcfce44db0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024? ", "original_text": "Good afternoon, everybody. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1fc67a6-829f-438c-a194-eb93875f5329", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year? ", "original_text": "Q \nThanks. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54729fe848e15d4c77cb1d738522c102c44f29ef527c578a52937235c1fe6268", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a931cce7-ea72-4ddf-beeb-1eb77e40d1f4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n ", "original_text": "So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n"}, "hash": "983b7aeaa5f7bca6f3a28667680eb8773d95ed7432a5c528356344e14938c0cd", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, everybody. ", "start_char_idx": 1544, "end_char_idx": 1571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a931cce7-ea72-4ddf-beeb-1eb77e40d1f4": {"__data__": {"id_": "a931cce7-ea72-4ddf-beeb-1eb77e40d1f4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n ", "original_text": "So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0fe2c25-8ae1-4a0e-a011-fbbcfce44db0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024? ", "original_text": "Good afternoon, everybody. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e966efdd4b4b90d5ec22aaf38e4fb10b08671f5c05ba68647ecd67db51dc13ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da798918-1e9b-415f-b39a-74711201ecfb", "node_type": "1", "metadata": {"window": "Q \nThanks.  Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year? "}, "hash": "39c9caedc11ce5cd4dac548641d4437b708826787338c3f04582a2a187f30947", "class_name": "RelatedNodeInfo"}}, "text": "So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n", "start_char_idx": 1571, "end_char_idx": 1761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da798918-1e9b-415f-b39a-74711201ecfb": {"__data__": {"id_": "da798918-1e9b-415f-b39a-74711201ecfb", "embedding": null, "metadata": {"window": "Q \nThanks.  Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year? ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a931cce7-ea72-4ddf-beeb-1eb77e40d1f4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n ", "original_text": "So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ab110ed8ac8b77f8aeb1a857772a036bf2ce7b398e90f87281aa04392967efd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17a064d9-a3eb-4b62-9c87-31c91792313e", "node_type": "1", "metadata": {"window": "Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis. ", "original_text": "And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024? "}, "hash": "327e54d299d46f2a5cd25003328fb5e7f1c83a844dbef304b793cbcab3c62e9e", "class_name": "RelatedNodeInfo"}}, "text": "I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year? ", "start_char_idx": 1761, "end_char_idx": 1958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17a064d9-a3eb-4b62-9c87-31c91792313e": {"__data__": {"id_": "17a064d9-a3eb-4b62-9c87-31c91792313e", "embedding": null, "metadata": {"window": "Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis. ", "original_text": "And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024? ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da798918-1e9b-415f-b39a-74711201ecfb", "node_type": "1", "metadata": {"window": "Q \nThanks.  Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year? ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3aac9dff776c4a1a4f1cd765d0d9553e9dbfa9e448a52821104e712f2eb4f74c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63396179-965c-4729-b5f7-0a1c2d3aadd3", "node_type": "1", "metadata": {"window": "So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n", "original_text": "Thanks.  \n "}, "hash": "ae30557756369e2285e6e23456df09ada05806b043fd3b896f7dbc291c023d18", "class_name": "RelatedNodeInfo"}}, "text": "And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024? ", "start_char_idx": 1958, "end_char_idx": 2112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63396179-965c-4729-b5f7-0a1c2d3aadd3": {"__data__": {"id_": "63396179-965c-4729-b5f7-0a1c2d3aadd3", "embedding": null, "metadata": {"window": "So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n", "original_text": "Thanks.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17a064d9-a3eb-4b62-9c87-31c91792313e", "node_type": "1", "metadata": {"window": "Good afternoon, everybody.  So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis. ", "original_text": "And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024? ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67a889b3098f023363c5c6c71ce7e898aa5a1730c1a1cee2990b5c7cd12a4310", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9c55eb4-649c-4978-aef7-124344603377", "node_type": "1", "metadata": {"window": "I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "f824cd6febb3244fbbe886fa9c5583b7bf9ed6b9c09885864e02482f41a419d7", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2112, "end_char_idx": 2123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9c55eb4-649c-4978-aef7-124344603377": {"__data__": {"id_": "a9c55eb4-649c-4978-aef7-124344603377", "embedding": null, "metadata": {"window": "I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63396179-965c-4729-b5f7-0a1c2d3aadd3", "node_type": "1", "metadata": {"window": "So relative to our own EPS bridge we had built previously from FY 2022 to \n2023, biggest source of upside from our view is the $0.85 to $1.15 EPS you still expect from the European assets. \n I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n", "original_text": "Thanks.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f592b56fd25180db0abbd4644ffe689e9ee0205ed9d4daa9fa5fc6f619828383", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b770261b-fe18-4f16-9111-b48a879a9b34", "node_type": "1", "metadata": {"window": "And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that. ", "original_text": "A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis. "}, "hash": "d6349a06c6381803cee753eb9cbc568a977623c2af451d9a07557c2fc3b9da62", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 2123, "end_char_idx": 2480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b770261b-fe18-4f16-9111-b48a879a9b34": {"__data__": {"id_": "b770261b-fe18-4f16-9111-b48a879a9b34", "embedding": null, "metadata": {"window": "And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that. ", "original_text": "A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9c55eb4-649c-4978-aef7-124344603377", "node_type": "1", "metadata": {"window": "I guess in that piece, I was curious, too, is there any color on whether or not that will be heavily front -end loaded \nin the first quarter or two or maybe more evenly spread throughout the year?  And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e8d8a7e8f3bb8a5525964ecbcc1d0891a50377cfe37fd7f6156edbe2586dee6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee86b109-629d-4dca-898b-91b2392bbfdd", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this. ", "original_text": "Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n"}, "hash": "5b4f733d33eacc4fb9f633d6368612aa8673fc4681618d6b69c193502caf1d2c", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis. ", "start_char_idx": 2480, "end_char_idx": 2581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee86b109-629d-4dca-898b-91b2392bbfdd": {"__data__": {"id_": "ee86b109-629d-4dca-898b-91b2392bbfdd", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this. ", "original_text": "Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b770261b-fe18-4f16-9111-b48a879a9b34", "node_type": "1", "metadata": {"window": "And then at the risk of maybe \nlooking too far ahead, should we assume that al l of that $0.85 to $1.15 would essentially disappear in your fiscal \n2024?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that. ", "original_text": "A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90eb0bca701fd8b9fe5b25834fc2b853047267d65d13d7771b5ccd1ae260b406", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb07b223-df77-4597-bc12-213fb83ae238", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.  ", "original_text": "So I guess it would be more first three quarters loaded than just half -and-half. \n \n"}, "hash": "11201ae224479cde919f8551746b680ca016035d64811dab1d23f45d80f9dd3e", "class_name": "RelatedNodeInfo"}}, "text": "Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n", "start_char_idx": 2581, "end_char_idx": 2709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb07b223-df77-4597-bc12-213fb83ae238": {"__data__": {"id_": "fb07b223-df77-4597-bc12-213fb83ae238", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.  ", "original_text": "So I guess it would be more first three quarters loaded than just half -and-half. \n \n", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee86b109-629d-4dca-898b-91b2392bbfdd", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this. ", "original_text": "Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97bf6a7b391588a81a56c982bd2f872448c988d26032db3c72763a748af1630d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "472f28ed-b705-4921-869a-46e73a9b7e11", "node_type": "1", "metadata": {"window": "A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that. ", "original_text": "As it relates to 2024, I think it's little early to start talking about that. "}, "hash": "3182a6829938a941bdd3d2c29bc9f0a3f786f5871fbf878874043e5bb62f10d6", "class_name": "RelatedNodeInfo"}}, "text": "So I guess it would be more first three quarters loaded than just half -and-half. \n \n", "start_char_idx": 2709, "end_char_idx": 2794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "472f28ed-b705-4921-869a-46e73a9b7e11": {"__data__": {"id_": "472f28ed-b705-4921-869a-46e73a9b7e11", "embedding": null, "metadata": {"window": "A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that. ", "original_text": "As it relates to 2024, I think it's little early to start talking about that. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb07b223-df77-4597-bc12-213fb83ae238", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.  ", "original_text": "So I guess it would be more first three quarters loaded than just half -and-half. \n \n", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f743c261258c2d03d6eeba5e55bbe5d171ba2e60f6bce8d562ae77ead06ffddd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfa325fb-7e91-4140-b482-1d0ec53f28df", "node_type": "1", "metadata": {"window": "Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n ", "original_text": "We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this. "}, "hash": "f6992ec83e8939dcf1b29b4114d92a0fb474650dcc91619cf91590b16f1dcbd2", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to 2024, I think it's little early to start talking about that. ", "start_char_idx": 2794, "end_char_idx": 2872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfa325fb-7e91-4140-b482-1d0ec53f28df": {"__data__": {"id_": "cfa325fb-7e91-4140-b482-1d0ec53f28df", "embedding": null, "metadata": {"window": "Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n ", "original_text": "We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "472f28ed-b705-4921-869a-46e73a9b7e11", "node_type": "1", "metadata": {"window": "A \nYeah, I'd say that the cadence would be very similar to what I gave you on a consolidat ed basis.  Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that. ", "original_text": "As it relates to 2024, I think it's little early to start talking about that. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0378d192c708d23126a8f91270c0dff01b16c6de6b9bc687ee19db6fe7cb4cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d504e7f8-02b8-4626-b29d-4afb39bd0ae1", "node_type": "1", "metadata": {"window": "So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "It's too early to \nreally talk about any transactions along those lines.  "}, "hash": "0c2829b4e1915a366b6f5bc216d63f1b91c28eb90616ca3fdafdf0bed67fec08", "class_name": "RelatedNodeInfo"}}, "text": "We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this. ", "start_char_idx": 2872, "end_char_idx": 3016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d504e7f8-02b8-4626-b29d-4afb39bd0ae1": {"__data__": {"id_": "d504e7f8-02b8-4626-b29d-4afb39bd0ae1", "embedding": null, "metadata": {"window": "So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "It's too early to \nreally talk about any transactions along those lines.  ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfa325fb-7e91-4140-b482-1d0ec53f28df", "node_type": "1", "metadata": {"window": "Now, we do \nexpect that the transaction that we talked about with PHOENIX is going to close in the second half of fiscal 2023. \n So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n ", "original_text": "We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e79fabe345f2588f80de2f07613970ac7e533d6a8643d3d0562d0814e6baddf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "242f1687-34de-4da5-b15f-99db2cb3a74a", "node_type": "1", "metadata": {"window": "As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that. "}, "hash": "1e4c7d30883f7294d61c0e5651c62daaf44cd387c16a0a57b69e42f9328a5962", "class_name": "RelatedNodeInfo"}}, "text": "It's too early to \nreally talk about any transactions along those lines.  ", "start_char_idx": 3016, "end_char_idx": 3090, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "242f1687-34de-4da5-b15f-99db2cb3a74a": {"__data__": {"id_": "242f1687-34de-4da5-b15f-99db2cb3a74a", "embedding": null, "metadata": {"window": "As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d504e7f8-02b8-4626-b29d-4afb39bd0ae1", "node_type": "1", "metadata": {"window": "So I guess it would be more first three quarters loaded than just half -and-half. \n \n As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "It's too early to \nreally talk about any transactions along those lines.  ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c9c306dab3001e6dfa9de4b80e90ef12169e97afa001824900f101bd75deab5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32a8ab6d-b89b-4baf-87e3-6944dce8d0ee", "node_type": "1", "metadata": {"window": "We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "But those continue to be countries that we operate in.  \n "}, "hash": "5c003fe1cd532849848d13fc080fd0452cb22df73ff3145fd65d5c2caab18c31", "class_name": "RelatedNodeInfo"}}, "text": "And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that. ", "start_char_idx": 3090, "end_char_idx": 3194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32a8ab6d-b89b-4baf-87e3-6944dce8d0ee": {"__data__": {"id_": "32a8ab6d-b89b-4baf-87e3-6944dce8d0ee", "embedding": null, "metadata": {"window": "We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "But those continue to be countries that we operate in.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "242f1687-34de-4da5-b15f-99db2cb3a74a", "node_type": "1", "metadata": {"window": "As it relates to 2024, I think it's little early to start talking about that.  We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0fec4f099271c3ca2f32b9259f5863ac007194fc7241ede083b6aeb11a40fb9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7186965-a337-4b46-b23b-43b3f3c2dd9e", "node_type": "1", "metadata": {"window": "It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n "}, "hash": "a3ed3a074fb7f4516b4bf8328566628845707f514def108e83c213e26a129d4a", "class_name": "RelatedNodeInfo"}}, "text": "But those continue to be countries that we operate in.  \n ", "start_char_idx": 3194, "end_char_idx": 3252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7186965-a337-4b46-b23b-43b3f3c2dd9e": {"__data__": {"id_": "d7186965-a337-4b46-b23b-43b3f3c2dd9e", "embedding": null, "metadata": {"window": "It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32a8ab6d-b89b-4baf-87e3-6944dce8d0ee", "node_type": "1", "metadata": {"window": "We've talked to you about the fact that \nNorway and Denmark are still two countries that we're evaluating opportunities for to fully exit this.  It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "But those continue to be countries that we operate in.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ab534bae13143987d655c385006b9e634107198330ca99b5354e602feedc039", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ac4015b-92e1-47c1-9752-35bf898b58df", "node_type": "1", "metadata": {"window": "And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. "}, "hash": "943d99b5f8edc4beb9d013380855500af12706bcbb12e47646711912e02851d5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "start_char_idx": 489, "end_char_idx": 852, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ac4015b-92e1-47c1-9752-35bf898b58df": {"__data__": {"id_": "7ac4015b-92e1-47c1-9752-35bf898b58df", "embedding": null, "metadata": {"window": "And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7186965-a337-4b46-b23b-43b3f3c2dd9e", "node_type": "1", "metadata": {"window": "It's too early to \nreally talk about any transactions along those lines.   And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a121ecc1a67ea7ff466463ec226bdc05e62e472243b984ab5e9017bd8cc1217f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "839144fa-7d39-4f8c-b2bb-d6ba901fd3de", "node_type": "1", "metadata": {"window": "But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good afternoon. ", "original_text": "We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n "}, "hash": "abcefd26651059715803178029fe7a909df4e0725b82f37a1b2ca453ba968121", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "start_char_idx": 3615, "end_char_idx": 3911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "839144fa-7d39-4f8c-b2bb-d6ba901fd3de": {"__data__": {"id_": "839144fa-7d39-4f8c-b2bb-d6ba901fd3de", "embedding": null, "metadata": {"window": "But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good afternoon. ", "original_text": "We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ac4015b-92e1-47c1-9752-35bf898b58df", "node_type": "1", "metadata": {"window": "And we still operate those businesses, and we'll just continue \nto evaluate opportunities to exit that.  But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d5b47e57ad17205891adceb9cf6fd162fe8f9f334bc61414bd5ca47b8d47967", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3dfee405-0a66-4536-809a-5e47a898c23f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good afternoon.  So two clarification questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "3db44b8bc285348bc960e5fb007d23b238d4288d5d5eb6f176c4a93dbfb06e4d", "class_name": "RelatedNodeInfo"}}, "text": "We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n ", "start_char_idx": 3911, "end_char_idx": 3986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3dfee405-0a66-4536-809a-5e47a898c23f": {"__data__": {"id_": "3dfee405-0a66-4536-809a-5e47a898c23f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good afternoon.  So two clarification questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "839144fa-7d39-4f8c-b2bb-d6ba901fd3de", "node_type": "1", "metadata": {"window": "But those continue to be countries that we operate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good afternoon. ", "original_text": "We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11a6389cf6d400bf9fdffae85d1a2dcffb1b1d49b28cf8503ab8ae65627073a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa6ab2c7-308a-471e-9cee-f64a367eda4b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good afternoon.  So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97. ", "original_text": "LLC  Q \nYeah, hi. "}, "hash": "6b6ff038e8d6bbefeb0c40ee0eb150e5e85eff87d9545f3cea759b8a6620c614", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 3986, "end_char_idx": 4310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa6ab2c7-308a-471e-9cee-f64a367eda4b": {"__data__": {"id_": "fa6ab2c7-308a-471e-9cee-f64a367eda4b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good afternoon.  So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97. ", "original_text": "LLC  Q \nYeah, hi. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3dfee405-0a66-4536-809a-5e47a898c23f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good afternoon.  So two clarification questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36462d8f88e9894ba266bed8d3b77f6438ab2cb6a9ae6d2c3b5f5a612e5cd07c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25a10e0a-b117-4a5f-813c-ba98a3dac857", "node_type": "1", "metadata": {"window": "We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good afternoon.  So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n", "original_text": "Good afternoon. "}, "hash": "b72002808ca478feb06a96be0766ca0a152e787e4af4f1bc8f712c4e5f05b8e9", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah, hi. ", "start_char_idx": 4310, "end_char_idx": 4328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25a10e0a-b117-4a5f-813c-ba98a3dac857": {"__data__": {"id_": "25a10e0a-b117-4a5f-813c-ba98a3dac857", "embedding": null, "metadata": {"window": "We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good afternoon.  So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n", "original_text": "Good afternoon. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa6ab2c7-308a-471e-9cee-f64a367eda4b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good afternoon.  So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97. ", "original_text": "LLC  Q \nYeah, hi. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0f34f2b94177f930c011baa28cad28a336940af20522cb7305a3e399a535895", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "962b30cb-7140-4ff7-9c2d-ffac21bb125d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good afternoon.  So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n", "original_text": "So two clarification questions. "}, "hash": "60f81227505c81e81741db1f51030d2be593ffa4c5037254dcf395fa8d60babf", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon. ", "start_char_idx": 4328, "end_char_idx": 4344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "962b30cb-7140-4ff7-9c2d-ffac21bb125d": {"__data__": {"id_": "962b30cb-7140-4ff7-9c2d-ffac21bb125d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good afternoon.  So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n", "original_text": "So two clarification questions. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25a10e0a-b117-4a5f-813c-ba98a3dac857", "node_type": "1", "metadata": {"window": "We'll take our next question from Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good afternoon.  So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n", "original_text": "Good afternoon. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd51067de33b89b7120ac4e3b9f31373ab2b2461f90b8688958e5f1ac04724e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d16ceb96-5b4e-4350-9a07-c3d129bb2f2f", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah, hi.  Good afternoon.  So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%. ", "original_text": "So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97. "}, "hash": "3ba526e0d63bf8902058ffaf8a2ec7cb3fbf494bf582c3283d93bdaa7d5eeab1", "class_name": "RelatedNodeInfo"}}, "text": "So two clarification questions. ", "start_char_idx": 4344, "end_char_idx": 4376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d16ceb96-5b4e-4350-9a07-c3d129bb2f2f": {"__data__": {"id_": "d16ceb96-5b4e-4350-9a07-c3d129bb2f2f", "embedding": null, "metadata": {"window": "LLC  Q \nYeah, hi.  Good afternoon.  So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%. ", "original_text": "So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "962b30cb-7140-4ff7-9c2d-ffac21bb125d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi.  Good afternoon.  So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n", "original_text": "So two clarification questions. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9ad713d6f555d62cca5f6d4786860f34b03d4f06bc3579b9b080b1f83c14953", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29192c13-02a5-45d2-850a-771c343eaf50", "node_type": "1", "metadata": {"window": "Good afternoon.  So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%.  I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%. ", "original_text": "Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n"}, "hash": "7898c60ebf1425b9dfb53cc06d3508b9d05ecd6520dc447a9daa698a017da796", "class_name": "RelatedNodeInfo"}}, "text": "So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97. ", "start_char_idx": 4376, "end_char_idx": 4486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29192c13-02a5-45d2-850a-771c343eaf50": {"__data__": {"id_": "29192c13-02a5-45d2-850a-771c343eaf50", "embedding": null, "metadata": {"window": "Good afternoon.  So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%.  I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%. ", "original_text": "Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d16ceb96-5b4e-4350-9a07-c3d129bb2f2f", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah, hi.  Good afternoon.  So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%. ", "original_text": "So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "145aeb1077e062cb64f6ab7d2f04da992bbc935f39c9ee17ff6cb50bff21cc03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbf1a4a7-1e22-4632-9d0f-89fc4fdeb1a0", "node_type": "1", "metadata": {"window": "So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%.  I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%.  So should we ", "original_text": "But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n"}, "hash": "20575a82376eef1eee9c2df3fb8c4692594eaecce7a02486a8d0cd51cd32b200", "class_name": "RelatedNodeInfo"}}, "text": "Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n", "start_char_idx": 4486, "end_char_idx": 4665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbf1a4a7-1e22-4632-9d0f-89fc4fdeb1a0": {"__data__": {"id_": "fbf1a4a7-1e22-4632-9d0f-89fc4fdeb1a0", "embedding": null, "metadata": {"window": "So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%.  I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%.  So should we ", "original_text": "But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29192c13-02a5-45d2-850a-771c343eaf50", "node_type": "1", "metadata": {"window": "Good afternoon.  So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%.  I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%. ", "original_text": "Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e67b58d5de87d1e96f12c4c968bb29f55cf00750821e890f2f2d75c53094dc50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ce0df08-bc5f-4054-845b-8b447b425a7c", "node_type": "1", "metadata": {"window": "So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%.  I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%.  So should we ", "original_text": "And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%. "}, "hash": "b4876b0fa185b4c49a8615dc2f31c9a28aef9a7c3fff78ef801acb96814f0923", "class_name": "RelatedNodeInfo"}}, "text": "But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n", "start_char_idx": 4665, "end_char_idx": 4775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ce0df08-bc5f-4054-845b-8b447b425a7c": {"__data__": {"id_": "0ce0df08-bc5f-4054-845b-8b447b425a7c", "embedding": null, "metadata": {"window": "So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%.  I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%.  So should we ", "original_text": "And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbf1a4a7-1e22-4632-9d0f-89fc4fdeb1a0", "node_type": "1", "metadata": {"window": "So two clarification questions.  So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%.  I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%.  So should we ", "original_text": "But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d383c2ba6d1987ae4b763c82249f4b670f603ccae678724f95fa8bcab51ec24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cbf70e4-1697-4b20-a74b-48d051489ce4", "node_type": "1", "metadata": {"window": "Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%.  I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%.  So should we ", "original_text": "I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%. "}, "hash": "12cbd3da58bfbc75fc718dc3d546c46a4373b7f8301ef0c2406f551e7a18620b", "class_name": "RelatedNodeInfo"}}, "text": "And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%. ", "start_char_idx": 4775, "end_char_idx": 4992, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cbf70e4-1697-4b20-a74b-48d051489ce4": {"__data__": {"id_": "4cbf70e4-1697-4b20-a74b-48d051489ce4", "embedding": null, "metadata": {"window": "Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%.  I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%.  So should we ", "original_text": "I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ce0df08-bc5f-4054-845b-8b447b425a7c", "node_type": "1", "metadata": {"window": "So one, as we think about the European contrib ution, I \nthink that's page 16 in your slide deck, that $1.97.  Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%.  I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%.  So should we ", "original_text": "And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "660fa28870fb4738f84538c45409c686706e888e3b81250219bbc07321563969", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf44e458-302d-4a77-94ff-3a5b664363a5", "node_type": "1", "metadata": {"window": "But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%.  I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%.  So should we ", "original_text": "So should we "}, "hash": "06bab4e8ec14d949d19713bf39c106b1c51f536da710db57f5f15672220f16dd", "class_name": "RelatedNodeInfo"}}, "text": "I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%. ", "start_char_idx": 4992, "end_char_idx": 5113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf44e458-302d-4a77-94ff-3a5b664363a5": {"__data__": {"id_": "bf44e458-302d-4a77-94ff-3a5b664363a5", "embedding": null, "metadata": {"window": "But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%.  I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%.  So should we ", "original_text": "So should we ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "312d451798747345a49865ffdc32fc8bd5366fb6ecbaa039ce17bd9a7c38ce7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cbf70e4-1697-4b20-a74b-48d051489ce4", "node_type": "1", "metadata": {"window": "Is the take here is really that, that European contribution \nultimately will be replaced by buybacks even for that, I think you have $0.85 to $1.15 in assets that you still own. \n But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%.  I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%.  So should we ", "original_text": "I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%. ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d947afc2ec1df06b12b8f34a3ece8c9599bbffe623cb23b30929ac246870456f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e85a2c6c-ab5e-4571-97d8-6635983986df", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation?  Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "McKesson Corp.  "}, "hash": "f85919b9d8ed095d6268846fc1ea56482c6fbcce0ad67461adb58c8a83d83c90", "class_name": "RelatedNodeInfo"}}, "text": "So should we ", "start_char_idx": 5113, "end_char_idx": 5126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e85a2c6c-ab5e-4571-97d8-6635983986df": {"__data__": {"id_": "e85a2c6c-ab5e-4571-97d8-6635983986df", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation?  Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf44e458-302d-4a77-94ff-3a5b664363a5", "node_type": "1", "metadata": {"window": "But if you divest  them, should think about this as replaceable with capital allocation through buybacks?  \n \n And then similar to that, if we think about the cost inflation that's, sort of, embedded in result, I think in the slides \nyou talk about, if you adjust for COVID costs, then distribution segment would have grown 2%.  I think on the call, \nyou said if you adjust for that, aim for higher rate than inflation, then you would have grown 4%.  So should we ", "original_text": "So should we ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e17d096b20716d3cb13d714d7763c536296fd14d9057fbe127f60319bd8803ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d9523ed-f519-46de-9eff-8026c2f48d65", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation?  Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation? "}, "hash": "ac937564b63ce646ec8a58e70bc5a7757307479376ed872e5b4c40129d3f4a8f", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d9523ed-f519-46de-9eff-8026c2f48d65": {"__data__": {"id_": "9d9523ed-f519-46de-9eff-8026c2f48d65", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation?  Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation? ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e85a2c6c-ab5e-4571-97d8-6635983986df", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation?  Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8de1be44d65a44d4a67014d7c32bc613d2ba124cefee82011fa28fb059ef6455", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cacb6e7-26e4-4350-b96c-097c6e13e8b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation?  Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky.  Let me try to take those in order. ", "original_text": "Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n "}, "hash": "1abf55cbe81467d62092750f0e023a096eccfe86d1a398334098ae40d5cdd004", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation? ", "start_char_idx": 16, "end_char_idx": 239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cacb6e7-26e4-4350-b96c-097c6e13e8b7": {"__data__": {"id_": "5cacb6e7-26e4-4350-b96c-097c6e13e8b7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation?  Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky.  Let me try to take those in order. ", "original_text": "Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d9523ed-f519-46de-9eff-8026c2f48d65", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation?  Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation? ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6fb47ab253b06a4498fad690b395e5127e17c13fe901a87d14e0c03dbbb4d26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36acdd3b-030d-42d8-9bbb-51dac5e38a6e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation?  Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky.  Let me try to take those in order.  Let m e first talk about Europe. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "752d70dc918932c95fb5dfa70d3d949c8a5ca79ce681ff1844e9351b58129415", "class_name": "RelatedNodeInfo"}}, "text": "Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n ", "start_char_idx": 239, "end_char_idx": 351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36acdd3b-030d-42d8-9bbb-51dac5e38a6e": {"__data__": {"id_": "36acdd3b-030d-42d8-9bbb-51dac5e38a6e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation?  Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky.  Let me try to take those in order.  Let m e first talk about Europe. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cacb6e7-26e4-4350-b96c-097c6e13e8b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation?  Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky.  Let me try to take those in order. ", "original_text": "Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8daf820c50fe7f432934eff3190238e06bc4b758ddedb501b18caf0f894a6048", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "945b604f-15b8-42c9-bd44-1ec37fa8ebd6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation?  Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky.  Let me try to take those in order.  Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022. ", "original_text": "A \nThanks for the questions, Ricky. "}, "hash": "60a3e4eb687b6baca2504284579a248fe5c259da12497bcc9c8b6744cb3ef067", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 351, "end_char_idx": 708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "945b604f-15b8-42c9-bd44-1ec37fa8ebd6": {"__data__": {"id_": "945b604f-15b8-42c9-bd44-1ec37fa8ebd6", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation?  Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky.  Let me try to take those in order.  Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022. ", "original_text": "A \nThanks for the questions, Ricky. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36acdd3b-030d-42d8-9bbb-51dac5e38a6e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation?  Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky.  Let me try to take those in order.  Let m e first talk about Europe. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ac6c5605a7129ae509c0f3bfea3a02f8e2d9924a2a8458bd30f27f3bc102f63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb97a69f-7236-4371-99fd-b88f88290933", "node_type": "1", "metadata": {"window": "Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky.  Let me try to take those in order.  Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023. ", "original_text": "Let me try to take those in order. "}, "hash": "7294e6926bddb4adfb1950084cb7ae0e16da6ae8d37471c0957e3eed68c718e1", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for the questions, Ricky. ", "start_char_idx": 708, "end_char_idx": 744, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb97a69f-7236-4371-99fd-b88f88290933": {"__data__": {"id_": "fb97a69f-7236-4371-99fd-b88f88290933", "embedding": null, "metadata": {"window": "Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky.  Let me try to take those in order.  Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023. ", "original_text": "Let me try to take those in order. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "945b604f-15b8-42c9-bd44-1ec37fa8ebd6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation?  Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky.  Let me try to take those in order.  Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022. ", "original_text": "A \nThanks for the questions, Ricky. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "939645adfba9a403dbeac8ecb93ff8c5c20c57b328d61fb3b765a833b09391f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60a31c9d-aed8-4891-9f24-5840e70ab868", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky.  Let me try to take those in order.  Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe. ", "original_text": "Let m e first talk about Europe. "}, "hash": "b632f166799ea6210ce4aaec534ff6307fa38593faece36f3d174902dc487d0c", "class_name": "RelatedNodeInfo"}}, "text": "Let me try to take those in order. ", "start_char_idx": 744, "end_char_idx": 779, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60a31c9d-aed8-4891-9f24-5840e70ab868": {"__data__": {"id_": "60a31c9d-aed8-4891-9f24-5840e70ab868", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky.  Let me try to take those in order.  Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe. ", "original_text": "Let m e first talk about Europe. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb97a69f-7236-4371-99fd-b88f88290933", "node_type": "1", "metadata": {"window": "Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky.  Let me try to take those in order.  Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023. ", "original_text": "Let me try to take those in order. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5b0c2c872471ea73afa7fc0dc11be6ae13d0c527f701bac8b22809399f9f87d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf103914-fe78-4523-95d9-9a1af98b7ae9", "node_type": "1", "metadata": {"window": "A \nThanks for the questions, Ricky.  Let me try to take those in order.  Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks. ", "original_text": "We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022. "}, "hash": "8c6e9d1761c5159552c9fb91a6d09e8227654c6f8c6a87c3f9bb63494bf5ad0c", "class_name": "RelatedNodeInfo"}}, "text": "Let m e first talk about Europe. ", "start_char_idx": 779, "end_char_idx": 812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf103914-fe78-4523-95d9-9a1af98b7ae9": {"__data__": {"id_": "bf103914-fe78-4523-95d9-9a1af98b7ae9", "embedding": null, "metadata": {"window": "A \nThanks for the questions, Ricky.  Let me try to take those in order.  Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks. ", "original_text": "We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60a31c9d-aed8-4891-9f24-5840e70ab868", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the questions, Ricky.  Let me try to take those in order.  Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe. ", "original_text": "Let m e first talk about Europe. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "798f0567066072d95c4dd47a6a6bbe99ad52c9a9fce0b71c0a5f13ec734b8788", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "506f1716-43a8-4e27-ba93-204895bdaafb", "node_type": "1", "metadata": {"window": "Let me try to take those in order.  Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you. ", "original_text": "And then we \ntalked about what we thought the operations would contribute in 2023. "}, "hash": "7eb5bfc0a1c6a4e54e502bd78eb4191d47919ce3149e46dfb79126153e55efa8", "class_name": "RelatedNodeInfo"}}, "text": "We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022. ", "start_char_idx": 812, "end_char_idx": 925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "506f1716-43a8-4e27-ba93-204895bdaafb": {"__data__": {"id_": "506f1716-43a8-4e27-ba93-204895bdaafb", "embedding": null, "metadata": {"window": "Let me try to take those in order.  Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you. ", "original_text": "And then we \ntalked about what we thought the operations would contribute in 2023. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf103914-fe78-4523-95d9-9a1af98b7ae9", "node_type": "1", "metadata": {"window": "A \nThanks for the questions, Ricky.  Let me try to take those in order.  Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks. ", "original_text": "We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b3a45645002701081c7889fb4cdb03b7e94fee4530279f870690d28b006b829", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c0b244d-bf31-4d38-bf07-c27f3fca3b16", "node_type": "1", "metadata": {"window": "Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n", "original_text": "We fully intend to exit Europe. "}, "hash": "c6f3093c60eabe38e54b1a79299a7a92acad7612d66612f8085e7a3cdad5a63c", "class_name": "RelatedNodeInfo"}}, "text": "And then we \ntalked about what we thought the operations would contribute in 2023. ", "start_char_idx": 925, "end_char_idx": 1008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c0b244d-bf31-4d38-bf07-c27f3fca3b16": {"__data__": {"id_": "1c0b244d-bf31-4d38-bf07-c27f3fca3b16", "embedding": null, "metadata": {"window": "Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n", "original_text": "We fully intend to exit Europe. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "506f1716-43a8-4e27-ba93-204895bdaafb", "node_type": "1", "metadata": {"window": "Let me try to take those in order.  Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you. ", "original_text": "And then we \ntalked about what we thought the operations would contribute in 2023. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c405fe5934ef6ff40e6aa9313e57536a7eab087977029baa04c7c6ba8ce71294", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f1947e7-c6f3-41b6-94fb-f92c0e5f710e", "node_type": "1", "metadata": {"window": "We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way. ", "original_text": "And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks. "}, "hash": "6838e7e14feee1ed6c256f75d1e4cb800ef32799b70095f0216d7e2938790fa1", "class_name": "RelatedNodeInfo"}}, "text": "We fully intend to exit Europe. ", "start_char_idx": 1008, "end_char_idx": 1040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f1947e7-c6f3-41b6-94fb-f92c0e5f710e": {"__data__": {"id_": "0f1947e7-c6f3-41b6-94fb-f92c0e5f710e", "embedding": null, "metadata": {"window": "We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way. ", "original_text": "And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c0b244d-bf31-4d38-bf07-c27f3fca3b16", "node_type": "1", "metadata": {"window": "Let m e first talk about Europe.  We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n", "original_text": "We fully intend to exit Europe. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf3ee0868f14ed3de37c11a00d376dd7b132db7caba51f4a23bcfe3803662007", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a82db49-3f22-4afd-9c49-0a33285f6f30", "node_type": "1", "metadata": {"window": "And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year. ", "original_text": "And we've tried to lay that out for you. "}, "hash": "3dddb88dfa426c85f8cf9100576b53e336e75c88ca1ee2e685289ad02d257bff", "class_name": "RelatedNodeInfo"}}, "text": "And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks. ", "start_char_idx": 1040, "end_char_idx": 1206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a82db49-3f22-4afd-9c49-0a33285f6f30": {"__data__": {"id_": "1a82db49-3f22-4afd-9c49-0a33285f6f30", "embedding": null, "metadata": {"window": "And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year. ", "original_text": "And we've tried to lay that out for you. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f1947e7-c6f3-41b6-94fb-f92c0e5f710e", "node_type": "1", "metadata": {"window": "We've tried to \nlay out here for you as transparently as we could what the European contribution was in FY 2022.  And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way. ", "original_text": "And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7d10278a82afdda05c3ee4dc8f3c916cac875084af3e9b1048d221a6f539d95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a44f9de-5804-44ab-badd-3da8644298cf", "node_type": "1", "metadata": {"window": "We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses. ", "original_text": "And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n"}, "hash": "0e3b0ea5e5d46cb000d4d2e74f0361b8848fbe465d6e9877a00e2b66590a7e0d", "class_name": "RelatedNodeInfo"}}, "text": "And we've tried to lay that out for you. ", "start_char_idx": 1206, "end_char_idx": 1247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a44f9de-5804-44ab-badd-3da8644298cf": {"__data__": {"id_": "5a44f9de-5804-44ab-badd-3da8644298cf", "embedding": null, "metadata": {"window": "We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses. ", "original_text": "And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a82db49-3f22-4afd-9c49-0a33285f6f30", "node_type": "1", "metadata": {"window": "And then we \ntalked about what we thought the operations would contribute in 2023.  We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year. ", "original_text": "And we've tried to lay that out for you. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65565b32e50625b2c9e3e685e83f04d4719e7252153511986dc5acfeebc40088", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a72e4003-9da9-4dc0-84e2-c6886fc8a113", "node_type": "1", "metadata": {"window": "And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n", "original_text": "As it relates to the comment on the US Pharmaceutical segment, let me break it up this way. "}, "hash": "988640095a80274be39c5ad4c4abd26b86737ad453117010514ccb2729d3721c", "class_name": "RelatedNodeInfo"}}, "text": "And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n", "start_char_idx": 1247, "end_char_idx": 1402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a72e4003-9da9-4dc0-84e2-c6886fc8a113": {"__data__": {"id_": "a72e4003-9da9-4dc0-84e2-c6886fc8a113", "embedding": null, "metadata": {"window": "And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n", "original_text": "As it relates to the comment on the US Pharmaceutical segment, let me break it up this way. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a44f9de-5804-44ab-badd-3da8644298cf", "node_type": "1", "metadata": {"window": "We fully intend to exit Europe.  And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses. ", "original_text": "And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be6d14c92637ef39dec9bb8bd33e0c56875d3100b2f20c7bd8c53b1a3f6f62b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0074681f-fa05-479e-8ec5-40c0b0c10056", "node_type": "1", "metadata": {"window": "And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment. ", "original_text": "When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year. "}, "hash": "15cb3354cd27a3ffca731d5ec91fb09882ace8c5144f90616cc66be4fb57f5a2", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the comment on the US Pharmaceutical segment, let me break it up this way. ", "start_char_idx": 1402, "end_char_idx": 1494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0074681f-fa05-479e-8ec5-40c0b0c10056": {"__data__": {"id_": "0074681f-fa05-479e-8ec5-40c0b0c10056", "embedding": null, "metadata": {"window": "And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment. ", "original_text": "When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a72e4003-9da9-4dc0-84e2-c6886fc8a113", "node_type": "1", "metadata": {"window": "And  what \nwe've also said is that when we do that, the loss contribution from those earnings, we would replace with capital \ndeployment, principally share buybacks.  And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n", "original_text": "As it relates to the comment on the US Pharmaceutical segment, let me break it up this way. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c087efdbd973d5fcd0677282088ee09318485d2bb99386ff9931c68b93bcb14f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fe9369c-72b5-407f-b0a6-57f95da164f3", "node_type": "1", "metadata": {"window": "And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment.  It's nothing different than we've talked about before. ", "original_text": "We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses. "}, "hash": "76aea0df623fed56b806819f38a051b9a40fc444e404773dc1076bc6df1185b5", "class_name": "RelatedNodeInfo"}}, "text": "When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year. ", "start_char_idx": 1494, "end_char_idx": 1669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fe9369c-72b5-407f-b0a6-57f95da164f3": {"__data__": {"id_": "0fe9369c-72b5-407f-b0a6-57f95da164f3", "embedding": null, "metadata": {"window": "And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment.  It's nothing different than we've talked about before. ", "original_text": "We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0074681f-fa05-479e-8ec5-40c0b0c10056", "node_type": "1", "metadata": {"window": "And we've tried to lay that out for you.  And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment. ", "original_text": "When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffc7830943cd0bd17e271e1dd55d6a2dc7151b2d1567a22c784ca72eaf91a67e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4b7d87f-91a0-42e7-9496-4865238657b7", "node_type": "1", "metadata": {"window": "As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment.  It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year. ", "original_text": "That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n"}, "hash": "bf038a5de47c317ab1deca17467cb95bd5d78ece6ea65c45d2ebb85918fc1d24", "class_name": "RelatedNodeInfo"}}, "text": "We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses. ", "start_char_idx": 1669, "end_char_idx": 1862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4b7d87f-91a0-42e7-9496-4865238657b7": {"__data__": {"id_": "e4b7d87f-91a0-42e7-9496-4865238657b7", "embedding": null, "metadata": {"window": "As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment.  It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year. ", "original_text": "That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fe9369c-72b5-407f-b0a6-57f95da164f3", "node_type": "1", "metadata": {"window": "And so, yes, the way we've laid it \nout for you is that you should think about Europe eventually going away and being replaced by capital \ndeployment.  \n \n As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment.  It's nothing different than we've talked about before. ", "original_text": "We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7808c8e84abdc0de03a21abe03b139684b8508e85859ee7605c5d06df06e75d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be166c42-3234-4cf6-b6ee-286c291b087e", "node_type": "1", "metadata": {"window": "When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment.  It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter. ", "original_text": "And so, I wanted just to make that comment. "}, "hash": "78fc4f6b6a209886cd8d75ecff1baa502088c0463a15d1fa8f185f035538b5f8", "class_name": "RelatedNodeInfo"}}, "text": "That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n", "start_char_idx": 1862, "end_char_idx": 1982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be166c42-3234-4cf6-b6ee-286c291b087e": {"__data__": {"id_": "be166c42-3234-4cf6-b6ee-286c291b087e", "embedding": null, "metadata": {"window": "When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment.  It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter. ", "original_text": "And so, I wanted just to make that comment. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4b7d87f-91a0-42e7-9496-4865238657b7", "node_type": "1", "metadata": {"window": "As it relates to the comment on the US Pharmaceutical segment, let me break it up this way.  When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment.  It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year. ", "original_text": "That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04d7eeaaca025cf24bbf3322a348df8737ab497fc15a34080672f929eb16a014", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84561c35-46a1-4503-82bf-14cb73b0102b", "node_type": "1", "metadata": {"window": "We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment.  It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n ", "original_text": "It's nothing different than we've talked about before. "}, "hash": "0ecb872ed9072e67166bc11a299a8a19f213572cc9b1995a176db25a9cedeb36", "class_name": "RelatedNodeInfo"}}, "text": "And so, I wanted just to make that comment. ", "start_char_idx": 1982, "end_char_idx": 2026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84561c35-46a1-4503-82bf-14cb73b0102b": {"__data__": {"id_": "84561c35-46a1-4503-82bf-14cb73b0102b", "embedding": null, "metadata": {"window": "We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment.  It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n ", "original_text": "It's nothing different than we've talked about before. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be166c42-3234-4cf6-b6ee-286c291b087e", "node_type": "1", "metadata": {"window": "When you think \nabout excluding the COVID -related items, which, again,  we've talked about those pretty transparently since the \nbeginning, we had 2% growth year -over-year.  We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment.  It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter. ", "original_text": "And so, I wanted just to make that comment. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0f2060d1d4c31dc7c9103d76bca16dfde26144bbc92576cec1b3265ac110ed2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60eac8e5-0265-4be1-9dd2-57f011ba506e", "node_type": "1", "metadata": {"window": "That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment.  It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year. "}, "hash": "24008ac54e6c1af13e4633c8e7da4b4352e1590387efe5a1b8951faac4e30481", "class_name": "RelatedNodeInfo"}}, "text": "It's nothing different than we've talked about before. ", "start_char_idx": 2026, "end_char_idx": 2081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60eac8e5-0265-4be1-9dd2-57f011ba506e": {"__data__": {"id_": "60eac8e5-0265-4be1-9dd2-57f011ba506e", "embedding": null, "metadata": {"window": "That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment.  It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84561c35-46a1-4503-82bf-14cb73b0102b", "node_type": "1", "metadata": {"window": "We did talk about beginning on our second quarter earnings call \nthat we were making additional investments into our US -based businesses to have continuity of service through \nlabor expenses.  That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment.  It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n ", "original_text": "It's nothing different than we've talked about before. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d934e41da729035ef0526483da75350bc5bb4617616f2fb148e44e5428efcda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7337cf8-6e8b-4726-8f66-a01833df8f1f", "node_type": "1", "metadata": {"window": "And so, I wanted just to make that comment.  It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "That, for the US \nPharmaceutical segment, was about 2% in the quarter. "}, "hash": "adf5ed54050c26d9533e5de9f64a7ff5f86ca9ca25e9fcdda34be6080794796b", "class_name": "RelatedNodeInfo"}}, "text": "We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year. ", "start_char_idx": 2081, "end_char_idx": 2197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7337cf8-6e8b-4726-8f66-a01833df8f1f": {"__data__": {"id_": "c7337cf8-6e8b-4726-8f66-a01833df8f1f", "embedding": null, "metadata": {"window": "And so, I wanted just to make that comment.  It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "That, for the US \nPharmaceutical segment, was about 2% in the quarter. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60eac8e5-0265-4be1-9dd2-57f011ba506e", "node_type": "1", "metadata": {"window": "That accounted for about 2% of the year -over-year impact in the US Pharmaceutical business in \nthe fourth quarter.  \n \n And so, I wanted just to make that comment.  It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6cccfdf5b2b59719d883130e0ac2b92b1da8260bb3195043b7614f56bc14af52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71fa6631-a82c-488b-a86e-33c0deab02d3", "node_type": "1", "metadata": {"window": "It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n ", "original_text": "So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n "}, "hash": "95492902c883aa09340f67b0a758eff714ac8909b0cee4b78bff0fe57740c640", "class_name": "RelatedNodeInfo"}}, "text": "That, for the US \nPharmaceutical segment, was about 2% in the quarter. ", "start_char_idx": 2197, "end_char_idx": 2268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71fa6631-a82c-488b-a86e-33c0deab02d3": {"__data__": {"id_": "71fa6631-a82c-488b-a86e-33c0deab02d3", "embedding": null, "metadata": {"window": "It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n ", "original_text": "So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7337cf8-6e8b-4726-8f66-a01833df8f1f", "node_type": "1", "metadata": {"window": "And so, I wanted just to make that comment.  It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "That, for the US \nPharmaceutical segment, was about 2% in the quarter. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "673acf256f8c8f39fda88d9b9676fb7ca62db4ff77837a3d0b6ce81bae2732e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "054d87bd-dde7-4afc-9c84-b99815dbb7d4", "node_type": "1", "metadata": {"window": "We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n "}, "hash": "83b1ef8d7d9ec215706233b8b83ebc83e5604f820c5a1fa020120621866e33e7", "class_name": "RelatedNodeInfo"}}, "text": "So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n ", "start_char_idx": 2268, "end_char_idx": 2379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "054d87bd-dde7-4afc-9c84-b99815dbb7d4": {"__data__": {"id_": "054d87bd-dde7-4afc-9c84-b99815dbb7d4", "embedding": null, "metadata": {"window": "We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71fa6631-a82c-488b-a86e-33c0deab02d3", "node_type": "1", "metadata": {"window": "It's nothing different than we've talked about before.  We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n ", "original_text": "So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e812ebf36de641846c33972e6d254782f13d94190cc2cd424f567186ae44a1ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95d81409-6369-4e10-926d-870d254ac401", "node_type": "1", "metadata": {"window": "That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. "}, "hash": "dc10137da6978d1fe6b79236e448c2d3ed33350ef5790e89ba82e2cbe6a76b27", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "start_char_idx": 2379, "end_char_idx": 2742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95d81409-6369-4e10-926d-870d254ac401": {"__data__": {"id_": "95d81409-6369-4e10-926d-870d254ac401", "embedding": null, "metadata": {"window": "That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "054d87bd-dde7-4afc-9c84-b99815dbb7d4", "node_type": "1", "metadata": {"window": "We talk ed about \nthe contribution that we'll be making and the investment we'd be making about $0.20 for the year.  That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4b15f4519af8fdbfb2db24919bc480160e4fc73373a40e4b610197d3753f5e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8b95a58-87d9-41ad-989d-65a58a38a6ba", "node_type": "1", "metadata": {"window": "So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits? ", "original_text": "We'll take our next question from Kevin Caliendo with UBS.  \n "}, "hash": "748826320858237aba679ca7349a7f41365a8c16ab084184a194617cbd6784ae", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "start_char_idx": 2742, "end_char_idx": 3038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8b95a58-87d9-41ad-989d-65a58a38a6ba": {"__data__": {"id_": "d8b95a58-87d9-41ad-989d-65a58a38a6ba", "embedding": null, "metadata": {"window": "So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits? ", "original_text": "We'll take our next question from Kevin Caliendo with UBS.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95d81409-6369-4e10-926d-870d254ac401", "node_type": "1", "metadata": {"window": "That, for the US \nPharmaceutical segment, was about 2% in the quarter.  So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5062d1a5cc33bb02ace2f910155341e9dad008ff854a0bdc81c6038347ca0553", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fd124fb-f356-4ae4-a7dd-ef423ac7ea1d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question. "}, "hash": "ebd47a05be461e18a5cd00086755b64e4d18bbff2551c3248ba16fe9280cab2f", "class_name": "RelatedNodeInfo"}}, "text": "We'll take our next question from Kevin Caliendo with UBS.  \n ", "start_char_idx": 3038, "end_char_idx": 3100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fd124fb-f356-4ae4-a7dd-ef423ac7ea1d": {"__data__": {"id_": "2fd124fb-f356-4ae4-a7dd-ef423ac7ea1d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8b95a58-87d9-41ad-989d-65a58a38a6ba", "node_type": "1", "metadata": {"window": "So that's why we called that out, just as a sort of a \nconfirmation of what we'v e talked about previously.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits? ", "original_text": "We'll take our next question from Kevin Caliendo with UBS.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9bd7ae36558d3bb450f1a53a7243573e8787be2efdb321f3efdd3c44f8c7484b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bd90271-49bc-4870-ba26-1104ab50a316", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n ", "original_text": "Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID. "}, "hash": "5e22f216e1c0171507f5cb0371ccf43848a66bf23475fa7f8903a7258e2eedea", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question. ", "start_char_idx": 3100, "end_char_idx": 3452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bd90271-49bc-4870-ba26-1104ab50a316": {"__data__": {"id_": "2bd90271-49bc-4870-ba26-1104ab50a316", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n ", "original_text": "Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fd124fb-f356-4ae4-a7dd-ef423ac7ea1d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fa8cac340a76639a878b09986568207e5b1fc1805659189f9f4de78ad8d69e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f495dc9-c785-4596-bece-6735a957bec1", "node_type": "1", "metadata": {"window": "We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.  ", "original_text": "But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits? "}, "hash": "2c45e6b0a833a9d29d757a4e52de36eabdcb678cd937d6e65e24dbcbdc609cc0", "class_name": "RelatedNodeInfo"}}, "text": "Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID. ", "start_char_idx": 3452, "end_char_idx": 3573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f495dc9-c785-4596-bece-6735a957bec1": {"__data__": {"id_": "5f495dc9-c785-4596-bece-6735a957bec1", "embedding": null, "metadata": {"window": "We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.  ", "original_text": "But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits? ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bd90271-49bc-4870-ba26-1104ab50a316", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n ", "original_text": "Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16d73828b0dd83e540e4852d806854480913a749dd7cc92d27513b73e14610d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a32e8735-d1a2-4205-b63a-2336b4d186cb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses. ", "original_text": "You've talked a little bit about what you expect on the \nPharma side. "}, "hash": "3fb94778fde771c41fc6ccfd914f5338c5160efd4d771b0b70abace19ae20b65", "class_name": "RelatedNodeInfo"}}, "text": "But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits? ", "start_char_idx": 3573, "end_char_idx": 3704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a32e8735-d1a2-4205-b63a-2336b4d186cb": {"__data__": {"id_": "a32e8735-d1a2-4205-b63a-2336b4d186cb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses. ", "original_text": "You've talked a little bit about what you expect on the \nPharma side. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f495dc9-c785-4596-bece-6735a957bec1", "node_type": "1", "metadata": {"window": "We'll take our next question from Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.  ", "original_text": "But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits? ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "045a84b116588e6bc3c44b3635be9381bee6ebf5db757a2792bb932a53f493ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e53a603-266a-4965-a30f-cdbe0bb7e9a5", "node_type": "1", "metadata": {"window": "Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business. ", "original_text": "Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n "}, "hash": "274cfcfd98853f2cdefa80e73ad4deb20e1c2ffb3c1b1844dac43d81fb14d7c3", "class_name": "RelatedNodeInfo"}}, "text": "You've talked a little bit about what you expect on the \nPharma side. ", "start_char_idx": 3704, "end_char_idx": 3774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e53a603-266a-4965-a30f-cdbe0bb7e9a5": {"__data__": {"id_": "8e53a603-266a-4965-a30f-cdbe0bb7e9a5", "embedding": null, "metadata": {"window": "Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business. ", "original_text": "Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a32e8735-d1a2-4205-b63a-2336b4d186cb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my question.  Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses. ", "original_text": "You've talked a little bit about what you expect on the \nPharma side. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3cecf23828632754ef21d0a6f2217770180ec98eae6d9005751179df0c40afa5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ab9b04c-02af-4136-9121-54d1e757c8bb", "node_type": "1", "metadata": {"window": "But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.  "}, "hash": "293458bf349330c68f3f473a94f87bca7d422034febc90a1dfb95b590724ccb9", "class_name": "RelatedNodeInfo"}}, "text": "Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n ", "start_char_idx": 3774, "end_char_idx": 3904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ab9b04c-02af-4136-9121-54d1e757c8bb": {"__data__": {"id_": "8ab9b04c-02af-4136-9121-54d1e757c8bb", "embedding": null, "metadata": {"window": "But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e53a603-266a-4965-a30f-cdbe0bb7e9a5", "node_type": "1", "metadata": {"window": "Just a lot of the margin change \u2013 the guidance and the change in margins across \nthe segments can be explained by COVID.  But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business. ", "original_text": "Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9fd261f6235359a2d735510dcc401cc4dad9c16ad68ec6a6705e973c1a5b7173", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10d3df49-871b-4749-bfd1-157c6d3b46ec", "node_type": "1", "metadata": {"window": "You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline. ", "original_text": "A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses. "}, "hash": "b3e439c90405c410064ae7409a466ddc7f85e3e9982543393112b4b7a90f4b25", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.  ", "start_char_idx": 3904, "end_char_idx": 4262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10d3df49-871b-4749-bfd1-157c6d3b46ec": {"__data__": {"id_": "10d3df49-871b-4749-bfd1-157c6d3b46ec", "embedding": null, "metadata": {"window": "You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline. ", "original_text": "A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ab9b04c-02af-4136-9121-54d1e757c8bb", "node_type": "1", "metadata": {"window": "But when I look at, say, PTS and Medical -Surgical, is there anything \nelse we should think about in terms of the mix or benefits?  You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eef72a57fa2c3abebc24651e8abcc34dd98ea76bca0550d27e13e03260eb2dfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7108c21-4c7a-482d-b10b-242dbe2350e3", "node_type": "1", "metadata": {"window": "Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit. ", "original_text": "We're continuing to see good strength in our primary care business in the Medical business. "}, "hash": "25b9768b7317be91e7b4185ebee3da51c70098bfb1336fb3873ff5ef1e3c3a27", "class_name": "RelatedNodeInfo"}}, "text": "A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses. ", "start_char_idx": 4262, "end_char_idx": 4386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7108c21-4c7a-482d-b10b-242dbe2350e3": {"__data__": {"id_": "b7108c21-4c7a-482d-b10b-242dbe2350e3", "embedding": null, "metadata": {"window": "Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit. ", "original_text": "We're continuing to see good strength in our primary care business in the Medical business. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10d3df49-871b-4749-bfd1-157c6d3b46ec", "node_type": "1", "metadata": {"window": "You've talked a little bit about what you expect on the \nPharma side.  Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline. ", "original_text": "A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2656f4d3fe6f1d22d0a51694de014f595db79152ef7258e12efbedda1fbaf920", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3feace80-945d-45eb-a92b-7e1ed84b0696", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit.  So we had strong performance at the margin line as well. ", "original_text": "We \nexpect that will continue into FY 2023. "}, "hash": "5e1e24786538024cfb1b4673ce5cd38b81a8b09b206394e4fe3ff7ee2eabab49", "class_name": "RelatedNodeInfo"}}, "text": "We're continuing to see good strength in our primary care business in the Medical business. ", "start_char_idx": 4386, "end_char_idx": 4478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3feace80-945d-45eb-a92b-7e1ed84b0696": {"__data__": {"id_": "3feace80-945d-45eb-a92b-7e1ed84b0696", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit.  So we had strong performance at the margin line as well. ", "original_text": "We \nexpect that will continue into FY 2023. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7108c21-4c7a-482d-b10b-242dbe2350e3", "node_type": "1", "metadata": {"window": "Is there anything in those two segments outside of COVID that we should be thinking about that \nmight impact margins for 2023?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit. ", "original_text": "We're continuing to see good strength in our primary care business in the Medical business. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3cbc012c198b3e567515c14ef110c6f416899d61d3019dc0e989c3db41c5757", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3eb64c8-f6f0-4e99-a06a-39e6e17858bf", "node_type": "1", "metadata": {"window": "A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit.  So we had strong performance at the margin line as well.  And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023. ", "original_text": "And in our RxTS business, I mean, we had strong growth in the revenue \nline. "}, "hash": "ae39d6bdd4cc7cabd218e513ade7a48f2ef5d2bed619c855cb00d2fea120eade", "class_name": "RelatedNodeInfo"}}, "text": "We \nexpect that will continue into FY 2023. ", "start_char_idx": 4478, "end_char_idx": 4522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3eb64c8-f6f0-4e99-a06a-39e6e17858bf": {"__data__": {"id_": "d3eb64c8-f6f0-4e99-a06a-39e6e17858bf", "embedding": null, "metadata": {"window": "A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit.  So we had strong performance at the margin line as well.  And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023. ", "original_text": "And in our RxTS business, I mean, we had strong growth in the revenue \nline. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3feace80-945d-45eb-a92b-7e1ed84b0696", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execu tive Vice President, McKesson Corp.   A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit.  So we had strong performance at the margin line as well. ", "original_text": "We \nexpect that will continue into FY 2023. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3990b3cf9c36cb6fd9722b029623e3cb2c8d1b34f2aac3f56745f8d33a003ac7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1b38022-70ac-4b79-a5a0-7b3318bbe955", "node_type": "1", "metadata": {"window": "We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit.  So we had strong performance at the margin line as well.  And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023.  So I wouldn't \nguide you to any different mix in 2023 than we've seen in 2022.  ", "original_text": "We had 26% growth in operating profit. "}, "hash": "c23a79200c98f6a8c96eaab9b03008e1bb843adcb6903e11ee89397fe0277c79", "class_name": "RelatedNodeInfo"}}, "text": "And in our RxTS business, I mean, we had strong growth in the revenue \nline. ", "start_char_idx": 4522, "end_char_idx": 4599, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1b38022-70ac-4b79-a5a0-7b3318bbe955": {"__data__": {"id_": "f1b38022-70ac-4b79-a5a0-7b3318bbe955", "embedding": null, "metadata": {"window": "We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit.  So we had strong performance at the margin line as well.  And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023.  So I wouldn't \nguide you to any different mix in 2023 than we've seen in 2022.  ", "original_text": "We had 26% growth in operating profit. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3eb64c8-f6f0-4e99-a06a-39e6e17858bf", "node_type": "1", "metadata": {"window": "A \nAs we think about 2023, wouldn't think that there would be much change in terms of the mix within those two \nbusinesses.  We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit.  So we had strong performance at the margin line as well.  And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023. ", "original_text": "And in our RxTS business, I mean, we had strong growth in the revenue \nline. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea698f08cd22003a76fa1cbb496a736824cf7ecc4d23966b0311dbf9ab6fcee0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a444bb92-ee25-4428-9680-5c0e0ed0aec3", "node_type": "1", "metadata": {"window": "We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit.  So we had strong performance at the margin line as well.  And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023.  So I wouldn't \nguide you to any different mix in 2023 than we've seen in 2022.  ", "original_text": "So we had strong performance at the margin line as well. "}, "hash": "b0889d0720ac513f8c0c6f9042a36405d8269ea11daeab6e6cf13a8257bfde8f", "class_name": "RelatedNodeInfo"}}, "text": "We had 26% growth in operating profit. ", "start_char_idx": 4599, "end_char_idx": 4638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a444bb92-ee25-4428-9680-5c0e0ed0aec3": {"__data__": {"id_": "a444bb92-ee25-4428-9680-5c0e0ed0aec3", "embedding": null, "metadata": {"window": "We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit.  So we had strong performance at the margin line as well.  And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023.  So I wouldn't \nguide you to any different mix in 2023 than we've seen in 2022.  ", "original_text": "So we had strong performance at the margin line as well. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1b38022-70ac-4b79-a5a0-7b3318bbe955", "node_type": "1", "metadata": {"window": "We're continuing to see good strength in our primary care business in the Medical business.  We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit.  So we had strong performance at the margin line as well.  And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023.  So I wouldn't \nguide you to any different mix in 2023 than we've seen in 2022.  ", "original_text": "We had 26% growth in operating profit. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "324ca6b670a3dbbad3eab10cb89604434786506cb39a924768245407144faf77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d68edf8-19ce-4630-b208-b6ed4fb29fa6", "node_type": "1", "metadata": {"window": "And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit.  So we had strong performance at the margin line as well.  And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023.  So I wouldn't \nguide you to any different mix in 2023 than we've seen in 2022.  ", "original_text": "And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023. "}, "hash": "106239395d35492c58aaf2c2fd39c7db095dd410e4333eb6235b8cd8d49d5c6b", "class_name": "RelatedNodeInfo"}}, "text": "So we had strong performance at the margin line as well. ", "start_char_idx": 4638, "end_char_idx": 4695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d68edf8-19ce-4630-b208-b6ed4fb29fa6": {"__data__": {"id_": "8d68edf8-19ce-4630-b208-b6ed4fb29fa6", "embedding": null, "metadata": {"window": "And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit.  So we had strong performance at the margin line as well.  And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023.  So I wouldn't \nguide you to any different mix in 2023 than we've seen in 2022.  ", "original_text": "And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a444bb92-ee25-4428-9680-5c0e0ed0aec3", "node_type": "1", "metadata": {"window": "We \nexpect that will continue into FY 2023.  And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit.  So we had strong performance at the margin line as well.  And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023.  So I wouldn't \nguide you to any different mix in 2023 than we've seen in 2022.  ", "original_text": "So we had strong performance at the margin line as well. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7955706ebe9b2622ed213cd89f712ac2f862b6932a3d992aa25ca68393299b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c9c7f51-f149-4b9a-a4b4-5eecae2d86a5", "node_type": "1", "metadata": {"window": "We had 26% growth in operating profit.  So we had strong performance at the margin line as well.  And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023.  So I wouldn't \nguide you to any different mix in 2023 than we've seen in 2022.  ", "original_text": "So I wouldn't \nguide you to any different mix in 2023 than we've seen in 2022.  "}, "hash": "f4914d62c543dccd3d2a49d8b55a8a22a0a223a01713c1b7fdef6c9e973b708c", "class_name": "RelatedNodeInfo"}}, "text": "And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023. ", "start_char_idx": 4695, "end_char_idx": 4801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c9c7f51-f149-4b9a-a4b4-5eecae2d86a5": {"__data__": {"id_": "0c9c7f51-f149-4b9a-a4b4-5eecae2d86a5", "embedding": null, "metadata": {"window": "We had 26% growth in operating profit.  So we had strong performance at the margin line as well.  And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023.  So I wouldn't \nguide you to any different mix in 2023 than we've seen in 2022.  ", "original_text": "So I wouldn't \nguide you to any different mix in 2023 than we've seen in 2022.  ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6a22510990b2bf7a05bb0a72fa1e81b53312770041ab5f8f75e11e7bfc3917b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d68edf8-19ce-4630-b208-b6ed4fb29fa6", "node_type": "1", "metadata": {"window": "And in our RxTS business, I mean, we had strong growth in the revenue \nline.  We had 26% growth in operating profit.  So we had strong performance at the margin line as well.  And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023.  So I wouldn't \nguide you to any different mix in 2023 than we've seen in 2022.  ", "original_text": "And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023. ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31e55f227b88a22a22322cf179cfd1b3eb4637a9285abd3f9194873e70dcccb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cae699f-5340-4cde-abfa-dd1680187b17", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W. ", "original_text": "McKesson Corp.  "}, "hash": "5b54b303aaacee3a84dc79fee871c15ad8fd871372e151633b74fd31976c3315", "class_name": "RelatedNodeInfo"}}, "text": "So I wouldn't \nguide you to any different mix in 2023 than we've seen in 2022.  ", "start_char_idx": 4801, "end_char_idx": 4881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cae699f-5340-4cde-abfa-dd1680187b17": {"__data__": {"id_": "5cae699f-5340-4cde-abfa-dd1680187b17", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c9c7f51-f149-4b9a-a4b4-5eecae2d86a5", "node_type": "1", "metadata": {"window": "We had 26% growth in operating profit.  So we had strong performance at the margin line as well.  And we \nexpect that our adherence and access pr ograms will continue to have growth as we move into 2023.  So I wouldn't \nguide you to any different mix in 2023 than we've seen in 2022.  ", "original_text": "So I wouldn't \nguide you to any different mix in 2023 than we've seen in 2022.  ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a44d37d51ff0afeee1ef1b344de5c6e4dc6bba8024f6842984bbf24d4f57df9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9d9c5c0-62aa-49cb-866f-210a884ae411", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W.  Baird.  \n ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n "}, "hash": "d3a1abdb5e079b002d2d6940df51f95f4fac1bf7f0a20921b6f4a6931d25bafb", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9d9c5c0-62aa-49cb-866f-210a884ae411": {"__data__": {"id_": "b9d9c5c0-62aa-49cb-866f-210a884ae411", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W.  Baird.  \n ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cae699f-5340-4cde-abfa-dd1680187b17", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b38b3d7b4d0dd4c56da5c764eb30cd8f261fcb0b71a5ec38cef0492d447c5497", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35e6c8e8-ec44-4586-97ea-d991bf68a323", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W.  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. "}, "hash": "dc515e80ced68e92571674b6551377ba9b5fac443b5e38e64fe5276258c03c73", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "start_char_idx": 16, "end_char_idx": 272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35e6c8e8-ec44-4586-97ea-d991bf68a323": {"__data__": {"id_": "35e6c8e8-ec44-4586-97ea-d991bf68a323", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W.  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9d9c5c0-62aa-49cb-866f-210a884ae411", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W.  Baird.  \n ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4d06bea80dbbebc2643ae61e854a6fd597ed2649c21bdd0c4e2c0128b0a018f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f969717-f957-46d8-b31e-a56391951e20", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W.  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi. ", "original_text": "Our next question comes from Eric Coldwell with R.W. "}, "hash": "8723fde577e3d89a69925de86dd725d0ce45fd6c77cd072dd4f722535a613d7b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "start_char_idx": 272, "end_char_idx": 568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f969717-f957-46d8-b31e-a56391951e20": {"__data__": {"id_": "6f969717-f957-46d8-b31e-a56391951e20", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W.  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi. ", "original_text": "Our next question comes from Eric Coldwell with R.W. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35e6c8e8-ec44-4586-97ea-d991bf68a323", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W.  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa253e3912e8a60baf1c1d161a169d788640521b38e0873fb3a0416f6e62439b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f10101e-7e95-40af-9d84-13dee5686100", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W.  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  Thank you. ", "original_text": "Baird.  \n "}, "hash": "21e721fe0436a3071ee2b8da3024037094b494a7528fa0606c752044f87f5cf0", "class_name": "RelatedNodeInfo"}}, "text": "Our next question comes from Eric Coldwell with R.W. ", "start_char_idx": 568, "end_char_idx": 621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f10101e-7e95-40af-9d84-13dee5686100": {"__data__": {"id_": "8f10101e-7e95-40af-9d84-13dee5686100", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W.  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  Thank you. ", "original_text": "Baird.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f969717-f957-46d8-b31e-a56391951e20", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W.  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi. ", "original_text": "Our next question comes from Eric Coldwell with R.W. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2bcd179d0335eec0dc5c184f54b8af84dde11bfdf982d96921778fff3139c389", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52e70f44-d693-41f3-8b02-52be64d412c7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W.  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  Thank you.  Good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  "}, "hash": "c128b43ab440c400ac86ac40649d62490209739831baeb7c31fce772ad0bde72", "class_name": "RelatedNodeInfo"}}, "text": "Baird.  \n ", "start_char_idx": 621, "end_char_idx": 631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52e70f44-d693-41f3-8b02-52be64d412c7": {"__data__": {"id_": "52e70f44-d693-41f3-8b02-52be64d412c7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W.  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  Thank you.  Good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f10101e-7e95-40af-9d84-13dee5686100", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W.  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  Thank you. ", "original_text": "Baird.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba30cb5057bbb48f2a424e06551c80e0a2d5b347dbda7399ad52f31e5dc9231f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc2bff56-7877-4886-83ab-d807fb98f65a", "node_type": "1", "metadata": {"window": "Our next question comes from Eric Coldwell with R.W.  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  Thank you.  Good afternoon.  Fairly simple one, I hope. ", "original_text": "Q \nHi. "}, "hash": "a9bc54d17819b6b12e25648e0a892b4ae268abf98f901ffa1ef2e4a727051c8f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "start_char_idx": 631, "end_char_idx": 963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc2bff56-7877-4886-83ab-d807fb98f65a": {"__data__": {"id_": "bc2bff56-7877-4886-83ab-d807fb98f65a", "embedding": null, "metadata": {"window": "Our next question comes from Eric Coldwell with R.W.  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  Thank you.  Good afternoon.  Fairly simple one, I hope. ", "original_text": "Q \nHi. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52e70f44-d693-41f3-8b02-52be64d412c7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W.  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  Thank you.  Good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54ac8f445901ea5e4855b123ddc47c0c29f1a42ae6d573cdb51617d77c8c5470", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "192e0393-587f-4fe2-b835-9bec16303ae8", "node_type": "1", "metadata": {"window": "Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  Thank you.  Good afternoon.  Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly. ", "original_text": "Thank you. "}, "hash": "6a96af8f35955a7a0b0d2b9a964af9e5fa121658286b6db2ab6b5b19b8d2d71e", "class_name": "RelatedNodeInfo"}}, "text": "Q \nHi. ", "start_char_idx": 963, "end_char_idx": 970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "192e0393-587f-4fe2-b835-9bec16303ae8": {"__data__": {"id_": "192e0393-587f-4fe2-b835-9bec16303ae8", "embedding": null, "metadata": {"window": "Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  Thank you.  Good afternoon.  Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly. ", "original_text": "Thank you. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc2bff56-7877-4886-83ab-d807fb98f65a", "node_type": "1", "metadata": {"window": "Our next question comes from Eric Coldwell with R.W.  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  Thank you.  Good afternoon.  Fairly simple one, I hope. ", "original_text": "Q \nHi. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "811e757c6a72d3fa5302c6c4116d749b91fa05ccefeb315645aa6f91f8a52b1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d92513a-08af-4647-8ba6-b34c5fff5e9c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  Thank you.  Good afternoon.  Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million. ", "original_text": "Good afternoon. "}, "hash": "c2709ed98685a379540b3d8a2e84e0c619e1324205ef6ecb9e2de31bc027d388", "class_name": "RelatedNodeInfo"}}, "text": "Thank you. ", "start_char_idx": 557, "end_char_idx": 568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d92513a-08af-4647-8ba6-b34c5fff5e9c": {"__data__": {"id_": "9d92513a-08af-4647-8ba6-b34c5fff5e9c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  Thank you.  Good afternoon.  Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million. ", "original_text": "Good afternoon. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "192e0393-587f-4fe2-b835-9bec16303ae8", "node_type": "1", "metadata": {"window": "Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  Thank you.  Good afternoon.  Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly. ", "original_text": "Thank you. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1bcbf1eaf613bf5d0176a32a4776b9025f813055db956846a3f3df6607a99a6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "430332bf-5c0a-4828-9e8e-388f6d4039bc", "node_type": "1", "metadata": {"window": "Q \nHi.  Thank you.  Good afternoon.  Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation. ", "original_text": "Fairly simple one, I hope. "}, "hash": "7d6dd52b2443c8afd9d2c8617ecc37a8385d22b1d8c16489deaad5b5016a13f9", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon. ", "start_char_idx": 981, "end_char_idx": 997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "430332bf-5c0a-4828-9e8e-388f6d4039bc": {"__data__": {"id_": "430332bf-5c0a-4828-9e8e-388f6d4039bc", "embedding": null, "metadata": {"window": "Q \nHi.  Thank you.  Good afternoon.  Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation. ", "original_text": "Fairly simple one, I hope. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d92513a-08af-4647-8ba6-b34c5fff5e9c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  Thank you.  Good afternoon.  Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million. ", "original_text": "Good afternoon. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a44f549c22a2de65643ed8d80024c0cc5870621d778098a91893d6c76c6d225a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fdf9616-6c02-4ca9-a652-4ead4cb19e5f", "node_type": "1", "metadata": {"window": "Thank you.  Good afternoon.  Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two? ", "original_text": "Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly. "}, "hash": "0b640befb9142135496831bc97e6d3f95a99d4e493db9295fd4207c7415aa455", "class_name": "RelatedNodeInfo"}}, "text": "Fairly simple one, I hope. ", "start_char_idx": 997, "end_char_idx": 1024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fdf9616-6c02-4ca9-a652-4ead4cb19e5f": {"__data__": {"id_": "8fdf9616-6c02-4ca9-a652-4ead4cb19e5f", "embedding": null, "metadata": {"window": "Thank you.  Good afternoon.  Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two? ", "original_text": "Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "430332bf-5c0a-4828-9e8e-388f6d4039bc", "node_type": "1", "metadata": {"window": "Q \nHi.  Thank you.  Good afternoon.  Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation. ", "original_text": "Fairly simple one, I hope. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a57bee3f22184a4363392b2f062365704c1d1711f6ab5b4e62b8f54f65a781f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbb25293-2d94-4d34-beef-81b8e55428f4", "node_type": "1", "metadata": {"window": "Good afternoon.  Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million? ", "original_text": "You had $130 million \nexpense, and you're saying it will be $40 million. "}, "hash": "626dc2a4c8d5b123670be1a7674ff6a28c4258a59ca92bb9fe8080a93c628482", "class_name": "RelatedNodeInfo"}}, "text": "Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly. ", "start_char_idx": 1024, "end_char_idx": 1170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbb25293-2d94-4d34-beef-81b8e55428f4": {"__data__": {"id_": "cbb25293-2d94-4d34-beef-81b8e55428f4", "embedding": null, "metadata": {"window": "Good afternoon.  Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million? ", "original_text": "You had $130 million \nexpense, and you're saying it will be $40 million. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fdf9616-6c02-4ca9-a652-4ead4cb19e5f", "node_type": "1", "metadata": {"window": "Thank you.  Good afternoon.  Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two? ", "original_text": "Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee2bc2f62da8135266e2eb257281f204423d070644a801d967ae130b361b0256", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53ab00ab-655a-47b0-a7eb-1823e71fa78c", "node_type": "1", "metadata": {"window": "Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense? ", "original_text": "That's a really big delta between the two companies for the same \nsituation. "}, "hash": "3c69dc6f94b5a39bd13c793c4e944d0ea4f66e43fd78e2926e4791f2f1424a5e", "class_name": "RelatedNodeInfo"}}, "text": "You had $130 million \nexpense, and you're saying it will be $40 million. ", "start_char_idx": 1170, "end_char_idx": 1243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53ab00ab-655a-47b0-a7eb-1823e71fa78c": {"__data__": {"id_": "53ab00ab-655a-47b0-a7eb-1823e71fa78c", "embedding": null, "metadata": {"window": "Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense? ", "original_text": "That's a really big delta between the two companies for the same \nsituation. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbb25293-2d94-4d34-beef-81b8e55428f4", "node_type": "1", "metadata": {"window": "Good afternoon.  Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million? ", "original_text": "You had $130 million \nexpense, and you're saying it will be $40 million. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1453b31b1dcb9c72caf2be0d7a0b711b182d76833341e2d97b9b24e44ca1792b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74f91b39-4eea-4226-85e5-5dc2df5fa94f", "node_type": "1", "metadata": {"window": "Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n ", "original_text": "Any sense on what the delta is between you two? "}, "hash": "2d2724e4183c2474ffa11d2362fdf0342301935561167a99475597396b099f39", "class_name": "RelatedNodeInfo"}}, "text": "That's a really big delta between the two companies for the same \nsituation. ", "start_char_idx": 1243, "end_char_idx": 1320, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74f91b39-4eea-4226-85e5-5dc2df5fa94f": {"__data__": {"id_": "74f91b39-4eea-4226-85e5-5dc2df5fa94f", "embedding": null, "metadata": {"window": "Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n ", "original_text": "Any sense on what the delta is between you two? ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53ab00ab-655a-47b0-a7eb-1823e71fa78c", "node_type": "1", "metadata": {"window": "Fairly simple one, I hope.  Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense? ", "original_text": "That's a really big delta between the two companies for the same \nsituation. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd376e9fddcb5ae8c99beff58737d42991c131aa48aaccbf13ba43d7f8783854", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cc9c8d3-8e69-46cc-bcfe-83b9c43cb142", "node_type": "1", "metadata": {"window": "You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.  ", "original_text": "H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million? "}, "hash": "c33c0860582ace758f229fca1ce1070192183c3cdfe8713e63756055cd5e6c7c", "class_name": "RelatedNodeInfo"}}, "text": "Any sense on what the delta is between you two? ", "start_char_idx": 1320, "end_char_idx": 1368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cc9c8d3-8e69-46cc-bcfe-83b9c43cb142": {"__data__": {"id_": "1cc9c8d3-8e69-46cc-bcfe-83b9c43cb142", "embedding": null, "metadata": {"window": "You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.  ", "original_text": "H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million? ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74f91b39-4eea-4226-85e5-5dc2df5fa94f", "node_type": "1", "metadata": {"window": "Your competitor who reported today had $115 million of \nopioid expense last year, said  that their expense next year would be down only modestly.  You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n ", "original_text": "Any sense on what the delta is between you two? ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01b970f4d33768843b020fdbdb896b531920e849a230f73731f57a314f5fcc0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca65bb9d-116e-4865-8faf-8e413f3dc802", "node_type": "1", "metadata": {"window": "That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta. ", "original_text": "Or what might explain this \nsubstantial delta in opioid litigation expense? "}, "hash": "a557447260e48fb98d70a5413ad7ff778019105f108032be2b400010755b0073", "class_name": "RelatedNodeInfo"}}, "text": "H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million? ", "start_char_idx": 1368, "end_char_idx": 1509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca65bb9d-116e-4865-8faf-8e413f3dc802": {"__data__": {"id_": "ca65bb9d-116e-4865-8faf-8e413f3dc802", "embedding": null, "metadata": {"window": "That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta. ", "original_text": "Or what might explain this \nsubstantial delta in opioid litigation expense? ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cc9c8d3-8e69-46cc-bcfe-83b9c43cb142", "node_type": "1", "metadata": {"window": "You had $130 million \nexpense, and you're saying it will be $40 million.  That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.  ", "original_text": "H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million? ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0eef0d552cf2c387fcc002b8766c23f8d2f7a197e5faf03f504ff1543f9ed220", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ed20217-1186-4fb3-8492-aa254f4b9709", "node_type": "1", "metadata": {"window": "Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided. ", "original_text": "Thanks very much.  \n "}, "hash": "57944c5b6dda50fe883b2b6dcc7599b8cd559bdbab53e4b20bcb98795d7280e0", "class_name": "RelatedNodeInfo"}}, "text": "Or what might explain this \nsubstantial delta in opioid litigation expense? ", "start_char_idx": 1509, "end_char_idx": 1585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ed20217-1186-4fb3-8492-aa254f4b9709": {"__data__": {"id_": "3ed20217-1186-4fb3-8492-aa254f4b9709", "embedding": null, "metadata": {"window": "Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided. ", "original_text": "Thanks very much.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca65bb9d-116e-4865-8faf-8e413f3dc802", "node_type": "1", "metadata": {"window": "That's a really big delta between the two companies for the same \nsituation.  Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta. ", "original_text": "Or what might explain this \nsubstantial delta in opioid litigation expense? ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a812b456f51a36e10ecafa7caf09690289cc6ab4bef94e9ed864dfd6d9a33e44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a293faa9-3628-4b66-bbc6-f1baf214f54f", "node_type": "1", "metadata": {"window": "H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.  "}, "hash": "b65eb586ca602b66ca41003fe9718eea315ffa813a443bf0f5e0ec3a303b2f16", "class_name": "RelatedNodeInfo"}}, "text": "Thanks very much.  \n ", "start_char_idx": 1585, "end_char_idx": 1606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a293faa9-3628-4b66-bbc6-f1baf214f54f": {"__data__": {"id_": "a293faa9-3628-4b66-bbc6-f1baf214f54f", "embedding": null, "metadata": {"window": "H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ed20217-1186-4fb3-8492-aa254f4b9709", "node_type": "1", "metadata": {"window": "Any sense on what the delta is between you two?  H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided. ", "original_text": "Thanks very much.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0270f970fcd9b3e32b1972db84224c717b77f827959d2c8e10d362ae02dcc2a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30f80553-d99e-4381-89c6-369709d3deb0", "node_type": "1", "metadata": {"window": "Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n ", "original_text": "A \nI don't know that we can speak to the delta. "}, "hash": "5c191553b020d0b66c812d84659e79a4a8d52e8a9c8b7f11f8c612fb9497d199", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.  ", "start_char_idx": 1606, "end_char_idx": 1948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30f80553-d99e-4381-89c6-369709d3deb0": {"__data__": {"id_": "30f80553-d99e-4381-89c6-369709d3deb0", "embedding": null, "metadata": {"window": "Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n ", "original_text": "A \nI don't know that we can speak to the delta. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a293faa9-3628-4b66-bbc6-f1baf214f54f", "node_type": "1", "metadata": {"window": "H ave you excluded the injunctive relief costs, the \ndata, the tracking, the integrity costs that come with the program in this $40 million?  Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24b176243716d231ae1177e8f16920ad73e0e372f13643c9aab19dadded432c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddae6a7b-1443-41d5-9b93-5052020d472c", "node_type": "1", "metadata": {"window": "Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We can speak to the guidance that we provided. "}, "hash": "4065e00735fb25dcc895db9beae0bb6e0c00dbbc411afd3a6fd1faaf891ee556", "class_name": "RelatedNodeInfo"}}, "text": "A \nI don't know that we can speak to the delta. ", "start_char_idx": 1948, "end_char_idx": 1996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddae6a7b-1443-41d5-9b93-5052020d472c": {"__data__": {"id_": "ddae6a7b-1443-41d5-9b93-5052020d472c", "embedding": null, "metadata": {"window": "Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We can speak to the guidance that we provided. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30f80553-d99e-4381-89c6-369709d3deb0", "node_type": "1", "metadata": {"window": "Or what might explain this \nsubstantial delta in opioid litigation expense?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n ", "original_text": "A \nI don't know that we can speak to the delta. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2891415893994c6928f32549694a48d86aa492dc24820ac21de575ecd4144355", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fea72eae-58bf-4a28-8a0c-14c088e501a1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction. ", "original_text": "As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits. "}, "hash": "05d3e7c22001f52bc8841b65b84a4aedfff92feb003a043e1d3e3112a77ed516", "class_name": "RelatedNodeInfo"}}, "text": "We can speak to the guidance that we provided. ", "start_char_idx": 1996, "end_char_idx": 2043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fea72eae-58bf-4a28-8a0c-14c088e501a1": {"__data__": {"id_": "fea72eae-58bf-4a28-8a0c-14c088e501a1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction. ", "original_text": "As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddae6a7b-1443-41d5-9b93-5052020d472c", "node_type": "1", "metadata": {"window": "Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We can speak to the guidance that we provided. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83a99df92987d3cda38f8e7ca67e527fd5adf656087094d53c10ba9c6927dafe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1101b39-eaef-493a-ae4c-9642304dadb5", "node_type": "1", "metadata": {"window": "A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen. ", "original_text": "And that number we \nprovided was $40 million.  \n "}, "hash": "80c306399b6500f3e1a7443649d0f0b37d251564fdbb0342b4f1f7f8e26e5555", "class_name": "RelatedNodeInfo"}}, "text": "As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits. ", "start_char_idx": 2043, "end_char_idx": 2265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1101b39-eaef-493a-ae4c-9642304dadb5": {"__data__": {"id_": "f1101b39-eaef-493a-ae4c-9642304dadb5", "embedding": null, "metadata": {"window": "A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen. ", "original_text": "And that number we \nprovided was $40 million.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fea72eae-58bf-4a28-8a0c-14c088e501a1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Ex ecutive Officer & Director, McKesson Corp.   A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction. ", "original_text": "As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2747599094b3b1df4760bde135b83eddd09a9426a6c03d8cfd113be98df75bb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52bbd652-1fb7-4bb5-a8d7-fbd66cb1665d", "node_type": "1", "metadata": {"window": "We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "03aab96560afdaba125f06599eb6570ab8499c63bd4b5d15c06013713e056f9b", "class_name": "RelatedNodeInfo"}}, "text": "And that number we \nprovided was $40 million.  \n ", "start_char_idx": 2265, "end_char_idx": 2314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52bbd652-1fb7-4bb5-a8d7-fbd66cb1665d": {"__data__": {"id_": "52bbd652-1fb7-4bb5-a8d7-fbd66cb1665d", "embedding": null, "metadata": {"window": "We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1101b39-eaef-493a-ae4c-9642304dadb5", "node_type": "1", "metadata": {"window": "A \nI don't know that we can speak to the delta.  We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen. ", "original_text": "And that number we \nprovided was $40 million.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a38bacd3bbd9ffab5b1e9b3499645e76183f164b058e9a41692796099b925bab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a51479e-5561-4751-a1ee-f91d378477fd", "node_type": "1", "metadata": {"window": "As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n ", "original_text": "A \nAnd as I pointed out,  there are some factors that could drive that number in either direction. "}, "hash": "d71c86781331f61227a64e98122e7e4f6a01c7c6b67c7daa9f1618043507f438", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 2314, "end_char_idx": 2671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a51479e-5561-4751-a1ee-f91d378477fd": {"__data__": {"id_": "1a51479e-5561-4751-a1ee-f91d378477fd", "embedding": null, "metadata": {"window": "As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n ", "original_text": "A \nAnd as I pointed out,  there are some factors that could drive that number in either direction. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52bbd652-1fb7-4bb5-a8d7-fbd66cb1665d", "node_type": "1", "metadata": {"window": "We can speak to the guidance that we provided.  As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d823a6d1b9167ba3ffb787e959825e0a22080bb28416aa2900e5081b039df464", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee3712dd-0de2-45f3-b1a6-a65351075a1d", "node_type": "1", "metadata": {"window": "And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen. "}, "hash": "5bb9f03ce8ead256309130e108f4c93671c7a91528b13eeaec9a01aab10f90aa", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd as I pointed out,  there are some factors that could drive that number in either direction. ", "start_char_idx": 2671, "end_char_idx": 2770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee3712dd-0de2-45f3-b1a6-a65351075a1d": {"__data__": {"id_": "ee3712dd-0de2-45f3-b1a6-a65351075a1d", "embedding": null, "metadata": {"window": "And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a51479e-5561-4751-a1ee-f91d378477fd", "node_type": "1", "metadata": {"window": "As we look at the \nlitigation, the litigation calendar, open issues that are ahead of us, this is our best view based on what we know \ntoday of what we would anticipate to spend in defending ourselves against these suits.  And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n ", "original_text": "A \nAnd as I pointed out,  there are some factors that could drive that number in either direction. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc1283546f95ebdbce33025c4f0d257006e130a30985324a721c6aab3589e8a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97d54ede-701d-46bf-bb79-e1aabdd0fb1c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58). ", "original_text": "So we've given \nyou our best estimate based on our analysis of what remains. "}, "hash": "27e0b735ce5f6fd638bc222254700eb6e15a6340f8b95aedea12961c2a583850", "class_name": "RelatedNodeInfo"}}, "text": "That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen. ", "start_char_idx": 2770, "end_char_idx": 2891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97d54ede-701d-46bf-bb79-e1aabdd0fb1c": {"__data__": {"id_": "97d54ede-701d-46bf-bb79-e1aabdd0fb1c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58). ", "original_text": "So we've given \nyou our best estimate based on our analysis of what remains. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee3712dd-0de2-45f3-b1a6-a65351075a1d", "node_type": "1", "metadata": {"window": "And that number we \nprovided was $40 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6512738264364019bf34c4bd326d6582d1d019f76077f93676f1307f5ea13e31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8da9fe44-4e15-40a8-9d81-ceb069f448c6", "node_type": "1", "metadata": {"window": "A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n ", "original_text": "And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n "}, "hash": "44f62ac9cf7dea062dc3f77fc26605edff2617bf5afa83c4c94876741fab9d02", "class_name": "RelatedNodeInfo"}}, "text": "So we've given \nyou our best estimate based on our analysis of what remains. ", "start_char_idx": 2891, "end_char_idx": 2968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8da9fe44-4e15-40a8-9d81-ceb069f448c6": {"__data__": {"id_": "8da9fe44-4e15-40a8-9d81-ceb069f448c6", "embedding": null, "metadata": {"window": "A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n ", "original_text": "And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97d54ede-701d-46bf-bb79-e1aabdd0fb1c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58). ", "original_text": "So we've given \nyou our best estimate based on our analysis of what remains. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65e23ecc2f56c805d27c3df636487693c78f4c85deb2a85c23ba1e1a63ad9ed4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9ed8c7f-6369-4223-b568-6c30210d42b1", "node_type": "1", "metadata": {"window": "That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "e0132396b446fbc21612762bf8d4966611e9eef54351c494feeaf31b81b131d0", "class_name": "RelatedNodeInfo"}}, "text": "And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n ", "start_char_idx": 2968, "end_char_idx": 3072, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9ed8c7f-6369-4223-b568-6c30210d42b1": {"__data__": {"id_": "b9ed8c7f-6369-4223-b568-6c30210d42b1", "embedding": null, "metadata": {"window": "That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8da9fe44-4e15-40a8-9d81-ceb069f448c6", "node_type": "1", "metadata": {"window": "A \nAnd as I pointed out,  there are some factors that could drive that number in either direction.  That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n ", "original_text": "And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b44e0868263deb56d719496c312ba1e53c83c2584e596e08d1e62b0196d143de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48361710-a738-4429-a882-e08c752c9f5e", "node_type": "1", "metadata": {"window": "So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight. ", "original_text": "A \nThat is the legal expense [indiscernible] (01:03:58). "}, "hash": "93ec6bba5333f0e9a8aaa526cb8385735105831145f2e0cd872dfca0b50f5e08", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3072, "end_char_idx": 3413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48361710-a738-4429-a882-e08c752c9f5e": {"__data__": {"id_": "48361710-a738-4429-a882-e08c752c9f5e", "embedding": null, "metadata": {"window": "So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight. ", "original_text": "A \nThat is the legal expense [indiscernible] (01:03:58). ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9ed8c7f-6369-4223-b568-6c30210d42b1", "node_type": "1", "metadata": {"window": "That could be the \npace of any trials or trials themselves and any of the work that goes into any trials that do happen.  So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9065cadd639e8e35e79fec3a4768c30b4377956b3c00411d96a1c3eb570a64a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92583168-888d-4934-80d4-f2d452dda8c8", "node_type": "1", "metadata": {"window": "And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n ", "original_text": "That is $40 milli on for legal defense.  \n "}, "hash": "ea628e9672cf00ed48ba8769731650ab5b3974ea256552a77ada04ab55fbec6b", "class_name": "RelatedNodeInfo"}}, "text": "A \nThat is the legal expense [indiscernible] (01:03:58). ", "start_char_idx": 3413, "end_char_idx": 3470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92583168-888d-4934-80d4-f2d452dda8c8": {"__data__": {"id_": "92583168-888d-4934-80d4-f2d452dda8c8", "embedding": null, "metadata": {"window": "And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n ", "original_text": "That is $40 milli on for legal defense.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48361710-a738-4429-a882-e08c752c9f5e", "node_type": "1", "metadata": {"window": "So we've given \nyou our best estimate based on our analysis of what remains.  And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight. ", "original_text": "A \nThat is the legal expense [indiscernible] (01:03:58). ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1367d1b5aac33b7adf9f948f645e268001e96175aa89af1d9084f468068b0653", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f32782c9-1ed8-42c7-96f6-c8b281cfaee4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "6d5bdd42fc01752a66f4e0e504654a8f77977e55e5762ac4dc0e3387d0ad0598", "class_name": "RelatedNodeInfo"}}, "text": "That is $40 milli on for legal defense.  \n ", "start_char_idx": 3470, "end_char_idx": 3513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f32782c9-1ed8-42c7-96f6-c8b281cfaee4": {"__data__": {"id_": "f32782c9-1ed8-42c7-96f6-c8b281cfaee4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92583168-888d-4934-80d4-f2d452dda8c8", "node_type": "1", "metadata": {"window": "And again, as Brian said, it's really can't comment \non how is somebody else is thinking about this.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n ", "original_text": "That is $40 milli on for legal defense.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16c261384b6ee1c4da5c9b90072b5917ae076b8410dde2b07e5e201c662c27bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a44e2862-1ee0-4a20-9b51-e31f1223891a", "node_type": "1", "metadata": {"window": "A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "A \nRight. "}, "hash": "b9a6d4ead33e11ea8338ca15ec544d510d50b830aa4b1397ae4211f17a1fe75e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 2314, "end_char_idx": 2671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a44e2862-1ee0-4a20-9b51-e31f1223891a": {"__data__": {"id_": "a44e2862-1ee0-4a20-9b51-e31f1223891a", "embedding": null, "metadata": {"window": "A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "A \nRight. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f32782c9-1ed8-42c7-96f6-c8b281cfaee4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "230f066d657227010f680ad07598358623f3a9093356b4fafe1f6e5e49a7c81c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba21e276-f330-4311-9d2f-36ad3bba3458", "node_type": "1", "metadata": {"window": "That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n ", "original_text": "Consistent as it's been since we began reporting this to you three years ago.  \n "}, "hash": "709d368912da78546b1aeb3f2ff06876eb33edd16e4831dcd475dcb7f887b130", "class_name": "RelatedNodeInfo"}}, "text": "A \nRight. ", "start_char_idx": 3870, "end_char_idx": 3880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba21e276-f330-4311-9d2f-36ad3bba3458": {"__data__": {"id_": "ba21e276-f330-4311-9d2f-36ad3bba3458", "embedding": null, "metadata": {"window": "That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n ", "original_text": "Consistent as it's been since we began reporting this to you three years ago.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a44e2862-1ee0-4a20-9b51-e31f1223891a", "node_type": "1", "metadata": {"window": "A \nThat is the legal expense [indiscernible] (01:03:58).  That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "A \nRight. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c701e546350e8a07b5592b78a06bf161cc88197f8e40788ff7ef56f933c06df9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d99e2178-a057-4358-88d5-0cf3d84030f0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n "}, "hash": "bbe3eff8c7cb3362a58a6a08721b556ea479d8dfae99a1a7c4474d308533cc1d", "class_name": "RelatedNodeInfo"}}, "text": "Consistent as it's been since we began reporting this to you three years ago.  \n ", "start_char_idx": 3880, "end_char_idx": 3961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d99e2178-a057-4358-88d5-0cf3d84030f0": {"__data__": {"id_": "d99e2178-a057-4358-88d5-0cf3d84030f0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba21e276-f330-4311-9d2f-36ad3bba3458", "node_type": "1", "metadata": {"window": "That is $40 milli on for legal defense.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n ", "original_text": "Consistent as it's been since we began reporting this to you three years ago.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a5ca7259d2dd16f3caba3682d559014ff89be75d0b77f3d5052be91ec42cca4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba049ebb-1f3f-43be-bbf0-fa6cbfe4d072", "node_type": "1", "metadata": {"window": "A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. "}, "hash": "3cf552a888db16bf7401fdf565022cdb35eb38f85f572a7a0bcfe64a15af476e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "start_char_idx": 3961, "end_char_idx": 4324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba049ebb-1f3f-43be-bbf0-fa6cbfe4d072": {"__data__": {"id_": "ba049ebb-1f3f-43be-bbf0-fa6cbfe4d072", "embedding": null, "metadata": {"window": "A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d99e2178-a057-4358-88d5-0cf3d84030f0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a541de957b1a6f589e3c1c730bedf1ab91823b883ca0db84644670482c67beb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9cebea9-84c2-46b2-918b-8aea9eda74d9", "node_type": "1", "metadata": {"window": "Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q ", "original_text": "We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n "}, "hash": "3c1eb7a297ebf2a69c3f2618702001d040a17261e84074d4601c6bdec7848e70", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "start_char_idx": 272, "end_char_idx": 568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9cebea9-84c2-46b2-918b-8aea9eda74d9": {"__data__": {"id_": "a9cebea9-84c2-46b2-918b-8aea9eda74d9", "embedding": null, "metadata": {"window": "Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q ", "original_text": "We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba049ebb-1f3f-43be-bbf0-fa6cbfe4d072", "node_type": "1", "metadata": {"window": "A \nRight.  Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f42e5cfff320c88d9e4060d49bf935fa8cf7e068e8f5e3accf196e2dde94fd8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1969c404-e3a2-4fe0-b8b6-c4de1505acb3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q "}, "hash": "63583820e5cb8a130fe76b68ca92f17cfd7d7d042300112e5f5e24ef272b7e64", "class_name": "RelatedNodeInfo"}}, "text": "We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n ", "start_char_idx": 4620, "end_char_idx": 4695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1969c404-e3a2-4fe0-b8b6-c4de1505acb3": {"__data__": {"id_": "1969c404-e3a2-4fe0-b8b6-c4de1505acb3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16a3ebf06c5c19d0525474ec18e858814483c0f82898bc046d7805a95e7023db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9cebea9-84c2-46b2-918b-8aea9eda74d9", "node_type": "1", "metadata": {"window": "Consistent as it's been since we began reporting this to you three years ago.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q ", "original_text": "We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da0d3e0f85ac63ce0d6b7775037a4ea90940511f9932c7adc5305ad4095ece71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4f8cd46-b5c1-442c-bb59-06a665de9701", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys.  Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n ", "original_text": "McKesson Corp.  "}, "hash": "05d0270b3b87a42e75b2a751b18c02d6a4a9e070edca6c7e8fcc2abbcda90120", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q ", "start_char_idx": 4695, "end_char_idx": 5013, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4f8cd46-b5c1-442c-bb59-06a665de9701": {"__data__": {"id_": "b4f8cd46-b5c1-442c-bb59-06a665de9701", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys.  Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1969c404-e3a2-4fe0-b8b6-c4de1505acb3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question from Elizabeth Anderson with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d55e62093897dadec6b4ed4f0d8ceca1bf7a3efcee220d831093b0b182ff606", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea901e00-ef6d-4ddb-9f38-c61e6fe4aabd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys.  Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys. "}, "hash": "c30f732cab1690a26250238ded8948a64beb1276955507f61eccfdf170ebb20c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea901e00-ef6d-4ddb-9f38-c61e6fe4aabd": {"__data__": {"id_": "ea901e00-ef6d-4ddb-9f38-c61e6fe4aabd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys.  Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4f8cd46-b5c1-442c-bb59-06a665de9701", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys.  Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3febd1a4165a5a31c5b1e468bb3cd3077cbd629b5d7f505062c17c3b87931c6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b646426f-458e-4c50-a5e0-831ecadb1dbb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys.  Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question. ", "original_text": "Thanks so much for the question. "}, "hash": "6152191fae2c9b4ea220536d758cb97bf72af19f174320b69e36a7e290171150", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys. ", "start_char_idx": 16, "end_char_idx": 191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b646426f-458e-4c50-a5e0-831ecadb1dbb": {"__data__": {"id_": "b646426f-458e-4c50-a5e0-831ecadb1dbb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys.  Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question. ", "original_text": "Thanks so much for the question. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea901e00-ef6d-4ddb-9f38-c61e6fe4aabd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys.  Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83c501423c49b3d10cb4268971c6bc8623c8d6e7a598a46486a1139c82229c5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "443f1f83-b68f-4ba6-b6d8-d7f70ce098fa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys.  Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  We didn't touch on that. ", "original_text": "I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n "}, "hash": "4290b6ed894351cffb8b9ac4d87bb1f208a1a97870f910e1220eafa551772bcd", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much for the question. ", "start_char_idx": 191, "end_char_idx": 224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "443f1f83-b68f-4ba6-b6d8-d7f70ce098fa": {"__data__": {"id_": "443f1f83-b68f-4ba6-b6d8-d7f70ce098fa", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys.  Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  We didn't touch on that. ", "original_text": "I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b646426f-458e-4c50-a5e0-831ecadb1dbb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys.  Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question. ", "original_text": "Thanks so much for the question. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d985c13d6edeaaac16766ae5844c7dddb33971de65432effcf810bbb3d6cb0c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dd14ee8-910c-49f4-9295-45ece46db33b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys.  Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "0418d7dccf60cc16544569254c879e91d36d034847c876286cd0bf515011a7a5", "class_name": "RelatedNodeInfo"}}, "text": "I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n ", "start_char_idx": 224, "end_char_idx": 416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dd14ee8-910c-49f4-9295-45ece46db33b": {"__data__": {"id_": "8dd14ee8-910c-49f4-9295-45ece46db33b", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys.  Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "443f1f83-b68f-4ba6-b6d8-d7f70ce098fa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys.  Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  We didn't touch on that. ", "original_text": "I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80da9d5fa1c65dbc53820d54c1240a4558a29f695ea6f44cec4aeb702a59eec4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f45af4e-20cf-4ad9-92cf-c7b66759e1f3", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022. ", "original_text": "A \nYeah, thanks for the question. "}, "hash": "09685cb04fffc4725a170670233ff27b747a30e694ac0412299baf08b3047dd1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 416, "end_char_idx": 773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f45af4e-20cf-4ad9-92cf-c7b66759e1f3": {"__data__": {"id_": "6f45af4e-20cf-4ad9-92cf-c7b66759e1f3", "embedding": null, "metadata": {"window": "Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022. ", "original_text": "A \nYeah, thanks for the question. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dd14ee8-910c-49f4-9295-45ece46db33b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys.  Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94ee453bb0fab830e808e48a2041de512e2d1d44ba72a66dad781651daaf6184", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9db72625-c85b-4514-b809-1800765aa645", "node_type": "1", "metadata": {"window": "I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation. ", "original_text": "We didn't touch on that. "}, "hash": "54889f902c04140c0b1aab8fcd1d11a94e1aa919561a7cb98afc448a7094d095", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, thanks for the question. ", "start_char_idx": 773, "end_char_idx": 807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9db72625-c85b-4514-b809-1800765aa645": {"__data__": {"id_": "9db72625-c85b-4514-b809-1800765aa645", "embedding": null, "metadata": {"window": "I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation. ", "original_text": "We didn't touch on that. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f45af4e-20cf-4ad9-92cf-c7b66759e1f3", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022. ", "original_text": "A \nYeah, thanks for the question. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd9f0d0863893885758a44919493c81a0488c66d73163eb02dec2437f910e179", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f6253f8-c082-43ae-81f1-c178b4468673", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side. ", "original_text": "We historically have talked about the environment around \nthe branded inflation and generic inflation. "}, "hash": "b40379634c2380c555b9f809f18b27bb3d6507fbae4a3f820efc9b05f64dfa8d", "class_name": "RelatedNodeInfo"}}, "text": "We didn't touch on that. ", "start_char_idx": 807, "end_char_idx": 832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f6253f8-c082-43ae-81f1-c178b4468673": {"__data__": {"id_": "0f6253f8-c082-43ae-81f1-c178b4468673", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side. ", "original_text": "We historically have talked about the environment around \nthe branded inflation and generic inflation. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9db72625-c85b-4514-b809-1800765aa645", "node_type": "1", "metadata": {"window": "I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation. ", "original_text": "We didn't touch on that. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40479d910afc83be8e8a534fc4e8aeddc0a7b45ac13a2aa9339a1c3a242fb53b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae849bc0-063c-4ce6-a4ae-3d98b1b4946b", "node_type": "1", "metadata": {"window": "A \nYeah, thanks for the question.  We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n ", "original_text": "We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022. "}, "hash": "8e43bedd6fa2f7562325128423a65ab1b6d6a1b8de297e6ae07064f1047d08f7", "class_name": "RelatedNodeInfo"}}, "text": "We historically have talked about the environment around \nthe branded inflation and generic inflation. ", "start_char_idx": 832, "end_char_idx": 935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae849bc0-063c-4ce6-a4ae-3d98b1b4946b": {"__data__": {"id_": "ae849bc0-063c-4ce6-a4ae-3d98b1b4946b", "embedding": null, "metadata": {"window": "A \nYeah, thanks for the question.  We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n ", "original_text": "We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f6253f8-c082-43ae-81f1-c178b4468673", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, thanks for the question.  We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side. ", "original_text": "We historically have talked about the environment around \nthe branded inflation and generic inflation. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9fee81133a7b3313f07b600c050a37ffaff9b7b252f3f1a40db2770f62c7884f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9946d133-56d3-4a9f-ad0b-8c329b7cc0f0", "node_type": "1", "metadata": {"window": "We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "So we see relative stability in both bran ded price inflation. "}, "hash": "51438c43f959b06fa1fa6821b4b72e775379c050f04289f87a9dfd9b49597b74", "class_name": "RelatedNodeInfo"}}, "text": "We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022. ", "start_char_idx": 935, "end_char_idx": 1014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9946d133-56d3-4a9f-ad0b-8c329b7cc0f0": {"__data__": {"id_": "9946d133-56d3-4a9f-ad0b-8c329b7cc0f0", "embedding": null, "metadata": {"window": "We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "So we see relative stability in both bran ded price inflation. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae849bc0-063c-4ce6-a4ae-3d98b1b4946b", "node_type": "1", "metadata": {"window": "A \nYeah, thanks for the question.  We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n ", "original_text": "We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f84a2bdd7f1d080a123b0b398d6b0e3d159366338f4e57f17961921c2496cee7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8203606c-9977-4db7-bb86-a1fd4a5b2468", "node_type": "1", "metadata": {"window": "We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side. "}, "hash": "7cbf54b15c90dd2ec046ad0545bfda0e22b7fca177d596e8e5a8cf8a015f6aed", "class_name": "RelatedNodeInfo"}}, "text": "So we see relative stability in both bran ded price inflation. ", "start_char_idx": 1014, "end_char_idx": 1077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8203606c-9977-4db7-bb86-a1fd4a5b2468": {"__data__": {"id_": "8203606c-9977-4db7-bb86-a1fd4a5b2468", "embedding": null, "metadata": {"window": "We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9946d133-56d3-4a9f-ad0b-8c329b7cc0f0", "node_type": "1", "metadata": {"window": "We didn't touch on that.  We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "original_text": "So we see relative stability in both bran ded price inflation. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f9f5a4076bde287cc7c0ea6043216e6d6b3cfcda1d782781f4f993a252bc34d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fba770f3-a013-456c-9071-c368b115392e", "node_type": "1", "metadata": {"window": "We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n ", "original_text": "So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n "}, "hash": "a776bedb21590a4bf91806729bc779ce1dcd6d2721153cdfd9874185ff74e163", "class_name": "RelatedNodeInfo"}}, "text": "And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side. ", "start_char_idx": 1077, "end_char_idx": 1406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fba770f3-a013-456c-9071-c368b115392e": {"__data__": {"id_": "fba770f3-a013-456c-9071-c368b115392e", "embedding": null, "metadata": {"window": "We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n ", "original_text": "So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8203606c-9977-4db7-bb86-a1fd4a5b2468", "node_type": "1", "metadata": {"window": "We historically have talked about the environment around \nthe branded inflation and generic inflation.  We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d5efd953d0da7340c8582d748327cce9850234cf633dcfe60538a91fab28c03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f62419a5-b996-4556-8e9a-af1095b50238", "node_type": "1", "metadata": {"window": "So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n "}, "hash": "607fde1fd99a6520fa008ed7208402a7596326da0d13929906460ec304ea431c", "class_name": "RelatedNodeInfo"}}, "text": "So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n ", "start_char_idx": 1406, "end_char_idx": 1555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f62419a5-b996-4556-8e9a-af1095b50238": {"__data__": {"id_": "f62419a5-b996-4556-8e9a-af1095b50238", "embedding": null, "metadata": {"window": "So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fba770f3-a013-456c-9071-c368b115392e", "node_type": "1", "metadata": {"window": "We don't see any change in our FY 2023 outlook to what we've seen in \nFY 2022.  So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n ", "original_text": "So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28da5c8803c4d5c8131666287a87caacc7628c6b34e352f9e1ebc33f6d51c9b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29b0b81e-ee03-4236-9fb0-8ebbfe50a61f", "node_type": "1", "metadata": {"window": "And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. "}, "hash": "e85a3346861ab8cd1068a75eddd97c90aa86b8a31c7ca9131d0b083bae726a13", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "start_char_idx": 1555, "end_char_idx": 1918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29b0b81e-ee03-4236-9fb0-8ebbfe50a61f": {"__data__": {"id_": "29b0b81e-ee03-4236-9fb0-8ebbfe50a61f", "embedding": null, "metadata": {"window": "And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f62419a5-b996-4556-8e9a-af1095b50238", "node_type": "1", "metadata": {"window": "So we see relative stability in both bran ded price inflation.  And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5701f442183ba35f1053b4842cd9e1ec7d46e8786d02df06bdae5fc956da5674", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5de480d2-97a0-4f6c-bb3e-e005baa99b5a", "node_type": "1", "metadata": {"window": "So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good evening, guys, and I appreciate you taking my question. ", "original_text": "We'll take our next question comes from George Hill with Deutsche Bank.  \n "}, "hash": "51bfc2037a33f477729d53bdb7a8853139ecfa280829c5a7eb470969497445e3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "start_char_idx": 1918, "end_char_idx": 2214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5de480d2-97a0-4f6c-bb3e-e005baa99b5a": {"__data__": {"id_": "5de480d2-97a0-4f6c-bb3e-e005baa99b5a", "embedding": null, "metadata": {"window": "So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good evening, guys, and I appreciate you taking my question. ", "original_text": "We'll take our next question comes from George Hill with Deutsche Bank.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29b0b81e-ee03-4236-9fb0-8ebbfe50a61f", "node_type": "1", "metadata": {"window": "And from a generics perspective, we continue \nto see a stable but competitive environment that is supported by the strong sourcing operations that we have and \nour focus is on providing our customers, stability of supply, good pricing an d our ability to do that through good \nsourcing and disciplined approach to the sell side.  So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6693c2813d64f1c2c5416d277b0bffaaf296a8089fa912f589c72d07fdbbdb48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6b6155a-615c-4406-9c49-ca892abc5607", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  "}, "hash": "310fc5ec9230c2308a44f214de2de32db95d19f95e743bb8839d1b67ee61b0ef", "class_name": "RelatedNodeInfo"}}, "text": "We'll take our next question comes from George Hill with Deutsche Bank.  \n ", "start_char_idx": 2214, "end_char_idx": 2289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6b6155a-615c-4406-9c49-ca892abc5607": {"__data__": {"id_": "a6b6155a-615c-4406-9c49-ca892abc5607", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5de480d2-97a0-4f6c-bb3e-e005baa99b5a", "node_type": "1", "metadata": {"window": "So from our perspective, as we look at the pricing \nenvironments around branded and generics, we see relative stability in 2023 compared to 2022.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good evening, guys, and I appreciate you taking my question. ", "original_text": "We'll take our next question comes from George Hill with Deutsche Bank.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc5d13b46276a4c896f01b5141b969788ec0ae7a045f8cf2c5c8006905c419db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a617f904-96ff-4a87-8ca1-e108e429d165", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively? ", "original_text": "Q \nHey. "}, "hash": "1bcd574e7ed84d17a883cc15db1c4ea8dc6437d1f7f7323574861229085dbba8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "start_char_idx": 2289, "end_char_idx": 2616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a617f904-96ff-4a87-8ca1-e108e429d165": {"__data__": {"id_": "a617f904-96ff-4a87-8ca1-e108e429d165", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively? ", "original_text": "Q \nHey. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6b6155a-615c-4406-9c49-ca892abc5607", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7aac8495753678efabbcb1dddeef24e15b13bc41d8b7315c55edb8d47e02b6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e0bf72a-3aa5-4521-8e9c-3e6c5dfe228f", "node_type": "1", "metadata": {"window": "We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n ", "original_text": "Good evening, guys, and I appreciate you taking my question. "}, "hash": "5f595e182041163867973df1e66c7564ceddd6fec0ca8f17525fa44dc1d0fbe1", "class_name": "RelatedNodeInfo"}}, "text": "Q \nHey. ", "start_char_idx": 2616, "end_char_idx": 2624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e0bf72a-3aa5-4521-8e9c-3e6c5dfe228f": {"__data__": {"id_": "2e0bf72a-3aa5-4521-8e9c-3e6c5dfe228f", "embedding": null, "metadata": {"window": "We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n ", "original_text": "Good evening, guys, and I appreciate you taking my question. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a617f904-96ff-4a87-8ca1-e108e429d165", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively? ", "original_text": "Q \nHey. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b366101c15dbd2237867333847ec2532eacb7cf6dd373c7ecb1dd2ac2045f88c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e996f86-047a-439f-b761-411c0a9fb861", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses. "}, "hash": "6ad814a2f0d4586e42ed9d1b468b9aa4bee3063d8934f633b0eff09ce1e01a8c", "class_name": "RelatedNodeInfo"}}, "text": "Good evening, guys, and I appreciate you taking my question. ", "start_char_idx": 2624, "end_char_idx": 2685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e996f86-047a-439f-b761-411c0a9fb861": {"__data__": {"id_": "4e996f86-047a-439f-b761-411c0a9fb861", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e0bf72a-3aa5-4521-8e9c-3e6c5dfe228f", "node_type": "1", "metadata": {"window": "We'll take our next question comes from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n ", "original_text": "Good evening, guys, and I appreciate you taking my question. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f1f7388c81a500edfcb6f88e299e8b24738e79e2bc3cea09edf19cb95fe90db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afb13fb8-f2b5-4b22-8963-d79231753891", "node_type": "1", "metadata": {"window": "Q \nHey.  Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "And I guess, are they both \nperforming in line and positively? "}, "hash": "3ed1af703cd3b52aef32b66bc583c2d62e469b43f9acb13ba683578f86733c1d", "class_name": "RelatedNodeInfo"}}, "text": "I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses. ", "start_char_idx": 2685, "end_char_idx": 2929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afb13fb8-f2b5-4b22-8963-d79231753891": {"__data__": {"id_": "afb13fb8-f2b5-4b22-8963-d79231753891", "embedding": null, "metadata": {"window": "Q \nHey.  Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "And I guess, are they both \nperforming in line and positively? ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e996f86-047a-439f-b761-411c0a9fb861", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f2ad8517246e255dbe2eeb7c98f8827feffe7b3d67219163abebac18869e3fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d27e5cb3-3aee-4a0c-9c8f-ec3eb2286d96", "node_type": "1", "metadata": {"window": "Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Let me start, and then certainly, Brian can add on to this. ", "original_text": "Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n "}, "hash": "6855b77bb0c3a0c9a85ade98526d8afe3b68a58dc14dbfd0ca8b961a4db333d3", "class_name": "RelatedNodeInfo"}}, "text": "And I guess, are they both \nperforming in line and positively? ", "start_char_idx": 2929, "end_char_idx": 2992, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d27e5cb3-3aee-4a0c-9c8f-ec3eb2286d96": {"__data__": {"id_": "d27e5cb3-3aee-4a0c-9c8f-ec3eb2286d96", "embedding": null, "metadata": {"window": "Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Let me start, and then certainly, Brian can add on to this. ", "original_text": "Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afb13fb8-f2b5-4b22-8963-d79231753891", "node_type": "1", "metadata": {"window": "Q \nHey.  Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "And I guess, are they both \nperforming in line and positively? ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4662f1bbf84e4905a7add18480bc32246a30184c20b8bb7606c42bd80e315e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6ee16f3-7f6c-40ed-940d-4e3b4c00b6a1", "node_type": "1", "metadata": {"window": "I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "1d039e118403714731c7510a450343443b59c02fd96f9c221d8f1d86cf0c6f19", "class_name": "RelatedNodeInfo"}}, "text": "Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n ", "start_char_idx": 2992, "end_char_idx": 3161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6ee16f3-7f6c-40ed-940d-4e3b4c00b6a1": {"__data__": {"id_": "a6ee16f3-7f6c-40ed-940d-4e3b4c00b6a1", "embedding": null, "metadata": {"window": "I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d27e5cb3-3aee-4a0c-9c8f-ec3eb2286d96", "node_type": "1", "metadata": {"window": "Good evening, guys, and I appreciate you taking my question.  I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Let me start, and then certainly, Brian can add on to this. ", "original_text": "Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eef1428b65795dd68600293dcad8d4609c66db27cca31c31e4e34c5fcade0d28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf17efa4-a7f6-49ba-aa43-819a1b6148e0", "node_type": "1", "metadata": {"window": "And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth. ", "original_text": "A \nYeah. "}, "hash": "2125d6ceeab0bf139ac9393a7fca6d160193e82f0a347f8d8fd466d71b9b86aa", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 416, "end_char_idx": 773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf17efa4-a7f6-49ba-aa43-819a1b6148e0": {"__data__": {"id_": "cf17efa4-a7f6-49ba-aa43-819a1b6148e0", "embedding": null, "metadata": {"window": "And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth. ", "original_text": "A \nYeah. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6ee16f3-7f6c-40ed-940d-4e3b4c00b6a1", "node_type": "1", "metadata": {"window": "I guess, Britt, I would ask if you could talk a \nlittle bit about inside of the Pharmaceutical segment, kind of, the difference between what's happening in the core \nwholesaling business versus the more manufacturer facing services businesses.  And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92d17c278d754572d72c725d0e061c6278d0e4102524d8b2edca0428e2ec2022", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60d24d54-4d3a-43ec-a2c9-a53fb66b7c04", "node_type": "1", "metadata": {"window": "Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms. ", "original_text": "Let me start, and then certainly, Brian can add on to this. "}, "hash": "5cb61bcaecb61c6170d41d1ebd38f9e9660debca0ee124dd49c6f90fb662a4b0", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 3518, "end_char_idx": 3527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60d24d54-4d3a-43ec-a2c9-a53fb66b7c04": {"__data__": {"id_": "60d24d54-4d3a-43ec-a2c9-a53fb66b7c04", "embedding": null, "metadata": {"window": "Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms. ", "original_text": "Let me start, and then certainly, Brian can add on to this. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf17efa4-a7f6-49ba-aa43-819a1b6148e0", "node_type": "1", "metadata": {"window": "And I guess, are they both \nperforming in line and positively?  Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth. ", "original_text": "A \nYeah. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "589729d2b06f205c7bf011453f7201f9392011d98be13930f2cfabc676cd4b1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b6a0a8c-28c9-42f3-9e7c-86b2ed36c1b8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n", "original_text": "Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment. "}, "hash": "f861acdcbfc8f6a23134ce61cbb1f88da9bf6c5211f46febfd33177adb7562e4", "class_name": "RelatedNodeInfo"}}, "text": "Let me start, and then certainly, Brian can add on to this. ", "start_char_idx": 3527, "end_char_idx": 3587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b6a0a8c-28c9-42f3-9e7c-86b2ed36c1b8": {"__data__": {"id_": "2b6a0a8c-28c9-42f3-9e7c-86b2ed36c1b8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n", "original_text": "Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60d24d54-4d3a-43ec-a2c9-a53fb66b7c04", "node_type": "1", "metadata": {"window": "Or is there a meaningful divergence on how the \u2013 what I would call the \npharmacy facing business is performing versus the manufacturer facing business is performing?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms. ", "original_text": "Let me start, and then certainly, Brian can add on to this. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f27e8b74ab8617deff259537e99213c1fa0639996a9d891e2d0d96cf935df4e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6cf8304-5f3a-4a1d-83a6-0c0a7bc73a1c", "node_type": "1", "metadata": {"window": "A \nYeah.  Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions. ", "original_text": "And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth. "}, "hash": "02d7f560a15cb0e32c49f0afbc91c367abefd8c06b054f06ff3459be1a54b103", "class_name": "RelatedNodeInfo"}}, "text": "Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment. ", "start_char_idx": 3587, "end_char_idx": 3725, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6cf8304-5f3a-4a1d-83a6-0c0a7bc73a1c": {"__data__": {"id_": "b6cf8304-5f3a-4a1d-83a6-0c0a7bc73a1c", "embedding": null, "metadata": {"window": "A \nYeah.  Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions. ", "original_text": "And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b6a0a8c-28c9-42f3-9e7c-86b2ed36c1b8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n", "original_text": "Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59dabe2c83feddc669e8b6bfa725bb2d39624ee971e5c3b4683496af9c7689d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "299025d5-265d-4d93-95c0-bf1beac77859", "node_type": "1", "metadata": {"window": "Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n", "original_text": "We're seeing \nmore brands being added to our platforms. "}, "hash": "b9d142145488e3ad71a3a93c2accc136cf94a1c7de679f6e1b79e2e12c4120bc", "class_name": "RelatedNodeInfo"}}, "text": "And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth. ", "start_char_idx": 3725, "end_char_idx": 3838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "299025d5-265d-4d93-95c0-bf1beac77859": {"__data__": {"id_": "299025d5-265d-4d93-95c0-bf1beac77859", "embedding": null, "metadata": {"window": "Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n", "original_text": "We're seeing \nmore brands being added to our platforms. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6cf8304-5f3a-4a1d-83a6-0c0a7bc73a1c", "node_type": "1", "metadata": {"window": "A \nYeah.  Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions. ", "original_text": "And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41d07a40fad3bff52852eb905a69340b5bbb5b3181514cb41446eb0da02b83eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5741895-247c-44cf-a50a-1a765ab72dbc", "node_type": "1", "metadata": {"window": "Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes. ", "original_text": "We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n"}, "hash": "01cf2cf3e29e14ec8803445db09c01af983014abf76b4b15e42dffe1e454cc10", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing \nmore brands being added to our platforms. ", "start_char_idx": 3838, "end_char_idx": 3894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5741895-247c-44cf-a50a-1a765ab72dbc": {"__data__": {"id_": "f5741895-247c-44cf-a50a-1a765ab72dbc", "embedding": null, "metadata": {"window": "Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes. ", "original_text": "We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "299025d5-265d-4d93-95c0-bf1beac77859", "node_type": "1", "metadata": {"window": "Let me start, and then certainly, Brian can add on to this.  Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n", "original_text": "We're seeing \nmore brands being added to our platforms. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b557ff9ff5f51613695683b949047baa25fe952ad01c8a73fc7784d0b19c8ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8890db6-6011-44f3-a59a-1a8fdfea2799", "node_type": "1", "metadata": {"window": "And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n ", "original_text": "In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions. "}, "hash": "8c3f11558185220778fd693d5cf1f6fa59e9a6b7e732c16d9bb8aa23e4cbebf4", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n", "start_char_idx": 3894, "end_char_idx": 3987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8890db6-6011-44f3-a59a-1a8fdfea2799": {"__data__": {"id_": "a8890db6-6011-44f3-a59a-1a8fdfea2799", "embedding": null, "metadata": {"window": "And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n ", "original_text": "In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5741895-247c-44cf-a50a-1a765ab72dbc", "node_type": "1", "metadata": {"window": "Our biopharma services, I think, as you've \ncaptured on manufacturer services, those businesses are captured in our Rx Solutions segment.  And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes. ", "original_text": "We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36daeda29d6ed3be006c2b6d477edc36abbb9c3580da6f6ca6bd72353e2eea95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3425f9b2-8abf-4a06-ac95-421b8e1ca43c", "node_type": "1", "metadata": {"window": "We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n"}, "hash": "a775ef9355da3f7d73e8d918e0cacb8e9951408ade5363d6353f4fcfc73ca759", "class_name": "RelatedNodeInfo"}}, "text": "In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions. ", "start_char_idx": 3987, "end_char_idx": 4094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3425f9b2-8abf-4a06-ac95-421b8e1ca43c": {"__data__": {"id_": "3425f9b2-8abf-4a06-ac95-421b8e1ca43c", "embedding": null, "metadata": {"window": "We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8890db6-6011-44f3-a59a-1a8fdfea2799", "node_type": "1", "metadata": {"window": "And as we've \ntalked about, that business continues to generate really good revenue, top line and profit growth.  We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n ", "original_text": "In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "38a2979eaf638a00b8704a0472162abf7a6d08aef72ac38e90a62c8ae022bf85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7dc8fd0a-cc20-407f-a150-6c0f4c7df810", "node_type": "1", "metadata": {"window": "We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes. "}, "hash": "af80b3c34933fa0305125ee4d58e20bfff0f1fbd0b585ceb80aaa8f86756cd0a", "class_name": "RelatedNodeInfo"}}, "text": "And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n", "start_char_idx": 4094, "end_char_idx": 4215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7dc8fd0a-cc20-407f-a150-6c0f4c7df810": {"__data__": {"id_": "7dc8fd0a-cc20-407f-a150-6c0f4c7df810", "embedding": null, "metadata": {"window": "We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3425f9b2-8abf-4a06-ac95-421b8e1ca43c", "node_type": "1", "metadata": {"window": "We're seeing \nmore brands being added to our platforms.  We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28f0612df861fd0912b763d600b62d3d0cc3f1fc4d4e4df751fe6734f33cfad5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fd77417-dc84-4c4b-a455-c8bb346e79c2", "node_type": "1", "metadata": {"window": "In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business. ", "original_text": "Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n "}, "hash": "af60a88eebbdab2e2d592df0823fa5dbff049cbf1be51c92b78e3f02cd618a09", "class_name": "RelatedNodeInfo"}}, "text": "So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes. ", "start_char_idx": 4215, "end_char_idx": 4330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fd77417-dc84-4c4b-a455-c8bb346e79c2": {"__data__": {"id_": "9fd77417-dc84-4c4b-a455-c8bb346e79c2", "embedding": null, "metadata": {"window": "In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business. ", "original_text": "Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7dc8fd0a-cc20-407f-a150-6c0f4c7df810", "node_type": "1", "metadata": {"window": "We're seeing good acceptance in the marketplace of our access a nd \nadherence solutions.  \n \n In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "747a445110cd609f89f725bd89ed67aa22aad036ab8b32c41242f2fc49ccf1d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cd3bd59-b62b-46be-9e84-9561a65710a8", "node_type": "1", "metadata": {"window": "And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business.  Our forward guide for  FY 2023 is in line. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "90141671efe59a7f9bbb43f811fab77d8ff30090f56e8f96079ec144184e3ce6", "class_name": "RelatedNodeInfo"}}, "text": "Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n ", "start_char_idx": 4330, "end_char_idx": 4460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cd3bd59-b62b-46be-9e84-9561a65710a8": {"__data__": {"id_": "2cd3bd59-b62b-46be-9e84-9561a65710a8", "embedding": null, "metadata": {"window": "And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business.  Our forward guide for  FY 2023 is in line. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fd77417-dc84-4c4b-a455-c8bb346e79c2", "node_type": "1", "metadata": {"window": "In both of our businesses, as I talked about, we're seeing improved transaction volume from prescriptions.  And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business. ", "original_text": "Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ed99f014d47fd91d1f1c72d0a6cb2d177ffc88dfe304c784ff5a82ef556e15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6490d48-8519-4e11-87c5-866db0f1dc0f", "node_type": "1", "metadata": {"window": "So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business.  Our forward guide for  FY 2023 is in line. ", "original_text": "A \nYeah. "}, "hash": "c6962a5bf4b0d6fc633651e35d079638e4d8667b774942bb1eb2338cc7a790ce", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 4460, "end_char_idx": 4801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6490d48-8519-4e11-87c5-866db0f1dc0f": {"__data__": {"id_": "a6490d48-8519-4e11-87c5-866db0f1dc0f", "embedding": null, "metadata": {"window": "So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business.  Our forward guide for  FY 2023 is in line. ", "original_text": "A \nYeah. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cd3bd59-b62b-46be-9e84-9561a65710a8", "node_type": "1", "metadata": {"window": "And \nthat certainly is benefiting our Prescription Technology Solutions segment very well, both new and existing brand. \n So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business.  Our forward guide for  FY 2023 is in line. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77c5e901eaeb0308d741fc62c38151162702b5bc053de5d1cdb3e1bdcfa863c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "448c69b2-5614-4bce-a3a9-20dcdf1fb57d", "node_type": "1", "metadata": {"window": "Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business.  Our forward guide for  FY 2023 is in line. ", "original_text": "And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business. "}, "hash": "0d953aac66303dcc04d66240f673a5a05a4948c557be9f1401819f988e126400", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 3518, "end_char_idx": 3527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "448c69b2-5614-4bce-a3a9-20dcdf1fb57d": {"__data__": {"id_": "448c69b2-5614-4bce-a3a9-20dcdf1fb57d", "embedding": null, "metadata": {"window": "Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business.  Our forward guide for  FY 2023 is in line. ", "original_text": "And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6490d48-8519-4e11-87c5-866db0f1dc0f", "node_type": "1", "metadata": {"window": "So I'd say both of those businesses are benefiting from the macro factors of seeing improved transaction \nvolumes.  Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business.  Our forward guide for  FY 2023 is in line. ", "original_text": "A \nYeah. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58478ed0d7c14f89f74bc58f71e22826133208d9941ceb9e5b09bc459fa5adb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c3bbdce-a0dc-4a00-878b-74fcba3572bd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business.  Our forward guide for  FY 2023 is in line. ", "original_text": "Our forward guide for  FY 2023 is in line. "}, "hash": "9dee8eec21f60ab22d48dd3157a1d5bd7b3f7232d26e339083a6cee48d18ae80", "class_name": "RelatedNodeInfo"}}, "text": "And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business. ", "start_char_idx": 4810, "end_char_idx": 4986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c3bbdce-a0dc-4a00-878b-74fcba3572bd": {"__data__": {"id_": "9c3bbdce-a0dc-4a00-878b-74fcba3572bd", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business.  Our forward guide for  FY 2023 is in line. ", "original_text": "Our forward guide for  FY 2023 is in line. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6076041a28ce829cad687b9258bfaf5ae4a1f599b58ea0c2a7184fd8b801d81", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "448c69b2-5614-4bce-a3a9-20dcdf1fb57d", "node_type": "1", "metadata": {"window": "Clearly, the growth of our technology solutions in RxTS and our access and adherence solutions are \nseeing really good growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business.  Our forward guide for  FY 2023 is in line. ", "original_text": "And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66ddfdac5ef4e02bfdc9c18f256ab274858591744c514e53c70c9c008d431997", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ca7b467-3bc3-482f-858c-a397de2f6772", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target.  So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n", "original_text": "McKesson Corp.  "}, "hash": "5448b60b7a6166b9088b6697daa890290dcd852b82be4b248dc2583b59f3fbe9", "class_name": "RelatedNodeInfo"}}, "text": "Our forward guide for  FY 2023 is in line. ", "start_char_idx": 4986, "end_char_idx": 5029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ca7b467-3bc3-482f-858c-a397de2f6772": {"__data__": {"id_": "9ca7b467-3bc3-482f-858c-a397de2f6772", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target.  So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c3bbdce-a0dc-4a00-878b-74fcba3572bd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  And I'd just say, we've created RxTS segment to give you visibility into how that business is performing, \nand we're quite pleased that both the core pharma and RxTS business.  Our forward guide for  FY 2023 is in line. ", "original_text": "Our forward guide for  FY 2023 is in line. ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "025317c26f3d8513125edf34f217744b486814765b6edb9a4c837785fbab27fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "305915ba-1433-429b-ae73-e718207b31c0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target.  So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target. "}, "hash": "b4e9864fee2140492c56a0da1e55c80cca9d1276dfe155d79d69b1dacfe350a1", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "305915ba-1433-429b-ae73-e718207b31c0": {"__data__": {"id_": "305915ba-1433-429b-ae73-e718207b31c0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target.  So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ca7b467-3bc3-482f-858c-a397de2f6772", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target.  So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ae2f9c3c8b0b21293ae194bf39233d2fae3143a4b5ec304c49775e6d034abcc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4d60107-9f59-4788-b9a0-17b065cc939a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target.  So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay.  Well, thank you. ", "original_text": "So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n "}, "hash": "a533e87036b80c51c452edb4461e8ff92d2e009b617e4344dd1150057d4e7acf", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target. ", "start_char_idx": 16, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4d60107-9f59-4788-b9a0-17b065cc939a": {"__data__": {"id_": "a4d60107-9f59-4788-b9a0-17b065cc939a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target.  So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay.  Well, thank you. ", "original_text": "So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "305915ba-1433-429b-ae73-e718207b31c0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target.  So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay. ", "original_text": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "763724a689ea9b94a002d31fdf3c56f9b10b75bed3d055b0dc619d2872d754a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "babaa589-afbf-4f30-b21d-14b620f2e482", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target.  So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay.  Well, thank you.  Thanks for your patience. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n"}, "hash": "caa29f7d31107f204b7eed1a63ccea189de31d81bda21819c5595963cd212b77", "class_name": "RelatedNodeInfo"}}, "text": "So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n ", "start_char_idx": 283, "end_char_idx": 373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "babaa589-afbf-4f30-b21d-14b620f2e482": {"__data__": {"id_": "babaa589-afbf-4f30-b21d-14b620f2e482", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target.  So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay.  Well, thank you.  Thanks for your patience. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4d60107-9f59-4788-b9a0-17b065cc939a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target.  So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay.  Well, thank you. ", "original_text": "So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6495e3fc40f216d9545b2c10bd17823db7f9fc686381c34084a10888afc1e876", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0543237c-8f19-44ce-b47d-a2f7d908979a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target.  So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay.  Well, thank you.  Thanks for your patience.  I know we ran a few minutes longer than we normally do. ", "original_text": "Okay. "}, "hash": "3e8465f4e435d103e3517733f74690fc05557cc6b77c7db119eb5d8a20fce7c6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n", "start_char_idx": 373, "end_char_idx": 716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0543237c-8f19-44ce-b47d-a2f7d908979a": {"__data__": {"id_": "0543237c-8f19-44ce-b47d-a2f7d908979a", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target.  So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay.  Well, thank you.  Thanks for your patience.  I know we ran a few minutes longer than we normally do. ", "original_text": "Okay. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "babaa589-afbf-4f30-b21d-14b620f2e482", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target.  So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay.  Well, thank you.  Thanks for your patience. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "076a78e5ceb6234d68cc0827b30d99ce2eea8e086a0adb802a046ca68e0429de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dfd5cb7-27d4-4771-a8e8-ceb575c336a6", "node_type": "1", "metadata": {"window": "So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay.  Well, thank you.  Thanks for your patience.  I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call. ", "original_text": "Well, thank you. "}, "hash": "365b3d6e259a22d0843750428a5d6f7fc5495618572c0d3bbad7929a86f15534", "class_name": "RelatedNodeInfo"}}, "text": "Okay. ", "start_char_idx": 716, "end_char_idx": 722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dfd5cb7-27d4-4771-a8e8-ceb575c336a6": {"__data__": {"id_": "8dfd5cb7-27d4-4771-a8e8-ceb575c336a6", "embedding": null, "metadata": {"window": "So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay.  Well, thank you.  Thanks for your patience.  I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call. ", "original_text": "Well, thank you. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0543237c-8f19-44ce-b47d-a2f7d908979a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target.  So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay.  Well, thank you.  Thanks for your patience.  I know we ran a few minutes longer than we normally do. ", "original_text": "Okay. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "867f30d88c73c7c72e03da1096cebfb5865f7f64d843cf9f3f8470e70a9b000d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "163dab90-ad5a-44e2-bc76-26aec57daa86", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay.  Well, thank you.  Thanks for your patience.  I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call. ", "original_text": "Thanks for your patience. "}, "hash": "5a6f241ffd3b1c1bba0969419c870dc5059e460735a2338b2ab8d22577ca4121", "class_name": "RelatedNodeInfo"}}, "text": "Well, thank you. ", "start_char_idx": 722, "end_char_idx": 739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "163dab90-ad5a-44e2-bc76-26aec57daa86": {"__data__": {"id_": "163dab90-ad5a-44e2-bc76-26aec57daa86", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay.  Well, thank you.  Thanks for your patience.  I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call. ", "original_text": "Thanks for your patience. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dfd5cb7-27d4-4771-a8e8-ceb575c336a6", "node_type": "1", "metadata": {"window": "So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay.  Well, thank you.  Thanks for your patience.  I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call. ", "original_text": "Well, thank you. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9dc59448867afc0cbbd019a3db458a14bbd01871546306f6f625ff6459123b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43a2061a-c3b6-405c-b785-fc7431ec0c09", "node_type": "1", "metadata": {"window": "Okay.  Well, thank you.  Thanks for your patience.  I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson. ", "original_text": "I know we ran a few minutes longer than we normally do. "}, "hash": "7f0a2e5a4a96a3c9b752e2ad568e2c8410aed569330d18487451511eb1461463", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for your patience. ", "start_char_idx": 739, "end_char_idx": 765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43a2061a-c3b6-405c-b785-fc7431ec0c09": {"__data__": {"id_": "43a2061a-c3b6-405c-b785-fc7431ec0c09", "embedding": null, "metadata": {"window": "Okay.  Well, thank you.  Thanks for your patience.  I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson. ", "original_text": "I know we ran a few minutes longer than we normally do. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "163dab90-ad5a-44e2-bc76-26aec57daa86", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n Okay.  Well, thank you.  Thanks for your patience.  I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call. ", "original_text": "Thanks for your patience. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03c54a43ccebf10ff13cb33c49b5e0a07f9928dbe3fa2a01d0d6daf01b698426", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30eac066-cf25-4481-87df-c1fc5a30caa7", "node_type": "1", "metadata": {"window": "Well, thank you.  Thanks for your patience.  I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n", "original_text": "It's \ntypical at a year -end or year kick -off call. "}, "hash": "2f980be64a849154d239dbaa0e6e121e42efe804cc3681d7d2eb339d266bbacc", "class_name": "RelatedNodeInfo"}}, "text": "I know we ran a few minutes longer than we normally do. ", "start_char_idx": 765, "end_char_idx": 821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30eac066-cf25-4481-87df-c1fc5a30caa7": {"__data__": {"id_": "30eac066-cf25-4481-87df-c1fc5a30caa7", "embedding": null, "metadata": {"window": "Well, thank you.  Thanks for your patience.  I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n", "original_text": "It's \ntypical at a year -end or year kick -off call. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43a2061a-c3b6-405c-b785-fc7431ec0c09", "node_type": "1", "metadata": {"window": "Okay.  Well, thank you.  Thanks for your patience.  I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson. ", "original_text": "I know we ran a few minutes longer than we normally do. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0295b11afdd2c5ba9b0e7f4836d343e22c0c8a335dc02b10e253688362dc491", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f978aca1-69ad-4678-8c37-d333283485de", "node_type": "1", "metadata": {"window": "Thanks for your patience.  I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023. ", "original_text": "I want to thank everyone for your time and for joining this call. "}, "hash": "abe9dab8af6fb21395f01b2d9150f654386cb3a8bfd5bb0e5e1b38ca2cb061a1", "class_name": "RelatedNodeInfo"}}, "text": "It's \ntypical at a year -end or year kick -off call. ", "start_char_idx": 821, "end_char_idx": 874, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f978aca1-69ad-4678-8c37-d333283485de": {"__data__": {"id_": "f978aca1-69ad-4678-8c37-d333283485de", "embedding": null, "metadata": {"window": "Thanks for your patience.  I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023. ", "original_text": "I want to thank everyone for your time and for joining this call. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30eac066-cf25-4481-87df-c1fc5a30caa7", "node_type": "1", "metadata": {"window": "Well, thank you.  Thanks for your patience.  I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n", "original_text": "It's \ntypical at a year -end or year kick -off call. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ff740e92b518e10c7df8bab249a30c1f8f37bcf3e0e00d5516d48f810f05975", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e44a8435-3ab5-4f11-92f1-01afa75de97a", "node_type": "1", "metadata": {"window": "I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n", "original_text": "We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson. "}, "hash": "30409b19d1010bed71c8f4d48af478f6cd9fff2650efc1cd2e0ba6dc6c8e72d9", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank everyone for your time and for joining this call. ", "start_char_idx": 874, "end_char_idx": 940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e44a8435-3ab5-4f11-92f1-01afa75de97a": {"__data__": {"id_": "e44a8435-3ab5-4f11-92f1-01afa75de97a", "embedding": null, "metadata": {"window": "I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n", "original_text": "We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f978aca1-69ad-4678-8c37-d333283485de", "node_type": "1", "metadata": {"window": "Thanks for your patience.  I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023. ", "original_text": "I want to thank everyone for your time and for joining this call. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35581ef5ea67a1d49e37a59e252d25b7e9012fa1ffbfbd08896b63473b3e6305", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3506f200-2808-4676-ad26-40a1d2b15a61", "node_type": "1", "metadata": {"window": "It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business. ", "original_text": "Thank you, Cody, for facilitating \nthe call for us.  \n \n"}, "hash": "f0b4be078e14ce8560254ccea9a305c26578cee63838da86b0afe94479ea16ad", "class_name": "RelatedNodeInfo"}}, "text": "We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson. ", "start_char_idx": 940, "end_char_idx": 1031, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3506f200-2808-4676-ad26-40a1d2b15a61": {"__data__": {"id_": "3506f200-2808-4676-ad26-40a1d2b15a61", "embedding": null, "metadata": {"window": "It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business. ", "original_text": "Thank you, Cody, for facilitating \nthe call for us.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e44a8435-3ab5-4f11-92f1-01afa75de97a", "node_type": "1", "metadata": {"window": "I know we ran a few minutes longer than we normally do.  It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n", "original_text": "We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dccd5e3f8370f29a779eff3cd557294f1bf0f3acfc8cd45a28d9f61c55320823", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7322081f-ef2d-4f47-a656-476ded2b905e", "node_type": "1", "metadata": {"window": "I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact. ", "original_text": "Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023. "}, "hash": "d3494adfc2f6dac173988932e80b1402094313fd813ca910093feb125052e48a", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Cody, for facilitating \nthe call for us.  \n \n", "start_char_idx": 1031, "end_char_idx": 1087, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7322081f-ef2d-4f47-a656-476ded2b905e": {"__data__": {"id_": "7322081f-ef2d-4f47-a656-476ded2b905e", "embedding": null, "metadata": {"window": "I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact. ", "original_text": "Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3506f200-2808-4676-ad26-40a1d2b15a61", "node_type": "1", "metadata": {"window": "It's \ntypical at a year -end or year kick -off call.  I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business. ", "original_text": "Thank you, Cody, for facilitating \nthe call for us.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8050ed63f65c6d274ce662bd2b8d56be10f64e9786bebf3c09ce0fdce199e1a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bf542bf-550f-4345-bb0e-02971b4568f8", "node_type": "1", "metadata": {"window": "We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody. ", "original_text": "I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n"}, "hash": "0955accacbf2197dfa9a37b4818c39569c25978206895273b05c7b38004e48f0", "class_name": "RelatedNodeInfo"}}, "text": "Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023. ", "start_char_idx": 1087, "end_char_idx": 1289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bf542bf-550f-4345-bb0e-02971b4568f8": {"__data__": {"id_": "8bf542bf-550f-4345-bb0e-02971b4568f8", "embedding": null, "metadata": {"window": "We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody. ", "original_text": "I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7322081f-ef2d-4f47-a656-476ded2b905e", "node_type": "1", "metadata": {"window": "I want to thank everyone for your time and for joining this call.  We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact. ", "original_text": "Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93d3829eda7b8379530afefd69a44df926087342ecaba887d27490e75a1765dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90067233-3eaf-4a78-b79a-1c4a09f55711", "node_type": "1", "metadata": {"window": "Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n ", "original_text": "Of course, it's all due to the people that make up Team McKesson acros s all areas of our business. "}, "hash": "b1c4fe9ee32855830a6749106d5cf7508c90e0ac4176bfc747cda03be2d2efbb", "class_name": "RelatedNodeInfo"}}, "text": "I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n", "start_char_idx": 1289, "end_char_idx": 1408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90067233-3eaf-4a78-b79a-1c4a09f55711": {"__data__": {"id_": "90067233-3eaf-4a78-b79a-1c4a09f55711", "embedding": null, "metadata": {"window": "Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n ", "original_text": "Of course, it's all due to the people that make up Team McKesson acros s all areas of our business. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bf542bf-550f-4345-bb0e-02971b4568f8", "node_type": "1", "metadata": {"window": "We really \nappreciate your thoughtful questions, and certainly, your interest in McKesson.  Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody. ", "original_text": "I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e85e9873866265866c9bfdb9d617b38a01d58885b932023d039d60c055f76a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23f8c802-fc94-42b4-a5a1-d3047df6b6ba", "node_type": "1", "metadata": {"window": "Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact. "}, "hash": "4b2ba25c454aef66e82636ca71b7665f7be285275ab639af2a249d5191a4d289", "class_name": "RelatedNodeInfo"}}, "text": "Of course, it's all due to the people that make up Team McKesson acros s all areas of our business. ", "start_char_idx": 1408, "end_char_idx": 1508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23f8c802-fc94-42b4-a5a1-d3047df6b6ba": {"__data__": {"id_": "23f8c802-fc94-42b4-a5a1-d3047df6b6ba", "embedding": null, "metadata": {"window": "Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90067233-3eaf-4a78-b79a-1c4a09f55711", "node_type": "1", "metadata": {"window": "Thank you, Cody, for facilitating \nthe call for us.  \n \n Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n ", "original_text": "Of course, it's all due to the people that make up Team McKesson acros s all areas of our business. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8773a68dd75de2309b659e3e3af3854a9c259379bf7d352b732a3128b2d502ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92d79c00-da0d-40f1-8546-a9c187209cbe", "node_type": "1", "metadata": {"window": "I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n ", "original_text": "T hanks, \neveryone \u2013 again, everybody. "}, "hash": "c360e592e76a0ef95e1c5ae25fdb27a6a45f9d20f8808a30afcccda42f694400", "class_name": "RelatedNodeInfo"}}, "text": "I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact. ", "start_char_idx": 1508, "end_char_idx": 1736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92d79c00-da0d-40f1-8546-a9c187209cbe": {"__data__": {"id_": "92d79c00-da0d-40f1-8546-a9c187209cbe", "embedding": null, "metadata": {"window": "I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n ", "original_text": "T hanks, \neveryone \u2013 again, everybody. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23f8c802-fc94-42b4-a5a1-d3047df6b6ba", "node_type": "1", "metadata": {"window": "Just to conclude, McKesson delivered a strong fiscal 2022 with double -digit adjusted operating profit growth and I \nam excited ab out the continued progress of our company priorities into fiscal 2023.  I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "320d56cbbbd143684524d34d58c08a93ed43d3d0af3943bb7e7e08bf9e574f88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a3b7629-d792-4aee-9a8a-4044721eae46", "node_type": "1", "metadata": {"window": "Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "original_text": "I hope you all have a terrific evening.  \n "}, "hash": "1c0871760415987811c99752751c19791c7d0e7a8a3088a2204f6c3840f74e08", "class_name": "RelatedNodeInfo"}}, "text": "T hanks, \neveryone \u2013 again, everybody. ", "start_char_idx": 1736, "end_char_idx": 1775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a3b7629-d792-4aee-9a8a-4044721eae46": {"__data__": {"id_": "8a3b7629-d792-4aee-9a8a-4044721eae46", "embedding": null, "metadata": {"window": "Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "original_text": "I hope you all have a terrific evening.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92d79c00-da0d-40f1-8546-a9c187209cbe", "node_type": "1", "metadata": {"window": "I'm confident about our ability \nto deliver strong growth, solid financial results and shareholder value creation.  \n \n Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n ", "original_text": "T hanks, \neveryone \u2013 again, everybody. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6920120caeb081d0cf964a08419e4f7a7e6730f984eb822ebb6ff2815541872", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84fd8819-cf18-4d9c-9e45-9eb59a31742e", "node_type": "1", "metadata": {"window": "I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. "}, "hash": "225aff12a867963affcea14a8ee732003eb71b79489e8b8d4570d781e3d389d9", "class_name": "RelatedNodeInfo"}}, "text": "I hope you all have a terrific evening.  \n ", "start_char_idx": 1775, "end_char_idx": 1818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84fd8819-cf18-4d9c-9e45-9eb59a31742e": {"__data__": {"id_": "84fd8819-cf18-4d9c-9e45-9eb59a31742e", "embedding": null, "metadata": {"window": "I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a3b7629-d792-4aee-9a8a-4044721eae46", "node_type": "1", "metadata": {"window": "Of course, it's all due to the people that make up Team McKesson acros s all areas of our business.  I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "original_text": "I hope you all have a terrific evening.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8cde34efcbf3ea39bdd095f05260cdf1049bf13198fe7a219ffde4e7593f357f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ef78bc0-64bd-4733-84b0-a37e88f7fbb2", "node_type": "1", "metadata": {"window": "T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions. ", "original_text": "You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n "}, "hash": "354c5c58b8df18e4f486d509a83b419d3cee5d2c4f28871f8b851fe3210fd7b8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "start_char_idx": 1818, "end_char_idx": 2150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ef78bc0-64bd-4733-84b0-a37e88f7fbb2": {"__data__": {"id_": "0ef78bc0-64bd-4733-84b0-a37e88f7fbb2", "embedding": null, "metadata": {"window": "T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions. ", "original_text": "You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84fd8819-cf18-4d9c-9e45-9eb59a31742e", "node_type": "1", "metadata": {"window": "I want to \nthank them for their hard work and their dedication to executing on our strategies, for living our culture and our \nvalues and bringing positive changes to our partners, our customers and the patients that we impact.  T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d8eba53d7c442cea52ef41b82a95ebf0119e393627e6f33a67d976650966f1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8cc0cb1-4826-4d96-8f97-5e079764ae5c", "node_type": "1", "metadata": {"window": "I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n"}, "hash": "080a256d68ffcf2f2a6e850b0101f8cc4f38f610e396a4cdee850a887e89555f", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n ", "start_char_idx": 2150, "end_char_idx": 2197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8cc0cb1-4826-4d96-8f97-5e079764ae5c": {"__data__": {"id_": "b8cc0cb1-4826-4d96-8f97-5e079764ae5c", "embedding": null, "metadata": {"window": "I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ef78bc0-64bd-4733-84b0-a37e88f7fbb2", "node_type": "1", "metadata": {"window": "T hanks, \neveryone \u2013 again, everybody.  I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions. ", "original_text": "You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d9e17261da4c6f71068f3dda547e956c7ffc375c62e2cd687cfd8a25a61bcbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e93b84a-4067-457a-8960-08c09161c792", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. "}, "hash": "61ba61190611b9ee6ff0a540595f150e8575fff999b549a85a040ffbb4288e3a", "class_name": "RelatedNodeInfo"}}, "text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "start_char_idx": 2197, "end_char_idx": 2406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e93b84a-4067-457a-8960-08c09161c792": {"__data__": {"id_": "4e93b84a-4067-457a-8960-08c09161c792", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8cc0cb1-4826-4d96-8f97-5e079764ae5c", "node_type": "1", "metadata": {"window": "I hope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e710150b87462b8c1bfb1e6638c4c39ae2f0e7a91d88bee3416a20a51040344b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c033c49-08ce-4f5c-9d88-c16a209bfb6f", "node_type": "1", "metadata": {"window": "You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions. "}, "hash": "6109ad8713a8ce394922eaa9e202799280778eea8753e175618043d1755ca6fd", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "start_char_idx": 2406, "end_char_idx": 2528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c033c49-08ce-4f5c-9d88-c16a209bfb6f": {"__data__": {"id_": "6c033c49-08ce-4f5c-9d88-c16a209bfb6f", "embedding": null, "metadata": {"window": "You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e93b84a-4067-457a-8960-08c09161c792", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73024f6a69441c6d6a57ada9bda0953d3a9a8e43d51d1af9c22360f5fde68b0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "608d90ed-54f9-49a8-a5bb-689bae829e1a", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investor. "}, "hash": "3aa3ec5de3e2d0ed4699ec1585273ad076b0ca405add75ef3be0ea3cf6903070", "class_name": "RelatedNodeInfo"}}, "text": "You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions. ", "start_char_idx": 2528, "end_char_idx": 2822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "608d90ed-54f9-49a8-a5bb-689bae829e1a": {"__data__": {"id_": "608d90ed-54f9-49a8-a5bb-689bae829e1a", "embedding": null, "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investor. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c033c49-08ce-4f5c-9d88-c16a209bfb6f", "node_type": "1", "metadata": {"window": "You may now disconnect.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a577247b646f4fa601f2b1013aeb0035e387bb1d14f11f76d3f5e24c1fa20cf4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "991054af-3942-48f3-8abd-4b9784817c07", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. "}, "hash": "4a53dd7f7917eaf9994ea1175a1036d47e8c091c60940f742c9bf8622e3ff68f", "class_name": "RelatedNodeInfo"}}, "text": "It should not be construed as advice designed to meet the particular investment needs of any investor. ", "start_char_idx": 2822, "end_char_idx": 2925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "991054af-3942-48f3-8abd-4b9784817c07": {"__data__": {"id_": "991054af-3942-48f3-8abd-4b9784817c07", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "608d90ed-54f9-49a8-a5bb-689bae829e1a", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but  is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investor. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d404ddf8da7166d0903cd6339e9832e4f1001c53974b163b48759adc1803a4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dc962b6-3410-4ab2-bb83-fecccd5d726d", "node_type": "1", "metadata": {"window": "You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any  \ninformation expressed herein on this date is subject to change without notice. "}, "hash": "f57d82cef43b8b7e1c29a5a6161d4054b3a7655a32636da42246ea6557ba1950", "class_name": "RelatedNodeInfo"}}, "text": "Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "start_char_idx": 2925, "end_char_idx": 3184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dc962b6-3410-4ab2-bb83-fecccd5d726d": {"__data__": {"id_": "2dc962b6-3410-4ab2-bb83-fecccd5d726d", "embedding": null, "metadata": {"window": "You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any  \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "991054af-3942-48f3-8abd-4b9784817c07", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8086962108f6972ea1c304f133dd48bd5e20aebe00a0e25c6b81c2c91e317797", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd474117-3df5-4cf4-8a47-b976033f9a3e", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. "}, "hash": "c8a39a0d0e922a85cd03f75d1481e059f0b4d7047a95ae9f5a4733512bf2f420", "class_name": "RelatedNodeInfo"}}, "text": "Any  \ninformation expressed herein on this date is subject to change without notice. ", "start_char_idx": 3184, "end_char_idx": 3269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd474117-3df5-4cf4-8a47-b976033f9a3e": {"__data__": {"id_": "cd474117-3df5-4cf4-8a47-b976033f9a3e", "embedding": null, "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dc962b6-3410-4ab2-bb83-fecccd5d726d", "node_type": "1", "metadata": {"window": "You  must eval uate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof inv estment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any  \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d8bc39a6a338f82ae317497d61b9ebafc35ac460e2cc53608b852f45d8c4f24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a255a4cc-f426-4758-b7a0-36cd92559f06", "node_type": "1", "metadata": {"window": "Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n"}, "hash": "b6a33bb86cf8661919824e5469ea1250238b44acadd42bf0299545a2655ea038", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "start_char_idx": 3269, "end_char_idx": 3398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a255a4cc-f426-4758-b7a0-36cd92559f06": {"__data__": {"id_": "a255a4cc-f426-4758-b7a0-36cd92559f06", "embedding": null, "metadata": {"window": "Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd474117-3df5-4cf4-8a47-b976033f9a3e", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investor.  Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b0735508944c92313e28a60d0185e31e2339a0c03fc733ca6eb1e6ebb6ebb0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62504520-cea0-4036-816d-2933ff847a05", "node_type": "1", "metadata": {"window": "Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother tradema rks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. "}, "hash": "b393ba17af5d54c99fe8d90d2202a1e5f694ff5c184849df2e33b565a68aa458", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "start_char_idx": 3398, "end_char_idx": 3561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62504520-cea0-4036-816d-2933ff847a05": {"__data__": {"id_": "62504520-cea0-4036-816d-2933ff847a05", "embedding": null, "metadata": {"window": "Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother tradema rks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a255a4cc-f426-4758-b7a0-36cd92559f06", "node_type": "1", "metadata": {"window": "Thi s report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to se ll or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6111a076d508e2312b67a8f491cf6cd69d45e9d9edbc728256702f91e8480616", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d80d32f-2dc8-45d8-97a5-301bb75e06b0", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother tradema rks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n"}, "hash": "bcb28bd09f83597d46bed7821085c611dc74d51605707bd62a68ea01fa36bea4", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "start_char_idx": 3561, "end_char_idx": 3996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d80d32f-2dc8-45d8-97a5-301bb75e06b0": {"__data__": {"id_": "0d80d32f-2dc8-45d8-97a5-301bb75e06b0", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother tradema rks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62504520-cea0-4036-816d-2933ff847a05", "node_type": "1", "metadata": {"window": "Any  \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother tradema rks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1b08dd099f1ed206b8daebef4c9176a6c93b0221d8cb36448b685ac63c89a46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab87ad88-027a-4877-af57-f61f356dec03", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother tradema rks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. "}, "hash": "e45831e145af0ab7af4d18ebd6c773bb47c1740b8f0213672a8dd30ef00e228e", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "start_char_idx": 3996, "end_char_idx": 4676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab87ad88-027a-4877-af57-f61f356dec03": {"__data__": {"id_": "ab87ad88-027a-4877-af57-f61f356dec03", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother tradema rks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d80d32f-2dc8-45d8-97a5-301bb75e06b0", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nform ation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother tradema rks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab258f2823b6c61908ff1181b1bef0dfa1db4080ad12c3f7e19aca4bbdd3fbf1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c86dd5f7-092b-4198-adbd-a3b656933831", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother tradema rks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother tradema rks mentioned are trademarks of their respective companies. "}, "hash": "4a11de366527e322301d2cd33f22389f1d6207e6bbdbd6d249d2db795ad609dd", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "start_char_idx": 4676, "end_char_idx": 4865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c86dd5f7-092b-4198-adbd-a3b656933831": {"__data__": {"id_": "c86dd5f7-092b-4198-adbd-a3b656933831", "embedding": null, "metadata": {"window": "THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother tradema rks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother tradema rks mentioned are trademarks of their respective companies. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab87ad88-027a-4877-af57-f61f356dec03", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother tradema rks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3240ead9ba4d9d6491caf98ce0dafd7e2d8fc4a886e6cb3465632da132975b01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d86abaf5-8eac-42ea-8395-e96457dbf081", "node_type": "1", "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother tradema rks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "41e3e418f888914c4f41a396e1278e8363dd08f942cdb134b50cc198c157fac8", "class_name": "RelatedNodeInfo"}}, "text": "All \nother tradema rks mentioned are trademarks of their respective companies. ", "start_char_idx": 4865, "end_char_idx": 4944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d86abaf5-8eac-42ea-8395-e96457dbf081": {"__data__": {"id_": "d86abaf5-8eac-42ea-8395-e96457dbf081", "embedding": null, "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother tradema rks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afe8a66b1120aaa1097a9365873c634651d686138cea7e2c67b011998d2127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c86dd5f7-092b-4198-adbd-a3b656933831", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVID ED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND I TS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, I NCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMB ERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STO PPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PR OVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother tradema rks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother tradema rks mentioned are trademarks of their respective companies. ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ff6e1d377851bb4db838d78dfb3f6734d47d526a9578a1537f77c1229a92fd9", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 4944, "end_char_idx": 4966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"89e91609-8300-403c-8a16-5c909af0a20f": {"doc_hash": "5cfc1ab61a9ff19e7528682a9c20764f6d16c7b98c4502cf93b611f785231f28", "ref_doc_id": "baae0df7-953e-4720-95bd-38a16e5bf756"}, "8d778772-5bfa-4e89-bf36-0bb7977b33ee": {"doc_hash": "2fe7ba83ab58a087a8284a17f6cba418ddda333b0e1a1e2870801dd29984f67b", "ref_doc_id": "baae0df7-953e-4720-95bd-38a16e5bf756"}, "2feead10-4c59-4c4f-8b15-8c432c0f088b": {"doc_hash": "94f595c07abdcce751113c0ca81fca5ed059795aca4fa8d1b29a006992caa29c", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "64ac9878-9309-4ecc-a1ea-b90553d9ad49": {"doc_hash": "460079a58a01bb9e4f44e8268e478510a4eeb449ccd0fa7139008a6d4e6cb59b", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "43a439df-074a-4278-8358-8582e42fe32f": {"doc_hash": "6ca92ee3e5ab9b8f26ca55065714582a5bb03a6b5118480fec40be09a5df9ffd", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "8fc16a0b-0bbd-4830-a3ac-d81781261c50": {"doc_hash": "d2612c097dde70757b1cc3b194aeeb4aab891c9e458c8645b696fcb940ecb41f", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "4786bc9c-763a-413a-91f9-b4a3ba612cd8": {"doc_hash": "f17b44b6fea187fd38588ab214918886ec44ee0d43c2f228b12a7fe206cc8f64", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "d198de46-9ea7-4082-88f7-96f23f538a18": {"doc_hash": "1af5b54f2d6e9b9bc75c1db2f0fa79734fcf33fc6d3956eb3be6ccc76398e25b", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "94174878-5cdb-4c24-bd5e-a24217bfd767": {"doc_hash": "8ed269342d1bbde82be2849a1fd024abaed2d7ae4e3a9b6aeced3903d2243ae4", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "e278bfba-e323-46a8-98f3-fef431761110": {"doc_hash": "769ca083a793a3c616efdd0db29e13bdb991d121ddff1d3e4b3a547d45703a46", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "656c1288-957d-48a4-833d-f690b311deb7": {"doc_hash": "b609cc4f503472bcaeeb043f5c528106259f402d9f7c87e7e2fee965504dfaa9", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "a50431fa-7351-4370-8ef3-270d6fc1e202": {"doc_hash": "dc2753730ae90a7f461bcae2c90de61289b97446eaf54b1c6d5d52782455dd23", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "1cf794a0-ef8e-4575-a584-800b2d1c92b6": {"doc_hash": "92b19c5a7ba0a8f9c8271a7ffa39b4f73e003a257781938d2f0bbd8c299da302", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "dc3c2b17-5152-46b9-8c01-77696e6e7010": {"doc_hash": "17fb1fd929859232845c6027177956aaf676b19a4d022a5f99b6ccff24311588", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "2a0492f6-9225-468a-b2ab-ea3c69e118d8": {"doc_hash": "b7971cb55e2c706c6633c21810b1e705649945978808bf2cfe6b20e6c9f77dfe", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "096abc7d-af08-40d6-bb8d-6b32101a1e4c": {"doc_hash": "ade4122428280e448ee40ce46843c9563ab0a7cfbd294215336a6cdca6bc8cd1", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "25951412-b0b7-4c07-b807-8178d738dfad": {"doc_hash": "a36fc16830ec8795499d45cbf74884341193e2ff88bd674fcd98c55f1d32da7d", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "52002498-2c4c-4a52-a673-bce6487dec92": {"doc_hash": "b30506f57fb4366b0d41aafd999ab6388ddce4fe77f2e590fa6821d64540975e", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "f7d1b1a6-4dce-48ac-9654-cc5f40c9970c": {"doc_hash": "357ac8dcc59391ffa700368d935a40d911a5ba6e7e895de9f57e7c8b9a1dc5c8", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "2717e0fc-cd94-44a0-ad67-b17d46547955": {"doc_hash": "265d01dd38c40f103f9e5e8132d97fb00646a43a6fba1cd9a556c316ede41964", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "07533d6d-b587-4c20-8789-b9defb73b1ab": {"doc_hash": "a4185a6fbd7b3c6cadd595510d3f92b0e264406efbcc0151288285011a178163", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "3b8e8fd6-d29a-4d4d-8f57-f95654ef8cdc": {"doc_hash": "bf608322bf7266f8621c4622cf7c1389b6d06512699597158c9a362e2e942682", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "8d888966-792e-440d-ba47-ec3143ae25fc": {"doc_hash": "1ce805ed0c4ad7a8931d0ab1bb5c0299feb4e04b8bb4792db1948be7481b3813", "ref_doc_id": "d9dc5b91-f4dc-4392-bf57-63fc47031cd2"}, "4c1db801-9393-456f-8b74-c581df4d1279": {"doc_hash": "e75f5a0037a68cbfc261a30fc3fe050e7b14ecc9ed140a485a20dd9fe329c97e", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "e5fac8b6-b329-4b53-b0b4-4257bdb18c9c": {"doc_hash": "af1a8db74b8babcd7d6a11310619259bdf4700858a3ffeded8bbb637a785374c", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "e5e885aa-2a4d-48fe-8134-047337be6f73": {"doc_hash": "071fff5bf2e796a3cd3f2ae2436713410293de6d00ce3906951fd5afbc6fc816", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "082d9b25-2b05-42e4-abf9-58d197abf50a": {"doc_hash": "abae596015cc0d878e9219ce31414abd3c927c422005af87da51308555f1e2bd", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "e5614a1b-4f45-4307-bec8-bce3d7e827a0": {"doc_hash": "178eb8f8bce2094d2a306d7985d578c391d03327fb9114af5fc84547be4e4a3d", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "2d0caadb-bdd7-4177-9d6c-51715ebc48f5": {"doc_hash": "aa38c4c72027f49919d1e66bfeab4200c341a1bf62c2f0ecf8e9aa4135da5e5d", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "b7bd429c-c3cf-4e77-9900-2dffff7e5653": {"doc_hash": "cf2d9cb6744a7e5af659c20b9e45396253777774d9e135e72080631785d29836", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "c4047de3-01ca-422d-801f-1b29462e3660": {"doc_hash": "01be8a711cd1fed81aaecea5944aa191076aa3340889cac3e586061c07ad3629", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "357fa8f7-5cc4-425d-ab54-0fe77a68c821": {"doc_hash": "06f36e90ec7f9aa078d2e7ee96beffa073506e353c9e1f08744e5aa773c46c40", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "97818f61-bd83-451a-b046-2ef5f2071b0b": {"doc_hash": "8fe1cd479a958f16922ceda7398f36784122d6c34ae585345b723018521f77f3", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "4f8e2e4f-d023-4cd7-bb2a-04fcba40deab": {"doc_hash": "437793672c6b6ee005549ece5802d94a479de5b928e04a592ae4d62cadf2b312", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "3ef94ccf-d797-4fc9-9eea-c3cced54c926": {"doc_hash": "4b456e762d3af3596597813880a7be903ef6ada49c731195c1b4fff03b4ee854", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "8ecd5abe-c37a-44d8-a668-4caf27f7664d": {"doc_hash": "e7c2f779d153504f182fdf89649d8943213836819248a043d6d6d3254ac18126", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "5753debf-d048-4bec-939a-a3953bbd8cd6": {"doc_hash": "72602b82327b6a206f820a4b125edef4a07a5cfdb3dc897a3f5e9371b5ea1d57", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "ae74e046-4632-4aff-a06a-af08e6f0cc8e": {"doc_hash": "033e91b0d038a1ff4c3b4294a016c7dcc69cfb3d3ddddf6b458ace15f7b52d01", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "2502a652-a707-4995-9e43-aa0474e3b394": {"doc_hash": "6dfbc2ba036ff08566397f060c07d95a2dd0547911cdd3ea90b6c6f7184aed21", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "6d06dfa6-7550-48b8-b0f9-7fe2f378e08d": {"doc_hash": "f017176988339692e19d03da65a2ea7ee868d17d16d0b1f41b1ffdf974dc3d38", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "40525deb-909c-401b-a150-e56826d05f62": {"doc_hash": "d729d9ae9e3eb515c19f319af61056b9e199145929c7c961d152d12b6dc34c18", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "193f0654-cc72-437a-81b6-2511473c7985": {"doc_hash": "4ac98dfc2950beec75255761ea59c3cd456b93f93a76e3c6336618704ee3065d", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "fb66e65c-9049-414f-b0ad-858d12bf857f": {"doc_hash": "05b4937703849d952df3a2549b5e5779503191e30518de93481d8727de748c14", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "d95f2a1a-0ad7-4719-a24b-138c11bf1f8d": {"doc_hash": "e0e55669c4dfeaaa3e18354c1a3dc2bb4314acabad6eb3634e7b1c4d73fcd8a9", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "afec1a3b-f4ed-4e6d-a800-d2fd0b919a12": {"doc_hash": "b60d60a8d5c46199da3808d75d22523ec484ed4e19ed8268baa0c5d2654689e9", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "40f643db-d67a-4ff0-b2cc-0f79f73306db": {"doc_hash": "7f65fe6ae002f5cf4180a6e7dba7a5fdec94f89b79d371b344d922a4acf71e6e", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "0b336b42-e38f-48c5-8185-617cd53850c1": {"doc_hash": "0d70c96c548803e00fd5f5e7fd249c230031f0756fd7443594705ec1bf5199f1", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "6b9a6dd2-b1f8-4463-8c32-c7e06eb62816": {"doc_hash": "62d1f1ef54948059b53fded8bd5f28afa4ae6efb2c82d560f5309fea05ab21bf", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "174c494e-f0b3-4bbb-93ee-6597f3b31dc9": {"doc_hash": "9f9adabbeb7de0078ab8f4f445353d5ae0fde22fbd3cff525998ef0e312a5127", "ref_doc_id": "8d074d81-1bd7-425e-811e-44bde442548f"}, "58fda9e2-dc1a-4e28-a0c6-e8fd841ab362": {"doc_hash": "9367fc8a45d62756444e483a554a3b7278b0b5f401972d84491f5b9f349884cd", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "a6dd38de-ac47-48d7-b352-e66a29fd0be1": {"doc_hash": "3fa1cce2710347b8039dcb2fc4fd2ca888c07b748852c19a69e66fc93ae24b42", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "17d08110-8fa2-4256-8eb3-f84090361c53": {"doc_hash": "07fb89b23c6afdb17a165f036c5456d843fa0e1fee65c4aa55698aed25359afc", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "72d8f633-051b-4ea5-bc44-ee32e466aa25": {"doc_hash": "2e2dfe6dbb2d15c59cecf4fdddbead90ac02ffc9857b7c42c6704ddf18daec85", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "46d06cdb-d344-403a-ae6f-2e8065d5ed94": {"doc_hash": "a7774481e478d39ce8befbaa93828801e9bbeb8acc2a42c745ee3788da484fc5", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "b44256d8-13ca-4538-abbb-e09cd993944f": {"doc_hash": "9e4339ac5ca5099071dfb233acd489dfbabbf3d618cadc48f63c6fc2e8b91e91", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "07c48158-25ac-4f58-91af-560e0fb63e7b": {"doc_hash": "3bd05f2f527a6b80c6bd085f38ccdf94174c7f09ae9ade1b192a7a1827ef1415", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "a84597eb-df79-431a-b8db-0546684b499a": {"doc_hash": "ca4ad2d79316ce8475c0c7d4d0b977578355dcf91e43f1e2241e091d43087b6e", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "91a3cca3-8889-4e7c-954b-e29be15699f8": {"doc_hash": "b8f764552ce67f4dc85491890bf28d4017138c2cac5ec941ae1fdb4f72a84464", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "68973b4c-b39d-4e9e-a4f3-71a4a6eb17c0": {"doc_hash": "d151c41cdc17cae079712e0f77e81eb02d6f72131f42856e2b8addaf47c0c921", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "c485067f-8878-4e7c-a878-deadce5cffa1": {"doc_hash": "a7290b065c1699e5b1418cd403a7a97b52ca2f5cb86dca6913d9fce2bc9e00d0", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "638ab611-bcb1-4007-a4fd-06d337f0be6a": {"doc_hash": "5fa0c0c08a6167f4d78b937697d4dcc23d49a28094dbd7d50987e8c0cf22b61a", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "1fabb066-fe80-45a0-86b3-7c25f5d00c47": {"doc_hash": "c5d7fc0924aed1c12f2a674f913dbd74957482cef8b172ce36e36202531d79eb", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "4caa1008-b2cb-45fc-9645-d40f0bec8220": {"doc_hash": "7a63e11e72c1af8eb126e72514e25e8b0a302ab071d8b0ab012bff034cc357f6", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "ec591f95-4724-409d-9507-01914ef461bf": {"doc_hash": "1c258a9a5c7ef98aa00e1617f2a6dfd5719660cedf4257ad08c2c945a987ddad", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "54ea9f1f-591c-42ff-9dba-1ca8554a39a4": {"doc_hash": "af6e3c85126f81833214da010fedfa184a782d6ea7594e0aee1338fd8d8db672", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "f5c8bac8-65bb-4cf9-8b59-c0463a0559e9": {"doc_hash": "db2515d28dce99758d74a0c8f5b69d9c562df3fea765f5ffb99c24ec9efb0e7b", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "ce1362f8-468d-4071-a0dd-e2710ac25a1a": {"doc_hash": "0d89f014a81048a42b62ac4ddee1b1299d477a6261792dbc7149eee26a1c2dc8", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "19396ee7-cfa1-40b7-ad62-a6db98a9f1fb": {"doc_hash": "2a65263f1235fcdd87ed1e09a2a9f79fa661d6bf701193ac023bd0a82c16d9e7", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "a821f068-f1ca-4ab0-a9de-b57047866b02": {"doc_hash": "e34880444f9d66de5e5d1fe06f724e5803091f38adc01e5b2e79aafc03f7e65e", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "bbe10637-90b5-4e04-9b6b-9b8b1de4b1f4": {"doc_hash": "0669f12f3bc26f7d2a09cbbd69842e2f6148e94e3fdcf033c68ec79f9d79bb94", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "b2455a41-0131-4b46-929c-60855624774c": {"doc_hash": "2e7fe2dc7eb28b64a5f86e55502f238f5402e3e1afdfdde6f6fc11baaa5c07b5", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "f535ce6f-06ab-4e50-9fa2-78a4f3a9db31": {"doc_hash": "df3d7b70e7ac6d57e3f3dc7237d746e928c3fea565731d5a5be0be8000923103", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "489e7690-4ee3-4293-b4c2-99cf6d9c7f0d": {"doc_hash": "f37209a858a24e70b27964596d53536ad9ced4f3b757f097072c7a90d229f040", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "c0567a2c-924b-4c3c-b551-e2c79adbf1cf": {"doc_hash": "3a1c5d6b5d1d112feb2877e0570336fd6b650d4bab3b658e151f073658a07e25", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "8ee3416f-f4c9-4f7c-8a1c-fad340f80653": {"doc_hash": "3ee2c100d6e41e8e5ee1aca43ea7af20661179612d5bd144604e4ebdd931f343", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "21922e87-afe8-4f74-9d0d-644e96c8598d": {"doc_hash": "31633e4a5acd349eee72bb5915a0d5e8cfa48d265f61b6ee5cb90029585512e6", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "d132fe53-de53-420c-824e-d86c09017b6c": {"doc_hash": "3ec8032feef3c36ce09b5153122d7ca7bc1bf99e956f764da342ed50ea5a54f0", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "e52ff292-435f-4172-bb77-4b025e7b239b": {"doc_hash": "b5107cf9e7ef14faf4fafc2df1f2309b29f5862736b9e483d11b135c7f5dc2c4", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "4fc5da29-b25c-4fa8-a5fb-0da8022a5b67": {"doc_hash": "64510abb7ae57f3d4bdfc82923486070b721c064d16f2d58ef534e951eb15065", "ref_doc_id": "a53b4cd4-682b-463e-878b-a2b9249c415b"}, "5ab5be79-b572-4bcd-ab10-cc5ad47cd760": {"doc_hash": "4f3adbf1f3aa58577faed507f9983479b52f4e2a5e0fde5657a80d8d534e88dc", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "9ac388f5-6b06-4d74-9354-f8ce7ffee17e": {"doc_hash": "dd46ad335ae390809e35625effe58155e2e3d079774495ec2902aaecab68bc18", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "945b463b-c738-4652-b48a-2ac15c8be6e3": {"doc_hash": "aea1223cedcae533ff2c2e4d1f2120fdd2ca6dad9d0efb59cae64a49aa6c8806", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "01c2a223-cf44-44e6-bf5c-528d66536c90": {"doc_hash": "1ec0b16da3053d707925a19431f511077da5b1cc2cc010a931da8f3716bf034a", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "bff08f0f-f372-49eb-bc86-0cb170baebb4": {"doc_hash": "bf69fda33bfc0d14f115ca72bbc76655c7b33410e48512e760d8c8d939953a59", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "4d1e896c-1256-42fb-90d5-619f9ab57f61": {"doc_hash": "d86638081f15618c7bf332a29920f1fa78508605647b2a11024ea26833d5275c", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "c2a16816-adda-4586-94bf-099105089531": {"doc_hash": "c3a656d8f9bbef419ad205fa825fae312bc11243146ea440848e8083842ea4a7", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "8ff855f2-4404-4b3b-86b5-4e39a8219c68": {"doc_hash": "97886e7498ab2ffa733257a4f699d12f7861c845d9d8ee6c15da6eceb70e65bd", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "ea4142de-0b4f-4733-8ffd-de467d47073c": {"doc_hash": "9ee03606796e6ad68cc20f9cbfb7bb405093000b6821b2cf1ad0b7bb3e54f43b", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "34dbb818-1c77-4821-97f8-a6248313213e": {"doc_hash": "30eb766f47da81413d2b4841999d2204002120c057a83e29530befd27cf1a047", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "b09e1998-e572-4043-a356-bb50a043edbc": {"doc_hash": "5e9504851d0f51f86941c5a5903255c946ad7fb31a034db2290aa7378ecc33f9", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "15d60f01-c451-415c-b01a-012e01a5921f": {"doc_hash": "2631f12b012040b965c6d7b602281d731e43ef6f2eaaa569ca2e7af2bd409f81", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "edcaa561-82d5-4d08-91a7-d492fe98f770": {"doc_hash": "fda412b61f81a9572f81de532cb0e3cd60efbd9679dd947b09e9ab95b47344a2", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "85e6f891-4c75-4612-b641-1aeaaa48e6c6": {"doc_hash": "ae295dd5eefd4f1aa348bcd2f19aba3d0f8304d1f7d4b98f3bc8ed2e7f0172c5", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "6668e86e-0a9a-4818-a7c1-00d0ee72ecb3": {"doc_hash": "a6c7fd9a7fe2cd77cec39e76f4cdc2375b7fe785d03a2fd7858fdbab06a2dc3d", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "f9ca4c93-bf85-4fe4-80e4-d22061b7aae6": {"doc_hash": "51e00eb15c7d31ea5088c6d8eddcb72db658ef50fdf85c641b40c7011543aee8", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "03543b73-9e11-436c-b5d1-d2e1a59183d0": {"doc_hash": "3d1de5448e72c30596f5390466ba9926470d9f9202d80568c4a1b40ac1a54088", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "6925a4d9-e3bb-4e35-80f0-e05a7de8ed29": {"doc_hash": "f2a274edfc07a0136d99a46168a209e0c0dcc730c5fe958872d99aacaee23747", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "e2144bd6-1fd6-4d3e-9566-3b934ca24256": {"doc_hash": "cd386e7881ebbecc885848fffaeb77c23ca84c9df400cd5cf0e439f69fe413aa", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "835df4e2-9a47-4124-8ad2-f9f69517a392": {"doc_hash": "0348307eb6557c0908c60d9e50de4ca12a46f9adecd0a13702bb473d71a8af0b", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "91b74c32-3ba3-4c8c-864f-8f8c13caebca": {"doc_hash": "bda2f770d790869f139bc3b88df439b651b76d3ebb65111168e246d5c6eb8ae8", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "59fc82d6-2de2-4483-9a25-afb9c223c377": {"doc_hash": "7348ce42999732dcc169b3e081521d2681b9a6cb71a1c49ca083e8ec5d6f6f60", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "9320ba0d-23a8-4b84-8afb-190a946c05a1": {"doc_hash": "afe62c4f466ded613531762a3d056c5f967c25bdc4c2fcbf48ac0500dea60f6d", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "6fa60293-f663-40ce-bae3-77b164862455": {"doc_hash": "7e18e4ab1e4cff5292ec25859d1c32abc58ee9dd36e0ab3b9c276157c570bd9c", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "68477a31-b874-419a-98de-2dfe1987eb59": {"doc_hash": "bf4b5c9ed57013c658577aaddc2202b9213ff5071f7a0cd236e7f558e7331a8d", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "dc73872b-aeeb-4ebd-89b9-c87e2d399f49": {"doc_hash": "3cdce3b0e9aa9c9616c813a3b7c31f65ec4bb840b8749b625dd3f6b636ee67e4", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "336e013f-1b92-4803-a9a3-76e54d8b0e9d": {"doc_hash": "c72a3cdd6727bac3df49d065474dec9013c2af0a8d79a49a72a2fe6b73f44c39", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "69cf131d-5e5a-4f44-8755-8c0ae5bd214b": {"doc_hash": "0a761268d5ffd9f2409161ac9244f3194326acaf4d3b5e43a8f5164f24af9746", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "8256e61f-f149-4b59-867f-a9dce617a158": {"doc_hash": "8559d3606cd548e3d3dfa623c3a674c46d5a28be12c6afa806407c44796d6378", "ref_doc_id": "b59636fb-a268-4883-88cc-1c218d89aa46"}, "98451494-4b63-4cd0-8f87-c676e55694fa": {"doc_hash": "0ba0228420c55695cbdafd788da1eaca140ccb49d0529fb26b16f05ad92710f6", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "48c7fbf9-0805-41af-994d-26905b185118": {"doc_hash": "0726945ca19050b9a518ddcd66599a39d203f196c4f15031c5c1b0c15ecbf235", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "9a2d3023-7b0a-4b3a-a160-c91704ee2781": {"doc_hash": "33dd947f1c82a3be4225284855f134036e67c3ac8fb77f9eb0ab34ad66fca83e", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "7e18f049-b282-46a9-974f-02a2ebabaf51": {"doc_hash": "ed1e0f7bd65efaba94a24c117baa28e345f3cf1f2f715c5f6ae6aa5c2f90eb24", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "e675f606-3713-4992-baeb-7727df3c6746": {"doc_hash": "03715b464ef81627b40e380f313e90a858f2fc3d865aa1929e663a8e866470f0", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "3b0de301-8d82-4046-a86d-a37a1459a604": {"doc_hash": "f6e31496ad768dc933427a8aa36d955dbe0ce9e5e0e2ba23f899eb35aac093ad", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "f82d514b-77ad-4154-9614-7930af66e07c": {"doc_hash": "e83d12cdcac6cb90297e4676ff22f61034714cc3a09b03474ea9dee22c53393e", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "781f2940-427b-4605-adc5-5c9771c20be7": {"doc_hash": "847cb99eaf024f7355bb09bee1562e7106f8a17886e383cf37be8fdc894c210b", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "dd4cc339-ec70-432f-b791-371b14549512": {"doc_hash": "b01e9e47b0b1ae6485e6482a215a07f14d8a6be6886f4da2a2e4d5b084c9b3ed", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "85910fe1-e6d5-4de2-9927-a908820dd349": {"doc_hash": "80f733ae73a5a006128ce242008b3c6aef38cefdd7ecb599a358a876a70052bb", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "b4a5446e-45e2-4f28-83fd-86f67b6ab95b": {"doc_hash": "c87c26d7c1b47d5261b50ce592c31546a10e6653391c3dc8127cd702f5ff63b4", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "123a6163-eebd-4916-9d1d-432858c146b9": {"doc_hash": "434c823bf461bfefa5cfd45713030fddfaa2e04a96aae3631642814340d79e23", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "dd66ed84-b850-42f9-9233-62d8bdf2bf38": {"doc_hash": "d2bb1c5407d05c7ad7c70d317889a3b42a288a9819af30bbd29e2d91bd0fb93e", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "2816ba57-cbdb-4cdf-b04c-e0cfb87bec59": {"doc_hash": "4273bc1c4f9b70375bdb7645c1477f1f610e4df3f0f4dc87b8b61569b6cd11a4", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "5ca47f81-6757-486b-a689-d53717395cc6": {"doc_hash": "84a232c56d0b7aff1bf8a0b3eaec6e6f2d7fa44a6d17a57faf1d4fecd1048df3", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "86367960-0e92-431c-a6ee-940ef861a68a": {"doc_hash": "c9160850c73708663b620c9a3cdc8299d9290b56c0b6126192148410281b1d18", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "08b1d8af-df10-46d3-bc31-6dabbe0e14b6": {"doc_hash": "6aefb16b20c4cd67f4347d4a9c07876ec818102c450461ae28a884d686c5ce01", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "a5615432-a377-4d22-9309-b043a3ea4e07": {"doc_hash": "620b5ff01572558e043e885874c411bd2341fd52a414e5695efa956e72a5439e", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "288c46e9-fe5b-4bbe-a627-3078e37bab4a": {"doc_hash": "c0f8cb3e51e5ea815d771e6d9740aa89fe66f681ff4679ab81595537c38b3c6d", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "4723a1f4-6ea3-4c66-9d75-1a5680542769": {"doc_hash": "01e33501f6c87e34580aebe8403122d09a02557fbc8e4a3452841808670ed287", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "c2a25d0c-5efb-4fa4-b1e4-db7d5a4f2b2f": {"doc_hash": "dd06ab973c2745d1d5fffc1d7d99c6e0b7de5b918c95bf66a1196a3302cfd0f9", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "b2f548b0-abec-4ad3-92b9-9156acfb766f": {"doc_hash": "3fd94097e3c8e868277a4db2d8ca11510658b02e1ef731038b4dc0870874955f", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "1cfe7d68-aa5f-4d31-a15f-032105460c55": {"doc_hash": "4b0ba6fb0725e9148e21a44ef7fd78ceb7b8d71c82bfb8d438dc8c2ba26fa7ca", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "7e9dc1e5-f147-4a67-b6ba-e93d9f1353fd": {"doc_hash": "002ff23226e5510aed97ad90792cbb4080a103f58bbd1bfbc38ff851868b0eff", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "3821714c-cc1d-4e76-a207-480259b7a4b4": {"doc_hash": "d997d40b55c51622dd1b40fdaf621f35793ab1ff093c22ade29dc0a1aa4b5a00", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "eef3ae1e-65e8-43d3-ae66-fe9f83b6ac62": {"doc_hash": "d18ccd6b5ccf6d3ae7e781545ad12d92e7933eaeb88296551b5e2ea7b40c0a01", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "b22915bf-2b18-4cec-a473-1c7e2457be7f": {"doc_hash": "699a662a52790168a9c10d3c175338172901032fdd2087433e5b3d61129f1b26", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "afc2d9bc-fe55-4d99-85c4-c626e82b43e4": {"doc_hash": "2b1318f2fd0165e767209aed91c99422fbf28a175565c726ca8599c13ca5cf90", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "a4cfbd8b-14b8-4047-b91e-f72123eb3c27": {"doc_hash": "53da391fff613981700fa7fbbf20cdb08e52c6379390ed9e91194ca707dec339", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "972e6428-79f6-4c33-b812-6ec6a28e7c03": {"doc_hash": "350ce4d64eca77bcfa814692036002d041c08dd8008ec3fd2fea99a68268ea49", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "c61139b9-ce3a-4e9a-9f17-57446da1a7b4": {"doc_hash": "4d0e0f75343621db9b7f94c24c2811aa2ac759711feb3bebbe679c3bc4f21bf5", "ref_doc_id": "efcdcca8-a1b8-4097-ad70-f9603582a650"}, "6bf18227-d224-42b0-bf69-378bc64c813e": {"doc_hash": "9ac0da37e1ad52db5a64fab94ab853a32adcbf19a8979135a1ede5ffd34373d8", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "1246137c-41ec-45c1-aa05-0d16c44f06b1": {"doc_hash": "b9596dbac8942c61338bb0c4e9485740c75793a1bcecfabc869510e5f78ddbc3", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "ac8bbf51-4da6-467d-9163-9c313da7136a": {"doc_hash": "f4c0492dae4c31c88fecb6758f91813edd76f7f913313ac865f9baaf15a82ccb", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "fe72e066-2e1e-49a4-aef7-32bf38f8ddf8": {"doc_hash": "8a7aa55f1cf44b24dd6af97e9a50b82c4aab551c1264eee069bdbd8305480037", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "f9ee8681-b886-4edb-b2b4-e9572984e55a": {"doc_hash": "6009cf41d9c7c0ecf4379fa79164ab0f37ee3e447f1eaf0971e764e501e3345f", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "87a43fee-fb98-4c40-87c2-0fbaef3f86d0": {"doc_hash": "a1255b3657f72ae831a5962071855f45acf417898f243a6f05e55c758d5ff036", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "bb1d3003-07a8-48ff-950c-173e49a0bbcd": {"doc_hash": "6aee82ba40d8f78196f50c821c0fc6d87cb6b7eec237707df2015d9525037dfd", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "6e841066-3a0b-42d6-b724-d865871f7861": {"doc_hash": "ddbaa4061eb6ced9a43cc734dddac81eabd7d379bd2c28a0826e048010afa24d", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "299c3038-c5cf-4261-b678-7585f1145bf1": {"doc_hash": "699d2bd1b47bf73e0d81fba855bf22c2ae4fc57160569929d0918643262c4cee", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "3d5ee86d-fe89-4a36-89d3-4105bef4aad7": {"doc_hash": "54dc43a7413a0c18e30e1a9cf087efbdde8b85c718b1135f3a14bd24234266af", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "37b07e55-1f54-4e2e-98e3-1eefd2e69fbf": {"doc_hash": "56bf5f038eb8197cab9d31161f22b30c5c456c04ac3db7c6a7e344dea5061614", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "4ab69789-a2d1-4568-a0d6-6996870ac038": {"doc_hash": "9ba16c55133ad6ab90dff78ee189ac487193568238c25159ecd1161d9b48ff8a", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "57182291-3090-40d3-ad02-24fd0efc644b": {"doc_hash": "0659663189ceacdeb65389b20e113ca16e5d2dad7aa253aeb8f090771291e26f", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "a6490911-41d9-4cd6-b743-f952f888da13": {"doc_hash": "480c3e720bb06c6dbc233c985d3abd1093ed23bde319489e067dac99c0b4b9d3", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "f79cf1e5-4f33-4b28-8d1e-d156f1bee76f": {"doc_hash": "5db09a89d297fc0c4ef6889f03b7c540aede63527e3ce0074ff4542c08547f3a", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "e1d715ee-20dd-42cf-9fd3-aacd07c3c0fc": {"doc_hash": "42e4151fe59f4842a8876fb7dfce96845d5765c72e285c0a972123a7be5027db", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "76784bda-8c8b-4382-8747-3adf92373023": {"doc_hash": "46258b12eb4a6d2174583aae5a391321556ef986cd440c93a662fe5117842dfc", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "0c15bdcc-b26c-45db-a69e-88d5765a8bb8": {"doc_hash": "cca4278b17bb313765d2ca9235c0f4a144cb8948104ef0f7d1440398f904584f", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "8089abb8-6866-4686-a736-3af4a14037dd": {"doc_hash": "d1939e32e65a83f9c6e21dcb4964d77c7edfe5c4df360bf562cc623d547f3482", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "c0a8ff78-3829-42ae-baf0-6c4fcbbec85c": {"doc_hash": "92ef5b34c9ff3c1f82a1978aeaeab6cd4279e515500b41bb4fbe487f6d2977ac", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "ce44142d-4a41-4700-88e9-2192a8b73c2f": {"doc_hash": "47c1f69564b0042d54514bc72ce0678f08a8dd8e07fcd3b38cc7d13ea879c511", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "b5055356-aeac-48de-a002-2e3f14105c56": {"doc_hash": "c6cab8b313b544c7c1232480a83d3b2ade9300d6887dc7eaad24cca7825f7379", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "e288efb5-0178-4b17-9333-8a492e1f1f4c": {"doc_hash": "c8e5ff55da4055a034c7a6a79bd0346d22cddb56ad27de1632a9d0b352103dcc", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "6877b028-1d28-40e8-91eb-6c48635d90ae": {"doc_hash": "8483b600c873e863dc958ab53be424cbcfe5ae7d59dc7b6831d7cdac7449342b", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "e1ca2b38-7781-423a-8c5d-a1568bca4ceb": {"doc_hash": "5ce6da82cd18cf3af666eb2c1ee7a492654d84cfd855702e02604c4dbcf0ea02", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "cd0e40ab-d27e-4a82-b510-ef92e0866ef0": {"doc_hash": "9e465b2e9c1a02bff8ff6a8ccb17daac720783459444469ec9a5a3181a90bb30", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "e7e2d9d6-0ba8-4158-a80c-dcd43c338344": {"doc_hash": "3f0dcc47ff7f6f3e8ca6fccf657fa2306af5dbb4ceec675719405b4899b09147", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "5f9bb349-2a96-47a9-96f6-4bd42cac966a": {"doc_hash": "3781d51f2676ca0439cec1ceb552c0b2dae6f747bb25671bb0034b1a5317651d", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "dcc2e226-2c68-41d3-9a37-5eb8f6af3012": {"doc_hash": "a3bd940f76744170aab0d441cc27d78859fc4479f226bb673a9600e4641cab42", "ref_doc_id": "ef1bd7b8-6be4-4928-9aec-78b389bb0af7"}, "44bde4bf-342a-4588-a87e-92b8a2805fb2": {"doc_hash": "e35a9aa5477acf59bdd715a8051c21b9f2cabd40682eb3a2322463eeedb92f1a", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "72ec6a54-4e0f-404e-8cde-9ddcf21b6551": {"doc_hash": "bf3526eaf2432370145ba5c151188eef17fb36e70ee016878f75dadcd67bb495", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "21d062a3-7281-4cf1-a8b9-2b300aff087b": {"doc_hash": "f914be146621ce7b7f03b5105a4d76b071240de50022feaf9de149e4e9b57b0a", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "e16355f8-be5d-4c83-8e99-c89cddfb2e3f": {"doc_hash": "446ff5d1968bfa50e39eaff66b0d4c362cbe721b5d4e47f75c3c288a04445e0b", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "e58c2849-e4d3-40bb-933e-92d112dc1d54": {"doc_hash": "dd3535557554050a89d9ace3a34285f2e6ce57593fbe156b290e29a6e227f454", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "8d6dc1e9-de0d-4b87-ad8d-fee5ac76d19a": {"doc_hash": "035a1d8224002e19161869ae856c11764bbed21987c3ee5cf674f8ca25748aa6", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "19e1a2c6-16f2-4684-9ce4-ced99fb747d8": {"doc_hash": "6f889db876fa0a4190fbb7aeeee44db2359196001d8c3bd61306f821fc9bd5ff", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "92808fee-f86d-4be1-a71b-73ad0caeaad2": {"doc_hash": "e3a9d9c0bac4f07c2db7aba32718e6f14ce729728665548cf3556771da1495f5", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "0490f44e-7c9b-41f8-a360-6d3b77fd20f3": {"doc_hash": "ac6ecd1c83d916a25d007140db2b701fb0f55aff0be8182e4db3ba014c29fb47", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "de02070c-bbca-46c0-98c3-758b247725a3": {"doc_hash": "4fa1a18c151b83737625cdc836a0debefa4f47c241c5d418f0439ddd2269635d", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "c66ee338-994d-446c-87ec-782f7b556ca6": {"doc_hash": "23b04b0b7b1e24a116e7a8e150711ba1e4bd3eb095358c2abb84f76fa9d89895", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "ccb7ebdd-76e9-4497-b6a4-6982e52caf67": {"doc_hash": "3cb3340b792eefbfeaacb24afe88ae3447b1a047592d204e9d320db56b315349", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "bd3c9335-8347-468f-8dcf-d4697c1c62c1": {"doc_hash": "56b8244fcb9e38df4f60a00db60e0df8a73ba78bb623ba7369768d6eec2ad58d", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "6bc01857-8d11-40e6-b3a5-5d0bdf663596": {"doc_hash": "964a62398ffe56737de8d1894a11f929e747b129324855cfe5b5226affc6d2cd", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "aedd1890-6915-4b91-a83c-384640e01b6d": {"doc_hash": "7facf9eb5b1bab187409a61029f556b5ae2c727dacb1433b584ffb84f22ad21d", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "64217049-961d-440d-beb1-558a25ca4b0f": {"doc_hash": "59034704771c7c96c61d0f2df78dec0315ffc0277e4849e5b23a0af494139566", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "913596ed-20b0-480e-82db-fa35541f40f5": {"doc_hash": "dc3629b15c9f60e1bc911b4d8b674c80422a530fd42d82cfdb46a0049664c2b6", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "690bcf89-6ea6-4344-b070-0bb25bb860c0": {"doc_hash": "041655904fb4be4718ff45f94548deff7849595d8f766a4e02feb59b09059c34", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "c75ba3e8-4611-4d0c-9532-4cac7df35e47": {"doc_hash": "62f5b99790a641fc77416785d3b01c74e86bc44fc8150a96424cf2da4c7b01ef", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "cf4f6b40-360f-42f5-8c8c-c2aeee783f6d": {"doc_hash": "0da75b92cad54ff40c64cc687e130f0f4259537f211dd6f902f5ba7fa0d2e0df", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "c36818ee-1044-423f-bfeb-337bab6ffce4": {"doc_hash": "2942a5dc2554c64b4af4ffe88838bb166522f5409798547af1783109064ae27e", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "d21cd9b8-de22-415b-b8a5-8555d1799ff4": {"doc_hash": "3c795e5ee062dc28a673dc5f1fe8b8264882c709a6d40c3af7870c18afc2a414", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "9e070d70-1f37-405b-8821-bfd51171919b": {"doc_hash": "34e7a2df838b20da9cf52a912bbe16b3f3cf39520ed5c0568b6361b03ddfe227", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "c4344dc0-e97e-4444-bfae-9bc6b6a24ecb": {"doc_hash": "90d97eac0d0865d8ef125f4252b73af8921be347340805290b9e05874886f6a9", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "f28bb7ea-75b3-402f-a95f-fcc81d749292": {"doc_hash": "d1d444bdc9044d2d84206ab008c49d9f6846db6525acf5ad0e21ac72f7fa922a", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "1cb1b2c8-546e-4148-849f-64a070332db0": {"doc_hash": "f3f180b1d8a942c49d82947082a7df23f3821ba5108f0fdc9a8848ea7ef21530", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "9bde514c-461b-4369-a413-2ccaa1958449": {"doc_hash": "c1c3e8afbd117fc0a238bc66aaada7b55439cb13aae0fed73121b54e6823d527", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "8c0a0d13-7165-4596-8afc-c62b605b613d": {"doc_hash": "b14010fa14454fa1318713c690ff22c70f0347a39387720cd283ab6634a0dc1e", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "3cff709f-49c0-4d32-ae0b-a56a1d6acfe1": {"doc_hash": "fc8be76be680b9c7ebe4a49b26021661a6bd603be15da67a76f68b54207092fa", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "203dcdb7-3cd1-4c2f-a2c3-e514b5eac310": {"doc_hash": "68143c0b3e0d7ee4d2fda25a4dfa3cfa7f5925f04fffa54b580e7579e7651b1c", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "2ab86fff-da33-469f-b00b-31aee2e29dcc": {"doc_hash": "ba748f4419d393253615022677f5fb7f5de6562fde4e5a8a8f9afb5067a69188", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "e4fd860e-e1d6-4caa-9a71-2a6f5ae2e22a": {"doc_hash": "4f592ddca6a984cdc34997e938a7a02c95e4603ab1e92b2e28c1b3bbaa86e10b", "ref_doc_id": "4aa6b18c-74fb-4873-9d69-0a37e1120acd"}, "373b48b0-6822-45c1-affd-35f1e1da06f1": {"doc_hash": "49a8cc17712f421f68c949f3de695e650affd1b96b0f529ff5f5cac6f164c463", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "36759b1b-bd98-4a3c-b1ec-f00151f111bb": {"doc_hash": "0b17decb186833221d92bd6b8d6b12a5acee298809f0b0b85d3325c0a97d43fb", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "2933499a-944f-4e2b-b0bb-dea584594463": {"doc_hash": "6a508fe96d64b64e856ed423e68a2403c17b6533cffdbf775704964c87ea0b5c", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "f3c0f5bf-8a22-42c7-8898-958b661413f9": {"doc_hash": "447de49295131d3002fddc0a4ce2851b298115ec0e850b77611b2f8171212f9f", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "8c08c001-f687-4ac2-be7e-d3927641889f": {"doc_hash": "e7cc59cafde26b2703ffb0b8daf02a806ddce7a99aea85480b8967e7fbfe2330", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "04cb480e-3b88-45c6-96a8-b11b77e18d5c": {"doc_hash": "e7951e9d854a37dc147548c748db671759e01d0354298a28b790455e830b2d85", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "8438f943-4596-4b5c-8a09-f4e32fd4a413": {"doc_hash": "45af692554276dfc547f3782440992b09d3cc221034484dfa2593bd5d23bf80a", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "9b274f89-fc4e-409d-ac15-9e47749947a2": {"doc_hash": "789201a02efa783a7db029302f603d856010f130e7999cde267dc5349a992c3f", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "1de86ad0-a55e-4127-a76f-e02b86c3bc90": {"doc_hash": "c9153a234d3eed953ad581a4600dd7e2c2bfecc494e4e88ae2a5d8675efcf91f", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "cd277f21-520a-4766-9def-f2ccd8e4d5fe": {"doc_hash": "c8708c6de4def091bc25738b8b5c2b1a537c599c23824f4921d3e37f5e715c21", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "33899571-221f-48de-94ef-ffad9473c5de": {"doc_hash": "04fd3f68c3f76b417d57d8ca82da21c950ddc9e3e00e33b8c4b7acea69e5288f", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "4e9d9d30-99c4-4e34-beac-04717da66eb2": {"doc_hash": "bf8ad5e4cb68e5abcd6c24fa450864050c0c77c543ca9e4d4b65cb6376c51ab0", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "385549a4-e0be-4c16-ba88-a07b991911bc": {"doc_hash": "e8f8d423ca1f91663eeecdcb95d7b63f1ca09abac7953d90e33cfbf804a7ff74", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "9e5cccc7-a0e2-4bf0-85b2-e544a703a5c4": {"doc_hash": "5bc8279a30a758e9f169c5df816ef529abd27a99789e1410774d146b5f7c30cb", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "581798f0-677e-4d6e-8ff7-485945ef2d08": {"doc_hash": "a6d82355f8b7dbb9064e158eb8169b61dcb82f1db8768a825a08cec109b7300b", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "454c8d1b-569c-40d1-b1ad-d6468ab386cb": {"doc_hash": "9fa1a5cac48a216af5903959090e10fa66c21e4e87008d6d5aa54759dff55a94", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "b477abee-75fc-4134-8ff8-f8952a93393e": {"doc_hash": "72b30af1e252cf9c50497d787346079b04ab8ff8a914c9d1fd0a5ec891d2b980", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "8261fff9-f121-4f26-bd77-2e29f4d2bb42": {"doc_hash": "dd0fe8a2df0e136a26b7e61ffab8bca560be1563b98fd01c43ae44c375d57a73", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "57c3ff36-1420-4a19-b901-d47113db1208": {"doc_hash": "6805b38b18a5b8d02f6fbe07f5802f7b1564918d846405b2de1e7d66c66ef5fc", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "e6d02924-a9a9-4b20-89c7-7b116112f604": {"doc_hash": "0642e63ca34935672b49452f42729f02081f8bde72a593c62b4c96088a75b1dc", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "c3198925-3788-4679-947d-4f6651eb97fe": {"doc_hash": "52937342ccccf0e2ecc60f2c7e381c9408f055d34826c6c2e51e21681de59117", "ref_doc_id": "1e991624-f5f5-427d-b6b2-05772e7eff65"}, "6a705803-ad45-4b78-a17b-808f3af55086": {"doc_hash": "3499c5ed275911213788b54938ba18a8cd6f79e468cbf6f71b381c80fbf14ca9", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "385c028f-c654-4d1c-86fa-305c8841e92a": {"doc_hash": "d5f5f3f91b49b745d4a84fa7d004cb549c7722b3ff541406a8bd3ba99ba0d7cb", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "acb32a72-88a4-465e-b0b9-26b02953fe65": {"doc_hash": "e2498e9b3ccf6e6d19e15d817a9291a666d05c5ba5a1d8d1466409e90cdd2a6b", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "de29fbf8-ec2f-4976-8286-4b75f9f57be2": {"doc_hash": "5c778cb680b19f6084216ca178fcfe7c3d6c455cc0e7596b661d5ad92e031c65", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "6fe7e4cd-c4c6-46db-a0f5-7c59023f9c53": {"doc_hash": "a4070b4e3a75f2349ce046733d82369750b69848b223055ee6c3e52e61692a09", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "e257afae-8dda-446e-bee7-6314f68de5e1": {"doc_hash": "f874536db148b5af60caed39c4d5ddad9bde2598f5aeaeae16817602bf657b54", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "f79d9e8b-5196-4473-86a2-2a878b586ece": {"doc_hash": "3225ab181ffce281384fb57b1498a74fcf9c276b9f346cbcb4abdf959fd3b81d", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "b72e8c7d-c0a8-4b58-95e5-2be009bb409f": {"doc_hash": "f7a75efc7eec8bc4ff9736914d59f2bf9945c880133c9b10331f0afe34db9ce6", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "db7f4066-6772-4991-87d6-db6cf04abbab": {"doc_hash": "70093946f7957643d4463a9488b454377f1fcd2b6aaeeba40f360c1d270059a0", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "5b95cac1-3b64-4ffd-a244-90fffb52d9c6": {"doc_hash": "1601e8e2c1c9ccce0e16c4bf23f7c97408a65f6d0dee5507c8e3771cb6f975d2", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "a668adef-fbb9-4b8f-99b0-88742941e0a2": {"doc_hash": "cb5aad3a5423c0930d93d206ddfc2e1c93dd752ff3b1eef4d8da873591a611cf", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "beedcc14-36dc-4a19-ac6e-860b42219152": {"doc_hash": "91303b0c7919abad56ed72324ceab97d97729c9b1b127b3268680cd796bff55e", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "8c372ded-94f5-4c68-ab21-7be039c548b4": {"doc_hash": "16cc5a000b927b5551ae50279774787fdb3c1319a0abd7bccc4d55a27f18fa52", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "d16cf4a8-d3ae-4a1a-9bd2-c8defb66e57b": {"doc_hash": "bb22d0ae14fe4ec38da52e784b2a2cd4b4ed511618c18a120b3060cf336f91f4", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "7364491f-78ed-4024-8fb2-bf057f42b3ee": {"doc_hash": "f0fb1abf8542f71848fdbdd13f01fcfae2c6d81cd31aeefc007951fb1dfa5515", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "7c5e2992-ee2a-494d-bfa1-0dd66bbb3ef8": {"doc_hash": "4173c9df0a42016379c61640dce8f766c07f6a806e36ac29ce26157c2e63a267", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "372f4ab3-9b86-44d0-bc3c-d971b3b3d607": {"doc_hash": "980307db2b6f649653e854ce0928e440cc81ced7cb7c68d285b98c3608bfd525", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "0a8d944e-2f28-41ec-8f87-a975fa0cac3e": {"doc_hash": "4542c1a7fb8ac7d43a5f33af593105d5d28aecc84beafd920348a94a836ba46c", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "ba024599-da96-4f8f-82e6-70958cf4375e": {"doc_hash": "9b26e1560d03894ed9e508766c13a2f900fb70cc3a315c6d2b8de8a15b89be94", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "df9d9f0b-4900-485e-9cdd-b5acf67efd73": {"doc_hash": "8fc9c078d97bc0df059c0cf51980de4395042e04fbdf57ec0ab661b951e6bb37", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "a2879bc6-a4fb-46c3-8255-15ac3cfbc2b5": {"doc_hash": "e12e452668b6e5a733cf24745dd8eadc61083bcb48ecedf8d336de2985122518", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "e5e05e7c-5d55-4c60-bbf7-44643cb6dec6": {"doc_hash": "66e56ffe65e5b00ee6093223be3b519eff79b167bea580e124edcf6103faf2bb", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "18610205-32a7-4d9a-9a76-6ad7686b625e": {"doc_hash": "df9ee50a711f2f0a35b37044be0b954cbb1dd5322993734ae3ee0faa483f81bc", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "00d1c903-fe15-42a3-b67b-2abc4616edb3": {"doc_hash": "37b0d7de61024247667025f3d6db570a00f9a2c4ed281f36f1fc3226b5f9dba3", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "a3139ec5-7511-4624-8651-327266b98efc": {"doc_hash": "d862fdb21b5360a22e987c3048b24a52757253028fe4b303bfa93414227e34c3", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "d55e2fd6-3e7c-4751-82e3-7b170afa19a2": {"doc_hash": "e9ecd68d4fd60c6b2d2f15caeb85d08965150f7a5028c37603fcb036cafd1165", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "77ab0a39-be1c-414a-9c57-b9dfe4a8c1b7": {"doc_hash": "b70636a2e2c2a3090b541d6c119e89594750d4fc227efe74a537e76ed383a503", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "d4f3c630-0cc2-4554-9136-454abbdb0f2b": {"doc_hash": "343333e013d7082172a06689a8a727306e870c2b149195844e46fab89fa4c93f", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "768b23b2-ac8c-4e72-891e-26846b74387e": {"doc_hash": "5aab3f0870c8d1650f2c16b2a479b1ca82640717a36e564976f21568d29d34a9", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "4c70e09f-1931-4a71-8f2c-dc48ce59eec5": {"doc_hash": "439b79cbbec2e7969af717c9d7c52c9a83706078f06e4c41de857e4b808bcce5", "ref_doc_id": "68b8546f-bed4-4908-a8ee-d0c3086d712e"}, "6feeaf47-90a5-40c3-96e6-f59730bb4dc3": {"doc_hash": "7be6703317f7152515c97b3bdacb805e6660ed695161011ee3ca64068a64eece", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "1d3f28b6-6ba4-4c7f-94a1-5be7be8cfb93": {"doc_hash": "f605e7a58edae703493b7581c6d6e106311c0a1aaec9e3c9cf708063c8bf7b0c", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "9a4ca8fc-c8a1-4928-8586-f7a09578116f": {"doc_hash": "bba3e7cc24e026504b63e08ede5af674ef875aeb10ba8ff6a1cd41aba2794741", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "43f1af93-10d3-4af4-a3bd-914491f17183": {"doc_hash": "0119c7ad44fc3339ded3c81cd1a92d0bdf6cb3291a10e26154a73a3afee6b9e1", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "3f7b5f2b-7ad3-42a9-9e63-8ea1bc7801b5": {"doc_hash": "7d17dc6d816c17edf074757a501252ebfb60a1aa3dff12a6dde0c6877a1f5078", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "cf40a5f7-e592-4d55-89a3-803f4b3a7007": {"doc_hash": "03de7e5ab384613f674ed59e078187ac83a6de77af702a592e3f534375c0d26e", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "0b617408-2b40-43f0-a743-f0a97af0ddb2": {"doc_hash": "04479098df5dd56248a7f0a95617c6fa3e759ec6d261acded225ecb6f7001ec9", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "e1adeae0-276a-4275-bb30-6e9256b0bbfd": {"doc_hash": "59b969d57e72a3376abad0fff98fe45a77f4b9b3d987a0da4ab2f15d599e00ae", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "72050322-46e4-4848-ac79-0ccd13cfdd58": {"doc_hash": "886e24f9ce1f1859de0f481cd6eee5590e851e6df534f0b5e3f97653c1c8799a", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "ef97c86a-48fe-4d91-9941-1c9fab8e2803": {"doc_hash": "9a2453c55bb12de1caf52c6cf880dd48f87b1c167f57b79f7b588fcef7fbef28", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "a8a45a88-15d7-4c2f-b63f-a3973c55e4e2": {"doc_hash": "532f4219374db05b0de5892d77649dfdc7d53ab1373975090af3f5ab16f9cc11", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "dc8dec21-3bb4-4383-8898-71a58cc275e4": {"doc_hash": "5215f588596cc3791673de359c695f9259fc03539e366e55dc218ee486f02ffc", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "dbdef979-468f-4324-a608-008860bf44ed": {"doc_hash": "520ff337b581026493a578fe14bc56724a13df1f42f0eee8712edf1501df3b36", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "868c9160-e287-4a11-a9ef-f85c86634ea2": {"doc_hash": "a654563dd1f1b79ccdbd9a6b07e8d0f5d2e793f094642a4b40ff2128ec4c454a", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "7e9ff3b1-469b-49e2-9913-2dafc8023a8e": {"doc_hash": "f3b43c19ce91013b3487d7834c34960cab85f7e240dc670f2cfaa3938eb4ded1", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "42833547-fd87-4a50-a340-ac70f9037aa1": {"doc_hash": "336005569e2e1623e1740dd025ccc5b17837a46bc4fc7e7202a2d24081c4b480", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "27be2a1b-61e9-437d-a943-b2ae46922962": {"doc_hash": "b875759c0811a3d20c9651efcdecc5c9f5dc0b16094220afe4837c8d2e1ff490", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "81f9114b-3024-41e3-b42d-a991a575da80": {"doc_hash": "cda5dbbdb87ba3473133ccd87488be488fbd6f80703ae82c3e515e6bab8f87ae", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "3949c318-49b4-413c-a937-d4551b45a20e": {"doc_hash": "3b07137d6efa92baab6f38d3998a3672620dbeb632ebf0ac96fa9c6d1474b0b2", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "9186b913-c183-4717-bc03-de19ac62ee20": {"doc_hash": "d74d1b74cf6d2078892fbd093490d0954bb6bb5b205acb83bd055ba9daaa28cd", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "9615b1c8-4552-484a-b2a2-1d062eb922da": {"doc_hash": "1838432356c2193e9f6d340f6f3a9bec9c9d12f478077836eff55ab568b493b9", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "90e96a45-a254-4e61-9e29-40eb180f50a1": {"doc_hash": "8e05041cff36ed9c5d09bdc4ffc474f91683c6e0d35c5e068771e5775643b3be", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "6e685cd4-7307-4a07-83ea-fd5c73cdddfa": {"doc_hash": "5fd9aee51d27c6bea592d73c7cbc1b65da251cd91a6b015aaf5dd3f7d0c46742", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "74542ad2-a8b2-433c-9bcb-572a889956b6": {"doc_hash": "1c3896de05ee9f1330fe940bff39b0c9166d56410d9a96f003602f8afefd3201", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "6a7f2ed3-89a2-4400-8be2-e11680dcccc3": {"doc_hash": "ee6c938260529d0ac5248f8c89b8622f2f88a868bd5c380a2df26019a8011240", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "efdd76e4-8a1b-4d41-8f6a-332c1322ed6f": {"doc_hash": "c9430761e37ebb6241dfbf06614f4c7fd2b5a1d3c306e7b28140e1609aa9a83a", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "4a679ff7-5db2-490e-a4b3-5e6942e3b6d2": {"doc_hash": "6cb466d544f39729a3087c3d7ffa34c3b809a8b17efca7c06ed33f2b030c1dcb", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "a5886313-a3ec-4166-8815-b085525a6126": {"doc_hash": "bcbc2baa842577ac0a3a746b1dcc1f69bb0300089da95cdeb57043426e5aeeaf", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "34ec64b0-edd1-4a6e-9fe6-e05cb497499d": {"doc_hash": "230d0c1a670ab346ee88f08e630d9d675998590dd5f42e8c5c3d3fe519f0daed", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "b7c31bcb-cfbb-4d1a-8818-a6e9797e492f": {"doc_hash": "0d6a510e25e20c6a7db091d1c965bfdd498ea0eb55e4a9bf953432ce3de7c077", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "4db5f283-e360-42cb-a81b-bb71793a1d7d": {"doc_hash": "33379b0d65118f816536682d229a8a51000c5e09e544e32a9a055d07afa5ad2f", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "cc43818d-eee8-4108-b964-c31b610c1da6": {"doc_hash": "520d86efa360f3e912afb3006cd284767bc54f80f1fb284e434fca29d8c6c246", "ref_doc_id": "e02e0e95-027d-4624-bbb8-8d1987f05aa8"}, "dfbcaa48-02bd-4ecc-ba69-9c044f3923c0": {"doc_hash": "de5c0db42af5cdd8257e66fd3fb9c39f12674a09f9bd945d6318948baf58fbee", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "9ec72c84-e69c-4a18-be91-ff794f2773c7": {"doc_hash": "89c22b783d4f1cffcdfe030bd3cc34e006f257ae114145a679c6ad5540df9241", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "2bad1ab8-3d00-4cbb-a47f-7be609e60789": {"doc_hash": "51244577b669402f4a339c47568a46f978b19cc37343dbf3c924a772390baa0a", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "5fb99197-bfc0-4a24-af82-f2a11f1cecec": {"doc_hash": "15fcf0654f02724c8221b8679b6448ce74710f4e85b926e457ef25e6c0836b8d", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "61a9786a-26b8-473a-9504-6bd53d840275": {"doc_hash": "68d8781e89146e2d46be788f1b2834883ed5e8dbfa62f9cc25e68f5bc1df2c9d", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "cdeb5b83-2839-46ad-8ed7-b07bd510726c": {"doc_hash": "0076732d75eecd07a953377def14cabc592981f8d85d334cf21339e7ea2289d2", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "0f31db4d-bb3c-4862-b8e7-f8432228641a": {"doc_hash": "210c8ff70c2a0baf8534e71c9e58363c5e050ca15e32f4c3fbc8d516cd902ba6", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "b2caef75-0f6e-4c7f-ab60-515bb67da8bb": {"doc_hash": "3e412abd46c228802da124c02fff04e48325b636bc17ac40e7da94c99ce7c17d", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "f6f9ffd9-cee1-4031-a7bc-451904f2310f": {"doc_hash": "98e70026c76bb07f1555c308432e6c915ac6df95421110095e427c14c498d1b3", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "539defe2-e5a6-42c0-86af-4b4f19020094": {"doc_hash": "d68c0a913487454bda989010063c86a47620facbc304b25256fe0c49aa0cfede", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "33705577-5b64-4adf-a8e6-2956c674d6a8": {"doc_hash": "5a9f9fc70f72923436c16bd1aef2c73fc3cb699185858fdbf33de15f7261797a", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "a3164538-6719-4b3e-a397-453da29e823a": {"doc_hash": "f92cd1aeb87fc74794e874fcf8f4f43b76e7f11958f73ec69952c3d320a6d52d", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "4e05d07b-82ae-4b26-898e-0aeb843f96ef": {"doc_hash": "9dbbf6a93bdccb2bdf8de4d34ed7f62f20c48cf8da89fdf8e41ccf12fa3bd385", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "682ec1d8-8ab8-4aa2-a007-5739d696faea": {"doc_hash": "3ed4c322feaf6df5944706050b83cec2eef80abe813eb0f26164e1190626bcf2", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "97a83009-22e0-4f32-a771-f3643c06223c": {"doc_hash": "bbb4d85590d93908b78a907d3338ca3b7400254d49ec050e6d3da045ae9d96b3", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "2d1bddb9-c5f4-490a-ab09-4d1fd4df08e4": {"doc_hash": "b686ef1213ddcf4b6d410fec4a704dfa51a477987008271d8038167f948ff602", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "58c7c553-0b7c-4884-82a3-f7d793998bcc": {"doc_hash": "6a14678b3e163f239d38baf8ded26603d81a1686550e9ca99d6aaf307dbaa64d", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "a33ae062-b237-4c31-87a2-8bb01c49b7cf": {"doc_hash": "847f350eb3f704a2ec464a7cd57809625c84688cdf0b137d2712ab805f1dc481", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "d71fea52-4d1e-46ec-bc53-9a4efdc398ac": {"doc_hash": "977383f70303256900cd0515ff6ffcdefdd67184c214b0a8a2ab42863263f763", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "128a5a41-a728-4122-9518-1ad7b5cb93cf": {"doc_hash": "7eee01e8c78eb9728db0fadd2e50577840c0fa83a69d45119dc1b92d88d05ada", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "be4ea1f5-984b-449d-b8fb-752b2b6bd76a": {"doc_hash": "5ea1b85c92f40d05a4e834dfc6e437b3bb085cb1f660c89bd3a6e65ea93f329f", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "693ba4d1-d740-4c76-8aaf-63ec1e8f7c5e": {"doc_hash": "f5a5388b10588822536fcb5d2bc112f85d5511c824e66aeb87fd55313dff1a73", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "f7f555eb-ed1b-41c9-9163-05bef43378bc": {"doc_hash": "fb96e59c9febbd633faf85d7ab79c3a3bb543ec1e6dfc3e4d254324faf222619", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "e805506b-b139-4c1e-9034-3be7d42ab444": {"doc_hash": "6be8e0b354770bab955e64cc784f9f49c5561b27a5de8b1c0fa79293cad738e5", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "b71c2d34-3368-426b-9ac0-079daee37cec": {"doc_hash": "6a8b4960172b67062807201c7b7388b7f4d1087092dff8608a65ee826c24692f", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "2ec11ad0-ad6b-4649-a53f-0df8b7fef47b": {"doc_hash": "add794ee223817fbffd4a75703deb91a8567677f6c21d7fbd2b8ab00d26668dc", "ref_doc_id": "5dee6194-accf-44d6-83cd-5a00f361089d"}, "73a5999f-7e02-4f3e-a52a-8a40f5739277": {"doc_hash": "68f301012760d178efffe299c7a3c20e786f014d6a8b4de086bd4dc6846c42a6", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "25baa248-260a-4976-a94d-c930db8e6d94": {"doc_hash": "62502240808350984f1607d96d8ec3b7eea1b1fbe34a950a69d09ee0c4541b4a", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "0f847d14-11a7-4b9b-9bbc-19bd572d1d1f": {"doc_hash": "9fd136ebf3e38402cc8e6fb46b3960c3df6f0d72eb287607e33885d26717b7b5", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "f7972863-9294-4440-820e-efe2381940bc": {"doc_hash": "98f4376914f2f935bd81fbd7289efcf902cb4bb11f87333ff09c5ec502a0bfc4", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "f7bc2251-34f1-4d9d-89af-08784cd75ccc": {"doc_hash": "2c93df9c07d73ccacbddea3b959fba36d1060b5516db85280de1ff9b9bc28a0a", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "174cba22-54b3-47d9-a479-2615e13cd6f1": {"doc_hash": "aef9bd81fcc8aeea3ec4850342aa3d599756052a517be4a5f0b08f91cd523a29", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "992b6198-99bf-41b9-b128-c6818414a61a": {"doc_hash": "b136a03cca96195adab8050c0bfdd436844a9f59d39a766c98d27985b392819f", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "8c80c9c6-1ea9-45df-a56c-8e36418803db": {"doc_hash": "b9b6a81dd1507753cb093ac0c341606feb82ccefffaea48f6d958a4c3dd5c0ee", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "14001324-03d3-4f26-9618-42f00c835a64": {"doc_hash": "8a0595ace31b899a69357ed66f0630fd155159fb60cd7e67cd4681b1dbbf642d", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "53d95df9-c9c4-4040-be86-0bc0a7074714": {"doc_hash": "02afbffb9ca2470c5bfef13c7d3d2c9d4045386fe65b5e2cfb69c212e46d8df3", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "c3ead74d-1c0f-4102-af5f-02f75752f04d": {"doc_hash": "9c3be388c4126f2d4a635427a9c3aa28fae0f3d244ad5300f01c83c2ef252317", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "a202afdc-50ef-4fcc-89a0-001595c525c4": {"doc_hash": "6742377ae5a7e65d79580ba7293ca0d3a0adadc318a0afad35b8a8c159d16cba", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "66d3fb9a-ea36-420e-b8c2-ce8953076b12": {"doc_hash": "f79bd350512cc11f1dcec250bf3d28ff50bb7e45de9fde6465d76ab3acb67fbe", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "9b63ba14-b069-4562-9e94-8ff59e514131": {"doc_hash": "2478451ba334dbca5bdf2601a11cf8ac9a90bfcdafa2af3e3e995a27caf6e121", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "a9eacd4c-410c-4bda-bf5f-f38f0264f75f": {"doc_hash": "2ac3efb16c2b5504bf78662da6f0025d14b294945af02aff57dadf9e8a23c9ef", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "a7a7acfc-8c85-4ffe-8989-c380b677727a": {"doc_hash": "d33145a800bfbe91a90fffd6dc13877a8b0218cf99da921bde05bc6c7ee5d0b1", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "a0389721-b9c3-4bd9-842c-ba7b3ea57fc4": {"doc_hash": "1d405f12fd7421e05f440f2b7af0fb2165590ff069a79b23c346f577c49e23b9", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "6ffd4f07-da0d-44d7-9a30-b34c835c2d6a": {"doc_hash": "9856936772ab16108e10fca703222a28819264b5d387af38c19852f9e61ed093", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "e4764c91-e475-4d6a-b58e-0a2c08e09b49": {"doc_hash": "0b25cfad5386dacf8e4afd220f2e06d9785c63cdf2ee5d9e745a99a8434644f6", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "7ba60662-3a6a-48a9-8eb2-00b41f896b26": {"doc_hash": "33c828923b8f60fd042ac6e7e39ed8fafb0e4932b62eee4e8a0db78f709fb4fb", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "7994167b-a1f7-487e-a319-8abde81cb7dc": {"doc_hash": "235d51b1a2f1c24a817e5922c2f58ee1a464991c5a18f1ee5fc394d05f6f65e9", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "eac2d26e-d04a-4a97-a42e-2633aa8d6134": {"doc_hash": "243f752e0420a7b4730f4bee3671e2b926eced715781f87a7ccbad38ea5fc600", "ref_doc_id": "b8278bb6-77dd-472b-bfed-e5dd5e035ceb"}, "29be148c-810f-4a67-846d-9486f1af6475": {"doc_hash": "40ab32799628ff21a2359e9071f34e78fb7055abdebd7d5e075466b365b7ca7d", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "75b4a0fc-81e8-4912-ace5-90c0155ad0e3": {"doc_hash": "dacfec0e32d2f9188639b86afde9cb5cfd10d3a718a4145e786d99cfd69dc7a9", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "e564716b-242d-40c0-97c0-6bd418914c8b": {"doc_hash": "fede1609967044973bdb1a5c0bbb7c3ad9cab0a4ee803dc2981cc2ab4a42e4a0", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "4b152da9-3f39-4552-be03-c07fd0497b23": {"doc_hash": "6ea05f644e35532840b85345f24325c3cc64b9f62ea4e8d614f2994f641310e2", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "2f068dbe-115c-4dfc-9472-66a54f0c27ea": {"doc_hash": "ba4acaa7ab636cadfdcdc16fff2814e214323a5290363cc099ec8b1701294060", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "5e98418b-776c-43a2-ad59-873f656f9850": {"doc_hash": "06675ebcd3eaa4ca5a9731d4f50f86f0383b12c6389c38849b095b0beb483542", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "2a3db9ca-8dc3-4fdc-aca8-43b7f15642e9": {"doc_hash": "545c796bcf7c0c0e162339790460c7d027473af1dc4de513fb10baaf80096646", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "19dc97dd-deb2-4c54-9f26-511b66581860": {"doc_hash": "8eed47df183059411ae151669fde36a0f9c49597161740cadd0c567234ccba2c", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "c8543e6b-0e95-4774-935e-286b323a5bfa": {"doc_hash": "8040dcdcf45a0affbe64193d0d0ade09a92f063962bc539d25739aa24d8eb09d", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "5b7063ac-4714-4b2f-a2ce-8170a431f038": {"doc_hash": "e7a96f852a4f3bbd473f564021063c142d4e19c29ffbb8c1ffd0f22dcc8d67ef", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "e5f6e4a9-a26b-45fd-9291-a3c2f25076e3": {"doc_hash": "b278f981f329f9f987ca57a904ab26bacc1c1b141ad490ebd25c9b6c367beb60", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "2920c459-9ce6-4cad-b844-2ae2c633659e": {"doc_hash": "e151f49b290b576524d1e062864fa537a79fcc3123b53095487b9149ce1c5bf2", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "ecc14e03-d47d-469b-8850-1d61d1658053": {"doc_hash": "309a3e8852d76054f5a3b65438b92766b917bd50647e9c0f5a100ca8adb1019d", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "ddc5d9db-52e5-4bfa-a6e1-716beaee1972": {"doc_hash": "8c1c6fd757398c2825e8c33e9fafc1a2505d16b09309ff5eadac8040c4d344e5", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "68d58b73-43ca-49ff-a54b-f40d3ff1e9ff": {"doc_hash": "4e3491bbb097be3dd10234ff78f1c1c2c265a3edf12300f89f716166b2aa1e90", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "386870ee-d3d7-4522-a807-871e092e6b8a": {"doc_hash": "ceb0c32d5ff9df39715f7d370e742d7e18888b5e1bee57a770fdd48ec17f8495", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "20ae6df3-08e3-4138-85db-38a5f6578216": {"doc_hash": "c1aa9a599b0ba9034ba689bee096abba7ff993dad9c6dcbf5589bd6f3085d40b", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "b04a07ac-7e7b-4ae6-8ce1-1bfe65fa1e16": {"doc_hash": "6c3c3ba17f18529f6acd88467d8140bdea7db2272edcc266766c7f442ddfc42c", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "121e0bb1-6e58-49ef-8aa5-5e78ebd2ba69": {"doc_hash": "76d2beb8268a8a9d9b4939a86d81f0dbc3e5676c690600d288109fb3c09e4636", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "2e2ce2f9-76c0-4b9b-b936-61e72f2537db": {"doc_hash": "1abd6ede5e308999dc750105fe478413231ef07e3eb86c313881f184df7cb5c4", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "e7365184-8b45-4fd2-9058-652fbbd4af8b": {"doc_hash": "4b70bb17bbfa1135ebe27fcbb1912c0ced28c46a6cc4a6fca7b84351942643c7", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "ec0cbcfd-02cc-48fe-8b87-e2aaf0fe91da": {"doc_hash": "d4abb9b6534276c8f42dd8f968c69224638ca50cd40df38e6b99125c11d74b36", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "7c96c59e-cb45-4bd9-ad8f-32fa08d44e3f": {"doc_hash": "d6dc4130ccc76429bdbf7bb09cbb4f3dece6a58eebc436f8f3db7a15c37e557b", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "6ec743f4-7892-45f9-b74d-4063eaef8729": {"doc_hash": "8943ff3aa6ef3bc1dd84aef165b5699b1d26c3e6b582e39a61617d8c5ecc4e81", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "a7f91d9d-5305-4d44-9bbf-54201da34ec9": {"doc_hash": "6eee74a8d8a94768d67d22c75ee0058d086be07e33bb0c3f285dd089dcf8d4b7", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "bfb2ea87-9fc7-47d4-9a5c-4d875141065c": {"doc_hash": "7fb443b8020093a3c5e53a1f623dcdc40939430c03ae596f30715310a688f412", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "bddd7c4a-2f05-44ea-bd4f-53cc04363430": {"doc_hash": "6ddab1cdea78768bd8bd857230eb99b684d1c0b223cbc934c5c8a4a08f9f2ae9", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "dac15da0-98af-4e41-85b8-3ba13d415c68": {"doc_hash": "711dc9665e15ad5fd4b4a5b285aa4abe61779dd9d860a808daa3824af4359692", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "1d16eb41-a5d7-4df4-82ec-2c2c449bf047": {"doc_hash": "7e2dfcfeb5ab92b09bdb966b7814278ffe91aa57a5ea1e7827d23567ab6bb3f2", "ref_doc_id": "8076c054-5391-4925-b7fa-253b49ee3670"}, "75eae37e-e1d9-4a1c-9d7d-0a4492ae1eae": {"doc_hash": "36d0d29f731d96c749f19fb5110a9607ef2b960e9e5bd22d57b481df3ec66b83", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "baeafd69-3236-4475-bb36-da271c9a02bc": {"doc_hash": "d1996e568300ea6145fa970ec06840feac959b7538709cc8d683d22256e7e940", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "ffdc542f-3d1c-43f8-861c-044c7c50ad0d": {"doc_hash": "67007e60312f9ddc7207d526bc19763f3932ec900cdc1ce6ac2ab97c145770ac", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "6c80351f-7d37-4e24-af04-5bee454e1fca": {"doc_hash": "482ad3d6be2d92f4d74de2381e5b7996c025224b873d4052ccd78f73004a732b", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "bf4f5744-1e32-4850-88a8-a63fe0528fcb": {"doc_hash": "a092cc3e322a04e446af544dc8c481748502e279f3ab9f6aedad5e73dc4ba288", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "ba0182bf-e3a5-4a72-8513-dbbb747dea99": {"doc_hash": "094bc2e1165303dcdd52d5c37a438d02984380944132fa1300aba6384669ad74", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "1c8b268c-9037-49f9-b232-b350b0a4c6c2": {"doc_hash": "4eb6144cdfbc6018ba44a0c9d5ece343c54a1dca6ede86c84e35211f8d90af18", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "ce481a93-71dd-4d2f-99b4-bff9c8d8f323": {"doc_hash": "da185ef52e03e792f1b8619706e74a418fd36550e7bfcfe476e16b88f714fca5", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "8c1abde4-ed70-4f1a-9ebd-7c308cfb5f0b": {"doc_hash": "b26beda6a47581146db74031c4d12e5dc3e6ded510d44b1fd0af79bd5b015ac1", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "d041f137-a26a-41a3-a80b-e9494230f692": {"doc_hash": "6f3660d4646e4626e1a7cbe66f429f8eec32a6a73d1e3df588370db2cbdb49a9", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "17d145ed-bfd6-4932-b4bb-22ae74437964": {"doc_hash": "6592d3ce8b1730bce0d9c411a488040d5d4efc77d19e5a6d0a071d11aa375fd9", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "9afe32fb-c3da-4e5d-a132-3cae5c727993": {"doc_hash": "b628e176b031b39e6ec042b44407b3766fdba371ba093a8ed170cea06f78c9db", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "a045860d-2360-4e3b-b517-b19607006405": {"doc_hash": "cf38320986325be7ad973ab8e7d9892ad3b6ad7a8d53f85ebf53c9ea267fd2ec", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "6b562bcd-ca65-4125-9201-108104654752": {"doc_hash": "efcd46218faa692e74b4fce74dd063fc52b94387c40d2d17ca6872805fbc8d67", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "e264200b-9a48-4023-b6f8-58fa4889e140": {"doc_hash": "64da260c68f7410130be4285d3b09f48f5aaa751244034c0b8c3b23ac4b23613", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "912c769e-da7c-4cc5-abb8-62e60e279b5e": {"doc_hash": "9362d173f01ceb52d9ba38127cc8334ff064afd851ba9a22cda8eca857e53d1e", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "93640f74-ffc2-446e-9321-e583295650c2": {"doc_hash": "a47f41687e883066ff545bdae7faa8dca72d26aac448402e9b745d97911320ca", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "73b949f8-7def-4a3b-9a1f-8c26073300db": {"doc_hash": "10217ba41a98765be1724ff489e603326feb98490c03b39d5d3242986b6e51df", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "d68c7eed-f39e-4827-9230-d265f3bcd91f": {"doc_hash": "e67b9f56f5efe6658647de93bf19384d1bf04a8aecc2d3783915220fa43f326a", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "fb0258d9-cbb1-4057-bcec-33d55c16c6a2": {"doc_hash": "d7323e42e1745d9be373dce49cabe080af1e34da03d78f0029f9b23074c2ffa2", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "fde5a5a4-d297-4c36-8445-d6f046347e9c": {"doc_hash": "f9acdf4aaf4097fd83ed890fe68634b26ffbab2df8c5608d69eb9fd8bd169472", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "d39bda84-291e-45c3-bdd4-e7520d36ff2d": {"doc_hash": "712b72b93960d9b7e2e68ab479ef9cfa5fe16c96c6c3b14adb053498f0f1aa11", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "8937c1d1-1a35-4b5f-8372-404e4ce977c6": {"doc_hash": "98a4ba0e66a53ef464a46b64c997b742866681f92c228d4a2725781945e10f7c", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "dfc9b694-6729-4715-8c3b-285e70162c0d": {"doc_hash": "026551f3c129d5ffa90681c04ea2df2528f9bbbf66b01d5d727ed575c34068fe", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "92b3f5fa-ce72-484e-9a68-b5b77cfe10fa": {"doc_hash": "18691770369c178b58707c88e3d0f0364dcb93d38d30b90956971b12a249a45d", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "f488a4d5-8796-47df-acc9-c43a2c61f794": {"doc_hash": "b79f0e5f1e7316a9e458b5e2c09c8012b994e9cd2d381175717b4857d0eac22d", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "b05413a5-261b-4fab-8765-659ba0aad766": {"doc_hash": "ba0f28986492a7408fc77830f18d35dbe57801fc2bef55a9866d5035039d6c86", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "a621744f-55af-49c7-b666-153fbb9e845b": {"doc_hash": "eba2cd0c14626ae054277865a19de8e2decf6ed0c3768c910cdef641cf7cdb27", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "5852b25f-59d3-4161-acc5-5281c687a80a": {"doc_hash": "9377e7bd6d5abe5af4707ddaf951506b8e7e8e0b4d46912b0b30ed78ccd01591", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "8b74451a-3cd7-4af7-90b9-498485dbc43c": {"doc_hash": "b4ff580cb8e07aa8c2c867794d0a6fe8c72be292d2012924630cd6ef1457653e", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "2baa29f4-6bae-435a-b4af-24fb58d6c556": {"doc_hash": "a09c8c26d22cb9122cb0f4c40ccece6f76721a09dfe6ab805129e18f30029521", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "e40129f2-cb93-4160-9d7d-de67a14ec151": {"doc_hash": "7771017a0997d1fe12001a9999b64ab6eca0810a805c1baf143f69d5a06373ca", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "d27c988b-97a3-41e7-bba3-9e8624c3d29c": {"doc_hash": "12db1bc27ba5c02e3e5e098576aa7261f1d95956441eba95ffa031c59ce8c4d9", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "fe966659-ebcd-4625-b0e9-f7818fbd306f": {"doc_hash": "bef726941415e616d189278ae67fa51cf0ce2bd63e31c1c1986535610d346c48", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "3437d41a-cb2e-461d-8d55-4689becfb834": {"doc_hash": "79d47badcfffd0dc79342f75ad8dfe3824002e50310751d03a849cf1079413cf", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "86ff5e44-afe6-4d47-a782-8ed83c801d79": {"doc_hash": "0ab94cdc962cc8a172e875573d8c1d0574f778b8223b2b15a2894f0863fd5ead", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "f6bbb18c-5c37-424c-81cb-623bcf7fb5e9": {"doc_hash": "4813b6196b9ce13cb5fcdfcd4c40ee9b1158a2c8f5c971c0cf584792c3f577dc", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "13aee707-6f14-4919-bc18-83d853b037dc": {"doc_hash": "a30772bf4772cf43b0f4449961d34c0d84bd9706857e9d868f728b72ef5a6ab8", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "c90306a6-0db1-4873-b599-15a769020908": {"doc_hash": "f7b2ca06709c3ab85b41b1cf3673f2a2e812fcfa6dbccf5bb8d5f34f16df4df6", "ref_doc_id": "10252a18-bcc2-4230-b58b-3a6a18eb8e57"}, "9b071f51-7392-4b71-9136-47b8bcb063b4": {"doc_hash": "e2708613ee8526b3a8a4fb5a5f042de717e0dc0a49c234e37981ebf0f0669d09", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "8041f740-19ca-4b22-9ee8-56614b98db18": {"doc_hash": "976bdb1bc3157b7f0246c84aa7f498c7830387876ffab1a0728568dcdfc0277e", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "b583e0de-ee08-48b8-8af2-e6f330e8e6c3": {"doc_hash": "496fb486ffda06f90038b10cca2f78f69842b2ac879afd88268c31474bb84408", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "80147a08-ced5-4245-aec5-cdcc659b5000": {"doc_hash": "05c818b7d75aa1b037364df4c95ade7eb6330ac090a84b4d5d99d329373542b3", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "d85a4a64-296e-449d-96fb-7664fdd14c9a": {"doc_hash": "40a40187fc2c01740e71b1229843cbbff4e594380d75710469d538d871c27806", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "5b4e0f5d-47cc-4b7d-9b55-af0640563bbb": {"doc_hash": "14dfd3e0814cee957f67a183651b8eabc76b41fa4c1d6954d2efd39f2c74768c", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "001ee631-e42c-4f13-ac62-423d06193080": {"doc_hash": "9758ee07d58b736ca324187546cd5478396866273024a83bc2e941f5106d9f6d", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "e6e54d2b-395c-4f7a-8bec-2eb17a8ae656": {"doc_hash": "0d8781598de3c92272f906aae186a08e3646499b3c652c7e2c6df320b4b28274", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "81396d50-913c-4f33-927e-9e0fcf134a9d": {"doc_hash": "72ff5314e581dc4e201734922d829088ba5f4301400aa6492b812f4b08264f9f", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "c13eb7e3-c12b-41e0-9c07-1e3fdb5f3d65": {"doc_hash": "f7f6dc0cd73b20c6c956505e4a7b48dd3b1454588bb6b45ae3bada519b0ad7ff", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "471046f8-f35f-4920-9a84-c61e0f985943": {"doc_hash": "4d37dcd72511c3fa4a4765b86254e9420792a1c82a00c52d7a056716f7f761b1", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "eba3b6de-e9cc-4c30-95c2-5774275e3bf4": {"doc_hash": "31a698f234232c65f4825e3d295b60418ae583ecc595b00da479e5ba449b01f9", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "7bf37985-fa9d-4d67-9e6f-03f4c8ef3de5": {"doc_hash": "dbf3a92294e441e2c8278ee9550ae2298b0ec5bca06d7e9b27c6127b36aa6143", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "b8ab246d-4107-4a08-bd41-cfc1e9bd38ec": {"doc_hash": "df24e9ae819f92960b469d356c80c862d4cef1130677c1f990e9fe7810cea06b", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "35a86a96-2e30-4076-93b8-f3695cd8c0c0": {"doc_hash": "9356fc09cabb3750d02e0afae4c8f13512bba8e8fe360008127e6d8bd3503994", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "9c2123a0-73e4-407d-895c-9b9a67c7bef9": {"doc_hash": "6edfa2d7f0e97e54f254029dd76c7451d2170faf45846b2438330ce12b2c4c79", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "d7dc381e-cc46-426d-b6df-a3ad995f7e46": {"doc_hash": "35b5515141863784135123b3196ccbbc704a8ac283096a54dc1f464e26732d48", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "76b87cc6-c1af-4ecb-96db-038a9fbb9167": {"doc_hash": "2b435debffa24c2368d3e84d89022bc6b56dfda7ad3641546ff956297fe46388", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "6834afbd-6810-4714-8739-94dd7916cddb": {"doc_hash": "d25b617c332c89aa26c1125968591f7f10776e087eed15444e1f120017e4f911", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "d07dd57e-1180-4b36-be02-cb4a7f7622af": {"doc_hash": "c2ec39bcad77cb60cbdee2ecf383de703f14d233ee9d83e495f64b53d83a07e0", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "b2d06df2-b4b2-4e4b-873a-01ff3c62ae1e": {"doc_hash": "4b95a33e8e4683ca363cd1a04ab151d23e817acb9b25f789776c92d0b82e369f", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "0b110948-ea1f-4996-aacf-18f1ec13611f": {"doc_hash": "663e4c1a162310d1d67d2620760c8846f20a13768161a72c8c637552151e4394", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "f8c360aa-a2c6-40f7-9ff3-d319c6fadfa9": {"doc_hash": "749d680883a2d05cbbcfce7015560ba06dadff1e8e43581945bd22862d489835", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "7224e92e-cfaa-47a7-aeb5-57fe4df862dc": {"doc_hash": "d7e09d3a422fde73183754a401dcda16e1c99ff8ec77211a7193f32a4a7865d9", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "07d7b056-f88c-4eff-9dc2-a88a8f15c43e": {"doc_hash": "d1bd834c904c8044959c5b2927ce39e33b93532769171313c4d160ab0e6a11bf", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "2eae8e68-ec14-455f-8b49-61d12ee25fec": {"doc_hash": "8affd9fb3eed34df9f41764dd363030752214fdbebb3d6a7cfb572d2873727c3", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "a3543f29-c17a-4b62-a101-aafe368caa06": {"doc_hash": "49e6d12a5dc4fbe6611334784743aebef2b64a93cec0750ea32ad499eb3ce76d", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "da164256-8dd8-465c-b3b9-2cbd7e2c3a3d": {"doc_hash": "ae60014ed74782f2e7b9072c60dc1e1f1c9b5bbf6abf975b7af5ba53f27f39bd", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "89e50121-c273-47cb-93bb-681b2a138108": {"doc_hash": "84f38160cdc362d03572ca870e0383fdfc5821d4c840670c5cfa27a65ce2cd49", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "5a73e036-4e5a-41c9-9100-e5e36856ba0f": {"doc_hash": "a8f769d17f34a4865d0ef78708dad8672428dcd4a31e8858578e826e2d3b40af", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "98c27877-ecec-46c6-8631-233e42d1eed9": {"doc_hash": "ba2c6e976db7d63866ec9b7b8ee607965919b7fb54863638067e7b5e39780dcb", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "f408f4e1-80b0-4a28-885b-98a53a5d2d62": {"doc_hash": "36f14c47d93854194e9cbcfe401cd01a26a479f0e194c957e3ce9a3410e07c5d", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "63af9404-a88a-4fa3-8f19-af8c444ce061": {"doc_hash": "1959ac42ebf7ca4806181715aa6740547da2f3af8998b36c9bdad02bc797d9d0", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "24bc2aca-5e06-4a12-8d36-3b18ba3bee70": {"doc_hash": "f4d557a0f41cb73d2d72c80f03b584d86c22da8ae5423a80fd3aa1b534e2ac41", "ref_doc_id": "a20b62c6-333d-4df2-826a-8b17159ad9f9"}, "a54f700a-921b-44bd-993c-a235238820cc": {"doc_hash": "613e5b97ee50744d7c785bea19a3ee4df2f2830347776bc7bf7ddd5bdf8e4d88", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "0de4c3ac-8914-4709-b901-f4678d4ff008": {"doc_hash": "e20ac61d7dd1c09c4ec3a23b3a188c6f0d6e213387459cb7781222e177b791a9", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "d93bafa4-9887-4f60-98a4-16021ecea556": {"doc_hash": "61de1dba16d30bbb05a2da20a681e3b6c69fa7f7af85ddd85e41d61636f0812b", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "37d2f94c-1e26-45c7-b320-38e883cf9724": {"doc_hash": "a273869c613e499c7611444f45793eba5b69a965599a9dd0e301977db3adf844", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "18699c98-04ba-4eda-b757-2422a721ce30": {"doc_hash": "184312a710cde0665cdad3330f4f804ebff813640eeda6f9bd435d91a78b88b2", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "201f319f-d1c5-4ad3-b8a8-fdc8bb6c6eab": {"doc_hash": "5b089d259bced6e5381ecfe9d3b8f51b8618c9dbfee17d7b6ca3bbcbacf6f290", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "69dd2a4b-ce9a-4ca7-ac06-3163f83e3db5": {"doc_hash": "2340e9761e08346b9336e268cad294d7cb13afdf595349d9227a22b78dd41fea", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "a1fc67a6-829f-438c-a194-eb93875f5329": {"doc_hash": "54729fe848e15d4c77cb1d738522c102c44f29ef527c578a52937235c1fe6268", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "c0fe2c25-8ae1-4a0e-a011-fbbcfce44db0": {"doc_hash": "e966efdd4b4b90d5ec22aaf38e4fb10b08671f5c05ba68647ecd67db51dc13ab", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "a931cce7-ea72-4ddf-beeb-1eb77e40d1f4": {"doc_hash": "6ab110ed8ac8b77f8aeb1a857772a036bf2ce7b398e90f87281aa04392967efd", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "da798918-1e9b-415f-b39a-74711201ecfb": {"doc_hash": "3aac9dff776c4a1a4f1cd765d0d9553e9dbfa9e448a52821104e712f2eb4f74c", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "17a064d9-a3eb-4b62-9c87-31c91792313e": {"doc_hash": "67a889b3098f023363c5c6c71ce7e898aa5a1730c1a1cee2990b5c7cd12a4310", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "63396179-965c-4729-b5f7-0a1c2d3aadd3": {"doc_hash": "f592b56fd25180db0abbd4644ffe689e9ee0205ed9d4daa9fa5fc6f619828383", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "a9c55eb4-649c-4978-aef7-124344603377": {"doc_hash": "3e8d8a7e8f3bb8a5525964ecbcc1d0891a50377cfe37fd7f6156edbe2586dee6", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "b770261b-fe18-4f16-9111-b48a879a9b34": {"doc_hash": "90eb0bca701fd8b9fe5b25834fc2b853047267d65d13d7771b5ccd1ae260b406", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "ee86b109-629d-4dca-898b-91b2392bbfdd": {"doc_hash": "97bf6a7b391588a81a56c982bd2f872448c988d26032db3c72763a748af1630d", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "fb07b223-df77-4597-bc12-213fb83ae238": {"doc_hash": "f743c261258c2d03d6eeba5e55bbe5d171ba2e60f6bce8d562ae77ead06ffddd", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "472f28ed-b705-4921-869a-46e73a9b7e11": {"doc_hash": "e0378d192c708d23126a8f91270c0dff01b16c6de6b9bc687ee19db6fe7cb4cc", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "cfa325fb-7e91-4140-b482-1d0ec53f28df": {"doc_hash": "1e79fabe345f2588f80de2f07613970ac7e533d6a8643d3d0562d0814e6baddf", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "d504e7f8-02b8-4626-b29d-4afb39bd0ae1": {"doc_hash": "2c9c306dab3001e6dfa9de4b80e90ef12169e97afa001824900f101bd75deab5", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "242f1687-34de-4da5-b15f-99db2cb3a74a": {"doc_hash": "0fec4f099271c3ca2f32b9259f5863ac007194fc7241ede083b6aeb11a40fb9e", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "32a8ab6d-b89b-4baf-87e3-6944dce8d0ee": {"doc_hash": "3ab534bae13143987d655c385006b9e634107198330ca99b5354e602feedc039", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "d7186965-a337-4b46-b23b-43b3f3c2dd9e": {"doc_hash": "a121ecc1a67ea7ff466463ec226bdc05e62e472243b984ab5e9017bd8cc1217f", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "7ac4015b-92e1-47c1-9752-35bf898b58df": {"doc_hash": "4d5b47e57ad17205891adceb9cf6fd162fe8f9f334bc61414bd5ca47b8d47967", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "839144fa-7d39-4f8c-b2bb-d6ba901fd3de": {"doc_hash": "11a6389cf6d400bf9fdffae85d1a2dcffb1b1d49b28cf8503ab8ae65627073a9", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "3dfee405-0a66-4536-809a-5e47a898c23f": {"doc_hash": "36462d8f88e9894ba266bed8d3b77f6438ab2cb6a9ae6d2c3b5f5a612e5cd07c", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "fa6ab2c7-308a-471e-9cee-f64a367eda4b": {"doc_hash": "f0f34f2b94177f930c011baa28cad28a336940af20522cb7305a3e399a535895", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "25a10e0a-b117-4a5f-813c-ba98a3dac857": {"doc_hash": "dd51067de33b89b7120ac4e3b9f31373ab2b2461f90b8688958e5f1ac04724e0", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "962b30cb-7140-4ff7-9c2d-ffac21bb125d": {"doc_hash": "e9ad713d6f555d62cca5f6d4786860f34b03d4f06bc3579b9b080b1f83c14953", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "d16ceb96-5b4e-4350-9a07-c3d129bb2f2f": {"doc_hash": "145aeb1077e062cb64f6ab7d2f04da992bbc935f39c9ee17ff6cb50bff21cc03", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "29192c13-02a5-45d2-850a-771c343eaf50": {"doc_hash": "e67b58d5de87d1e96f12c4c968bb29f55cf00750821e890f2f2d75c53094dc50", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "fbf1a4a7-1e22-4632-9d0f-89fc4fdeb1a0": {"doc_hash": "1d383c2ba6d1987ae4b763c82249f4b670f603ccae678724f95fa8bcab51ec24", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "0ce0df08-bc5f-4054-845b-8b447b425a7c": {"doc_hash": "660fa28870fb4738f84538c45409c686706e888e3b81250219bbc07321563969", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "4cbf70e4-1697-4b20-a74b-48d051489ce4": {"doc_hash": "d947afc2ec1df06b12b8f34a3ece8c9599bbffe623cb23b30929ac246870456f", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "bf44e458-302d-4a77-94ff-3a5b664363a5": {"doc_hash": "e17d096b20716d3cb13d714d7763c536296fd14d9057fbe127f60319bd8803ad", "ref_doc_id": "092ed2a8-9fd1-431e-8a03-82388d2bb85a"}, "e85a2c6c-ab5e-4571-97d8-6635983986df": {"doc_hash": "8de1be44d65a44d4a67014d7c32bc613d2ba124cefee82011fa28fb059ef6455", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "9d9523ed-f519-46de-9eff-8026c2f48d65": {"doc_hash": "d6fb47ab253b06a4498fad690b395e5127e17c13fe901a87d14e0c03dbbb4d26", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "5cacb6e7-26e4-4350-b96c-097c6e13e8b7": {"doc_hash": "8daf820c50fe7f432934eff3190238e06bc4b758ddedb501b18caf0f894a6048", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "36acdd3b-030d-42d8-9bbb-51dac5e38a6e": {"doc_hash": "4ac6c5605a7129ae509c0f3bfea3a02f8e2d9924a2a8458bd30f27f3bc102f63", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "945b604f-15b8-42c9-bd44-1ec37fa8ebd6": {"doc_hash": "939645adfba9a403dbeac8ecb93ff8c5c20c57b328d61fb3b765a833b09391f3", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "fb97a69f-7236-4371-99fd-b88f88290933": {"doc_hash": "d5b0c2c872471ea73afa7fc0dc11be6ae13d0c527f701bac8b22809399f9f87d", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "60a31c9d-aed8-4891-9f24-5840e70ab868": {"doc_hash": "798f0567066072d95c4dd47a6a6bbe99ad52c9a9fce0b71c0a5f13ec734b8788", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "bf103914-fe78-4523-95d9-9a1af98b7ae9": {"doc_hash": "6b3a45645002701081c7889fb4cdb03b7e94fee4530279f870690d28b006b829", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "506f1716-43a8-4e27-ba93-204895bdaafb": {"doc_hash": "c405fe5934ef6ff40e6aa9313e57536a7eab087977029baa04c7c6ba8ce71294", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "1c0b244d-bf31-4d38-bf07-c27f3fca3b16": {"doc_hash": "cf3ee0868f14ed3de37c11a00d376dd7b132db7caba51f4a23bcfe3803662007", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "0f1947e7-c6f3-41b6-94fb-f92c0e5f710e": {"doc_hash": "e7d10278a82afdda05c3ee4dc8f3c916cac875084af3e9b1048d221a6f539d95", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "1a82db49-3f22-4afd-9c49-0a33285f6f30": {"doc_hash": "65565b32e50625b2c9e3e685e83f04d4719e7252153511986dc5acfeebc40088", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "5a44f9de-5804-44ab-badd-3da8644298cf": {"doc_hash": "be6d14c92637ef39dec9bb8bd33e0c56875d3100b2f20c7bd8c53b1a3f6f62b3", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "a72e4003-9da9-4dc0-84e2-c6886fc8a113": {"doc_hash": "c087efdbd973d5fcd0677282088ee09318485d2bb99386ff9931c68b93bcb14f", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "0074681f-fa05-479e-8ec5-40c0b0c10056": {"doc_hash": "ffc7830943cd0bd17e271e1dd55d6a2dc7151b2d1567a22c784ca72eaf91a67e", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "0fe9369c-72b5-407f-b0a6-57f95da164f3": {"doc_hash": "7808c8e84abdc0de03a21abe03b139684b8508e85859ee7605c5d06df06e75d6", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "e4b7d87f-91a0-42e7-9496-4865238657b7": {"doc_hash": "04d7eeaaca025cf24bbf3322a348df8737ab497fc15a34080672f929eb16a014", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "be166c42-3234-4cf6-b6ee-286c291b087e": {"doc_hash": "d0f2060d1d4c31dc7c9103d76bca16dfde26144bbc92576cec1b3265ac110ed2", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "84561c35-46a1-4503-82bf-14cb73b0102b": {"doc_hash": "6d934e41da729035ef0526483da75350bc5bb4617616f2fb148e44e5428efcda", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "60eac8e5-0265-4be1-9dd2-57f011ba506e": {"doc_hash": "6cccfdf5b2b59719d883130e0ac2b92b1da8260bb3195043b7614f56bc14af52", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "c7337cf8-6e8b-4726-8f66-a01833df8f1f": {"doc_hash": "673acf256f8c8f39fda88d9b9676fb7ca62db4ff77837a3d0b6ce81bae2732e7", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "71fa6631-a82c-488b-a86e-33c0deab02d3": {"doc_hash": "e812ebf36de641846c33972e6d254782f13d94190cc2cd424f567186ae44a1ae", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "054d87bd-dde7-4afc-9c84-b99815dbb7d4": {"doc_hash": "b4b15f4519af8fdbfb2db24919bc480160e4fc73373a40e4b610197d3753f5e1", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "95d81409-6369-4e10-926d-870d254ac401": {"doc_hash": "5062d1a5cc33bb02ace2f910155341e9dad008ff854a0bdc81c6038347ca0553", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "d8b95a58-87d9-41ad-989d-65a58a38a6ba": {"doc_hash": "9bd7ae36558d3bb450f1a53a7243573e8787be2efdb321f3efdd3c44f8c7484b", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "2fd124fb-f356-4ae4-a7dd-ef423ac7ea1d": {"doc_hash": "99fa8cac340a76639a878b09986568207e5b1fc1805659189f9f4de78ad8d69e", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "2bd90271-49bc-4870-ba26-1104ab50a316": {"doc_hash": "16d73828b0dd83e540e4852d806854480913a749dd7cc92d27513b73e14610d8", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "5f495dc9-c785-4596-bece-6735a957bec1": {"doc_hash": "045a84b116588e6bc3c44b3635be9381bee6ebf5db757a2792bb932a53f493ed", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "a32e8735-d1a2-4205-b63a-2336b4d186cb": {"doc_hash": "3cecf23828632754ef21d0a6f2217770180ec98eae6d9005751179df0c40afa5", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "8e53a603-266a-4965-a30f-cdbe0bb7e9a5": {"doc_hash": "9fd261f6235359a2d735510dcc401cc4dad9c16ad68ec6a6705e973c1a5b7173", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "8ab9b04c-02af-4136-9121-54d1e757c8bb": {"doc_hash": "eef72a57fa2c3abebc24651e8abcc34dd98ea76bca0550d27e13e03260eb2dfc", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "10d3df49-871b-4749-bfd1-157c6d3b46ec": {"doc_hash": "2656f4d3fe6f1d22d0a51694de014f595db79152ef7258e12efbedda1fbaf920", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "b7108c21-4c7a-482d-b10b-242dbe2350e3": {"doc_hash": "e3cbc012c198b3e567515c14ef110c6f416899d61d3019dc0e989c3db41c5757", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "3feace80-945d-45eb-a92b-7e1ed84b0696": {"doc_hash": "3990b3cf9c36cb6fd9722b029623e3cb2c8d1b34f2aac3f56745f8d33a003ac7", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "d3eb64c8-f6f0-4e99-a06a-39e6e17858bf": {"doc_hash": "ea698f08cd22003a76fa1cbb496a736824cf7ecc4d23966b0311dbf9ab6fcee0", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "f1b38022-70ac-4b79-a5a0-7b3318bbe955": {"doc_hash": "324ca6b670a3dbbad3eab10cb89604434786506cb39a924768245407144faf77", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "a444bb92-ee25-4428-9680-5c0e0ed0aec3": {"doc_hash": "b7955706ebe9b2622ed213cd89f712ac2f862b6932a3d992aa25ca68393299b8", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "8d68edf8-19ce-4630-b208-b6ed4fb29fa6": {"doc_hash": "31e55f227b88a22a22322cf179cfd1b3eb4637a9285abd3f9194873e70dcccb6", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "0c9c7f51-f149-4b9a-a4b4-5eecae2d86a5": {"doc_hash": "0a44d37d51ff0afeee1ef1b344de5c6e4dc6bba8024f6842984bbf24d4f57df9", "ref_doc_id": "70523b32-d06d-4172-b8d5-7aa7027b9b4b"}, "5cae699f-5340-4cde-abfa-dd1680187b17": {"doc_hash": "b38b3d7b4d0dd4c56da5c764eb30cd8f261fcb0b71a5ec38cef0492d447c5497", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "b9d9c5c0-62aa-49cb-866f-210a884ae411": {"doc_hash": "a4d06bea80dbbebc2643ae61e854a6fd597ed2649c21bdd0c4e2c0128b0a018f", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "35e6c8e8-ec44-4586-97ea-d991bf68a323": {"doc_hash": "fa253e3912e8a60baf1c1d161a169d788640521b38e0873fb3a0416f6e62439b", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "6f969717-f957-46d8-b31e-a56391951e20": {"doc_hash": "2bcd179d0335eec0dc5c184f54b8af84dde11bfdf982d96921778fff3139c389", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "8f10101e-7e95-40af-9d84-13dee5686100": {"doc_hash": "ba30cb5057bbb48f2a424e06551c80e0a2d5b347dbda7399ad52f31e5dc9231f", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "52e70f44-d693-41f3-8b02-52be64d412c7": {"doc_hash": "54ac8f445901ea5e4855b123ddc47c0c29f1a42ae6d573cdb51617d77c8c5470", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "bc2bff56-7877-4886-83ab-d807fb98f65a": {"doc_hash": "811e757c6a72d3fa5302c6c4116d749b91fa05ccefeb315645aa6f91f8a52b1b", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "192e0393-587f-4fe2-b835-9bec16303ae8": {"doc_hash": "1bcbf1eaf613bf5d0176a32a4776b9025f813055db956846a3f3df6607a99a6a", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "9d92513a-08af-4647-8ba6-b34c5fff5e9c": {"doc_hash": "a44f549c22a2de65643ed8d80024c0cc5870621d778098a91893d6c76c6d225a", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "430332bf-5c0a-4828-9e8e-388f6d4039bc": {"doc_hash": "4a57bee3f22184a4363392b2f062365704c1d1711f6ab5b4e62b8f54f65a781f", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "8fdf9616-6c02-4ca9-a652-4ead4cb19e5f": {"doc_hash": "ee2bc2f62da8135266e2eb257281f204423d070644a801d967ae130b361b0256", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "cbb25293-2d94-4d34-beef-81b8e55428f4": {"doc_hash": "1453b31b1dcb9c72caf2be0d7a0b711b182d76833341e2d97b9b24e44ca1792b", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "53ab00ab-655a-47b0-a7eb-1823e71fa78c": {"doc_hash": "cd376e9fddcb5ae8c99beff58737d42991c131aa48aaccbf13ba43d7f8783854", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "74f91b39-4eea-4226-85e5-5dc2df5fa94f": {"doc_hash": "01b970f4d33768843b020fdbdb896b531920e849a230f73731f57a314f5fcc0b", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "1cc9c8d3-8e69-46cc-bcfe-83b9c43cb142": {"doc_hash": "0eef0d552cf2c387fcc002b8766c23f8d2f7a197e5faf03f504ff1543f9ed220", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "ca65bb9d-116e-4865-8faf-8e413f3dc802": {"doc_hash": "a812b456f51a36e10ecafa7caf09690289cc6ab4bef94e9ed864dfd6d9a33e44", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "3ed20217-1186-4fb3-8492-aa254f4b9709": {"doc_hash": "0270f970fcd9b3e32b1972db84224c717b77f827959d2c8e10d362ae02dcc2a2", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "a293faa9-3628-4b66-bbc6-f1baf214f54f": {"doc_hash": "24b176243716d231ae1177e8f16920ad73e0e372f13643c9aab19dadded432c2", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "30f80553-d99e-4381-89c6-369709d3deb0": {"doc_hash": "2891415893994c6928f32549694a48d86aa492dc24820ac21de575ecd4144355", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "ddae6a7b-1443-41d5-9b93-5052020d472c": {"doc_hash": "83a99df92987d3cda38f8e7ca67e527fd5adf656087094d53c10ba9c6927dafe", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "fea72eae-58bf-4a28-8a0c-14c088e501a1": {"doc_hash": "2747599094b3b1df4760bde135b83eddd09a9426a6c03d8cfd113be98df75bb2", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "f1101b39-eaef-493a-ae4c-9642304dadb5": {"doc_hash": "a38bacd3bbd9ffab5b1e9b3499645e76183f164b058e9a41692796099b925bab", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "52bbd652-1fb7-4bb5-a8d7-fbd66cb1665d": {"doc_hash": "d823a6d1b9167ba3ffb787e959825e0a22080bb28416aa2900e5081b039df464", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "1a51479e-5561-4751-a1ee-f91d378477fd": {"doc_hash": "bc1283546f95ebdbce33025c4f0d257006e130a30985324a721c6aab3589e8a7", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "ee3712dd-0de2-45f3-b1a6-a65351075a1d": {"doc_hash": "6512738264364019bf34c4bd326d6582d1d019f76077f93676f1307f5ea13e31", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "97d54ede-701d-46bf-bb79-e1aabdd0fb1c": {"doc_hash": "65e23ecc2f56c805d27c3df636487693c78f4c85deb2a85c23ba1e1a63ad9ed4", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "8da9fe44-4e15-40a8-9d81-ceb069f448c6": {"doc_hash": "b44e0868263deb56d719496c312ba1e53c83c2584e596e08d1e62b0196d143de", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "b9ed8c7f-6369-4223-b568-6c30210d42b1": {"doc_hash": "9065cadd639e8e35e79fec3a4768c30b4377956b3c00411d96a1c3eb570a64a7", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "48361710-a738-4429-a882-e08c752c9f5e": {"doc_hash": "1367d1b5aac33b7adf9f948f645e268001e96175aa89af1d9084f468068b0653", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "92583168-888d-4934-80d4-f2d452dda8c8": {"doc_hash": "16c261384b6ee1c4da5c9b90072b5917ae076b8410dde2b07e5e201c662c27bf", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "f32782c9-1ed8-42c7-96f6-c8b281cfaee4": {"doc_hash": "230f066d657227010f680ad07598358623f3a9093356b4fafe1f6e5e49a7c81c", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "a44e2862-1ee0-4a20-9b51-e31f1223891a": {"doc_hash": "c701e546350e8a07b5592b78a06bf161cc88197f8e40788ff7ef56f933c06df9", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "ba21e276-f330-4311-9d2f-36ad3bba3458": {"doc_hash": "5a5ca7259d2dd16f3caba3682d559014ff89be75d0b77f3d5052be91ec42cca4", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "d99e2178-a057-4358-88d5-0cf3d84030f0": {"doc_hash": "a541de957b1a6f589e3c1c730bedf1ab91823b883ca0db84644670482c67beb8", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "ba049ebb-1f3f-43be-bbf0-fa6cbfe4d072": {"doc_hash": "3f42e5cfff320c88d9e4060d49bf935fa8cf7e068e8f5e3accf196e2dde94fd8", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "a9cebea9-84c2-46b2-918b-8aea9eda74d9": {"doc_hash": "da0d3e0f85ac63ce0d6b7775037a4ea90940511f9932c7adc5305ad4095ece71", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "1969c404-e3a2-4fe0-b8b6-c4de1505acb3": {"doc_hash": "9d55e62093897dadec6b4ed4f0d8ceca1bf7a3efcee220d831093b0b182ff606", "ref_doc_id": "5e225d9a-ce4a-47ab-a799-54be5042d8ec"}, "b4f8cd46-b5c1-442c-bb59-06a665de9701": {"doc_hash": "3febd1a4165a5a31c5b1e468bb3cd3077cbd629b5d7f505062c17c3b87931c6c", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "ea901e00-ef6d-4ddb-9f38-c61e6fe4aabd": {"doc_hash": "83c501423c49b3d10cb4268971c6bc8623c8d6e7a598a46486a1139c82229c5b", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "b646426f-458e-4c50-a5e0-831ecadb1dbb": {"doc_hash": "d985c13d6edeaaac16766ae5844c7dddb33971de65432effcf810bbb3d6cb0c7", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "443f1f83-b68f-4ba6-b6d8-d7f70ce098fa": {"doc_hash": "80da9d5fa1c65dbc53820d54c1240a4558a29f695ea6f44cec4aeb702a59eec4", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "8dd14ee8-910c-49f4-9295-45ece46db33b": {"doc_hash": "94ee453bb0fab830e808e48a2041de512e2d1d44ba72a66dad781651daaf6184", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "6f45af4e-20cf-4ad9-92cf-c7b66759e1f3": {"doc_hash": "bd9f0d0863893885758a44919493c81a0488c66d73163eb02dec2437f910e179", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "9db72625-c85b-4514-b809-1800765aa645": {"doc_hash": "40479d910afc83be8e8a534fc4e8aeddc0a7b45ac13a2aa9339a1c3a242fb53b", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "0f6253f8-c082-43ae-81f1-c178b4468673": {"doc_hash": "9fee81133a7b3313f07b600c050a37ffaff9b7b252f3f1a40db2770f62c7884f", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "ae849bc0-063c-4ce6-a4ae-3d98b1b4946b": {"doc_hash": "f84a2bdd7f1d080a123b0b398d6b0e3d159366338f4e57f17961921c2496cee7", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "9946d133-56d3-4a9f-ad0b-8c329b7cc0f0": {"doc_hash": "1f9f5a4076bde287cc7c0ea6043216e6d6b3cfcda1d782781f4f993a252bc34d", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "8203606c-9977-4db7-bb86-a1fd4a5b2468": {"doc_hash": "0d5efd953d0da7340c8582d748327cce9850234cf633dcfe60538a91fab28c03", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "fba770f3-a013-456c-9071-c368b115392e": {"doc_hash": "28da5c8803c4d5c8131666287a87caacc7628c6b34e352f9e1ebc33f6d51c9b0", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "f62419a5-b996-4556-8e9a-af1095b50238": {"doc_hash": "5701f442183ba35f1053b4842cd9e1ec7d46e8786d02df06bdae5fc956da5674", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "29b0b81e-ee03-4236-9fb0-8ebbfe50a61f": {"doc_hash": "6693c2813d64f1c2c5416d277b0bffaaf296a8089fa912f589c72d07fdbbdb48", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "5de480d2-97a0-4f6c-bb3e-e005baa99b5a": {"doc_hash": "fc5d13b46276a4c896f01b5141b969788ec0ae7a045f8cf2c5c8006905c419db", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "a6b6155a-615c-4406-9c49-ca892abc5607": {"doc_hash": "c7aac8495753678efabbcb1dddeef24e15b13bc41d8b7315c55edb8d47e02b6e", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "a617f904-96ff-4a87-8ca1-e108e429d165": {"doc_hash": "b366101c15dbd2237867333847ec2532eacb7cf6dd373c7ecb1dd2ac2045f88c", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "2e0bf72a-3aa5-4521-8e9c-3e6c5dfe228f": {"doc_hash": "3f1f7388c81a500edfcb6f88e299e8b24738e79e2bc3cea09edf19cb95fe90db", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "4e996f86-047a-439f-b761-411c0a9fb861": {"doc_hash": "8f2ad8517246e255dbe2eeb7c98f8827feffe7b3d67219163abebac18869e3fa", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "afb13fb8-f2b5-4b22-8963-d79231753891": {"doc_hash": "c4662f1bbf84e4905a7add18480bc32246a30184c20b8bb7606c42bd80e315e7", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "d27e5cb3-3aee-4a0c-9c8f-ec3eb2286d96": {"doc_hash": "eef1428b65795dd68600293dcad8d4609c66db27cca31c31e4e34c5fcade0d28", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "a6ee16f3-7f6c-40ed-940d-4e3b4c00b6a1": {"doc_hash": "92d17c278d754572d72c725d0e061c6278d0e4102524d8b2edca0428e2ec2022", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "cf17efa4-a7f6-49ba-aa43-819a1b6148e0": {"doc_hash": "589729d2b06f205c7bf011453f7201f9392011d98be13930f2cfabc676cd4b1a", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "60d24d54-4d3a-43ec-a2c9-a53fb66b7c04": {"doc_hash": "f27e8b74ab8617deff259537e99213c1fa0639996a9d891e2d0d96cf935df4e7", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "2b6a0a8c-28c9-42f3-9e7c-86b2ed36c1b8": {"doc_hash": "59dabe2c83feddc669e8b6bfa725bb2d39624ee971e5c3b4683496af9c7689d1", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "b6cf8304-5f3a-4a1d-83a6-0c0a7bc73a1c": {"doc_hash": "41d07a40fad3bff52852eb905a69340b5bbb5b3181514cb41446eb0da02b83eb", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "299025d5-265d-4d93-95c0-bf1beac77859": {"doc_hash": "4b557ff9ff5f51613695683b949047baa25fe952ad01c8a73fc7784d0b19c8ff", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "f5741895-247c-44cf-a50a-1a765ab72dbc": {"doc_hash": "36daeda29d6ed3be006c2b6d477edc36abbb9c3580da6f6ca6bd72353e2eea95", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "a8890db6-6011-44f3-a59a-1a8fdfea2799": {"doc_hash": "38a2979eaf638a00b8704a0472162abf7a6d08aef72ac38e90a62c8ae022bf85", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "3425f9b2-8abf-4a06-ac95-421b8e1ca43c": {"doc_hash": "28f0612df861fd0912b763d600b62d3d0cc3f1fc4d4e4df751fe6734f33cfad5", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "7dc8fd0a-cc20-407f-a150-6c0f4c7df810": {"doc_hash": "747a445110cd609f89f725bd89ed67aa22aad036ab8b32c41242f2fc49ccf1d6", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "9fd77417-dc84-4c4b-a455-c8bb346e79c2": {"doc_hash": "97ed99f014d47fd91d1f1c72d0a6cb2d177ffc88dfe304c784ff5a82ef556e15", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "2cd3bd59-b62b-46be-9e84-9561a65710a8": {"doc_hash": "77c5e901eaeb0308d741fc62c38151162702b5bc053de5d1cdb3e1bdcfa863c8", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "a6490d48-8519-4e11-87c5-866db0f1dc0f": {"doc_hash": "58478ed0d7c14f89f74bc58f71e22826133208d9941ceb9e5b09bc459fa5adb0", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "448c69b2-5614-4bce-a3a9-20dcdf1fb57d": {"doc_hash": "66ddfdac5ef4e02bfdc9c18f256ab274858591744c514e53c70c9c008d431997", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "9c3bbdce-a0dc-4a00-878b-74fcba3572bd": {"doc_hash": "025317c26f3d8513125edf34f217744b486814765b6edb9a4c837785fbab27fc", "ref_doc_id": "809dfba9-5e0e-426e-a87e-7ea984e977fe"}, "9ca7b467-3bc3-482f-858c-a397de2f6772": {"doc_hash": "8ae2f9c3c8b0b21293ae194bf39233d2fae3143a4b5ec304c49775e6d034abcc", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "305915ba-1433-429b-ae73-e718207b31c0": {"doc_hash": "763724a689ea9b94a002d31fdf3c56f9b10b75bed3d055b0dc619d2872d754a4", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "a4d60107-9f59-4788-b9a0-17b065cc939a": {"doc_hash": "6495e3fc40f216d9545b2c10bd17823db7f9fc686381c34084a10888afc1e876", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "babaa589-afbf-4f30-b21d-14b620f2e482": {"doc_hash": "076a78e5ceb6234d68cc0827b30d99ce2eea8e086a0adb802a046ca68e0429de", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "0543237c-8f19-44ce-b47d-a2f7d908979a": {"doc_hash": "867f30d88c73c7c72e03da1096cebfb5865f7f64d843cf9f3f8470e70a9b000d", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "8dfd5cb7-27d4-4771-a8e8-ceb575c336a6": {"doc_hash": "e9dc59448867afc0cbbd019a3db458a14bbd01871546306f6f625ff6459123b3", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "163dab90-ad5a-44e2-bc76-26aec57daa86": {"doc_hash": "03c54a43ccebf10ff13cb33c49b5e0a07f9928dbe3fa2a01d0d6daf01b698426", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "43a2061a-c3b6-405c-b785-fc7431ec0c09": {"doc_hash": "a0295b11afdd2c5ba9b0e7f4836d343e22c0c8a335dc02b10e253688362dc491", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "30eac066-cf25-4481-87df-c1fc5a30caa7": {"doc_hash": "9ff740e92b518e10c7df8bab249a30c1f8f37bcf3e0e00d5516d48f810f05975", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "f978aca1-69ad-4678-8c37-d333283485de": {"doc_hash": "35581ef5ea67a1d49e37a59e252d25b7e9012fa1ffbfbd08896b63473b3e6305", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "e44a8435-3ab5-4f11-92f1-01afa75de97a": {"doc_hash": "dccd5e3f8370f29a779eff3cd557294f1bf0f3acfc8cd45a28d9f61c55320823", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "3506f200-2808-4676-ad26-40a1d2b15a61": {"doc_hash": "8050ed63f65c6d274ce662bd2b8d56be10f64e9786bebf3c09ce0fdce199e1a9", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "7322081f-ef2d-4f47-a656-476ded2b905e": {"doc_hash": "93d3829eda7b8379530afefd69a44df926087342ecaba887d27490e75a1765dc", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "8bf542bf-550f-4345-bb0e-02971b4568f8": {"doc_hash": "4e85e9873866265866c9bfdb9d617b38a01d58885b932023d039d60c055f76a8", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "90067233-3eaf-4a78-b79a-1c4a09f55711": {"doc_hash": "8773a68dd75de2309b659e3e3af3854a9c259379bf7d352b732a3128b2d502ef", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "23f8c802-fc94-42b4-a5a1-d3047df6b6ba": {"doc_hash": "320d56cbbbd143684524d34d58c08a93ed43d3d0af3943bb7e7e08bf9e574f88", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "92d79c00-da0d-40f1-8546-a9c187209cbe": {"doc_hash": "f6920120caeb081d0cf964a08419e4f7a7e6730f984eb822ebb6ff2815541872", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "8a3b7629-d792-4aee-9a8a-4044721eae46": {"doc_hash": "8cde34efcbf3ea39bdd095f05260cdf1049bf13198fe7a219ffde4e7593f357f", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "84fd8819-cf18-4d9c-9e45-9eb59a31742e": {"doc_hash": "1d8eba53d7c442cea52ef41b82a95ebf0119e393627e6f33a67d976650966f1d", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "0ef78bc0-64bd-4733-84b0-a37e88f7fbb2": {"doc_hash": "3d9e17261da4c6f71068f3dda547e956c7ffc375c62e2cd687cfd8a25a61bcbf", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "b8cc0cb1-4826-4d96-8f97-5e079764ae5c": {"doc_hash": "e710150b87462b8c1bfb1e6638c4c39ae2f0e7a91d88bee3416a20a51040344b", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "4e93b84a-4067-457a-8960-08c09161c792": {"doc_hash": "73024f6a69441c6d6a57ada9bda0953d3a9a8e43d51d1af9c22360f5fde68b0f", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "6c033c49-08ce-4f5c-9d88-c16a209bfb6f": {"doc_hash": "a577247b646f4fa601f2b1013aeb0035e387bb1d14f11f76d3f5e24c1fa20cf4", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "608d90ed-54f9-49a8-a5bb-689bae829e1a": {"doc_hash": "3d404ddf8da7166d0903cd6339e9832e4f1001c53974b163b48759adc1803a4a", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "991054af-3942-48f3-8abd-4b9784817c07": {"doc_hash": "8086962108f6972ea1c304f133dd48bd5e20aebe00a0e25c6b81c2c91e317797", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "2dc962b6-3410-4ab2-bb83-fecccd5d726d": {"doc_hash": "3d8bc39a6a338f82ae317497d61b9ebafc35ac460e2cc53608b852f45d8c4f24", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "cd474117-3df5-4cf4-8a47-b976033f9a3e": {"doc_hash": "8b0735508944c92313e28a60d0185e31e2339a0c03fc733ca6eb1e6ebb6ebb0c", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "a255a4cc-f426-4758-b7a0-36cd92559f06": {"doc_hash": "6111a076d508e2312b67a8f491cf6cd69d45e9d9edbc728256702f91e8480616", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "62504520-cea0-4036-816d-2933ff847a05": {"doc_hash": "f1b08dd099f1ed206b8daebef4c9176a6c93b0221d8cb36448b685ac63c89a46", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "0d80d32f-2dc8-45d8-97a5-301bb75e06b0": {"doc_hash": "ab258f2823b6c61908ff1181b1bef0dfa1db4080ad12c3f7e19aca4bbdd3fbf1", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "ab87ad88-027a-4877-af57-f61f356dec03": {"doc_hash": "3240ead9ba4d9d6491caf98ce0dafd7e2d8fc4a886e6cb3465632da132975b01", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "c86dd5f7-092b-4198-adbd-a3b656933831": {"doc_hash": "7ff6e1d377851bb4db838d78dfb3f6734d47d526a9578a1537f77c1229a92fd9", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}, "d86abaf5-8eac-42ea-8395-e96457dbf081": {"doc_hash": "3b2e4492b95db49a64419ab3a8919073d578566ff01926820ba35603baa7e7d5", "ref_doc_id": "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3"}}, "docstore/ref_doc_info": {"baae0df7-953e-4720-95bd-38a16e5bf756": {"node_ids": ["89e91609-8300-403c-8a16-5c909af0a20f", "8d778772-5bfa-4e89-bf36-0bb7977b33ee"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n05-May -2022  \nMcKesson Corp.   (MCK ) \nQ4 2022 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n05-May -2022  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "d9dc5b91-f4dc-4392-bf57-63fc47031cd2": {"node_ids": ["2feead10-4c59-4c4f-8b15-8c432c0f088b", "64ac9878-9309-4ecc-a1ea-b90553d9ad49", "43a439df-074a-4278-8358-8582e42fe32f", "8fc16a0b-0bbd-4830-a3ac-d81781261c50", "4786bc9c-763a-413a-91f9-b4a3ba612cd8", "d198de46-9ea7-4082-88f7-96f23f538a18", "94174878-5cdb-4c24-bd5e-a24217bfd767", "e278bfba-e323-46a8-98f3-fef431761110", "656c1288-957d-48a4-833d-f690b311deb7", "a50431fa-7351-4370-8ef3-270d6fc1e202", "1cf794a0-ef8e-4575-a584-800b2d1c92b6", "dc3c2b17-5152-46b9-8c01-77696e6e7010", "2a0492f6-9225-468a-b2ab-ea3c69e118d8", "096abc7d-af08-40d6-bb8d-6b32101a1e4c", "25951412-b0b7-4c07-b807-8178d738dfad", "52002498-2c4c-4a52-a673-bce6487dec92", "f7d1b1a6-4dce-48ac-9654-cc5f40c9970c", "2717e0fc-cd94-44a0-ad67-b17d46547955", "07533d6d-b587-4c20-8789-b9defb73b1ab", "3b8e8fd6-d29a-4d4d-8f57-f95654ef8cdc", "8d888966-792e-440d-ba47-ec3143ae25fc"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "8d074d81-1bd7-425e-811e-44bde442548f": {"node_ids": ["4c1db801-9393-456f-8b74-c581df4d1279", "e5fac8b6-b329-4b53-b0b4-4257bdb18c9c", "e5e885aa-2a4d-48fe-8134-047337be6f73", "082d9b25-2b05-42e4-abf9-58d197abf50a", "e5614a1b-4f45-4307-bec8-bce3d7e827a0", "2d0caadb-bdd7-4177-9d6c-51715ebc48f5", "b7bd429c-c3cf-4e77-9900-2dffff7e5653", "c4047de3-01ca-422d-801f-1b29462e3660", "357fa8f7-5cc4-425d-ab54-0fe77a68c821", "97818f61-bd83-451a-b046-2ef5f2071b0b", "4f8e2e4f-d023-4cd7-bb2a-04fcba40deab", "3ef94ccf-d797-4fc9-9eea-c3cced54c926", "8ecd5abe-c37a-44d8-a668-4caf27f7664d", "5753debf-d048-4bec-939a-a3953bbd8cd6", "ae74e046-4632-4aff-a06a-af08e6f0cc8e", "2502a652-a707-4995-9e43-aa0474e3b394", "6d06dfa6-7550-48b8-b0f9-7fe2f378e08d", "40525deb-909c-401b-a150-e56826d05f62", "193f0654-cc72-437a-81b6-2511473c7985", "fb66e65c-9049-414f-b0ad-858d12bf857f", "d95f2a1a-0ad7-4719-a24b-138c11bf1f8d", "afec1a3b-f4ed-4e6d-a800-d2fd0b919a12", "40f643db-d67a-4ff0-b2cc-0f79f73306db", "0b336b42-e38f-48c5-8185-617cd53850c1", "6b9a6dd2-b1f8-4463-8c32-c7e06eb62816", "174c494e-f0b3-4bbb-93ee-6597f3b31dc9"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "a53b4cd4-682b-463e-878b-a2b9249c415b": {"node_ids": ["58fda9e2-dc1a-4e28-a0c6-e8fd841ab362", "a6dd38de-ac47-48d7-b352-e66a29fd0be1", "17d08110-8fa2-4256-8eb3-f84090361c53", "72d8f633-051b-4ea5-bc44-ee32e466aa25", "46d06cdb-d344-403a-ae6f-2e8065d5ed94", "b44256d8-13ca-4538-abbb-e09cd993944f", "07c48158-25ac-4f58-91af-560e0fb63e7b", "a84597eb-df79-431a-b8db-0546684b499a", "91a3cca3-8889-4e7c-954b-e29be15699f8", "68973b4c-b39d-4e9e-a4f3-71a4a6eb17c0", "c485067f-8878-4e7c-a878-deadce5cffa1", "638ab611-bcb1-4007-a4fd-06d337f0be6a", "1fabb066-fe80-45a0-86b3-7c25f5d00c47", "4caa1008-b2cb-45fc-9645-d40f0bec8220", "ec591f95-4724-409d-9507-01914ef461bf", "54ea9f1f-591c-42ff-9dba-1ca8554a39a4", "f5c8bac8-65bb-4cf9-8b59-c0463a0559e9", "ce1362f8-468d-4071-a0dd-e2710ac25a1a", "19396ee7-cfa1-40b7-ad62-a6db98a9f1fb", "a821f068-f1ca-4ab0-a9de-b57047866b02", "bbe10637-90b5-4e04-9b6b-9b8b1de4b1f4", "b2455a41-0131-4b46-929c-60855624774c", "f535ce6f-06ab-4e50-9fa2-78a4f3a9db31", "489e7690-4ee3-4293-b4c2-99cf6d9c7f0d", "c0567a2c-924b-4c3c-b551-e2c79adbf1cf", "8ee3416f-f4c9-4f7c-8a1c-fad340f80653", "21922e87-afe8-4f74-9d0d-644e96c8598d", "d132fe53-de53-420c-824e-d86c09017b6c", "e52ff292-435f-4172-bb77-4b025e7b239b", "4fc5da29-b25c-4fa8-a5fb-0da8022a5b67"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor the last several years, the enter prise has centered its strategic, its operational and financial decisions around \nour set of company priorities and the results have been outstanding.  We fundamentally changed the trajectory of \nthe company from declining financial performance to sustainable  growth across the business.  Through the \nfocused execution of the priorities, we improved efficiency, we defined our differentiated and strong market \nposition, and we established the right to play and win in oncology and the biopharma services markets.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "b59636fb-a268-4883-88cc-1c218d89aa46": {"node_ids": ["5ab5be79-b572-4bcd-ab10-cc5ad47cd760", "9ac388f5-6b06-4d74-9354-f8ce7ffee17e", "945b463b-c738-4652-b48a-2ac15c8be6e3", "01c2a223-cf44-44e6-bf5c-528d66536c90", "bff08f0f-f372-49eb-bc86-0cb170baebb4", "4d1e896c-1256-42fb-90d5-619f9ab57f61", "c2a16816-adda-4586-94bf-099105089531", "8ff855f2-4404-4b3b-86b5-4e39a8219c68", "ea4142de-0b4f-4733-8ffd-de467d47073c", "34dbb818-1c77-4821-97f8-a6248313213e", "b09e1998-e572-4043-a356-bb50a043edbc", "15d60f01-c451-415c-b01a-012e01a5921f", "edcaa561-82d5-4d08-91a7-d492fe98f770", "85e6f891-4c75-4612-b641-1aeaaa48e6c6", "6668e86e-0a9a-4818-a7c1-00d0ee72ecb3", "f9ca4c93-bf85-4fe4-80e4-d22061b7aae6", "03543b73-9e11-436c-b5d1-d2e1a59183d0", "6925a4d9-e3bb-4e35-80f0-e05a7de8ed29", "e2144bd6-1fd6-4d3e-9566-3b934ca24256", "835df4e2-9a47-4124-8ad2-f9f69517a392", "91b74c32-3ba3-4c8c-864f-8f8c13caebca", "59fc82d6-2de2-4483-9a25-afb9c223c377", "9320ba0d-23a8-4b84-8afb-190a946c05a1", "6fa60293-f663-40ce-bae3-77b164862455", "68477a31-b874-419a-98de-2dfe1987eb59", "dc73872b-aeeb-4ebd-89b9-c87e2d399f49", "336e013f-1b92-4803-a9a3-76e54d8b0e9d", "69cf131d-5e5a-4f44-8755-8c0ae5bd214b", "8256e61f-f149-4b59-867f-a9dce617a158"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOur best -in-class customer service and deep expertise in distributing medical -surgical products enables us to \ncapture the market opportunity, ensuring the right product to the right patient at the rig ht time.  \n \n We also continued to partner closely with the US government in its COVID -19 response effort.  It's been more than \na year now since we started shipping the COVID -19 vaccine and ancillary supplies. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "efcdcca8-a1b8-4097-ad70-f9603582a650": {"node_ids": ["98451494-4b63-4cd0-8f87-c676e55694fa", "48c7fbf9-0805-41af-994d-26905b185118", "9a2d3023-7b0a-4b3a-a160-c91704ee2781", "7e18f049-b282-46a9-974f-02a2ebabaf51", "e675f606-3713-4992-baeb-7727df3c6746", "3b0de301-8d82-4046-a86d-a37a1459a604", "f82d514b-77ad-4154-9614-7930af66e07c", "781f2940-427b-4605-adc5-5c9771c20be7", "dd4cc339-ec70-432f-b791-371b14549512", "85910fe1-e6d5-4de2-9927-a908820dd349", "b4a5446e-45e2-4f28-83fd-86f67b6ab95b", "123a6163-eebd-4916-9d1d-432858c146b9", "dd66ed84-b850-42f9-9233-62d8bdf2bf38", "2816ba57-cbdb-4cdf-b04c-e0cfb87bec59", "5ca47f81-6757-486b-a689-d53717395cc6", "86367960-0e92-431c-a6ee-940ef861a68a", "08b1d8af-df10-46d3-bc31-6dabbe0e14b6", "a5615432-a377-4d22-9309-b043a3ea4e07", "288c46e9-fe5b-4bbe-a627-3078e37bab4a", "4723a1f4-6ea3-4c66-9d75-1a5680542769", "c2a25d0c-5efb-4fa4-b1e4-db7d5a4f2b2f", "b2f548b0-abec-4ad3-92b9-9156acfb766f", "1cfe7d68-aa5f-4d31-a15f-032105460c55", "7e9dc1e5-f147-4a67-b6ba-e93d9f1353fd", "3821714c-cc1d-4e76-a207-480259b7a4b4", "eef3ae1e-65e8-43d3-ae66-fe9f83b6ac62", "b22915bf-2b18-4cec-a473-1c7e2457be7f", "afc2d9bc-fe55-4d99-85c4-c626e82b43e4", "a4cfbd8b-14b8-4047-b91e-f72123eb3c27", "972e6428-79f6-4c33-b812-6ec6a28e7c03", "c61139b9-ce3a-4e9a-9f17-57446da1a7b4"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nindications.  We are now serving the top 15 global life sciences companies, providing them valuable services to \naccelerate research and commercialization.  \n \n As I reflect on our progress  against the company priorities, I am very excited to see the meaningful impact it's \nbrought to our business, our customers and to patients. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ef1bd7b8-6be4-4928-9aec-78b389bb0af7": {"node_ids": ["6bf18227-d224-42b0-bf69-378bc64c813e", "1246137c-41ec-45c1-aa05-0d16c44f06b1", "ac8bbf51-4da6-467d-9163-9c313da7136a", "fe72e066-2e1e-49a4-aef7-32bf38f8ddf8", "f9ee8681-b886-4edb-b2b4-e9572984e55a", "87a43fee-fb98-4c40-87c2-0fbaef3f86d0", "bb1d3003-07a8-48ff-950c-173e49a0bbcd", "6e841066-3a0b-42d6-b724-d865871f7861", "299c3038-c5cf-4261-b678-7585f1145bf1", "3d5ee86d-fe89-4a36-89d3-4105bef4aad7", "37b07e55-1f54-4e2e-98e3-1eefd2e69fbf", "4ab69789-a2d1-4568-a0d6-6996870ac038", "57182291-3090-40d3-ad02-24fd0efc644b", "a6490911-41d9-4cd6-b743-f952f888da13", "f79cf1e5-4f33-4b28-8d1e-d156f1bee76f", "e1d715ee-20dd-42cf-9fd3-aacd07c3c0fc", "76784bda-8c8b-4382-8747-3adf92373023", "0c15bdcc-b26c-45db-a69e-88d5765a8bb8", "8089abb8-6866-4686-a736-3af4a14037dd", "c0a8ff78-3829-42ae-baf0-6c4fcbbec85c", "ce44142d-4a41-4700-88e9-2192a8b73c2f", "b5055356-aeac-48de-a002-2e3f14105c56", "e288efb5-0178-4b17-9333-8a492e1f1f4c", "6877b028-1d28-40e8-91eb-6c48635d90ae", "e1ca2b38-7781-423a-8c5d-a1568bca4ceb", "cd0e40ab-d27e-4a82-b510-ef92e0866ef0", "e7e2d9d6-0ba8-4158-a80c-dcd43c338344", "5f9bb349-2a96-47a9-96f6-4bd42cac966a", "dcc2e226-2c68-41d3-9a37-5eb8f6af3012"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nadjacent markets, such as specialty brands and medical benefits.  We continue to invest into the future growth of \nthis segment.  \n \n Moving on to Medical -Surgical, which has performed exceedingly well this pa st year. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "4aa6b18c-74fb-4873-9d69-0a37e1120acd": {"node_ids": ["44bde4bf-342a-4588-a87e-92b8a2805fb2", "72ec6a54-4e0f-404e-8cde-9ddcf21b6551", "21d062a3-7281-4cf1-a8b9-2b300aff087b", "e16355f8-be5d-4c83-8e99-c89cddfb2e3f", "e58c2849-e4d3-40bb-933e-92d112dc1d54", "8d6dc1e9-de0d-4b87-ad8d-fee5ac76d19a", "19e1a2c6-16f2-4684-9ce4-ced99fb747d8", "92808fee-f86d-4be1-a71b-73ad0caeaad2", "0490f44e-7c9b-41f8-a360-6d3b77fd20f3", "de02070c-bbca-46c0-98c3-758b247725a3", "c66ee338-994d-446c-87ec-782f7b556ca6", "ccb7ebdd-76e9-4497-b6a4-6982e52caf67", "bd3c9335-8347-468f-8dcf-d4697c1c62c1", "6bc01857-8d11-40e6-b3a5-5d0bdf663596", "aedd1890-6915-4b91-a83c-384640e01b6d", "64217049-961d-440d-beb1-558a25ca4b0f", "913596ed-20b0-480e-82db-fa35541f40f5", "690bcf89-6ea6-4344-b070-0bb25bb860c0", "c75ba3e8-4611-4d0c-9532-4cac7df35e47", "cf4f6b40-360f-42f5-8c8c-c2aeee783f6d", "c36818ee-1044-423f-bfeb-337bab6ffce4", "d21cd9b8-de22-415b-b8a5-8555d1799ff4", "9e070d70-1f37-405b-8821-bfd51171919b", "c4344dc0-e97e-4444-bfae-9bc6b6a24ecb", "f28bb7ea-75b3-402f-a95f-fcc81d749292", "1cb1b2c8-546e-4148-849f-64a070332db0", "9bde514c-461b-4369-a413-2ccaa1958449", "8c0a0d13-7165-4596-8afc-c62b605b613d", "3cff709f-49c0-4d32-ae0b-a56a1d6acfe1", "203dcdb7-3cd1-4c2f-a2c3-e514b5eac310", "2ab86fff-da33-469f-b00b-31aee2e29dcc", "e4fd860e-e1d6-4caa-9a71-2a6f5ae2e22a"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nThank you, Brian.  Good afternoon.  Today, I'll discuss our fourth quarter and full year fiscal 2022 results, then I'll \noutline our fiscal 2023 guidance. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "1e991624-f5f5-427d-b6b2-05772e7eff65": {"node_ids": ["373b48b0-6822-45c1-affd-35f1e1da06f1", "36759b1b-bd98-4a3c-b1ec-f00151f111bb", "2933499a-944f-4e2b-b0bb-dea584594463", "f3c0f5bf-8a22-42c7-8898-958b661413f9", "8c08c001-f687-4ac2-be7e-d3927641889f", "04cb480e-3b88-45c6-96a8-b11b77e18d5c", "8438f943-4596-4b5c-8a09-f4e32fd4a413", "9b274f89-fc4e-409d-ac15-9e47749947a2", "1de86ad0-a55e-4127-a76f-e02b86c3bc90", "cd277f21-520a-4766-9def-f2ccd8e4d5fe", "33899571-221f-48de-94ef-ffad9473c5de", "4e9d9d30-99c4-4e34-beac-04717da66eb2", "385549a4-e0be-4c16-ba88-a07b991911bc", "9e5cccc7-a0e2-4bf0-85b2-e544a703a5c4", "581798f0-677e-4d6e-8ff7-485945ef2d08", "454c8d1b-569c-40d1-b1ad-d6468ab386cb", "b477abee-75fc-4134-8ff8-f8952a93393e", "8261fff9-f121-4f26-bd77-2e29f4d2bb42", "57c3ff36-1420-4a19-b901-d47113db1208", "e6d02924-a9a9-4b20-89c7-7b116112f604", "c3198925-3788-4679-947d-4f6651eb97fe"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nimpact of fiscal 2021 inventory impairment charges related to personal protective equipment and other related \nproducts, fiscal 2022 earnings per diluted share increased 31% year -over-year.  \n \n For the fourth quarter, consolid ated revenues of $66.1 billion increased 12%, driven by growth in the US \nPharmaceutical segment due to increased volumes in specialty products, including higher volumes from retail \nnational account customers and market growth, partially offset by branded t o generic conversions.  Gross profit \nwas $3.4 billion for the quarter, an increase of 6%, primarily driven by our Medical -Surgical Solutions segment, \nresulting from prior year inventory charges on PPE and related products, and increases in patient care visi ts in \nour primary care business.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "68b8546f-bed4-4908-a8ee-d0c3086d712e": {"node_ids": ["6a705803-ad45-4b78-a17b-808f3af55086", "385c028f-c654-4d1c-86fa-305c8841e92a", "acb32a72-88a4-465e-b0b9-26b02953fe65", "de29fbf8-ec2f-4976-8286-4b75f9f57be2", "6fe7e4cd-c4c6-46db-a0f5-7c59023f9c53", "e257afae-8dda-446e-bee7-6314f68de5e1", "f79d9e8b-5196-4473-86a2-2a878b586ece", "b72e8c7d-c0a8-4b58-95e5-2be009bb409f", "db7f4066-6772-4991-87d6-db6cf04abbab", "5b95cac1-3b64-4ffd-a244-90fffb52d9c6", "a668adef-fbb9-4b8f-99b0-88742941e0a2", "beedcc14-36dc-4a19-ac6e-860b42219152", "8c372ded-94f5-4c68-ab21-7be039c548b4", "d16cf4a8-d3ae-4a1a-9bd2-c8defb66e57b", "7364491f-78ed-4024-8fb2-bf057f42b3ee", "7c5e2992-ee2a-494d-bfa1-0dd66bbb3ef8", "372f4ab3-9b86-44d0-bc3c-d971b3b3d607", "0a8d944e-2f28-41ec-8f87-a975fa0cac3e", "ba024599-da96-4f8f-82e6-70958cf4375e", "df9d9f0b-4900-485e-9cdd-b5acf67efd73", "a2879bc6-a4fb-46c3-8255-15ac3cfbc2b5", "e5e05e7c-5d55-4c60-bbf7-44643cb6dec6", "18610205-32a7-4d9a-9a76-6ad7686b625e", "00d1c903-fe15-42a3-b67b-2abc4616edb3", "a3139ec5-7511-4624-8651-327266b98efc", "d55e2fd6-3e7c-4751-82e3-7b170afa19a2", "77ab0a39-be1c-414a-9c57-b9dfe4a8c1b7", "d4f3c630-0cc2-4554-9136-454abbdb0f2b", "768b23b2-ac8c-4e72-891e-26846b74387e", "4c70e09f-1931-4a71-8f2c-dc48ce59eec5"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 29%, as a result of \nvolume growth related to biopharma services, including third -party logistics services and increased technology \nservice revenue, partially resulting from the growth of prescription volumes.  Operating profit increased 11% to \n$162 million, driven by growth from access and adherence solutions.  For the full year, operating profit was $5 90 \nmillion, an increase of 26%.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e02e0e95-027d-4624-bbb8-8d1987f05aa8": {"node_ids": ["6feeaf47-90a5-40c3-96e6-f59730bb4dc3", "1d3f28b6-6ba4-4c7f-94a1-5be7be8cfb93", "9a4ca8fc-c8a1-4928-8586-f7a09578116f", "43f1af93-10d3-4af4-a3bd-914491f17183", "3f7b5f2b-7ad3-42a9-9e63-8ea1bc7801b5", "cf40a5f7-e592-4d55-89a3-803f4b3a7007", "0b617408-2b40-43f0-a743-f0a97af0ddb2", "e1adeae0-276a-4275-bb30-6e9256b0bbfd", "72050322-46e4-4848-ac79-0ccd13cfdd58", "ef97c86a-48fe-4d91-9941-1c9fab8e2803", "a8a45a88-15d7-4c2f-b63f-a3973c55e4e2", "dc8dec21-3bb4-4383-8898-71a58cc275e4", "dbdef979-468f-4324-a608-008860bf44ed", "868c9160-e287-4a11-a9ef-f85c86634ea2", "7e9ff3b1-469b-49e2-9913-2dafc8023a8e", "42833547-fd87-4a50-a340-ac70f9037aa1", "27be2a1b-61e9-437d-a943-b2ae46922962", "81f9114b-3024-41e3-b42d-a991a575da80", "3949c318-49b4-413c-a937-d4551b45a20e", "9186b913-c183-4717-bc03-de19ac62ee20", "9615b1c8-4552-484a-b2a2-1d062eb922da", "90e96a45-a254-4e61-9e29-40eb180f50a1", "6e685cd4-7307-4a07-83ea-fd5c73cdddfa", "74542ad2-a8b2-433c-9bcb-572a889956b6", "6a7f2ed3-89a2-4400-8be2-e11680dcccc3", "efdd76e4-8a1b-4d41-8f6a-332c1322ed6f", "4a679ff7-5db2-490e-a4b3-5e6942e3b6d2", "a5886313-a3ec-4166-8815-b085525a6126", "34ec64b0-edd1-4a6e-9fe6-e05cb497499d", "b7c31bcb-cfbb-4d1a-8818-a6e9797e492f", "4db5f283-e360-42cb-a81b-bb71793a1d7d", "cc43818d-eee8-4108-b964-c31b610c1da6"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n2021.  Corporate expenses were $579 million for the full year, which were approximately flat compared to the prior \nyear.  \n \n In fiscal 2022, McKesson had net gains related to our equity investments within our McKesson Ventur es portfolio \nof approximately $98 million or $0.47 per share. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "5dee6194-accf-44d6-83cd-5a00f361089d": {"node_ids": ["dfbcaa48-02bd-4ecc-ba69-9c044f3923c0", "9ec72c84-e69c-4a18-be91-ff794f2773c7", "2bad1ab8-3d00-4cbb-a47f-7be609e60789", "5fb99197-bfc0-4a24-af82-f2a11f1cecec", "61a9786a-26b8-473a-9504-6bd53d840275", "cdeb5b83-2839-46ad-8ed7-b07bd510726c", "0f31db4d-bb3c-4862-b8e7-f8432228641a", "b2caef75-0f6e-4c7f-ab60-515bb67da8bb", "f6f9ffd9-cee1-4031-a7bc-451904f2310f", "539defe2-e5a6-42c0-86af-4b4f19020094", "33705577-5b64-4adf-a8e6-2956c674d6a8", "a3164538-6719-4b3e-a397-453da29e823a", "4e05d07b-82ae-4b26-898e-0aeb843f96ef", "682ec1d8-8ab8-4aa2-a007-5739d696faea", "97a83009-22e0-4f32-a771-f3643c06223c", "2d1bddb9-c5f4-490a-ab09-4d1fd4df08e4", "58c7c553-0b7c-4884-82a3-f7d793998bcc", "a33ae062-b237-4c31-87a2-8bb01c49b7cf", "d71fea52-4d1e-46ec-bc53-9a4efdc398ac", "128a5a41-a728-4122-9518-1ad7b5cb93cf", "be4ea1f5-984b-449d-b8fb-752b2b6bd76a", "693ba4d1-d740-4c76-8aaf-63ec1e8f7c5e", "f7f555eb-ed1b-41c9-9163-05bef43378bc", "e805506b-b139-4c1e-9034-3be7d42ab444", "b71c2d34-3368-426b-9ac0-079daee37cec", "2ec11ad0-ad6b-4649-a53f-0df8b7fef47b"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nresulting from the settlement.  For fiscal 2023, our current approximation is $40 million, and it can vary based on a  \nnumber of factors, including remaining non -governmental suits, trials and pace of legal proceedings, and we'll \ncontinue to update you accordingly.  \n \n Wrapping up our consolidated guidance, our fiscal 2023 earnings per diluted share outlook is $22.90 to $23. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "b8278bb6-77dd-472b-bfed-e5dd5e035ceb": {"node_ids": ["73a5999f-7e02-4f3e-a52a-8a40f5739277", "25baa248-260a-4976-a94d-c930db8e6d94", "0f847d14-11a7-4b9b-9bbc-19bd572d1d1f", "f7972863-9294-4440-820e-efe2381940bc", "f7bc2251-34f1-4d9d-89af-08784cd75ccc", "174cba22-54b3-47d9-a479-2615e13cd6f1", "992b6198-99bf-41b9-b128-c6818414a61a", "8c80c9c6-1ea9-45df-a56c-8e36418803db", "14001324-03d3-4f26-9618-42f00c835a64", "53d95df9-c9c4-4040-be86-0bc0a7074714", "c3ead74d-1c0f-4102-af5f-02f75752f04d", "a202afdc-50ef-4fcc-89a0-001595c525c4", "66d3fb9a-ea36-420e-b8c2-ce8953076b12", "9b63ba14-b069-4562-9e94-8ff59e514131", "a9eacd4c-410c-4bda-bf5f-f38f0264f75f", "a7a7acfc-8c85-4ffe-8989-c380b677727a", "a0389721-b9c3-4bd9-842c-ba7b3ea57fc4", "6ffd4f07-da0d-44d7-9a30-b34c835c2d6a", "e4764c91-e475-4d6a-b58e-0a2c08e09b49", "7ba60662-3a6a-48a9-8eb2-00b41f896b26", "7994167b-a1f7-487e-a319-8abde81cb7dc", "eac2d26e-d04a-4a97-a42e-2633aa8d6134"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nLet me conclude our fiscal 2023 outlook with a few comments on cash flow and capital deployment.  As I \ncommunicated at Investor Day, our capital allocation strategy prioritizes strategic growth, complemented b y a \nreturn of capital to our shareholders through share repurchases and a modest yet growing dividend.  Our \ninvestment -grade credit rating remains a priority and underpins our financial flexibility. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "8076c054-5391-4925-b7fa-253b49ee3670": {"node_ids": ["29be148c-810f-4a67-846d-9486f1af6475", "75b4a0fc-81e8-4912-ace5-90c0155ad0e3", "e564716b-242d-40c0-97c0-6bd418914c8b", "4b152da9-3f39-4552-be03-c07fd0497b23", "2f068dbe-115c-4dfc-9472-66a54f0c27ea", "5e98418b-776c-43a2-ad59-873f656f9850", "2a3db9ca-8dc3-4fdc-aca8-43b7f15642e9", "19dc97dd-deb2-4c54-9f26-511b66581860", "c8543e6b-0e95-4774-935e-286b323a5bfa", "5b7063ac-4714-4b2f-a2ce-8170a431f038", "e5f6e4a9-a26b-45fd-9291-a3c2f25076e3", "2920c459-9ce6-4cad-b844-2ae2c633659e", "ecc14e03-d47d-469b-8850-1d61d1658053", "ddc5d9db-52e5-4bfa-a6e1-716beaee1972", "68d58b73-43ca-49ff-a54b-f40d3ff1e9ff", "386870ee-d3d7-4522-a807-871e092e6b8a", "20ae6df3-08e3-4138-85db-38a5f6578216", "b04a07ac-7e7b-4ae6-8ce1-1bfe65fa1e16", "121e0bb1-6e58-49ef-8aa5-5e78ebd2ba69", "2e2ce2f9-76c0-4b9b-b936-61e72f2537db", "e7365184-8b45-4fd2-9058-652fbbd4af8b", "ec0cbcfd-02cc-48fe-8b87-e2aaf0fe91da", "7c96c59e-cb45-4bd9-ad8f-32fa08d44e3f", "6ec743f4-7892-45f9-b74d-4063eaef8729", "a7f91d9d-5305-4d44-9bbf-54201da34ec9", "bfb2ea87-9fc7-47d4-9a5c-4d875141065c", "bddd7c4a-2f05-44ea-bd4f-53cc04363430", "dac15da0-98af-4e41-85b8-3ba13d415c68", "1d16eb41-a5d7-4df4-82ec-2c2c449bf047"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question comes from Michael Cherny with Bank of \nAmerica.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "10252a18-bcc2-4230-b58b-3a6a18eb8e57": {"node_ids": ["75eae37e-e1d9-4a1c-9d7d-0a4492ae1eae", "baeafd69-3236-4475-bb36-da271c9a02bc", "ffdc542f-3d1c-43f8-861c-044c7c50ad0d", "6c80351f-7d37-4e24-af04-5bee454e1fca", "bf4f5744-1e32-4850-88a8-a63fe0528fcb", "ba0182bf-e3a5-4a72-8513-dbbb747dea99", "1c8b268c-9037-49f9-b232-b350b0a4c6c2", "ce481a93-71dd-4d2f-99b4-bff9c8d8f323", "8c1abde4-ed70-4f1a-9ebd-7c308cfb5f0b", "d041f137-a26a-41a3-a80b-e9494230f692", "17d145ed-bfd6-4932-b4bb-22ae74437964", "9afe32fb-c3da-4e5d-a132-3cae5c727993", "a045860d-2360-4e3b-b517-b19607006405", "6b562bcd-ca65-4125-9201-108104654752", "e264200b-9a48-4023-b6f8-58fa4889e140", "912c769e-da7c-4cc5-abb8-62e60e279b5e", "93640f74-ffc2-446e-9321-e583295650c2", "73b949f8-7def-4a3b-9a1f-8c26073300db", "d68c7eed-f39e-4827-9230-d265f3bcd91f", "fb0258d9-cbb1-4057-bcec-33d55c16c6a2", "fde5a5a4-d297-4c36-8445-d6f046347e9c", "d39bda84-291e-45c3-bdd4-e7520d36ff2d", "8937c1d1-1a35-4b5f-8372-404e4ce977c6", "dfc9b694-6729-4715-8c3b-285e70162c0d", "92b3f5fa-ce72-484e-9a68-b5b77cfe10fa", "f488a4d5-8796-47df-acc9-c43a2c61f794", "b05413a5-261b-4fab-8765-659ba0aad766", "a621744f-55af-49c7-b666-153fbb9e845b", "5852b25f-59d3-4161-acc5-5281c687a80a", "8b74451a-3cd7-4af7-90b9-498485dbc43c", "2baa29f4-6bae-435a-b4af-24fb58d6c556", "e40129f2-cb93-4160-9d7d-de67a14ec151", "d27c988b-97a3-41e7-bba3-9e8624c3d29c", "fe966659-ebcd-4625-b0e9-f7818fbd306f", "3437d41a-cb2e-461d-8d55-4689becfb834", "86ff5e44-afe6-4d47-a782-8ed83c801d79", "f6bbb18c-5c37-424c-81cb-623bcf7fb5e9", "13aee707-6f14-4919-bc18-83d853b037dc", "c90306a6-0db1-4873-b599-15a769020908"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nClearly, as we've talked about with the macro environment, we are pleased with the fact that we're seeing \nprescription volumes continue to increase.  And as the economy continues to \u2013 or I should say, patients continue \nto be more mobile as COVID restriction s continue to ease, that certainly is an opportunity for us to see \nprescription volumes continue to improve, not only in our Pharma business, but really across, as I talked about, in \nour Prescription Technology business as well.  We certainly have the oppor tunity to deploy capital. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "a20b62c6-333d-4df2-826a-8b17159ad9f9": {"node_ids": ["9b071f51-7392-4b71-9136-47b8bcb063b4", "8041f740-19ca-4b22-9ee8-56614b98db18", "b583e0de-ee08-48b8-8af2-e6f330e8e6c3", "80147a08-ced5-4245-aec5-cdcc659b5000", "d85a4a64-296e-449d-96fb-7664fdd14c9a", "5b4e0f5d-47cc-4b7d-9b55-af0640563bbb", "001ee631-e42c-4f13-ac62-423d06193080", "e6e54d2b-395c-4f7a-8bec-2eb17a8ae656", "81396d50-913c-4f33-927e-9e0fcf134a9d", "c13eb7e3-c12b-41e0-9c07-1e3fdb5f3d65", "471046f8-f35f-4920-9a84-c61e0f985943", "eba3b6de-e9cc-4c30-95c2-5774275e3bf4", "7bf37985-fa9d-4d67-9e6f-03f4c8ef3de5", "b8ab246d-4107-4a08-bd41-cfc1e9bd38ec", "35a86a96-2e30-4076-93b8-f3695cd8c0c0", "9c2123a0-73e4-407d-895c-9b9a67c7bef9", "d7dc381e-cc46-426d-b6df-a3ad995f7e46", "76b87cc6-c1af-4ecb-96db-038a9fbb9167", "6834afbd-6810-4714-8739-94dd7916cddb", "d07dd57e-1180-4b36-be02-cb4a7f7622af", "b2d06df2-b4b2-4e4b-873a-01ff3c62ae1e", "0b110948-ea1f-4996-aacf-18f1ec13611f", "f8c360aa-a2c6-40f7-9ff3-d319c6fadfa9", "7224e92e-cfaa-47a7-aeb5-57fe4df862dc", "07d7b056-f88c-4eff-9dc2-a88a8f15c43e", "2eae8e68-ec14-455f-8b49-61d12ee25fec", "a3543f29-c17a-4b62-a101-aafe368caa06", "da164256-8dd8-465c-b3b9-2cbd7e2c3a3d", "89e50121-c273-47cb-93bb-681b2a138108", "5a73e036-4e5a-41c9-9100-e5e36856ba0f", "98c27877-ecec-46c6-8631-233e42d1eed9", "f408f4e1-80b0-4a28-885b-98a53a5d2d62", "63af9404-a88a-4fa3-8f19-af8c444ce061", "24bc2aca-5e06-4a12-8d36-3b18ba3bee70"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Lisa Gill with JPMorgan. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "092ed2a8-9fd1-431e-8a03-82388d2bb85a": {"node_ids": ["a54f700a-921b-44bd-993c-a235238820cc", "0de4c3ac-8914-4709-b901-f4678d4ff008", "d93bafa4-9887-4f60-98a4-16021ecea556", "37d2f94c-1e26-45c7-b320-38e883cf9724", "18699c98-04ba-4eda-b757-2422a721ce30", "201f319f-d1c5-4ad3-b8a8-fdc8bb6c6eab", "69dd2a4b-ce9a-4ca7-ac06-3163f83e3db5", "a1fc67a6-829f-438c-a194-eb93875f5329", "c0fe2c25-8ae1-4a0e-a011-fbbcfce44db0", "a931cce7-ea72-4ddf-beeb-1eb77e40d1f4", "da798918-1e9b-415f-b39a-74711201ecfb", "17a064d9-a3eb-4b62-9c87-31c91792313e", "63396179-965c-4729-b5f7-0a1c2d3aadd3", "a9c55eb4-649c-4978-aef7-124344603377", "b770261b-fe18-4f16-9111-b48a879a9b34", "ee86b109-629d-4dca-898b-91b2392bbfdd", "fb07b223-df77-4597-bc12-213fb83ae238", "472f28ed-b705-4921-869a-46e73a9b7e11", "cfa325fb-7e91-4140-b482-1d0ec53f28df", "d504e7f8-02b8-4626-b29d-4afb39bd0ae1", "242f1687-34de-4da5-b15f-99db2cb3a74a", "32a8ab6d-b89b-4baf-87e3-6944dce8d0ee", "d7186965-a337-4b46-b23b-43b3f3c2dd9e", "7ac4015b-92e1-47c1-9752-35bf898b58df", "839144fa-7d39-4f8c-b2bb-d6ba901fd3de", "3dfee405-0a66-4536-809a-5e47a898c23f", "fa6ab2c7-308a-471e-9cee-f64a367eda4b", "25a10e0a-b117-4a5f-813c-ba98a3dac857", "962b30cb-7140-4ff7-9c2d-ffac21bb125d", "d16ceb96-5b4e-4350-9a07-c3d129bb2f2f", "29192c13-02a5-45d2-850a-771c343eaf50", "fbf1a4a7-1e22-4632-9d0f-89fc4fdeb1a0", "0ce0df08-bc5f-4054-845b-8b447b425a7c", "4cbf70e4-1697-4b20-a74b-48d051489ce4", "bf44e458-302d-4a77-94ff-3a5b664363a5"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nabout and focused on is our approach to responsible and sustainable sourcing.  And we've really taken a lot of \nactions along those lines to also diversify our partners across the products that we serve.  So we feel like we have \nreally good strong sourcing prog ram in place, and we feel well -positioned.  \n ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "70523b32-d06d-4172-b8d5-7aa7027b9b4b": {"node_ids": ["e85a2c6c-ab5e-4571-97d8-6635983986df", "9d9523ed-f519-46de-9eff-8026c2f48d65", "5cacb6e7-26e4-4350-b96c-097c6e13e8b7", "36acdd3b-030d-42d8-9bbb-51dac5e38a6e", "945b604f-15b8-42c9-bd44-1ec37fa8ebd6", "fb97a69f-7236-4371-99fd-b88f88290933", "60a31c9d-aed8-4891-9f24-5840e70ab868", "bf103914-fe78-4523-95d9-9a1af98b7ae9", "506f1716-43a8-4e27-ba93-204895bdaafb", "1c0b244d-bf31-4d38-bf07-c27f3fca3b16", "0f1947e7-c6f3-41b6-94fb-f92c0e5f710e", "1a82db49-3f22-4afd-9c49-0a33285f6f30", "5a44f9de-5804-44ab-badd-3da8644298cf", "a72e4003-9da9-4dc0-84e2-c6886fc8a113", "0074681f-fa05-479e-8ec5-40c0b0c10056", "0fe9369c-72b5-407f-b0a6-57f95da164f3", "e4b7d87f-91a0-42e7-9496-4865238657b7", "be166c42-3234-4cf6-b6ee-286c291b087e", "84561c35-46a1-4503-82bf-14cb73b0102b", "60eac8e5-0265-4be1-9dd2-57f011ba506e", "c7337cf8-6e8b-4726-8f66-a01833df8f1f", "71fa6631-a82c-488b-a86e-33c0deab02d3", "054d87bd-dde7-4afc-9c84-b99815dbb7d4", "95d81409-6369-4e10-926d-870d254ac401", "d8b95a58-87d9-41ad-989d-65a58a38a6ba", "2fd124fb-f356-4ae4-a7dd-ef423ac7ea1d", "2bd90271-49bc-4870-ba26-1104ab50a316", "5f495dc9-c785-4596-bece-6735a957bec1", "a32e8735-d1a2-4205-b63a-2336b4d186cb", "8e53a603-266a-4965-a30f-cdbe0bb7e9a5", "8ab9b04c-02af-4136-9121-54d1e757c8bb", "10d3df49-871b-4749-bfd1-157c6d3b46ec", "b7108c21-4c7a-482d-b10b-242dbe2350e3", "3feace80-945d-45eb-a92b-7e1ed84b0696", "d3eb64c8-f6f0-4e99-a06a-39e6e17858bf", "f1b38022-70ac-4b79-a5a0-7b3318bbe955", "a444bb92-ee25-4428-9680-5c0e0ed0aec3", "8d68edf8-19ce-4630-b208-b6ed4fb29fa6", "0c9c7f51-f149-4b9a-a4b4-5eecae2d86a5"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nthink about that 2% difference is the cost and inflation?  Is this som ething that we can think about as we try to \nquantify what it is embedded in your 2023 guidance?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "5e225d9a-ce4a-47ab-a799-54be5042d8ec": {"node_ids": ["5cae699f-5340-4cde-abfa-dd1680187b17", "b9d9c5c0-62aa-49cb-866f-210a884ae411", "35e6c8e8-ec44-4586-97ea-d991bf68a323", "6f969717-f957-46d8-b31e-a56391951e20", "8f10101e-7e95-40af-9d84-13dee5686100", "52e70f44-d693-41f3-8b02-52be64d412c7", "bc2bff56-7877-4886-83ab-d807fb98f65a", "192e0393-587f-4fe2-b835-9bec16303ae8", "9d92513a-08af-4647-8ba6-b34c5fff5e9c", "430332bf-5c0a-4828-9e8e-388f6d4039bc", "8fdf9616-6c02-4ca9-a652-4ead4cb19e5f", "cbb25293-2d94-4d34-beef-81b8e55428f4", "53ab00ab-655a-47b0-a7eb-1823e71fa78c", "74f91b39-4eea-4226-85e5-5dc2df5fa94f", "1cc9c8d3-8e69-46cc-bcfe-83b9c43cb142", "ca65bb9d-116e-4865-8faf-8e413f3dc802", "3ed20217-1186-4fb3-8492-aa254f4b9709", "a293faa9-3628-4b66-bbc6-f1baf214f54f", "30f80553-d99e-4381-89c6-369709d3deb0", "ddae6a7b-1443-41d5-9b93-5052020d472c", "fea72eae-58bf-4a28-8a0c-14c088e501a1", "f1101b39-eaef-493a-ae4c-9642304dadb5", "52bbd652-1fb7-4bb5-a8d7-fbd66cb1665d", "1a51479e-5561-4751-a1ee-f91d378477fd", "ee3712dd-0de2-45f3-b1a6-a65351075a1d", "97d54ede-701d-46bf-bb79-e1aabdd0fb1c", "8da9fe44-4e15-40a8-9d81-ceb069f448c6", "b9ed8c7f-6369-4223-b568-6c30210d42b1", "48361710-a738-4429-a882-e08c752c9f5e", "92583168-888d-4934-80d4-f2d452dda8c8", "f32782c9-1ed8-42c7-96f6-c8b281cfaee4", "a44e2862-1ee0-4a20-9b51-e31f1223891a", "ba21e276-f330-4311-9d2f-36ad3bba3458", "d99e2178-a057-4358-88d5-0cf3d84030f0", "ba049ebb-1f3f-43be-bbf0-fa6cbfe4d072", "a9cebea9-84c2-46b2-918b-8aea9eda74d9", "1969c404-e3a2-4fe0-b8b6-c4de1505acb3"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  Our next question comes from Eric Coldwell with R.W. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "809dfba9-5e0e-426e-a87e-7ea984e977fe": {"node_ids": ["b4f8cd46-b5c1-442c-bb59-06a665de9701", "ea901e00-ef6d-4ddb-9f38-c61e6fe4aabd", "b646426f-458e-4c50-a5e0-831ecadb1dbb", "443f1f83-b68f-4ba6-b6d8-d7f70ce098fa", "8dd14ee8-910c-49f4-9295-45ece46db33b", "6f45af4e-20cf-4ad9-92cf-c7b66759e1f3", "9db72625-c85b-4514-b809-1800765aa645", "0f6253f8-c082-43ae-81f1-c178b4468673", "ae849bc0-063c-4ce6-a4ae-3d98b1b4946b", "9946d133-56d3-4a9f-ad0b-8c329b7cc0f0", "8203606c-9977-4db7-bb86-a1fd4a5b2468", "fba770f3-a013-456c-9071-c368b115392e", "f62419a5-b996-4556-8e9a-af1095b50238", "29b0b81e-ee03-4236-9fb0-8ebbfe50a61f", "5de480d2-97a0-4f6c-bb3e-e005baa99b5a", "a6b6155a-615c-4406-9c49-ca892abc5607", "a617f904-96ff-4a87-8ca1-e108e429d165", "2e0bf72a-3aa5-4521-8e9c-3e6c5dfe228f", "4e996f86-047a-439f-b761-411c0a9fb861", "afb13fb8-f2b5-4b22-8963-d79231753891", "d27e5cb3-3aee-4a0c-9c8f-ec3eb2286d96", "a6ee16f3-7f6c-40ed-940d-4e3b4c00b6a1", "cf17efa4-a7f6-49ba-aa43-819a1b6148e0", "60d24d54-4d3a-43ec-a2c9-a53fb66b7c04", "2b6a0a8c-28c9-42f3-9e7c-86b2ed36c1b8", "b6cf8304-5f3a-4a1d-83a6-0c0a7bc73a1c", "299025d5-265d-4d93-95c0-bf1beac77859", "f5741895-247c-44cf-a50a-1a765ab72dbc", "a8890db6-6011-44f3-a59a-1a8fdfea2799", "3425f9b2-8abf-4a06-ac95-421b8e1ca43c", "7dc8fd0a-cc20-407f-a150-6c0f4c7df810", "9fd77417-dc84-4c4b-a455-c8bb346e79c2", "2cd3bd59-b62b-46be-9e84-9561a65710a8", "a6490d48-8519-4e11-87c5-866db0f1dc0f", "448c69b2-5614-4bce-a3a9-20dcdf1fb57d", "9c3bbdce-a0dc-4a00-878b-74fcba3572bd"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nHi, guys.  Thanks so much for the question.  I was wondering if you could talk about the re lative contribution of \npricing increases to the revenue growth in your three remaining segments and the outlook that you provided for \n2023.  \n ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e4ffcfa1-8cee-41ac-b9a3-c29ad88c74e3": {"node_ids": ["9ca7b467-3bc3-482f-858c-a397de2f6772", "305915ba-1433-429b-ae73-e718207b31c0", "a4d60107-9f59-4788-b9a0-17b065cc939a", "babaa589-afbf-4f30-b21d-14b620f2e482", "0543237c-8f19-44ce-b47d-a2f7d908979a", "8dfd5cb7-27d4-4771-a8e8-ceb575c336a6", "163dab90-ad5a-44e2-bc76-26aec57daa86", "43a2061a-c3b6-405c-b785-fc7431ec0c09", "30eac066-cf25-4481-87df-c1fc5a30caa7", "f978aca1-69ad-4678-8c37-d333283485de", "e44a8435-3ab5-4f11-92f1-01afa75de97a", "3506f200-2808-4676-ad26-40a1d2b15a61", "7322081f-ef2d-4f47-a656-476ded2b905e", "8bf542bf-550f-4345-bb0e-02971b4568f8", "90067233-3eaf-4a78-b79a-1c4a09f55711", "23f8c802-fc94-42b4-a5a1-d3047df6b6ba", "92d79c00-da0d-40f1-8546-a9c187209cbe", "8a3b7629-d792-4aee-9a8a-4044721eae46", "84fd8819-cf18-4d9c-9e45-9eb59a31742e", "0ef78bc0-64bd-4733-84b0-a37e88f7fbb2", "b8cc0cb1-4826-4d96-8f97-5e079764ae5c", "4e93b84a-4067-457a-8960-08c09161c792", "6c033c49-08ce-4f5c-9d88-c16a209bfb6f", "608d90ed-54f9-49a8-a5bb-689bae829e1a", "991054af-3942-48f3-8abd-4b9784817c07", "2dc962b6-3410-4ab2-bb83-fecccd5d726d", "cd474117-3df5-4cf4-8a47-b976033f9a3e", "a255a4cc-f426-4758-b7a0-36cd92559f06", "62504520-cea0-4036-816d-2933ff847a05", "0d80d32f-2dc8-45d8-97a5-301bb75e06b0", "ab87ad88-027a-4877-af57-f61f356dec03", "c86dd5f7-092b-4198-adbd-a3b656933831", "d86abaf5-8eac-42ea-8395-e96457dbf081"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2022 Earnings Call  Corrected Transcript  \n05-May-2022   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nAnd in the case of RxTS exceeding what we said in December, we thought was a long -run growth target.  So \nwe're very pleased with both those businesses and feel we're very well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Direc tor, McKesson Corp.  \n", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 379142, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}